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Abstract 
 
In the complement system of innate immunity, factor H (FH) is a major regulator of its 
activation, and is comprised of 20 short complement regulator (SCR) domains. FH is 
related to age-related macular degeneration (AMD) through a Tyr402His 
polymorphism, and occurs in drusen deposits that are a key feature of early AMD. High 
concentrations of zinc are also present in drusen, and the function of FH is inhibited by 
zinc. In this thesis, FH self-association and its interaction with zinc were investigated. 
Using X-ray solution scattering and analytical ultracentrifugation, pooled heterozygous 
FH in physiological conditions self-associated to form 10-15 % of dimer and higher 
oligomers. Titrations of FH with zinc induced uncontrolled oligomerisation of FH when 
the zinc concentration was above 20 micromolar, and this correlated with the reduction 
of FH activity. Structurally distinct large oligomers were also observed for Cu, while 
Ni, Cd and Fe showed low amounts of oligomers, and Mg and Ca showed no change. 
These experiments were repeated for the native Tyr402 allotype and the disease-related 
His402 allotype of FH. X-ray scattering combined with constrained modelling showed 
that the homozygous Tyr402 and His402 allotypes of FH have indistinguishable folded-
back structures in solution. Both homozygous allotypes of full-length FH exhibit similar 
self-association properties in solution, showing no dependence on heterozygosity. 
Surface plasmon resonance confirmed these results, but showed that the His402 allotype 
of SCR-6/8 self-associates more than the Tyr402 allotype. Zinc titrations of the two FH 
allotypes showed that each allotype formed similar oligomers with zinc. While the 
major interaction sites of FH with zinc were located within the SCR-6/8 fragment, the 
surface exposed His402 residue in SCR-6/8 showed no preferential interactions with 
zinc. Overall, these findings provide insight on the development of drusen deposits in 
Bruch’s membrane and the uncontrolled inflammation associated with AMD.   ii
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Chapter One 
 
The complement system 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   2
1.1 General outline of the complement system 
 
Complement was first discovered by Jules Bordet in late 19
th century as a heat-labile 
component in normal serum (Bordet, 1909). The term ‘complement’ was introduced by 
Paul Ehrlich since this component augments the antibacterial activity of antibodies 
(Morikis & Lambris, 2005; Murphy et al., 2008). Later studies discovered that 
complement can also be activated in the absence of antibodies (Murphy et al., 2008). 
Therefore, complement is considered part of the innate immune system as well as part 
of the adaptive immune system. 
 
 The complement system contains more than 30 proteins that interact with one another 
both in plasma and on cell surface. There is more than 3 g/L of complement proteins in 
plasma which constitute about 15% of globulin fractions (Walport, 2001). The 
nomenclature of complement follows the order of discovery of the proteins. The 
complement system is composed of over 60 components and activation fragments 
which include the nine central components C1 to C9, activation products such as C3a, 
C3b, iC3b, C4a and C5a, proteases such as factor I, factor B and factor D, regulators 
such as factor H, factor H like protein-1 (FHL1), C1q, properdin and complement 
receptor type 1 (CR1), assembled enzymes in the cascades such as C3 convertases 
C a b2 4  and C bBb 3 , and receptors for the complement effectors such as C3a receptor, 
C5a receptor and C1q receptor (Zipfel & Skerka, 2009). Several complement proteins 
exist as zymogens which refer to the inactive proteases that only become activated after 
being cleaved by another specific protease. Those zymogens can be locally activated by 
the presence of pathogens including infectious invading organisms and altered host cells. 
Those activated proteases can trigger a series of enzyme cascades by cleaving other 
zymogens which then cleave their substrates. In this way, a huge complement response 
is rapidly generated by successively amplified enzymatic reaction started from the 
activation of a small number of zymogens (Murphy et al., 2008).  
 
The activation of the complement system results in three biological functions. Firstly, 
complement protects the host against infections by binding and then opsonising the 
pathogens for phagocytosis, acting as chemoattractants and activating leukocytes, and 
attacking and lysing cells and bacteria; secondly, complement plays an important role in 
activation of the adaptive immune system as the antigen-presenting cells and B-  3
lymphocytes bear receptors for complement proteins that coat antigens, and therefore 
this bridges innate and adaptive immunity; thirdly, complement can clear dead, 
damaged and apoptotic cells and immune complexes from the tissues, and therefore 
protects the host against immune attacks on the body’s own antigens (Goldsby et al., 
2000; Walport, 2001).  
 
1.2 Three pathways of complement activation 
 
Complement can be activated by three different pathways, the classical pathway 
through antibodies, C-reactive protein (CRP) and C1q, the alternative pathway through 
the low level spontaneous activation of C3, and the lectin pathway through multimeric 
lectin binding to repeated molecular patterns on pathogens. The final steps which lead 
to the membrane attack complex are the same in all pathways (Figure 1.1). Component 
C3 plays a central role in complement system, being common to all three pathways 
(Law & Reid, 1995). 
 
1.2.1 Classical pathway 
 
The classical pathway usually begins with antibodies complexed with antigens, and 
therefore it is part of the adaptive immune system. IgM and certain subclasses of IgG 
can activate the classical complement pathway (Figure 1.1) (Goldsby et al., 2000).  The 
initial steps involve the four central complement component proteins C1, C4, C2 and C3. 
C1 is a complex consisting of a single molecule C1q and two molecules each of C1r and 
C1s, held together in a complex (C1qr2s2), and C1q is composed of six identical 
subunits (Figure 1.2). The C1q molecules, which contain no enzymatic activity, 
recognise and bind to the pathogen surface or to the antigen antibody complexes (Figure 
1.2). The binding of more than one C1q head to a pathogen surface or to the constant 
region of antibodies leads to a conformational change in zymogen C1r to an active 
serine protease enzyme C r 1 , which then cleaves the associated zymogen C1s to a 
similar serine protease enzyme C s 1 , and therefore the enzymatic activity of C1 
complex is derived (Law & Reid, 1995). C s 1  hydrolyses C4 to an anaphylatoxin C4a 
and a large fragment C4b, and C4b may bind covalently to the pathogen surface. If C2 
zymogen binds to C4b by the neighboring C s 1 , C2 is cleaved by C s 1  into a non-   4
 
 
Figure 1.1 Schematic diagram of the complement system cascade.   5
 
 
 
Figure 1.2 The first proteins in the classical pathway of complement activation C1 
complex and the first proteins in the lectin pathway including the MBL-MASP complex 
and the ficolin-MASP complex (adapted from Murphy et al., 2008). 
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catalytic C2b subunit which then diffuses away and a catalytic C2a subunit which is 
bound to C4b to form C a b2 4 . In the classical pathway, the C a b2 4  complex is the C3 
convertase which activates C3 by the proteolytic cleavage of C3 into C3a and C3b. The 
release of C3a causes a conformational change in C3b, which leads to the exposure of 
an internal thioester bond which is buried and inaccessible in unactivated C3. This 
exposed thioester bond reacts with nucleophiles, including water and molecules bearing 
hydroxyl or amino groups, and therefore leads to C3b covalently bound to the cell 
which has those molecules on its surface. Some of the C3b molecules bind to C a b2 4  to 
form C b a b 3 2 4  which is the C5 convertase in the classical pathway (Law & Reid, 1995; 
Rother et al., 1998). 
 
The classical pathway also plays a role in the innate immune system. In the innate 
immune system, natural antibodies are produced in the absence of infections and can 
react to a broad range of self and microbial antigens. Most natural antibodies produced 
are of class IgM which can bind to C1q most efficiently, and therefore activate the 
classical pathway of the complement system. In addition, in the absence of antibodies, 
C1q can bind to C-reactive protein which binds to phosphocholine on bacterial cell 
surfaces. Therefore, the classical pathway is part of both the adaptive and innate 
immune systems (Murphy et al., 2008). 
 
1.2.2 Lectin pathway 
 
The lectin pathway is antibody-independent, and therefore it is one part of the innate 
immunity. The lectin pathway is homologous to the classical pathway (Figure 1.1). The 
activation of the lectin pathway is triggered by proteins very similar to C1q including 
mannose-binding lectin (MBL) and ficolins (Figure 1.2). Like C1q, MBL contains two 
to four identical subunits, and can forms complexes with two molecules each of the 
MBL-associated serine protease 1 (MASP-1) and 2 (MASP-2), the equivalent of C1r 
and C1s in the classical pathway. When MBL binds to the mannose residues on 
glycoproteins or carbohydrates on the surface of microorganisms, MASP-2 is activated 
to cleave C4 and then C2, and therefore MBL-MASPs complex mimics the activity of 
C1qr2s2 to trigger the formation of the C3 convertase (Goldsby et al., 2000). Similar in 
shape and function with MBL, ficolins which has a higher concentration in plasma can   7
also complex with MASP-1 and MASP-2, bind to the oligosaccharides containing N-
acetylglucosamine on pathogen surfaces, and then trigger the lectin pathway cascade 
(Murphy et al., 2008). 
 
1.2.3 Alternative pathway 
 
The initiation of the alternative pathway does not have a need for antigen-antibody 
complex formation, and therefore the alternative pathway is a part of the innate immune 
system. Activation of this pathway is initiated in the fluid phase with the spontaneous 
and continuous hydrolysis of C3 (also known as “enzymatic tickover”) (Figure 1.1), and 
the alternative pathway is constantly activated on biological surfaces and in most other 
body fluids (Zipfel & Skerka, 2009). The native C3 molecule consists of two 
polypeptide chains, α and β. Without loss of the C3a fragment, a spontaneous hydrolysis 
of the thioester in the α chain of C3 slowly leads to a formation of C3(H2O) (also 
known as C3i or C3u) which has an altered conformation like C3b. In the presence of 
protease factor D, C3(H2O) is able to bind factor B which then serves as the substrate 
for factor D. Factor D cleaves the C3(H2O)-bound factor B, releasing a small fragment 
Ba. An unstable fluid-phase C3 convertase C Bb O H ) ( 3 2   is then formed. All these 
processes only operate at a low level (Figure 1.1) (Law & Reid, 1995; Rother et al., 
1998).  
 
By proteolytic action, C3 convertase C Bb O H ) ( 3 2  generates the first metastable C3b 
molecules, much of which are attached to both host and foreign cells. Host cells protect 
themselves from complement attack with surface-bound sialic acids or other polyanions, 
and membrane-bound regulatory proteins. Activation proceeds on particles which lack 
those molecules. On those unprotected particles, a positive-feedback amplification of 
C3b occurs. C3b binds to Factor B which is then cleaved by factor D. Cleavage of C3b-
bound factor B yields the C3 convertase C bBb 3 . The activity of C3 convertase C bBb 3  
has a half-life of only 5 minutes, unless it binds to properdin, which stabilizes it and 
extends the half-life of its convertase activity to 30 minutes (Goldsby et al., 2000). C3 
convertase C bBb 3   cleaves C3 to generate more C3a and C3b, and thus creates an 
amplification loop for the cascade (Figure 1.1). C3 convertase C bBb 3  binds to another 
C3b to form C5 convertase C b bBb3 3 , which is analogous to C b a b 3 2 4  in the classical   8
pathway (Law & Reid, 1995; Rother et al., 1998). The activation of the alternative 
pathway is regulated by some plasma-derived regulators including properdin, factor H 
and factor I, and also by some membrane-bound regulators including decay-accelerating 
factor (DAF), membrane cofactor protein (MCP) and complement receptor type 1 (CR1) 
(Rother et al., 1998). 
 
1.3 Membrane attack 
 
C5 is cleaved by the C5 convertase, C b a b 3 2 4  in the classical pathway and the lectin 
pathway, or C b bBb3 3  in the alternative pathway. C5 is activated by a mechanism in 
which a small fragment, C5a, is released from C5b. C5a is the most potent of the 
anaphylatoxins, and is therefore the most essential complement-derived mediator in 
inflammation. C5b, the large fragment which is loosely bound to C3b, then initiates the 
assembly of the membrane attack complex (MAC). C5b binds to C6 to form the C5b6 
complex and then to C7 to form the C5b67 complex which is dissociated from C3b. 
C5b67 has hydrophobic binding sites which enable C5b67 to insert into the 
phospholipid bilayer. C8 is a complex composed of two protein molecules C8β and 
C8α-γ. The C8β binds to C5b of the membrane-bound C5b67 complex to form C5b678 
complex, and allows the hydrophobic domain of C8α-γ to become inserted into the 
phospholipid bilayer. The C5b678 complex is able to slowly lyse red blood cells, but 
the C5b678 complex mainly serves as a receptor for C9 and catalyses C9 
polymerization. The final step in the formation of MAC is the binding and 
polymerization of C9 to the C5b678 complex. The complete MAC has a composition of 
C5b678(9)n, where n lies from 10 to 16 (Figure 1.1). The MAC has a tubular form 10 
nm in diameter, and it forms a transmembrane channel which has a hydrophobic 
external face that associates with the lipid bilayer but a hydrophilic internal face to 
allow solutes and water to pass through the lipid bilayer. The disruption caused by 
MAC finally leads to cell swelling and eventually lysis of the pathogen (Law & Reid, 
1995; Murphy et al., 2008). 
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1.4 Complement component C3 
 
Complement component C3 plays a central role in the proteolytic cascade. Its activation 
product affects inflammation and both the innate and adaptive immune responses.  C3 is 
a member of the α2-macroglubulin (α2M) family, and two homologous complement 
proteins C4 and C5 which are 26-30% identical in sequence to C3 also belong to this 
family. A reactive thioester bond required for association with molecule or cell surface 
is characteristic for the α2M family proteins, although some members like C5 do not 
have this thioester bond (Gros et al., 2008).  The molecular mechanisms of the function 
of C3 are better understood as more structural data has been revealed. Crystal structures 
have been determined for native human C3 (Figure 1.3) (Janssen  et al., 2005), the 
activation fragments C3a (Huber et al., 1980), C3b (Janssen et al., 2006; Abdul Ajees et 
al., 2006), C3c (Janssen et al., 2005), C3d (Nagar et al., 1998), the C3b and factor H 
SCR-1/4 complex (Wu  et al., 2009), and the C3b and C3c complex with the 
complement receptor of the immunoglobulin superfamily (CRIg) (Wiesmann  et al., 
2006). Electron-microscopy images have been obtained for C3(H2O) and iC3b (Nishida 
et al., 2006). Mature C3 is composed of a α-chain and a β-chain which contain 13 
domains including eight macroglobulin (MG) domains MG1 to MG8, a linker domain 
(LNK), an anaphylatoxin domain (ANA), a complement C1r/C1s, UEGF, BMP1 
domain (CUB), a thioester-containing domain (TED) and a C345c domain (Figure 1.3) 
(Janssen et al., 2005). 
 
  In the complement system cascade, the three activation pathways all lead to the 
formation of the C3 convertase which then cleaves C3 to release the anaphylatoxin C3a 
and form C3b. The small fragment C3a can act on certain receptors to produce 
inflammatory responses. The thioester bond is hidden in the TED-MG8 interface of 
native C3. The release of the anaphylatoxin domain causes the conformation changes 
which expose the thioester bond. The exposed thioester bond becomes highly reactive, 
which results in C3b becoming covalently bound to the cell surface (Figure 1.3). The 
covalent association of C3b on the pathogen surface (opsonization) is essential for the 
amplication loop to generate C3b convertase in the alternative pathway. C3b 
participates in forming C5 convertase which finally leads to pathogen cell lysis. C3b 
can be cleaved by the protease factor I with the assistance of some regulators such as 
factor H, complement receptor type 1 (CR1) and membrane cofactor protein (MCP),    10
 
 
Figure 1.3 Conformational changes of complement component C3 in activation and 
degradation. (a) An X-ray crystal structure of native human C3 with PDB code 2a73; (b) 
Schematic representation of the structure of C3; (c) Schematic diagram of the 
conformational changes of C3 and its activation products in the complement cascade 
(adapted from Gros et al., 2008).   11
yielding the fragments C3f, iC3b, C3c and C3dg which can no longer form C3 
convertase. C3b and iC3b can bind receptors on macrophages to facilitate phagocytosis, 
while iC3b and C3dg can bind to receptors on B-cells and stimulate B-cells (Figure 1.3) 
(Gros et al., 2008).  
 
1.5 Regulation of the complement system  
 
Several mechanisms control the extent of complement activation at different stages of 
the cascade. Normal host cells are protected from inappropriate complement activation 
by both positive and negative regulatory proteins both in fluid phase and bound to the 
membrane (Table 1.1). 
 
At the beginning of the classical pathway, a plasma serine protease inhibitor, C1 
inhibitor (C1NH), regulates the activation of C1 complex by dissociating C1r and C1s 
during complex formation from C1q which remains bound to the pathogen surface, or 
suppressing spontaneous activation of C1 via a reversible interaction with zymogen C1r 
and C1s. C1 inhibitor can also regulates the lectin pathway by inactivation of MASP-2 
(Davis et al., 2008). 
 
At the formation stage of the C3 convertase, as the thioester bond in C3b and C4b is 
very reactive and cannot differentiate between the host cell surface and the pathogen 
surface, several protective mechanisms have developed to minimize the formation of C3 
convertase on the normal host cell surface. Firstly, the protease factor I is responsible 
for cleaving C3b and C4b into inactive fragments, when C3b and C4b are bound to the 
cofactor proteins (Murphy et al., 2008). For the cleavage of C3b, such cofactor include 
factor H (Pangburn, 2000), factor H-like protein 1 (FHL1) (Zipfel & Skerka, 1999), 
membrane cofactor protein (MCP) and complement receptor type 1 (CR1) (Kim & 
Song, 2006). The C4b-binding protein (C4BP) (Blom et al., 2004) is the cofactor for 
C4b cleavage by factor I. Secondly, regulators such as factor H, CR1 and the decay-
accelerating factor (DAF) can bind to C3b or C4b to displace Bb or C2a and therefore 
dissociate the C3 convertase C bBb 3  or the C4 convertase C a b2 4 ( Pangburn, 2000; 
Kim & Song, 2006). Thirdly, those regulators that bound to C3b or C4b can accelerate 
the dissociation of C bBb 3  or C a b2 4  that have already formed. Among those negative  
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regulators, factor H, FHL1 and C4BP are plasma regulators that can be attracted to the 
host cell surface, whereas CR1, DAF and MCP are membrane-bound on the normal host 
cells (Table 1.1). The regulators FH, FHL1, C4BP, CR1, MCP and DAF all belong to 
the ‘regulators of complement activation’ (RCA) family, and the RCA family proteins 
share one or more copies of a repeating motif of ~60 amino acids called the short 
complement regulator (SCR), also known as the complement control protein (CCP) 
repeat or the sushi domain (Morikis & Lambris, 2005). In addition, a newly identified 
membrane-bound regulator complement receptor of the immunoglobulin superfamily 
(CRIg) only inhibits the alternative pathway. The mechanism which is different from 
other established inhibitors is explained in Section 1.6.  In contrast, a positive plasma 
regulator, properdin, can be attracted to the pathogen surfaces or motified host cell 
surfaces, bind to and stabilize the C3 convertase (Hourcade, 2008). 
 
In addition, there are also mechanisms to prevent inappropriate membrane attack events 
on host cells. As mentioned in Section 1.3, C5b is produced upon the action of C5 
convertase, and then other complement components C6 and C7 bind to C5b to form the 
C5b67 complex. The plasma protein vitronectin, also known as S-protein, and the 
plasma protein clusterin, also known as SP-40, can bind to the C5b67 complex thus 
forming soluble C5b67, to stop the insertion of the complex into the cell membrane. 
The complement component C8 and C9 can bind to the C5b67 complex to form the 
C5b678(9)n complex. The binding of clusterin and vitronectin to nascent amphiphilic 
C5b678(9)n complex can make it water-soluble and lytic-inactive (Bhakdi et al., 1988; 
Tschopp et al., 1993). Factor H-related protein 1 (CFHR1), another plasma protein, is 
newly identified as inhibitor of the complement cascade, as it may control the C5 
convertase activity by contacting the C5 convertase C b bBb3 3 and the substrate C5 at 
the same time, and it also inhibits assembly of C5b67 complexes and prevents surface 
attachment (Heinen et al., 2009). The membrane-bound protein protectin on the host 
cells can inhibit the binding of C9 to the C5b678 complex (Murphy et al., 2008). Some 
regulators have some other biological functions. For example, clusterin binds to 
enzymatically modified low-density lipoprotein (LDL) and thus reduces fatty acid-
mediated cytotoxicity (Schwarz  et al., 2008). Vitronectin is one of the adhesive 
glycoproteins that functions in the attachment of cells to the matrix, and also plays a 
role in the blood coagulation and fibrinolytic systems (Table 1.1) (Preissner & Seiffert, 
1998).    15
1.6 Other biological functions mediated by receptors for the complement effectors 
 
The most important result of complement activation is to opsonise the pathogens and to 
induce phagocytosis by neutrophils and macrophages. As mentioned in Section 1.4, C3b 
is generated after the action of C3 convertase. Due to the regulation of C3 convertase 
formation on the normal host cell surfaces, C3b selectively binds to the pathogen 
surface. C3b and its fragment iC3b therefore act as opsonins, and then induce 
phagocytosis through specific recognition of C3b or iC3b by complement receptors 
(CRs) on phagocytes (Table 1.2). Similar to C3b, C4b can act as an opsonin, but to a 
smaller extent as much more C3b than C4b is generated (Murphy et al., 2008).   
 
Complement receptor types 1 CR1; (CD35) and 2 CR2; (CD21), are multifunctional 
glycoproteins which belong to the RCA family. CR1 is expressed on both macrophages 
and neutrophils. In addition to its regulatory role in C3b cleavage, CR1 mediates several 
other biological functions. Firstly, it can act as a receptor for phagocytosis. Pathogens 
coated with C3b can be recognized by CR1 molecules on polymorphonuclear cells and 
monocytes. Fc-γ receptor and CR1 can act together to facilitate the uptake of opsonised 
pathogens which are then internalized and destroyed in lysosomes. Secondly, it can 
clear immunecomplexes. CR1 molecules on erythrocytes can bind to the C3b/C4b 
opsonised immune complexes which are thus localised on erythrocytes and then 
transferred to the macrophages in the liver and spleen where the immune complexes are 
engulfed and metabolized. Thirdly, CR1 is also present on B-cells and T-cells. The CR1 
molecules present on B-cells appears to control the proliferation of B-cells (Khera & 
Das, 2009). On the other hand, CR2 is expressed by B lymphocytes, transformed B-
cells, follicular dendritic cells, thymocytes and T-cells. It binds to the inactive fragments 
of C3b including iC3b, C3dg and C3d. CR2 on B-cells can enhance the signal received 
through the B-cell antigen receptor on binding the pathogen coated with C3d, and in this 
way the complement activation contributes to a stronger antibody response in adaptive 
immune system (Isaak et al., 2006). 
 
The complement receptors types 3 (CR3) and 4 (CR4) are transmembrane heterodimers 
which belong to the β2 integrin family. CR3 is expressed on phagocytic cells, minor 
subsets of B and T cells, and natural killer (NK) cells. Most cells that express CR3 also 
express CR4, but only macrophages express more CR4 than CR3. The binding of CR3    16
Table 1.2 Distribution and function of receptors for complement effectors (adapted from 
Zipfel & Skerka, 2009). 
Receptor Ligands  Cell  expression  Function 
Complement 
receptor type 1 
(CD35) 
C3b, iC3b, C4b 
and C1q 
Many nucleated cells 
and erythrocytes, B 
cells, leukocytes, 
monocytes and 
follicular dendritic 
cells 
Clears the immune 
complexes; Enhances the 
phagocytosis; Regulates 
the C3 breakdown 
Complement 
receptor type 2 
(CD21) 
C3dg, C3d and 
iC3b 
B cells, T cells and 
follicular dendritic 
cells 
Regulates B cell 
functions; Acts like B cell 
co-receptor; Retents C3d 
tagged immune 
complexes 
Complement 
receptor type 3  iC3b and factor H 
Monocytes, 
macrophages, 
neutrophils, natural 
killer cells, 
eosinophils, myeloid 
cells, follicular 
dentritic cells, CD4+ 
T cells and CD8+ T 
cells 
iC3b enhances the 
contact of opsonized 
targets, resulting in 
phagocytosis and 
adhesion by CR3 
Complement 
receptor type 4  iC3b 
Monocytes and 
macrophages 
iC3b-mediated 
phagocytosis 
Complement 
receptor of the 
immunoglobulin 
superfamily 
C3b, iC3b and 
C3c Macrophages 
iC3b-mediated 
phagocytosis and 
inhibition of alternative 
pathway activation 
C1q receptor 
(CD93)  C1q 
Endothelial cells, 
neurons, monocytes 
and neutrophils 
Phagocytosis and cell 
adhesion 
SIGN-related 1  C1q  macrophages 
Initiates the classical 
pathway 
C3a receptor  C3a 
Neutrophils, 
monocytes, 
eosinophils, antigen-
presenting cells, T 
cells, astrocytes, 
neurons and glial 
cells 
Immune cell recruitment 
and inflammation 
C5a receptor 
(CD88) C5a 
Myeloid cells, 
monocytes, 
neutrophils, dendritic 
cells, antigen-
presenting cells, T 
cells, endothelial cells 
and renal tubular 
cells 
Immune cell recruitment 
and inflammation 
C5a receptor-like 2   C5a 
Macrophages and 
neutrophils 
Immune cell recruitment 
and inflammation 
 
   17
and CR4 to iC3b can induce phagocytosis. In addition, they also act as adhesion 
molecules mediating the diapedesis of leukocytes across the endothelium, and they are 
both involved in adhesion to the extracellular matrix and synapse formation (Ross, 
2000). 
 
The complement receptor of the immunoglobulin superfamily (CRIg; also known as 
VSIG4) is restrictly expressed by a subset of tissue resident macrophages. CRIg can 
bind to C3b, iC3b and C3c, and therefore mediates the phagocytosis of C3b or iC3b 
coated pathogens. CRIg is also a newly identified inhibitor of the alternative pathway. 
Different from the established regulators such as factor H, CR1 and DAF, CRIg neither 
competes with Bb to bind with C3b nor acts as a cofactor for factor I. Rather, CRIg 
inhibits only the alternative pathway by binding to the C3b but not the C4b subunit of 
the C3 and C5 convertases (Wiesmann et al., 2006; He et al., 2008).  
 
C1q is a subunit of the C1 complex. Beside its role in activating the classical pathway, 
C1q is able to trigger several other cellular responses mediated by specific receptors. 
One of these receptors, the C1q receptor (C1qRp), also known as CD93, is a 
transmembrane glycoprotein which is predominantly expressed on endothelial cells in 
human tissue and also on phagocytic cells, has been reported to mediate the 
phagocytosis of C1q coated pathogens (Fonseca et al., 2001). C1qRp molecules are also 
involved in the C1q-induced Endothelial Cell Adhesion and Spreading (Feng et al., 
2002). The dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) 
homologue SIGN-related 1 (SIGNR1), is a transmembrane C-type lectin which is 
expressed on splenic marginal zone macrophages and binds to C1q as well as 
polysaccharides. SIGNR1 is capable to bind to C1q and therefore initiate the classical 
pathway, and the SIGNR1 mediated classical pathway is crucial in the reorganization of 
Streptococcus Pneumoniae and defence against this pathogen (Kang et al., 2006). 
 
The small cleavage products of C3 and C5, C3a and C5a generated after complement 
activation, are often referred to as anaphylatoxins, because of the anaphylactic shock 
caused by a generalized circulatory collapse induced by large production of those small 
complement fragments. C5a is more active than C3a. The plasma protein 
Carboxypeptidase N (CPN), can cleave and partly inactive C3a and C5a and therefore 
protect the body from excessive accumulation of the anaphylatoxins (Skidgel & Erdos,   18
2007). The actions of anaphylatoxins are mediated by three members of the seven 
transmembrane spanning receptor family including C3a receptor (C3aR), C5a receptor 
(C5aR), and C5a receptor-like 2 (C5L2) (Table 1.2). Those receptors are coupled with 
intracellular guanine-nucleotide-binding protein called G proteins, through which those 
receptor signal (Zipfel & Skerka, 2009; Klos et al., 2009). Firstly, C3a and C5a produce 
local inflammatory response by acting on the receptors on the endothelial cells lining 
blood vessel to increase vascular permeability and induce adhesion molecules. As a 
result, fluid leakage from local blood vessels is increased, and antibodies, complement 
proteins, and phagocytes are more easily recruited to the site of infection. Secondly, the 
anaphylatoxins can also activate mast cells to release mediators such as histamine and 
tumor necrosis factor-α (TNF-α) which contribute to the inflammatory responses. The 
fluid and protein accumulation increase the movement of pathogen-bearing and 
pathogen-presenting cells to the lymph nodes, and the adaptive immune system is then 
initiated (Murphy et al., 2008).  
 
1.7 Complement related diseases 
 
The functions and distributions of complement effectors are tightly controlled, and 
defective regulation and misdirecting of complement effectors lead to various diseases. 
Some deficiencies in C3 convertase formation and regulation in the alternative pathway 
can result in host cell damage and accumulation of debris which then cause diseases 
such as atypical haemolytic uraemic syndrome (aHUS), membranoproliferative 
glomerulonephritis type ΙΙ (MPGN ΙΙ), also known as dense-deposit disease (DDD), 
age-related macular degeneration (AMD) and Alzheimer’s disease (AD). aHUS is a 
severe kidney disease which is related to gene mutations of factor H, MCP, factor I, 
factor B and C3 (Saunders et al., 2006; Saunders et al., 2007; Atkinson & Goodship, 
2007). MPGN ΙΙ is characterized by glomerular basement membrane thickening and 
dense intramembranous deposits. The genetic causes of MPGN ΙΙ include factor H and 
CFHR5 gene variations (Abrera-Abeleda et al., 2006). AMD is the most common cause 
of blindness in the elderly population in the Western world, and it is characterized by 
the formation of drusen. The Tyr402His polymorphism in factor H is strongly related to 
AMD (Hageman et al., 2001; Hageman et al., 2005; Klein et al., 2005; Haines et al., 
2005; Edwards et al., 2005; Hageman et al., 2006). Other genetically related 
complement proteins include factor B, C3, and C2 (Gold et al., 2006; Spencer et al.,   19
2007; Yates et al., 2007; Maller et al., 2007). AD is the most common cause of 
dementia worldwide, and is characterized by the formation of β-amyloid plaques. The 
factor H Tyr402His polymorphism has also been reported to be associated with AD 
(Zetterberg et al., 2008).  
 
Deficiencies in the classical pathway cause defective clearance of apoptotic cells, and 
are associated with an increased risk for developing the autoimmune disease systemic 
lupus erythematosus (SLE) and SLE-like disease. SLE manifests in multiple organs and 
is characterized by the presence of auto-antibodies directed against nuclear components. 
Deficiencies in C1 complex subunits (C1q, C1s, C1r) are strongly associated with SLE, 
and C4 and C2 are also genetically related to SLE. MBL deficiency has also been 
suggested to be a factor for SLE (Truedsson et al., 2007).  
 
Carcinoma cells are another type of modified host cells. Increased presence of 
complement inhibitors on carcinoma cells can result in the escape of carcinoma cells 
from immune responses. The expression of the membrane-bound complement inhibitors 
are present on various tumour cell lines. Furthermore, the expression of sialic acid 
residues is enhanced on certain malignant cells, and thus the binding of soluble 
inhibitors such as factor H is increased (Donin et al., 2003). 
 
The foreign pathogens such as bacteria and virus have evolved to be able to recruit 
complement inhibitors from the plasma, and express endogenous regulators that mimic 
the host complement regulators, and in this way these microbes protect themselves from 
host innate immune system. For example, Neisseria gonorrhoeae can express porin 1A 
(Por1A) protein which can bind to the complement inhibitor factor H, and weakly bind 
to FHL1 (Ngampasutadol  et al., 2008). The variola virus which causes the disease 
smallpox can express the smallpox inhibitor of complement enzymes (SPICE) to 
inactive human C3b and C4b (Rosengard et al., 2002). 
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In the alternative pathway of the innate immune system, factor H (FH) is an important 
regulator of the amplification cascade. FH consists of 20 globular SCR domains which 
are linked by 19 potentially flexible peptide links, and FH molecules form folded-back 
structures in solution. Different functions of FH are located in different domains, and it 
may form monomers or dimers. Zinc can facilitate the oligomerisation of FH. The 
polymorphism Tyr402His of FH is a major risk factor for developing age-related 
macular degeneration (AMD). The concentration of zinc in drusen which is a key 
feature of AMD is particularly high. How zinc causes FH to oligomerise, especially the 
Tyr402His variant, needs investigation.  
 
2.1 FH sequence and structure 
 
2.1.1 FH sequence and SCR domains 
 
The complete human FH sequence before secretion contains 1231 amino acid. The 
SWISSPROT accession number is P08603. The first 18 amino acids at the N-terminus 
is the signal peptide which is cleaved after the secretion of FH. Therefore, the mature 
form of human FH after secretion contains 1213 amino acid, and the numbering of the 
amino acid sequence starts from 19 (Figure 2.1 a) (Ripoche et al., 1988). The molecular 
weight (MW) of FH is 154 kDa (Aslam & Perkins, 2001; Fenaille et al., 2007). FH 
belongs to the RCA family which contains the complement regulators FH, FHL1, 
CFHR1-5, DAF, C4BP, MCP, CR1 and CR2. The RCA family proteins are 
characterized by the presence of a repeating motif called the SCR domain which 
contains about 60 amino acids (Section 1.5). SCR domains also exist in some non-RCA 
proteins such as C1r, C1s, MASP-1, MASP-2, C2, C6, C7, factor B and the blood-
clotting factor ΧΙΙΙ B subunit (FΧΙΙΙB) (Morikis & Lambris, 2005). FH consists entirely 
of 20 SCR domains arranged in tandem, and 19 flexible linkers between them (Figure 
2.1 a). The length of the linkers varies from three to eight residues (Figure 2.1 a). The 
sequence alignments of the SCR domains show that two cysteines (C
I and C
IV) are 
conserved at either end with another two cysteines (C
II and C
III) located between them. 
Another highly conserved residue tryptophan is present between C
III and C
IV, with an 
exception at SCR-10. There are some other residues such as proline, glycine and 
tyrosine conserved at different positions in the SCR sequences (Figure 2.1 a) (Aslam &   22
  Figure 2.1 FH sequence and SCR domains. (a) Sequence alignment of the SCR 
domains of FH. The consensus C
I, C
II, C
III, C
IV and Trp residues are highlighted in 
yellow. Other conserved residues are highlighted in blue. The position 402 is 
highlighted in red. The Define Secondary Structure Prediction (DSSP)-assigned β-
strand secondary structure regions are highlighted in grey, and labelled below the 
alignment. The 19 linkers are boxed. The nine potential glycosylation sites are circled. 
The disulphide bonds are notified by dashed and straight lines above the alignment. (b) 
Schematic diagram of the structure of a SCR domain. The β-strands 1-8 are notified by 
arrows. Disulphide bonds are indicated by thick grey dotted lines, and the hypervariable 
loop between β2 and β3 is indicated by a thick grey line (adapted from Morikis & 
Lambris, 2005).   23
Perkins, 2001; Morikis & Lambris, 2005; Saunders et al., 2006). Two disulphide bonds 
are formed in the pattern C
I - C
III and C
II - C
IV. The solved SCR structures show that 
there is no α-helix present, and up to eight β-strands in relatively constant positions 
form a scaffold-like β structure (Figure 2.1 b) (Morikis & Lambris, 2005). 
 
There are nine potential N-glycosylation sites in FH sequence, including Asn217 in 
SCR-4, Asn529 in SCR-9, Asn718 in SCR-12, Asn802 in SCR-13, Asn822 in SCR-14, 
Asn882 and Asn911 in SCR-15, Asn1029 in SCR-17, and Asn1095 in SCR-18 (Figure 
2.1 a). Except for the site at Asn217, eight sites are occupied. These eight sites are 
mainly glycosylated by biantennary disialylated glycans of 2204 Da in size (Fenaille et 
al., 2007).  
 
2.1.2 Structural studies of the SCR domains of FH 
 
Structures of several individual SCR domains or SCR domain groups within FH have 
been solved over the years by various methods including X-ray crystallography, nuclear 
magnetic resonance (NMR) and small angle X-ray scattering (SAXS) (Table 2.1). The 
first FH SCR structure solved was the structure of SCR-16 domain, and the method 
used was NMR (Norman et al., 1991). Since then, NMR has been used to determine the 
structures of SCR-15/16 (Barlow, et al, 1993), SCR-19/20 (Herbert et al., 2006), SCR-7 
(Herbert  et al., 2007), SCR-1/2, SCR-2/3 (Hocking  et al., 2008) and SCR-12/13 
(Schmidt  et al., 2010). Crystal structures have been determined for SCR-19/20 
(Jokiranta et al., 2006), SCR-6/7 in complex with sucrose octasulfate (Prosser et al., 
2007), the complex between SCR-1/4 and C3b (Wu  et al., 2009) and the complex 
between SCR-6/7 and Nerisseria meningitidis FH binding protein (Schneider et al., 
2009). SAXS combined with constrained modelling has been used to determine the 
structures in solution in physiological conditions for SCR-6/8 (Fernando et al., 2007), 
SCR-1/5, SCR-16/20 (Okemefuna et al., 2008), and SCR-1/20 (Aslam & Perkins, 2001; 
Okemefuna et al., 2009). 
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2.1.3 Structural studies of full-length FH  
 
The large size of FH, the 19 potential flexible peptide links between the 20 SCR 
domains and the existence of up to nine putative glycosylation sites have hindered the 
structural studies of full length FH by using X-ray crystallography and NMR (Perkins et 
al., 1991; Aslam & Perkins, 2001). It is difficult to predict the orientation between two 
adjacent SCR domains (Lehtinen et al., 2004). Although high resolution crystal or NMR 
structures have been determined for 13 out of 20 SCR domains so far through the 
studies of fragment of FH, the whole picture of full-length FH in solution cannot be 
obtained by simply joining those known SCR domain structures together. As shown by 
electron microscopy, most intact FH molecules are not extended, and they form 
different types of folded back structures (DiScipio, 1992). The combination of 
constrained X-ray solution scattering modelling, analytical ultracentrifugation (AUC) 
and homology modelling confirmed that the conformation of FH in solution is folded 
back, and revealed the medium-resolution structures of FH SCR-1/20 in solution for the 
first time (Aslam & Perkins, 2001; Perkins et al., 2005).  This is consistent with the fact 
that the structures of SCR-1/5, SCR-6/8, and SCR-16/20 in solution also show some 
degree of folding back (Fernando  et al., 2007; Okemefuna et al., 2008). Later, the 
structures of intact native FH in solution was investigated again using the same methods 
but with lower FH concentration, improved SAXS and AUC instrumentations, and more 
high resolution SCR domain structures. Improved medium-resolution structures of FH 
with a maximum length of 32 nm are then obtained (Figure 2.2 a). Electrostatic 
interactions contribute to the conformation of FH, as FH molecules become more 
elongated with increase in ion strength or pH. The oligosaccharides are found not to be 
significant in determining the conformation of FH (Okemefuna et al., 2009).  
 
2.2 Regulatory role of FH in the alternative pathway 
 
In the alternative pathway, the formation and activity of the amplification C3 convertase 
C bBb 3  is strictly controlled both in the fluid phase and on the surface of host cells or 
tissues. The regulator FH is an important and effective inhibitor of the amplification 
cascade (Zipfel et al., 2006). It acts as an inhibitor in three different ways. 
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Figure 2.2 Illustration of structure and functional domains of FH. (a) The best fitting 
solution structure (PDB entry code: 3GAV) of native full-length FH in physiological 
conditions obtained from X-ray solution scattering combined with constrained 
modelling (Okemefuna  et al., 2009). (b) Mapping of binding sites on the 20 SCR 
domains for the FH ligands: pathogen expressed proteins such as streptococcal M-
protein, FH binding proteins of N. meningitides (fHbp); polyanions such as heparin, 
sucrose octasulfate and sialic acid; C-reactive protein (CRP); potential self-association 
sites including SCR-6/8 and SCR-16/20; C3b. The eight oligosaccharides are shown as 
black forks. 
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Firstly, FH inhibits the assembly of the C3 convertase C bBb 3  by competing with factor 
B for binding to C3b. The function contributes to the discrimination by the alternative 
pathway between host cells and foreign cells. On host cells, polyanions such as sialic 
acids create a high affinity for FH, and therefore the alternative pathway is inhibited. By 
contrast, on foreign cells, a lack of polyanions results in a low affinity interaction 
between FH and C3b, and the binding of factor B to C3b is therefore favoured 
(Giannakis et al., 2001; Zipfel et al., 2006). 
 
Secondly, acting as a cofactor of factor I, FH inactivates C3b molecules. Factor I is a 
highly specific serine protease which is involved in the regulation of the C3 convertases. 
Using FH which is bound to C3b on host cells surfaces as a cofactor, factor I cleaves 
C3b to yield C3f and iC3b which is further degraded to C3c, C3dg and C3d, and thus 
C3b is permanently inactivated by factor I (Law & Reid, 1995; Zipfel et al., 2006).   
 
Thirdly, FH displays decay accelerating activity to destroy any existing C3 convertase 
C bBb 3 . If C3b forms the C3 convertase C bBb 3 , binding of FH together with other 
complement regulatory proteins will displace Bb from C3b, and therefore the C3b 
convertase C bBb 3  is destroyed (Rother, 1998; Zipfel et al., 2006). 
 
2.3 Ligands of FH 
 
2.3.1 Binding sites for C3b 
 
FH binds to multiple ligands. The binding sites for various ligands are located on 
different SCR domains (Figure 2.2 b). The regulation function of FH on the alternative 
pathway is mediated by the binding between FH and C3b. The first binding site for C3b 
identified is located in the N-terminal SCR-1/4. Studies have shown that SCR-1/4 is 
required and sufficient for the decay accelerating and co-factor activities of FH in fluid 
phase (Alsenz  et al., 1984; Kuhn & Zipfel, 1996). The dissociation constant (KD) 
between recombinant SCR-1/4 and C3b has been determined to be 11 µM by using 
surface plasmon resonance (SPR), and the crystal structure of the complex has been 
solved (Wu et al., 2009). FH SCR-1/4 does not bind to the inactive cleavage products of 
C3b, C3d and C3c, indicating that the reciprocal binding site on C3b is destroyed by the   28
cleavage (Jokiranta et al., 2000). The second C3b binding site has been mapped to the 
C-terminal SCR-16/20 and subsequently SCR-19/20, and the reciprocal binding site on 
C3b is located on the C3d part (Sharma & Pangburn, 1996; Jokiranta et al., 2000; 
Hellwage et al., 2002; Bhattacharjee et al., 2010). The KD of the interaction between FH 
SCR-19/20 and C3b is determined to be about 4 µM by using SPR (Schmidt et al., 
2008b). A third C3b-binding site specific for C3c has been suggested in the middle part 
of FH. It has been firstly suggested to be within or near SCR-6/10, and then SCR-12/14 
(Sharma & Pangburn, 1996; Jokiranta et al., 2000). SCR-10/12, or cooperation between 
two sub-sites including SCR-10 and the other within SCR-16/18 have also been 
hypothesised to be the locations (Schmidt et al., 2008a). SCR-6/8 has been suggested to 
be a weak binding site for C3b by using SPR (Schmidt et al., 2008b). Further evidence 
such as testing with appropriate constructs is needed for the mapping of the third C3b-
binding site.  
 
2.3.2 Binding sites for polyanions 
 
The interaction between FH and polyanion such as sialic acid and glycosaminoglycans 
(GAGs) is crucial for the surface recognition function of FH. Heparin is the most 
sulphated GAGs. There are at least two heparin binding sites in intact FH. The first 
heparin binding site in FH has been found within SCR-6/10, and subsequently been 
located in SCR-7 (Sharma & Pangburn, 1996; Blackmore et al., 1996). The crystal 
structure of FH SCR-6/8 with sucrose octasulfate which is an analogue of the GAGs 
revealed that SCR-6 and the linker between SCR-7 and SCR-8 also participate in glycan 
binding (Prosser et al., 2007). SCR-13 and SCR-9 have also been suggested to have 
heparin binding sites (Pangburn et al., 1991; Ormsby et al., 2004), but later studies have 
suggested the contrary (Blackmore  et al., 1996; Schmidt et al., 2008b). Another 
commonly approved heparin binding site is mapped to SCR-20 (Blackmore et al., 1998). 
The C-terminal polyanion- and C3b-binding region is necessary for intact FH to 
recognize and protect normal host cells bearing polyanion on the cell surface (Pangburn, 
2000; Pangburn, 2002; Oppermann et al., 2006). Sialic acid on the surface of serum 
resistant neisseria gonorrhoeae was proved to be able to bind SCR-16/20 part of FH, 
and therefore protect the microbe from complement attack in serum (Ram et al., 1998).  
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2.3.3 Binding sites for CRP 
 
C-reactive protein (CRP) is an acute phase protein with a MW of 115 kDa. Native CRP 
is a pentamer composed of 5 subunits, and the assembly is stabilised by the presence of 
2.5 mM Ca
2+ in plasma (Okemefuna et al., 2010). As mentioned in Section 1.2.1, CRP 
can activate the classical pathway by binding to the C1 complex. CRP has been reported 
to be able to inhibit the alternative pathway, which might be due to the recruitment of 
FH by CRP, but the mechanism of inhibition is still not clear (Mold et al., 1999). The 
removal of Ca
2+ can cause the CRP pentamer to dissociate to form modified CRP 
(mCRP) which is denatured and has functions different from the pentamer (Kinoshita et 
al., 1989). There is no firm evidence for the existence of mCRP in vivo (Okemefuna et 
al., 2010). The binding sites for CRP in FH have been originally located in SCR-7 and 
SCR-8/11 by using enzyme-linked immunosorbent assay (ELISA) and SPR (Jarva et al., 
1999; Giannakis, et al., 2003). However, later studies suggested that there is no such 
interaction because earlier observed FH-CRP interactions resulted from the use of 
denatured CRP (Bíró et al., 2007; Hakobyan et al., 2008). The latest study using AUC, 
SAXS and SPR confirmed the interactions between FH and native CRP, and two 
independent binding sites for native CRP are mapped in SCR-6/8 with a KD value of 3.9 
µM and SCR-16/20 with a KD value of 15.3 µM (Okemefuna et al., 2010). 
 
2.3.4 Self-association of FH 
 
The earliest studies of native FH showed that FH exists as monomer in solution (Sim & 
DiScipio, 1982). The dimerisation of native FH was firstly suggested in 1991. The MW 
of FH was determined to be 250 – 300 kDa at concentrations between 1 to 11 mg/ml in 
solution which almost doubled the MW calculated from the FH sequence, by using X-
ray solution scattering and neutron scattering. A V-shaped dimer model of two rods 
joined at an angle of 5° was proposed (Perkins et al., 1991). However, later gel filtration 
and electron microscopy studies showed no dimer form of native intact FH, although 
the harsh conditions used for electron microscopy might abrogate the dimerisation of 
FH (DiScipio, 1992). In 2001, native intact FH was investigated again by using X-ray 
solution scattering, neutron scattering and analytical altracentrifugation in 
concentrations from 0.7 to 14 mg/ml. FH was shown to be monomeric with a MW of 
147 kDa – 165 kDa in the physiological concentration range between 0.2 – 0.6 mg/ml,   30
and no concentration dependence of MW has been observed (Aslam & Perkins, 2001). 
On the other hand, various FH fragments have been demonstrated to self-associate. 
Fragments SCR-15/18 and SCR-15/20 were found to form some dimers by using non-
reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blotting analysis (Jokiranta et al., 2000). Fragment SCR-1/7 was observed to 
bind to intact FH by SPR, and the dissociation profile suggested that the complex is 
stable (Oppermann et al., 2006). Fragment SCR-6/8 in solution has been found to self-
associate weakly from AUC analysis, and a KD value of 40 µM was determined for the 
dimerisation of the His402 allotype of SCR-6/8 (Fernando et al., 2007). Also from AUC 
analysis, SCR-1/5 was found to be monomeric in solution, while SCR-16/20 exhibited a 
weak monomer-dimer equilibrium with a KD value of 16 µM (Okemefuna et al., 2008). 
Some studies suggested that polyanion such as dextran sulphate or heparin can induce 
FH to form tetramers by size-exclusion gel filtration and AUC, and the site that 
mediates this polyanion-induced self-association has been mapped in SCR-18/20 
(Pangburn et al., 2009). In Chapter 5 and Chapter 7 of this thesis, the evidence for 
progressive self-association of full-length FH and its implications for complement 
regulation and disease will be explained.  
 
2.3.5 Metal ligands for FH 
 
Metals have not been commonly considered as FH ligands. In 1980, it was reported that 
Zn
2+, but not Mg
2+, Mn
2+, Ca
2+, Co
2+, Ni
2+, all at 1000 µM, can inhibit the cleavage of 
C3b by factor I assisted by FH. This was demonstrated by fluid assays performed with 
0.065 mg/ml of C3b, 0.03 mg/ml of FI and 0.045 mg/ml of FH in 150 mM NaCl / 100 
mM sodium phosphate buffer, pH 7, incubated at 37 °C (Crossley & Porter, 1980). The 
inhibition of degradation of C3b by Zn
2+ was observed again by using fluid phase 
assays with 0.0014 mg/ml of 
125I-labelled C3b, 0.0014 mg/ml of FI, 0.0029 mg/ml of 
FH and 5000 µM of ZnCl2 in 150 mM NaCl / 2.5 mM Tris-HCl buffer (pH 7.5) 
incubated at 37 °C. In the same study, it has been suggested that FH and C3b interact 
with Zn
2+ with different affinities, whereas FI does not interact with Zn
2+, by using 
affinity chromatography on zinc chelate resin (Day & Sim, 1986). The zinc-induced 
oligomerisation of FH was firstly reported by X-ray solution scattering analyses of FH 
at concentrations of 2.7, 5.5, 8.2 and 10.9 mg/ml in 140 mM NaCl / 10 mM PIPES   31
[piperazine-N, N’-bis (2-ethanesulphonic acid)] buffer (pH 7.0) added with 10 to 500 
µM Zn
2+, and similar experiments showed that 100 µM Co
2+, Hg
2+, Mg
2+, Mn
2+ and 
Ni
2+ have no effect on FH. This suggested that the inhibitory effect of Zn
2+ reported 
originally is a result of zinc-induced rapid oligomerisation of FH (Perkins et al., 1991). 
However, it has been suggested that Zn
2+ at 100 – 500 µM enhances the FH activity and 
abolishes FH activity at 2000 µM and above, while Mg
2+, Ni
2+, Cu
2+, Co
2+, Fe
2+ at 1000 
µM or Ca
2+ at 3000 µM has no effect. This finding was concluded from fluid phase 
assays using 0.012 mg/ml C3b with trace amounts of 
125I-labelled C3b, 0.0051 mg/ml 
FI and 0.031 mg/ml FH in 150 mM NaCl / 50 mM Tris-HCl buffer (pH 7.4) incubated 
at 37 °C (Blom et al., 2003). The inhibitory role of zinc was investigated again later by 
incubating 75 ng/ml of 
125I-C3(NH3), 97 ng/ml of FI  and 310 ng/ml of FH in 10 mM 
potassium phosphate buffer at 37 °C. Zn
2+ inhibited the breakdown of 
125I-C3(NH3) by 
FI and FH at 20 or 100 µM, but did not have any effect on FI amidolytic activity 
without FH (Tsiftsoglou & Sim, 2004). This is consistent with the previous finding that 
Zn
2+ binding to FH but not to FI (Day & Sim, 1986; Tsiftsoglou & Sim, 2004). It is 
noticeable that all the fluid phase assays mentioned above were done with FH 
concentrations that are far lower than the physiological concentration (0.235 mg/ml - 
0.810 mg/ml in serum) (Neumann et al., 2003). The KD of the interaction between FH 
and Zn
2+ has not been obtained, and the zinc binding sites have not been identified. 
 
Four types of zinc binding sites have been identified in proteins: catalytic, cocatalytic, 
structural and protein interface. In the latter case, zinc sites are formed from ligands 
supplied by amino acid residues located at the binding surface between the two proteins. 
Such interactions can induce oligomerisation of the same protein or link two different 
proteins through intermolecular ligands (Auld, 2001). The most frequently observed 
coordination geometry of zinc binding sites is tetrahedral, and the sites  at protein 
interfaces often include surface His, Asp, Cys and Glu residues (Rulísek & Vondrásek, 
1998).  From analysis of zinc binding in known protein structures, the protein interface 
binding sites are primarily supplied by residues His, Glu and Asp, but sites containing 
Cys are also found, and β-sheets secondary structure predominately contribute to such 
ligands (Auld, 2001). Thus, the β-sheet-rich SCR domains of FH with His, Glu and Asp 
residues that are exposed on the surface could form potential zinc binding sites. 
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2.3.6 Other ligands of FH 
 
As mentioned in Section 1.7, to avoid complement attack from the host, various 
microorganisms have developed strategies to minimise the deposition of C3b on the 
pathogen surface. A streptococci bacterium can
 express type-specific surface proteins 
called M proteins which protect the microbes from phagocytosis by binding to FH and 
therefore down-regulating the opsonization mediated by C3b (Horstmann et al., 1988). 
The binding site for M protein in FH has been located in SCR-7 (Kotarsky et al., 1998). 
Site-directed mutagenesis has shown certain residues in SCR-7 that are commonly 
essential for binding of heparin, CRP and M protein (Giannakis et al., 2003). Another 
example of such microorganisms is Neisseria meningitidis. FH binding protein (fHbp) 
is a 27 kDa lipoprotein present on the surface of all strains of N. meningitidis. The 
binding site for fHbp is in SCR-6/7 of FH, and the KD of the interaction is about 5 nM 
(Schneider et al., 2009). In addition, FH is an adhesion ligand for human neutrophils. 
The presence of surface bound FH can enhance the neutrophil activities. The specific 
receptor on neutrophil cell surface for FH has been identified to be integrin 
alphaMbeta2 (CD11b/CD18) (DiScipio et al., 1998).  
 
2.4 FH expression and genetics 
 
2.4.1 FH biosynthesis 
 
Like the complement components C1r, C1s, C2 to C5, factor B and factor I, both FH 
and FHL1 are constitutively synthesised and secreted by the liver (Morris et al., 1982; 
Friese et al., 1999). Various amounts of both proteins are produced by different liver 
cell types such as hepatocytes and Kuffer cells (Schalf et al., 2001). Both FH and FHL1 
can also be synthesised locally at the sites of infection and inflammation by a wide 
range of extrahepatic cells such as endothelial cells, fibroblasts, myoblasts, mono-
nuclear phagocytes, neurons, glomerular mesangial cells, peripheral blood lymphocytes, 
glial cells and retinal pigment epithelial (RPE) cells (Friese et al., 1999; An et al., 2006; 
Chen  et al., 2007). Depending on the cell type, FH and FHL1 can be synthesised 
constitutively, and / or induced by cytokine mediators. Their expressions can be 
regulated differently depending on the cell type. Cytokines and inflammation mediators 
such as interferon-α (IFN- α), IFN-γ, interleukin-1 (IL-1), IL-2, IL-6, anti-inflammatory   33
agents (e.g. Dexamethasone), retinoid acid, phorbol myristate acetate and 
lipopolysaccharide are reported to be able to regulate the expression of FH and FHL1 
(Friese et al., 1999). In normal individuals, the concentration of FH varies from 235 to 
810 µg/ml in serum (Neumann et al., 2003). The level of FH is influenced by age, 
genetic and environmental factors (Esparza-Gordillo et al., 2004). 
 
2.4.2 FH gene 
 
As discussed in Section 1.5, FH is a member of the ‘regulators of complement 
activation’ (RCA) family. Its gene is located in the RCA gene cluster on chromosome 
1q32 (Figure 2.3 a) (Krushkal et al., 2000). The RCA gene cluster contains 60 genes, 
amongst which 15 genes encode for complement-related proteins. Those 15 genes are 
arranged within two DNA segments separated by a 14.59 cM long DNA which is not 
related to complement proteins. One DNA segment contains the genes encoding the FH 
family proteins including FH, CFHR3, CFHR1, CFHR4, CFHR2 and CFHR5, and the 
other DNA segments contains the genes encoding C4BPβ, C4BPα, C4BPαL1, 
C4BPαL2, DAF, CR2, CR1, MCPL1, CR1L1 and MCP. The FH gene is composed of 
23 exons and is 94 kb in length.  Exon 1 encodes for the un-translated 5’ end mRNA 
region and the 18 amino acid signal peptide of FH. Every other exon encodes for one 
SCR domain. There are two exceptions. The first one is that exon 3 and 4 together 
encode SCR-2. The second one is exon 10 which encodes exclusively for FHL-1 rather 
than FH (de Córdoba & de Jorge, 2008).   
 
2.4.3 FH family proteins 
 
The FH family proteins include FH, FHL1, as well as five FH-related proteins CFHR1, 
CFHR2, CFHR3, CFHR4 and CFHR5. Those closely related plasma glycoproteins are 
all mainly synthesised in the liver, and their genes arranged in tandem in the RCA gene 
cluster on chromosome 1q32 (Figure 2.3 a). Two transcripts, FH and FHL1, have been 
found for the FH gene, and another two transcripts, CFHR4A and CFHR4B, for the 
CFHR4 gene, as results of alternative splicing. Deletions within the FH and CFHR1-5 
gene region can cause a FH: CFHR1 hybrid gene and / or the deletion of the CFHR3 
and CFHR1 genes (Józsi & Zipfel, 2008).    34
 
Figure 2.3 Genetics of FH family proteins. (a) Arrangement of the RCA gene cluster 
and the composition of FH gene (adapted from de Córdoba & de Jorge, 2008). (b) 
Homology alignment of SCR domains among FH family proteins. Homologous SCR 
domains are aligned vertically, and the percentages of identity at the protein level to the 
corresponding FH SCR domain are notified in blue above the domains (adapted from 
Józsi & Zipfel, 2008).   35
The FH family proteins are exclusively composed of SCR domains. As discussed in 
Section 2.3.1 and Section 2.3.2, the functions of acting as a cofactor for factor I and 
accelerating the decay of C3 convertase are displayed by SCR-1/4 at the N-terminal of 
FH, whereas the surface binding and recognition functions are displayed by SCR-18/20 
at the C-terminal. Other FH family proteins are composed of four to nine SCR domains 
(Figure 2.3 b). FHL1 is another transcript of the FH gene, and contains SCR-1/7 of FH 
and a unique extension of four amino acids (Ser-Phe-Leu-Thr) at the C-terminal. 
Therefore FHL1 can regulate the complement cascades in a similar way as FH does. 
The homology study of SCR sequences of FH and CFH1-5 revealed that the central 
region (SCR-6/9) and surface binding region (SCR-18/20) of FH are conserved (Figure 
2.3 b). The homology of SCR domains implies similar ligand bindings and overlapping 
functions. For example, CFHR3, not CFHR4 has a domain homologous to SCR-7 of FH, 
and thus CFHR3, not CFHR4 can bind to M-protein and heparin. The lack of SCR-1/4 
of FH at the N-terminal in all CFHR proteins may explain the fact that CFHR proteins 
do not have complement cascade regulation functions, and the presence of the similar 
C-terminal region suggests the similar surface binding and recognition functions. The 
difference in binding affinities depends on the extent of homology between SCR 
domains. It is still not clear whether CFHR proteins cooperate or compete with FH in 
the complement regulation, or perform independent activities (Józsi & Zipfel, 2008).  
 
2.5 FH genetically related diseases 
 
Mutations, polymorphisms and large deletions in FH gene and FH related protein genes 
(Section 2.4.3) are related to several human diseases.  As discussed in Section 1.7, FH is 
one of the proteins that are genetically related to atypical haemolytic uraemic syndrome 
(aHUS), membranoproliferative glomerulonephritis type ΙΙ (MPGN ΙΙ), age-related 
macular degeneration (AMD) and Alzheimer’s disease (AD). It has been hypothesized 
that those diseases are caused by the mis-regulation of the complement system.  
 
2.5.1 FH and atypical haemolytic uraemic syndrome (aHUS) 
 
aHUS is a severe kidney disease that is characterized by thrombocytopenia, 
microangiopathic haemolytic anemia and acute kidney failure. The primary event of this 
disease is endothelial cell injury (Atkinson & Goodship, 2007). The mutations of FH   36
related to aHUS prevalently occur in the C-terminal region which is responsible for cell 
recognition and binding (de Córdoba & de Jorge, 2008).  The database http://www.fh-
hus.org showed an updated collection of aHUS-related FH mutations (Saunders et al., 
2006; Saunders et al., 2007). The mutant FH molecules showed weaker binding 
affinities to C3d part of C3b, heparin and endothelial cells in several cases (Manuelian 
et al., 2003; Józsi et al., 2006). In addition, deletion of the CFHR3 and CFHR1 genes 
and hybrid FH-CFHR1 gene caused by genomic deletion are also related to higher risks 
for developing aHUS (Zipfel et al., 2007; Venables et al., 2006). There are also five 
variants in CFHR5 associated with aHUS (Monteferrante at al., 2007). 
 
2.5.2 FH and membranoproliferative glomerulonephritis type ΙΙ (MPGN ΙΙ) 
 
MPGN ΙΙ is a rare kidney disease which is hallmarked by the presence of dense deposits 
within glomerular basement membrane (GBM) and the thickening of GBM. There are 
two types of FH mutations that are related to MPGN ΙΙ. The mutations of the first type 
can result in impaired FH secretion. Those mutations include those of essential 
consensus cysteine residues such as Cys431Ser, Cys673Ser and Cys959Tyr, and those 
of some other residues such as Arg127Leu. The second type includes mutations that 
cause reduced co-factor and decay accelerating functions of FH in plasma, such as a 
mutation that result in the deletion of Lys224 in SCR-4 (http://www.fh-hus.org). Further 
more, three variants on CFHR5 gene have also been reported more frequent in MPGN ΙΙ 
patients than in healthy populations (Abrera-Abeleda et al., 2006).  
 
2.5.3 FH and age-related macular degeneration (AMD) 
 
AMD is a leading cause of visual impairment and blindness in the elderly in the 
Western world (Hageman et al., 2005; Klein et al., 2005). Between 20 and 25 million 
people are affected worldwide, a figure that will triple with the increase in the ageing 
population in the next 30-40 years. According to the World Health Organization, due to 
AMD, 8 million people have severe blindness. Between 182,000 and 300,000 people in 
the United Kingdom are blind or partially sighted as a result of AMD (Chopdar et al., 
2003). AMD is characterised by degenerative and neovascular changes which cause 
central field visual loss, and occur at the interface between the neural retina and the 
underlying choroid. At this location are the retinal photoreceptors, the retinal pigmented   37
epithelium (RPE), Bruch’s membrane (BM), which is an extracellular matrix layer 
interposed between the retinal pigment epithelium (RPE) and the choroidal vasculature, 
and a network of choroidal capillaries (Hageman et al., 2005; Klein et al., 2005).  
 
A key feature of AMD is the appearance of sub-retinal pigment epithelial deposits 
(sRPEds) that can be focal (drusen) or diffuse (basal linear and laminar) in the early 
stages of this disease, and those extracellular deposits accumulate within the BM (Bird, 
1992; Bird et al., 1995; Guymer & Bird, 1998). The compositions of drusen include 
remnants of the RPE, dendric cell processes, oxidized lipids, carbohydrates, and over 
200 aggregated proteins such as tissue metalloproteinase inhibitor 3, clusterin, 
vitronectin, serum albumin, crystallin, immunoglobulins and a range of complement 
components such as C3 and C9, the membrane attack complex, activators and regulators 
such as FH (Figure 2.4 a) (Mullins et al., 2000; Crabb et al., 2002; Hageman et al., 
2005; Bok, 2005). The PRE is a local source for FH and FHL1 (Hageman et al., 2005).  
It has been suggested that oxidative injury and local complement activation related 
inflammation are associated with the formation of drusen (Crabb et al., 2002; Hageman, 
et al, 2001; Anderson et al., 2002; Hageman et al., 2005). High mM concentrations of 
zinc have also been found in sRPEds and Bruch’s membrane (Lengyel et al., 2007). The 
function of zinc in the retina and its possible relations to the pathology of AMD will be 
discussed in Chapter 3. The presence of FH and high concentration of zinc in drusen 
provides a possibility that the interation between FH and zinc (Section 2.3.5) might be 
involved in the formation of drusen. The investigations on this possibility will be 
explained in Chapter 6 and Chapter 8. 
 
Due to the similarity between the manifestations of MPGN ΙΙ and that of AMD, FH has 
been investigated as a prime candidate protein which is genetically related to AMD. A 
common polymorphism of FH, Tyr402His (Figure 2.4 b), was identified as a major risk 
factor for developing AMD. It is associated with 50 % of AMD cases (Klein et al., 2005; 
Haines  et al., 2005; Hageman et al., 2005; Edwards et al., 2005). The Tyr402His 
polymorphism is translated from a cDNA variant of FH, T1277C in exon 9 (Goodship, 
2006). Residue 402 is located in SCR-7 which contains a binding site for heparin, CRP 
and for various microbial antigens (Giannakis et al., 2003; Ormsby et al., 2006). The 
NMR structures of Tyr402 SCR-7 and His402 SCR-7 have been shown to be nearly 
identical, and the 402 side chain was observed to be solvent-exposed and far from the   38
 
 
Figure 2.4 FH and AMD. (a) Immunocytochemistry of a drusen (D) stained with 
antibodies against FH (green), C5b-9 membrane attack complex (orange) and 
autofluorescent lipofuscin granules (blue). FH staining is also visible in the lumen (L) 
of the capillaries (Taken from Bok, 2005). (b) NMR structures of FH SCR-7. The 
structure of Tyr402 SCR-7 is notified in blue (PDB entry code: 2JGX) and that of 
His402 SCR-7 is notified in red (PDB entry code: 2JGW). The residues including 
Glu395, Tyr/His402, Asp413, His417 and Glu433 are labelled, as residues His, Glu and 
Asp exposed on the surface have potential to contribute to form zinc binding sites.   39
interfaces with the neighbouring SCR-6 or SCR-8 (Herbert et al., 2007). In addition, the 
solution structure of FH SCR-6/8 in physiological conditions have also been solved by 
using a combination of solution scattering, analytical ultracentrifugation and modelling 
studies, and no conformational difference was detected between the Tyr402 and His402 
forms of FH SCR-6/8 (Fernando et al., 2007). However, due to the flexibility of the 
intact FH molecules and their folded back structures in solution, the impact of the 
change from the surface-exposed tyrosine to histidine at position 402 on the structure of 
full length FH needs to be studied (Chapter 7). 
 
Since the change from tyrosine to histidine near the binding sites may influence the 
binding of the ligands and thus leads to a dysfunctional FH, studies have been focused 
on comparing the binding affinities of the Tyr402 and His402 allotypes of FH with 
various ligands. The single domain recombinant His402 SCR-7 showed significant 
weaker binding than Tyr402 SCR-7 did to a heparin affinity column and to defined-
length sulphated heparin oligosaccharides employed in gel mobility shifts assays 
(Herbert et al., 2007). Accordingly, the Escherichia coli expressed recombinant His402 
FH SCR-6/8 showed weaker binding to a heparin affinity column than Tyr402 FH SCR-
6/8 did (Clark et al., 2006). However, equal binding affinities to heparin have been 
observed for the two forms of FH SCR-6/8 by using similar methods but Pichia pastoris 
expressed recombinant FH fragments, and also for two forms of full-length FH purified 
from human plasma (Herbert et al., 2007). The difference between the heparin bindings 
of FH SCR-6/8 and full-length FH might be due to the existence of other GAGs binding 
sites in the C-terminal SCR-20 domain (Section 2.3.2). In the context of FH binding to 
CRP, the His402 form of full-length FH, FHL1, recombinant FH SCR-5/7 and FH SCR-
6/8 showed reduced affinity to CRP measured by SPR and ELISA (Schmidt et al., 
2008a). As mentioned in Section 2.3.3, controversy has been raised by later studies 
suggested that the FH only interacts with CRP when native CRP pentamers disassociate 
by removing Ca
2+ (Bíró et al., 2007; Hakobyan et al., 2008). However, the latest study 
using AUC, SAXS and SPR confirmed the interactions between FH and native CRP, 
and that the His402 form of recombinant FH SCR-6/8 is a weaker binder (Okemefuna et 
al., 2010). Another supporting evidence for this ‘FH-CRP hypothesis’ is that higher 
level of CRP is present in the choroid with the risky His402 form of FH, although this 
could be a result of chronic inflammation which is a by-product of the defect 
complement regulatory function of FH (Johnson et al., 2006). In the context of C3b   40
binding, according to a SPR study, the two forms of recombinant FH SCR-6/8 bind to 
C3b with approximately same weak affinity (Schmidt et al., 2008b). Indeed, in another 
study both forms of full-length FH and FHL1 showed similar binding to C3b as 
determined by ELISA (Skerka et al., 2007). The deoxyribonucleic acid (DNA) and the 
extracellular matrix proteoglycan fibromodulin (FMOD) have also been identified as 
FH ligands which bind to SCR-6/8 part of FH. In one study the Tyr402 form of FH 
SCR-6/8 bound stronger to FMOD but weaker to DNA and necrotic cells than the 
His402 form of FH SCR-6/8 (Sjöberg et al., 2007). The His402 form of both full-length 
FH and FHL1 exhibited reduced binding to RPE cells and endothelial cells. The two 
forms of full-length FH and FHL1 showed similar cofactor activity in C3 degeneration 
in fluid phase, although the His402 form of FHL1 displayed weaker regulatory activity 
at the Chinese hamster ovary cell surface (Skerka et al., 2007). Although FH itself 
(Section 2.3.4) and Zn
2+ ( Section 2.3.5) are also FH ligands and abundant Zn
2+ is 
present in drusen, very few studies have been focused on comparing these properties 
between the Tyr402 form and His402 form of FH. In 2007, an AUC study suggested 
that the His402 form of FH SCR-6/8 can self-associate slightly greater than the Tyr402 
form. The effects of the Tyr402His polymorphism on the self-association properties of 
full-length FH will be discussed in Chapter 7. This polymorphism introduced a surface-
exposed histidine residue to SCR-7 which might contribute to form a zinc binding sites 
(Section 2.3.5), and its effects on zinc binding properties of FH and the implications for 
AMD will be discussed in Chapter 8.   
 
In addition, other polymorphisms of FH such as c.59-18insTT in intron 2, Ile62Val in 
SCR-1, Ala307Ala in SCR-5 and Ala473Ala in SCR-8 have also been found to be risk 
factors for developing AMD (http://www.fh-hus.org). One recent study is focused on 
comparing the Ile62 and the Val62 form of full-length FH, and it suggested that the Ile62 
form binds better to C3b and has stronger cofactor activity in fluid phase and surface bound 
C3 degeneration, based on ELISA and SPR analyses (Tortajada et al., 2009). It has been 
suggested that the deletion of CFHR3 and CFHR1 genes contributes to a lower risk for 
developing AMD (Hughes et al., 2006; Hageman et al., 2006). Until now, the molecular 
mechanism for the pathology of AMD is not clear.  
   41
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Three 
 
Zinc in the retina 
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3.1 Composition of the retina in the eye 
 
3.1.1 Structure of the eye 
 
The human eye is an approximate sphere which is about 2.5 cm in diameter and has a 
volume of 6.5 ml, but it actually contains two spheres including the smaller one, cornea, 
and the larger one, sclera (Figure 3.1). The coat of the eye consists three main layers. 
The outer layer is the fibrous coat formed by the cornea and sclera. The transparent 
cornea and associated tear film are responsible for most of the refraction of the eye. The 
sclera consists of dense irregular connective tissue and elastic tissue which make the 
sclera strong and flexible enough for protecting the intraocular contents and maintaining 
the global shape of the eye. The middle layer is the uvea tract which is composed of the 
choroid, ciliary body and iris. The iris is a thin circular disk which mimics the 
diaphragm of a camera. The middle opening of iris is the pupil which can change size to 
regulate the amount of light coming into the eye. The ciliary body functions together 
with the zonules to change the optic power of the lens (accommodation), and secretes 
the aqueous humour which fills the space between the lens and the cornea. The choroid 
is a vascular connective tissue which mainly functions to nourish the retina. The inner 
layer is the retina which is responsible for detecting lights in the retina image and 
converting the light energy into neural impulses that are transmitted to the brain. The 
contents surrounded by the coat contain the lens and the transparent media including the 
aqueous humour and the vitreous body. The lens can change shape and thus alter the 
refractive index of the light to focus on the retina and give a clear image. The posterior 
chamber and the anterior chamber are filled with the transparent aqueous humour which 
is essential for the transportation of the necessary metabolites to the lens and cornea and 
for the maintenance of intraocular pressure. The largest cavity in the eye, the vitreous 
cavity, contains vitreous humour which is a transparent viscoelastic gel. The vitreous 
humour is almost cell-less, but hyalocytes, the main cell types in the vitreous humour 
which are active phagocytes, are occasionally present (Oyster, 1999; Forrester et al., 
2002). 
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3.2.2 Structure of the retina  
 
The retina consists of two main layers. The outer layer is the retinal pigment epithelium 
(RPE), and the inner layer is the neurosensory retina. The RPE lies between the outer 
segments of the photoreceptor layers of the sensory retina and the Bruch’s membrane 
(BM). The BM is a very thin extra cellular matrix (2 µm to 3 µm in thickness). It is 
formed by the basement membranes of the RPE and choroidal endothelium, and a 
central layer composed of interlaced elastic fibers sandwiched between two layers of 
collagen fibers. The BM limits the passing of fluid between the choroid and the RPE, 
and gradually thickens with age (Oyster, 1999). The RPE is a single continous layer of 
cuboidal epithelial cells which is not directly involved in the neural events of vision. 
The RPE forms the blood-retina barrier, a selectively permeable barrier which controls 
the fluid flow between the neurosensory retina and the choroid. The RPE produces 
melanin which can absorb excess light energy and thus reduces the scattering of light in 
the eye. The RPE can also phagocytise the rod outer segments, and transport and store 
vitamins, especially vitamin A and metabolites. Among any cell layer in the human 
body, the RPE faces one of the strongest oxidative stresses (Federman et al., 1994).   
 
The neurosensory retina has been shown with nine layers, and it contains several 
different cell types of which neural cells predominate (Figure 3.2). Photoreceptors form 
four layers of the neurosensory retina. Two kinds of photoreceptors, rods and cones, are 
present in the human retina. Their outer and inner segments form the photoreceptor 
layer, the tight junctions between photoreceptors and Müller’s cells form the external 
limiting membrane, their nuclei form the outer nuclear layer, and their axons and 
terminals form the outer plexiform layer. The inner nuclear layer consists of the nuclei 
of the cells including bipolar cells, horizontal cells, most of amacrine cells, displaced 
ganglion cells, and interplexiform cells. The inner plexiform layer is composed of the 
interlaced dendrites of ganglian cells and the cells in the inner nuclear layer, and it 
contains multiple sublayers. The ganglion cell layer consists of the cell bodies of 
ganglion cells and displaced amacrine cells. Müller’s cells are the main cell types of the 
ganglion cells. The next layer is the nerve fiber layer which is formed by the axons of 
ganglion cells. The internal limiting membrane contains the terminal expansions of 
Müller’s cells which extend to the photoreceptor layer. Functionally speaking, the 
photoreceptors contain photopigments such as rhodopsin in the outer segment which   45
 
 
Figure 3.2 Layers of human retina. (a) A section of human retina which shows its 
organizations. Layers are labelled at the corresponding positions (adapted from 
Federman et al., 1994). (b) Different functions of neural cells in certain layers of the 
retina in the phototransduction (Taken from Guyton & Hall, 2006).    46
can absorb light, and thereafter the photoreceptors produce chemical signals which set 
off the phototransduction cascades. The signals produced by the photoreceptors are 
transmitted to the bipolar cells and subsequently to the ganglion cells by making 
synaptic contacts, and finally the signals are conveyed to the brain. This pathway is 
defined as the vertical pathway in the retina (Figure 3.2 b). There are also two levels of 
lateral pathways. The outer level is composed of horizontal cells, and the inner level is 
formed by amacrine cells. The horizontal cells and the amacrine cells make connections 
between the vertical pathways, and transform the signal in the vertical pathways from 
the amount of light to the illumination contrast between photoreceptors and their 
neighbours. In addition, there is another pathway called the recurrent pathway which is 
made up of the interplexiform cells which can received input signals from bipolar cells 
and amacrine cells in the inner retina and give output signals to horizontal cells in the 
outer retina. The recurrent pathway might play a role in adjusting the sensitivity of the 
retina (Oyster, 1999).  
 
3.2 Zinc in the eye 
 
3.2.1 Distribution of zinc in the human body 
 
Zinc is an important metal for the growth of plants and animals, and it is the second 
most abundant trace mineral in the human body. The normal content of zinc in the 
human body is about 2 g. Most zinc in the human body is intracellular, and the organs 
that contain relatively high zinc concentrations are the muscle, skin, liver, prostate 
gland, bones and eye (Karcioglu, 1982; Grahn et al., 2001). The average concentration 
of zinc in plasma is 12.7 µM (AREDS Research Group, 2002). Most of zinc in plasma 
is bound to various proteins. For example, 70-85% zinc in plasma is bound to serum 
albumin which has been considered as the major zinc transporter in plasma (Lu et al., 
2008). It has been shown that only 2-8% (0.25 – 1.02 µM) of zinc in plasma is free or 
chelatable or histochemically reactive (Blom et al., 2003). The RPE and choroid can 
take up and retain zinc from the blood (Newsome et al., 1992). Ocular tissues contain 
unusually high concentration of zinc. In human ocular tissues, the zinc concentrations in 
descending order are 472 µg/g of dry tissue in the RPE and choroid, 464 µg/g in the 
retina, 227 µg/g in the ciliary body, 132 µg/g in the iris, 113 µg/g in the optic nerves, 49 
µg/g in the sclera, 41 µg/g in the cornea and 21 µg/g in the lens (Galin et al., 1962).  It 
has been suggested that if zinc is distributed in retina in the same way it is distributed in   47
the brain, then only 10 % of retinal zinc is free or loosely bound to proteins (Ugarte & 
Osborne, 2001).  
 
3.2.2 Putative functions of zinc in the retina 
 
Although zinc is certainly important for the normal function of the retina, the reason for 
this is not well understood. However, some studies have provided evidence for several 
putative roles for zinc in the retina.  First of all, zinc has been suggested to be able to 
interact with vitamin A which is taken up by the RPE and is crucial for the activation of 
rhodopsin and thus the detection of light in the outer segments. Zinc also interacts with 
taurine, a free amino acid that is an essential neurochemical factor in the visual system, 
and therefore is involved in the normal functions of the retina. Secondly, zinc is 
commonly present in the disc membrane which is a component of the outer segment and 
is developed as obtrusions of the plasma membrane at the outer segment base. Since 
zinc is important for the normal function of the plasma membrane, it might be involved 
this way in the function of the photoreceptors. Thirdly, zinc has been reported to 
interact with rhodopsin and enhance its phosphorylation which initiates the 
phototransduction of rods. One supporting study found that zinc is mainly located in the 
photoreceptor perikarya in the outer nuclear layer and the RPE in the dark-adapted 
retina, but is translocated into the outer and inner segments in the light-adapted retina. 
The shift of the zinc location may suggest that zinc is involved in primary 
photochemical events. In addition, zinc might function as a regulator of synaptic 
transmission, because concentrated zinc has been found in the synaptic terminal regions 
of photoreceptors. Zinc has also been reported to be capable of modulating the response 
to the neurotransmitter γ-aminobutyric acid (GABA), a major inhibitory 
neurotransmitter, in horizontal cells, bipolar cells and ganglion cells. Furthermore, 
another hypothesised role of zinc is to serve as an antioxidant in the retina which is 
under intense oxidative stress, since zinc can protect thiol groups from oxidation and 
inhibit the production of reactive oxygen species by transition metals in some other 
tissues (Ugarte & Osborne, 2001; Grahn et al., 2001). However, in contrast to all the 
positive roles that zinc might play, exposure of the retinal tissue to excess amount of 
free zinc (>20 µM) can induce cell damage, as proved in vitro and in vivo. The RPE 
cells can accumulate zinc and prevent extra zinc from entering the neurosensory retina, 
but under stimuli such as light, the RPE cells can release protein-bound zinc to become  
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free zinc into the extracellular space in the neurosensory retina in an exaggerate manner 
and therefore cause damage (Ugarte & Osborne, 2001). 
 
3.3 Zinc and age-related macular degeneration (AMD)  
 
3.3.1 Main features of AMD 
 
The macula is a clinical term that defies a circular zone with a radius of about 3 mm 
centred on the fovea, the pit in the central retina which allows for the maximum vision 
acuity (Forrester et al., 2002). AMD has the worst effects in this central region (Young, 
1987). Two different kinds of classification schemes have been developed to classify 
the severity levels and progression stages of AMD. The first one needs detailed 
photographic review of the retina (Davis et al., 2005). The second one is a simplified 
scale which classifies the progression of AMD into early, intermediate and advanced 
stages based on the size of drusen (Section 2.8) and the level of hypopigmentary and 
hyperpigmentary changes of the RPE. Early AMD is featured by multiple small drusen 
(< 63 µm) and intermediate drusen (between 63 µm and 125 µm) with no evidence for 
advanced AMD. Intermediate AMD is featured by extensive intermediate drusen and 
large drusen (≥ 125 µm) with no evidence for advanced AMD (Figure 3.4 a). Advanced 
AMD is characterised by the presence of geographic atrophy (dry AMD) or neovascular 
AMD (wet AMD). Geographic atrophy involves the retinal depigmentation in a sharp 
discrete area at least 175 µm in diameter in the centre macula and visible choroid 
vessels without the features of neovascular AMD in the same eye, and the progression 
of vision loss is gradual (Figure 3.4 b). Neovascular AMD is characterized by the serous 
or haemorrhagic detachment of the RPE or the neurosensory retina, the occurrence of 
subretinal fibrous tissue or fibrosis, and the presence of fluid (exudates or blood) in the 
extracellular space between the RPE and the neurosensory retina (Figure 3.4 c). The 
onset of vision loss in neovascular AMD is acute (Ferris  et al., 2005). Drusen, a 
hallmark of early AMD, lie between the RPE and Bruch’s membrane, and may be 
‘hard’ or ‘soft’. Hard drusen are small and globular, and have discrete margins. Soft 
drusen are larger with indistinct edges, have a softer consistency, and are able to 
enlarge, break and spread. While hard drusen are a relatively common feature of retinal 
senescence (unless becoming numerous), soft drusen are more associated with the 
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development of advanced AMD (Figure 3.4 d) (Young, 1987; Gehrs et al., 2006). The 
strongest risk factor for developing AMD is age. Other risk factors such as exposure to 
sunlight, cigarette smoking, ethnic origin, blue iris colour, and several genetic factors 
have also been suggested (Coleman et al., 2008). 
 
3.3.2 Zinc supplements and AMD 
 
It is unlikely that systematic concentration change in zinc will lead to a significant 
change in the extracellular zinc concentration in retina, as only 0.2 % of zinc in blood 
will have access to the retinal extracellular space (Ugarte & Osborne, 2001). However, 
because of the possible antioxidant role of zinc in retina, many studies have focused on 
the relationship between zinc deficiency and AMD. The content of zinc and 
metallothioneins (which are zinc binding proteins in the RPE cells) are reduced in the 
human RPE with signs of AMD (Newsome  et al., 1995; Tate et al., 1993). In 
neurosensory retina, the content of zinc showed significant decreases as age increased 
(Wills et al., 2008). Various studies on the effect of zinc supplement on patients with 
AMD gave controversial results and have not clarified the issue. Among those studies, 
the Age-Related Eye Disease Study (AREDS) is a large-scale randomized, placebo-
controlled, clinical trial of the effects on AMD of high-dose supplementation with the 
antioxidants vitamins C and E and β carotene, and zinc with copper, with a 5-year 
follow-up. According to the findings of AREDS, the average serum zinc level of AMD 
patients raised from 12.7 µM to 14.7 µM after a 5-year daily supplement with 80 mg of 
zinc and 2 mg of copper (AREDS Research Group, 2002). A supplement with zinc 
alone, or with zinc together with vitamins C and E and β carotene reduced the risk for 
progression to advanced AMD, while supplement with only vitamins C and E and β 
carotene had no apparent improvement (AREDS Research Group, 2001a; AREDS 
Research Group, 2001b). Therefore this study recommended that patients with 
intermediate AMD or advanced AMD in one eye take the supplement with zinc together 
with vitamins C and E and β carotene. An interesting follow-up study genotyped the 
AREDS participants for the polymorphism Tyr402His in FH, and found that the 
treatment response to the AREDS-recommended supplement was influenced by this 
polymorphism. This supplementation correlated with a smaller reduction to progression 
of AMD in patients with high-risk homozygous His402 allotype of FH than in patients 
with the low-risk homozygous Tyr402 allotype of FH (Klein et al., 2008).    52
 
3.3.3 Zinc and drusen 
 
Zinc contributes to the formation of deposits in some neurodegenerative diseases such 
as Alzheimer’s disease. A high level of zinc has been detected in drusen in AMD by 
using microprobe synchrotron X-ray fluorescence (which was used to measure the total 
zinc concentration), and a zinc specific fluorescence sensor (which can visualize free 
zinc) (Figure 3.5). The average concentration of the total zinc present was determined to 
be 494 part per million (ppm) (predicted to be equivalent to 7.6 mM) in drusen in the 
macula and 252 ppm (3.9 mM) in drusen in the periphery. The fluorescence labelling 
confirmed the presence of free zinc in drusen, although the concentration of free zinc 
cannot be measured. The most likely sources of this high level of zinc in drusen are the 
RPE and the choroid. Considering the beneficial effects of zinc supplementation on the 
progression of AMD (Section 3.3.2), the increase in zinc concentration in drusen might 
have various effects on retina affected by AMD. It is of interest that some zinc binding 
proteins such as β-amyloid, crystallines, serum albumin and FH are also present in 
drusen (Crabb et al., 2002). The causes and functions behind the accumulation of zinc 
in the BM and drusen is not clear. The interaction between zinc and FH and its 
implication for AMD will be discussed in Chapters 6 and Chapter 8.    53
 
 
Figure 3.5 Detection of high level of zinc in drusen using fluorescent labelling (left 
panels) and microprobe synchrotron X-ray fluorescence (right panels). The labelling of 
free zinc (left panels) correlates well with the presence of total zinc accumulation (right 
panels) (adapted from Lengyel et al., 2007).   
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Chapter Four 
 
Methodology:  
Analytical ultracentrifugation, solution scattering and surface plasmon resonance 
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This chapter outlines the background to three major techniques used in this thesis. 
These are analytical ultracentrifugation (AUC), solution scattering and surface plasmon 
resonance (SPR).  
 
4.1 Analytical ultracentrifugation (AUC) 
 
Analytical ultracentrifugation (AUC) is a low-resolution technique for characterizing 
the solution-state behaviour of macromolecules by using the effects of centrifugal 
forces. It is used to check sample purity, characterise assembly and disassembly 
mechanisms of macromolecules, determine stoichiometries and conformations of 
macromolecule, and measure molecular weight, equilibrium constants and 
thermodynamic parameters (Cole & Hansen, 1999; Harding & Winzor, 2001). The 
advantages of this method are: i) its ability to study macromolecules in conditions close 
to physiological conditions; ii) easy access to the instruments within biochemical 
laboratories; iii) complementing NMR and crystallography for conformational analysis 
of macromolecules; iv) the ability to apply of constrained structural modelling to clarify 
the macromolecular structures. Two complementary views of macromolecular 
behaviour in solution can be obtained by using AUC, sedimentation velocity (SV) and 
sedimentation equilibrium (SE).  
 
4.1.1 Instrumentation 
 
An XL-A or XL-I analytical ultracentrifuge is composed of an ultracentrifuge and an 
optical detection system for detecting the sample concentration distribution during 
sedimentation. An ultracentrifugation rotor has eight (AnTi50 rotor) or four (AnTi60 
rotor) holes which accommodate the ultracentrifuge cells. Each cell contains one 
centrepiece that contains two or six channels that hold the sample solutions and 
reference buffers. Therefore, several samples can be analysed at once in an analytical 
ultracentrifuge. The centrepieces can be made of tough materials such as epoxy, 
anodized aluminium or titanium. The distributions of macromolecules in the sample are 
monitored in real time by the optical detection system. There are three different kinds of 
optical measurements, absorbance, interference and fluorescence (Cole & Hansen, 
1999). Different optical systems have different characteristics, and thus are suitable for 
measurements of different samples.   56
  
4.1.1.1 Absorbance optical system 
 
 In the ProteomeLab XL-A system, the monochromator is based on a scanning UV/VIS 
absorbance optical system which contains a xenon flashlamp and a spectrophotometer 
for measuring sample concentration at wavelengths ranging from 190 to 800 nm. The 
absorbance optical system provides sensitive and selective solute detection, and is 
especially sensitive to macromolecules containing strong chromophores, such as 
proteins and nucleic acid, and samples that contain non-dialyzable detergents (Cole & 
Hansen, 1999; Beckman CoulterTM ProteomeLab
TM XL-A/XL-I Protein 
Characterization System Instruction Manual, 2003). The absorbance value obtained 
from the spectrophotometer is proportional to the solute concentration under the 
conditions where the Beer-Lambert law  cl A ε =  applies, where A is the absorbance 
value, ε is the weight extinction coefficient of the solute, c is the weight concentration 
of the solute, and l is the optical pathlength (1.2 cm for the standard centerpieces). The 
absorbance optical system is sensitive enough to obtain good quality data from samples 
which generate no less than 0.1 Optical Density (OD) signal, and the best range of 
absorbance values is from 0.2 to 1.0 OD for the samples. The wavelength of the 
monochromator can be set between 190 and 800 nm depending on the properties of the 
samples, on the condition that the absorbance of the solvent in the samples at the 
operating wavelength should be less than about 0.5 OD. The signal-to-noise ratio in this 
system is about 100. The noise is usually random, neither radially-independent nor 
time-independent. The distance between each obsorbance data point is 20 to 50 µm. The 
time required for one complete scan is 60 to 300 seconds, which is the longest among 
the three optical systems. This might be a problem for sedimentation velocity 
experiments as the long scan times limit the number of scans obtained before the solute 
reaches complete sedimentation (Cole et al., 2008).  
In the scanning UV/VIS absorbance optic system, the light coming from the xenon 
flashlamp reaches a toroidally curved diffraction grating which varies the wavelength 
and collimates the light. Then before the light passes through the cell, its intensity is 
measured by an incident light detector which normalizes the variations of lamp intensity 
among different flashes.   The ultracentrifuge cells house samples and reference buffers. 
When the rotor spins, the photomultiplier tube, a light detector beneath the   57
ultracentrifuge, firstly measures the light intensity passing through the reference section 
in the cell, and then on the next rotation, the light intensity passing through the sample 
sector is measured. The difference between two signals is then converted into an 
absorbance value by the system software (Figure 4.1) (Beckman CoulterTM 
ProteomeLab
TM XL-A/XL-I Protein Characterization System Instruction Manual, 
2003). 
 
4.1.1.2 Interference optical system 
 
In the ProteomeLab XL-I system, the monochromator comprises a Rayleigh 
interference optical system added to the XL-A, and therefore the XL-I can obtain data 
using both kinds of optical measurements. The XL-I Rayleigh interference optical 
system is composed of a laser diode light source, imaging optics, and a charge-coupled 
device (CCD) detector. A single beam of collimated light is produced by a laser diode 
light source which is attached to the absorbance system monochromator. Two separated 
beams are produced by passing the single beam of light through a pair of parallel slits at 
the bottom of the laser source and just above the rotor. One beam passes through the 
sample sector in the cell, and another passes through the reference (buffer) sector. Then 
a fringe pattern is formed. If the same solutions are present in both sectors, an 
achromatic fringe will be produced along the optical axis since no refraction of light 
occurs. In cases that the sample solution contains solute and solvent with different 
refractive indices while the reference solution only contains solvent, the achromatic 
fringe will shift. During ultracentrifugation, in the sample sector, both sedimentation 
and diffusion of solute occur, and the difference of refractive index varies at different 
radial positions due to different concentrations. Therefore, the achromatic fringe shifts 
accordingly to the distribution of the concentration of solute, which is known as fringe 
displacement. The fringe pattern is detected by the CCD detector, via the imaging optics 
which includes a series of lenses and mirrors in the interference optical system. After a 
Fast Fourier transformation (FFT) performed by the system software, the digital data 
from the camera is displayed as a plot of fringe displacement versus radius (Beckman 
Model XL-A/XL-I Analytical Ultracentrifuge Optima
TM Series Training Guide, 1998; 
Beckman CoulterTM ProteomeLab
TM XL-A/XL-I Protein Characterization System 
Instruction Manual, 2003). 
   58
 
 
Figure 4.1 Schematic diagram of the scanning UV/VIS absorbance optical system 
(Taken from Beckman Model XL-A/XL-I Analytical Ultracentrifuge Optima
TM Series 
Training Guide, 1998) 
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The vertical displacement of the fringes ∆Y is dependent on the refractive index 
difference, ∆n (
dc
dn
c n n n reference sample = − = ∆ ), according to the equation: 
λ λ
dc
dn
lc n l
Y =
∆
= ∆  
Where  l is the optical pathlength (1.2 cm for the standard centerpieces), λ is the 
wavelength of light (670 nm for the Reyleigh interference optics), c is the weight 
concentration, and 
dc
dn
 is the refractive increment. The value of ∆Y is set to be zero at 
the first measured radical position in one scan, and all the subsequent ∆Y readings are 
relative to the first reading. The refractive increment 
dc
dn
 is mainly dependent on the 
atomic composition of a substance. The average value of 
dc
dn
 for proteins is 0.186, and 
therefore 1 mg/ml of protein can result in a fringe displacement ∆Y of about 3.331 
fringes (Laue, 1996).  
 
The interference optical system has some advantages. Firstly, the fringe displacement 
can be obtained from any substance that has a refractive index different from the 
reference buffer as long as the substances do not absorb at 670 nm. Therefore the 
interference optical system can produce better results when the solute macromolecules 
lack strong chromophores such as polysaccharides, and the solvent macromolecules 
significantly absorb. Furthermore, it is more accurate for characterising samples at very 
high concentration or high radial resolution. It is also able to track very steep gradients 
of concentrations (Cole & Hansen, 1999). The interference optical system is more 
sensitive than the absorbance optical system. The lowest concentration of biological 
materials that can produce signal with good quality is about 0.1 mg/ml. The time 
required to complete one scan is 1 to 10 seconds which allows more scans to be 
obtained over the course of sedimentation velocity experiments. The space between 
each data point is 10 µm, and the signal noise to ratio is about 1000 which allows more 
precise measurements. Unlike the absorbance system, the noise of the interference 
signal is mainly systematic. The systemic noise is caused by optical flaws such as 
scratches on the lenses or mirrors and oil smears, mechanical stress on the optics, very 
slight difference between the solvent composition in the sample sector and in the   60
reference sector, and the alignments of the cells. The windows in the cells have to be 
made of sapphire for the interference optical system to minimise the changes of 
refractive index caused by stresses on the optics (Laue, 1996; Arthur et al., 2009; Cole 
et al., 2008). 
 
4.1.1.3 Fluorescence optical system 
 
The Aviv AU Fluorescence Detector System (AU-FDS) is the newest addition to the 
ProteomeLab XL-I system, and it is not as well characterized as the absorbance and 
interference optical system are. The AU-FDS optic box which contains a light source, 
optics, mirrors and a detector is located over the top of the rotor. The light source is a 
compact solid state laser which emits excitation light at 488 nm. The light is firstly 
reflected by a folding mirror to change the direction, and then passes through the beam 
expander and the first gradium lens to be collimated. After being reflected by a dichroic 
mirror, the light is then directed vertically downward to pass the focus lens and is 
focused into a 10 µm spot that is above the cells. The focused light causes the sample to 
fluoresce, and the emitted fluorescence from the sample travels back through the same 
focus lens, is transmitted through the same dichroic mirror, passes through a pair of 
long-pass (> 505 nm) dichroic filters, and is then focused by a gradium lens into a ~100 
µm hole in front of the photomultiplier tube which is a very sensitive detector for light. 
The molecules that are studied by the fluorescence optical system are usually labelled 
extrinsically. The emission light greater than 505 nm can pass through the filters and be 
detected by the photomultiplier tube, and this results in a high sensitivity but no 
selectivity of different labels which have different emission wavelength (Beckman 
Analytical Ultracentrifuge Fluorescence Detection System and Advanced Operating 
System User Manual, 2009).  
 
  The fluorescence intensity signal F is proportional to the sample concentration: 
c Q I F o ε = , where c is the concentration, ε is the extinction coefficient, Q is the 
quantum yield, the fraction of photons that produce fluorescence signals, and Io is the 
incident intensity of the excitation light. The quantum yield Q is largely affected by 
environmental factors, and therefore, compared to the other two optical systems, it is 
harder to obtain sample concentrations from the fluorescence intensity. The noise of the   61
fluorescence signal consists of non-systematic noise which is similar to absorbance 
noise, and time-dependent systematic noise due to the fluorescent substances that stick 
to the windows and background fluorescence from the cell components. The signal to 
noise ratio is about 100. The radial resolution (spacing between each measurement) is 
20 to 50 µm. The time required for one scan is 60 to 90 sec (Cole et al., 2008).  
  
4.1.2 Sedimentation velocity 
 
4.1.2.1 Theoretical aspects 
 
Sedimentation velocity is a hydrodynamic technique which is sensitive to the mass and 
shape of the macromolecules. In a sedimentation velocity experiment, an application of 
a sufficiently high speed for centrifugation leads to a rapid sedimentation of solute at 
the top of the cell. During sedimentation, the solute in the region near the sample 
meniscus is depleted, and then the concentration of the solute reaches a stable stage 
known as the plateau. Therefore, a solute concentration gradient, the boundary is 
formed. The sample concentration, c, is measured as a function of radial distance, r, by 
recording a series of scans at regular intervals, and thus the rate of movement of the 
boundary as a function of time is determined (Figure 4.2)  (Cole & Hansen, 1999; 
Harding & Winzor, 2001; Perkins et al., 2005).  
 
In a sedimentation velocity experiment, a sedimenting solute molecule is under three 
forces including the gravitational force, the buoyancy force and the hydrodynamic 
friction. The gravitational force is  r M F p sed
2 ω = , where Mp is the mass of the solute 
molecule, and ω
2r is the strength of the centrifugal field (ω is the angular velocity, 
2π/60 rpm, and r is the radial distance from the centre of rotation). One counterforce, 
the buoyancy force is  r M F s b
2 ω = , where Ms is the mass of the solvent displaced by 
the solute molecule. The mass of solvent displaced is  ρ v M M p b = , where v  is the 
partial specific volume of the solute, and ρ is the solvent density. Another counterforce 
caused by the motion of the solute molecule through the solvent is  fv Ff = , where f is 
the translational frictional coefficient, and v is the velocity of the solute molecule. Those 
three forces on the solute molecule are in a balanced relationship:  62
 
 
 
 
 
Figure 4.2 Schematic view of a double sector centrifuge cell during a sedimentation 
velocity experiment.   63
() N r v M r v M r M r M fv p s p
2 2 2 2 ) 1 ( 1 ω ρ ω ρ ω ω − = − = − = , where M is the molar 
mass and N is Avogadro’s number. The ratio of the velocity of the solute to the strength 
of the centrifugal field is defined as the sedimentation coefficient s (Cole & Hansen, 
1999; Cole et al., 2008): 
( ) Nf v M r v s ρ ω − = = 1
2  
The value of the sedimentation coefficient is dependent on the shape of the 
macromolecule, and a more compact structure leads to a higher s value (Perkins et al., 
2005). As the experimentally observed sedimentation coefficient s varies with 
temperature and solution density, s is always converted to a standard state of 20 °C in 
water at infinite dilution (s
0
20,w) (Scott & Schuck, 2005). 
 
Diffusion, a time-dependent process of the solute molecules, causes the spreading of the 
sedimenting concentration boundaries. For sedimentation velocity, the diffusion of 
solute during the sedimentation is defined by the Stokes-Einstein relationship:  
Nf
RT
D =  
where D is the diffusion coefficient which shows the rate of spreading of a boundary, R 
is the gas constant (8.314 ·10
7 erg/mol K), and T is the temperature in Kelvin. Recalling 
( ) Nf v M r v s ρ ω − = = 1
2 , one can derive the Svedberg equation: 
( )
RT
v M
D
s ρ −
=
1
 
Therefore the molar mass of solute, M, can be calculated by : 
( ) ρ ν − = 1 D RTs M   
(Scott & Schuck, 2005; Beckman Model XL-A/XL-I Analytical Ultracentrifuge 
Optima
TM Series Training Guide, 1998). 
 
The translational frictional coefficient, f, is dependent on the size and shape of the 
solute macromolecules, as shown by Stokes law: 
s r f πη 6 =  
where η is the viscosity of the solvent, and rs refers to the radius of the equivalent 
hydrodynamic sphere, which leads to the dependence of f upon shape of the solute 
(Harding & Winzor, 2001). For analytical ultracentrifugation, the anisotropy ratio is 
given by the frictional ratio f/f0, where f0 is the frictional coefficient of a sphere of which   64
the volume is as same as that of the hydrated macromolecule. The degree to which the 
shape of the macromolecule deviates from that of a sphere which has a same volume is 
shown by the frictional ratio f/f0 (Perkins et al., 2005). 
 
The evolution of the complete radial profiles of the solute during the sedimentation 
velocity in the sector-shaped ultracentrifugation solution column can be described by 
the detailed sedimentation-diffusion equation, the Lamm equation: 
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The radial concentration c distribution as a function of time t, and the radial position r, 
c(r,t), is recorded by the optical systems. The angular velocity ω is provided by the 
ultracentrifuge. The diffusion coefficient D and the sedimentation coefficient s are to be 
determined (Scott & Schuck, 2005; Cole et al., 2008). 
 
4.1.2.2 Data analysis 
 
There are several different approaches to obtain the major parameters, s and D, from 
raw data. These methods include fitting of the boundaries to the Lamm equations, the 
integral sedimentation coefficient distributions G(s), the apparent sedimentation 
coefficient distributions g(s*) and the sedimentation coefficient distributions c(s) (Scott 
& Schuck, 2005). 
 
The  g(s*) distributions are obtained by subtracting closely spaced pairs of scans to 
generate a set of pairwise difference ∆c/∆t data which is taken approximately for the 
time derivative dc/dt. The subtraction removes systematic noise, and the differences are 
averaged to improve the signal to noise ratio. The asterisk on s means that the g(s*) is a 
distribution of apparent sedimentation coefficients which are the s values of 
hypothetical non-diffusing ideal particles (Philo, 2000). This method is implemented in 
the software DCDT+. For single homogeneous species including tightly associated 
complexes, the g(s*) distribution can be fitted to a Gaussian function which results in a 
bell-shaped peak (Figure 4.3 a). The concentration can be derived from the size of the 
Gaussian peak area. The s20,w value is given by the peak centre of Gaussian function, 
and the half-width of the bell-shaped peak is related to the diffusion  65
 
 
 
Figure 4.3 Analyses of sedimentation velocity data for human dimeric IgA1 (dIgA1). 
(a) In a sedimentation experiment for dIgA1, the difference between pairs of 
sedimentation scans are analysed using g(s*) distributions to result in a Gaussian 
function. A s*20,w value of 9.8 S is given by the DCDT+ program which used 4 - 20 
scans recorded at 20,000 rpm midway through the sedimentation profile shown in (b). 
(c) Sedimentation velocity c(s) distribution analysis of dIgA1 using SEDFIT by fitting 
every scans in the sedimentation profile (b) into the Lamm equation. An s value of 9.8 S 
was derived from the c(s) analysis (taken from Bonner et al., 2008). 
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coefficient  D. Therefore, the molecular weight M is calculated using the Svedberg 
equation (Cole & Hansen, 1999; Perkins et al., 2005; Scott & Schuck, 2005). 
Sedimentation coefficients are measured in units called Svedbergs which is equal to 10
-
13 second. More than one Gaussian peaks can be obtained if there are several distinct 
non-interacting species. The advantages of the g(s*) distribution are its simplicity, and 
no need for any models. The disadvantages of the g(s*) distribution caused by the ∆c/∆t 
~ dc/dt approximation include the artificial broadening of the Gaussian peaks which 
may hide the heterogeneity and missing-out of species with small s values. Another 
disadvantage is the difficulty of analysing heterogeneous samples with a broad range of 
s values (Scott & Schuck, 2005). 
 
The approach used in this thesis for sedimentation velocity data analysis is the 
sedimentation coefficient distributions c(s). The observed sedimentation profile of a 
heterogeneous sample can be described as a superposition of the sedimentation profile 
of each monodisperse subpopulation: 
∫ ≅ ) ( ) , , , ( ) ( ) , ( s d t r D s L s c t r a  
where  a(r,t) denotes to the observed signal, c(s)d(s) represents the distribution of 
species at every d(s) value, and L(s,D,r,t) is the solution of the Lamm equation of the 
monodisperse species with the sedimentation coefficient s. Therefore, using the c(s) 
distribution to analyse the observed profile is like fitting a combination of Lamm 
equation solutions directly to the data to find the combination that explains the observed 
sedimentation profile the best. By assuming every single species has the same frictional 
ratio f/f0 which means all the species have the same shape, the diffusion coefficient D 
can be estimated. The c(s) distribution method is implemented in the program SEDFIT 
and SEDPHAT. The c(s) analysis using SEDFIT software can fit all obtained scans to 
numerical Lamm equations using least-squares fitting procedure. The systematic noise 
can be removed during the fitting. The frictional ratio f/f0 can be floated during the 
fitting in order to achieve the best fit. The resulting c(s) distribution plot has shape 
peaks which are not diffusionally broadened (Figure 4.3 b & c). The molar mass 
distribution c(M) can be derived from the sedimentation distribution c(s). However the 
derived molar mass M of different species is calculated by using the same frictional 
ratio f/f0, and therefore the M value can be inaccurate. There are several advantages of 
this method. Firstly, it is sensitive to trace components. Secondly, all the scans can be   67
fitted. Thirdly, a broad range of rotor speeds can be used for the fits. Fourthly, 
multicomponent systems can be analysed. The disadvantage of SEDFIT software is that 
it does not analyse the back diffusion of the macromolecules, hence high rotor speeds 
are preferred (Schuck, 2000).  
 
4.1.2.3 Protein interactions in sedimentation velocity  
 
Reversible self-associations and heterogeneous interactions of solute molecules have 
been observed in sedimentation velocity experiments. It is of importance to determine 
the stoichiometry of the complex and the strength of the interaction in terms of the 
association constant KA for the biological relevant protein interactions. The equilibrium 
of the protein interactions can be defined as static (slow) or dynamic (rapid). Static 
equilibria are very slowly reversible or almost irreversible during the time course of the 
experiments, and therefore it is possible to separate and characterise the individual 
reactants and the complex as separating non-interacting species. Different components 
of the interaction appears as individual peaks that are independent of concentration in 
the c(s) analysis. Dynamic equilibria are rapidly reversible and the interaction takes 
place in the duration of the experiments. It is impossible to resolve the individual 
components of the interaction in the c(s) analysis, and the interaction appears as a 
concentration-independent peak of the smaller reactant and a second broad peak with a 
bigger s value which represents a “reaction boundary” rather than the individual species. 
The s value of the “reaction boundary” peak ranges between the values for the bigger 
reactant and the complex. The weight-average sedimentation coefficient sw can be 
obtained by integration of the sedimentation coefficient distribution c(s). The sw 
increases as the loading concentration increases, because the complex formed has a 
higher molar mass than individual reactants. In the case of the dynamic equilibrium, the 
stoichiometry and KA value might be determined by plotting the value of sw as a 
function of the loading concentration, if the data is produced from a broad concentration 
range (eg. 0.1 to 3-fold the KD value) (Schuck, 2005; Howlett et al., 2006). Recent 
developments to characterise dynamic equilibria include the programme SEDPHAT 
which has been designed to allow the global analysis of sedimentation velocity and 
sedimentation equilibrium experiments, and a computational approach for integrating 
multiple optical signals into the c(s) analysis of the components which combines the   68
size-dependent separation with discrimination of the distinguishable properties of the 
components (Schuck, 2003; Balbo et al., 2005).  
 
4.1.3 Sedimentation equilibrium 
 
4.1.3.1 Theoretical aspects 
 
Sedimentation equilibrium is a thermodynamic technique which is sensitive to the mass 
of solute macromolecules. In sedimentation equilibrium experiments, low rotor speeds 
are applied, and therefore solute macromolecules do not pellet at the bottom of the cell 
but are able to diffuse over time. During centrifugation, as the distance from the centre 
of rotation increases, the concentration of solute is increasing. After a period of time, 
the effect of sedimentation and that of diffusion on the solute macromolecule are 
balanced, and no apparent concentration change occurs. This is termed a sedimentation 
equilibrium experiment (Figure 4.4). The equilibrium distribution depends on the 
buoyant molecular weight, but not on the shape of the macromolecules, since there is no 
net transport at equilibrium. (Beckman Model XL-A/XL-I Analytical Ultracentrifuge 
Optima
TM Series Training Guide, 1998; Cole & Hansen, 1999; Harding & Winzor, 
2001).  
 
The measured signal for a single component system under ideal conditions generally 
approaches an exponential, and it can be defined as: 
() ( ) ( ) [ ] δ ω ρ ε + − − = RT a r v M l a c r a 2 1 exp ) (
2 2 2  
where r is the radius, a is the radius of the meniscus, a(r) is the measured signal at the 
radial position, c(a) is the molar concentration at the meniscus position a, M is the 
molar mass of the solute molecules, ε is the molar extinction coefficient for the 
absorbance optics, or the refractive increment multiplied by the molar mass and divided 
by the wavelength for the interference optics, l is the optical pathlength (1.2 cm for 
standard centrepieces), v  is the partial specific volume of the solute, ρ is the solvent 
density, ω is the angular velocity, R is the gas constant, T is the temperature in Kelvin, 
and δ is a baseline offset. The a(r) and c(a) are measured by optical detection systems.   69
 
Figure 4.4 Principles of sedimentation equilibrium experiments. (a) View of a six-
channel centrifuge cell used during a sedimentation equilibrium experiment. (b) 
Sedimentation equilibrium data for a reversible monomer-dimer equilibrium: (—) total, 
(···) monomer, (---) dimer (taken from Cole & Hansen, 1999).   70
By using known values of ε, l, v , ρ, and ω, the value for the molecular weight, M, can 
be calculated (Scott & Schuck, 2005). For a heterogeneous system, the concentration 
distribution can be described as a sum of the concentration distribution of all n species 
present (Figure 4.5) (Lebowitz et al., 2002):  
( ) ( ) ( ) δ ω ρ ε + − − =∑
n
n n n n RT a r v M l a c r a ] 2 1 exp[ ) (
2 2 2 . 
 
Sedimentation equilibrium can also be used to characterize oligomerisation of a single 
component (Self-association). The equation for simple component systems can be 
modified to account for self-association systems. The total concentration distribution is 
described as: 
() ( ) ( ) δ ω ρ ε + − − =∑
n
n
m n m RT a r v nM a c lK n r a ] 2 1 exp[ ) (
2 2 2  
where a(r) is the total observed signal of the mixture at the radial position r, cm(a) 
denotes the concentration of monomer at the meniscus a. The M denotes the molar mass 
of the monomer. The oligomer that formed by the monomer is defined as n-mer. The εm 
is the molar extinction coeifficient of the monomer, and therefore the value of the molar 
extinction coefficient of the n-mer is nεm. For the monomer-oligomer equilibrium 
reaction, the association constant, Kn, is defined as:  ( )
n
m n n c c K = , and therefore the 
concentration of oligomer at the meniscus a equals to Kncm(a)
n (McRorie & Voelker, 
1993). 
 
For a heterogeneous interaction system in which at least two species reversibly form a 
complex with a certain stoichiometry, such as an AB B A ⇔ +  interaction, the radial 
signal of sedimentation equilibrium can be described as: 
( ) ( )
() () δ ω ε ε
ω ε ω ε
+ − + + +
− + − =
] 2 exp[ ) ( ) ( ) (
] 2 exp[ ) ( ] 2 exp[ ) ( ) (
2 2 2
, ,
2 2 2
,
2 2 2
,
RT a r M M l K a c a c
RT a r M l a c RT a r M l a c r a
B b A b B A AB B A
B b B B A b A A
 
where the buoyant molar mass is defined as  ) 1 ( ρ v M M b − = , KAB is the association 
constant, therefore the concentration of the complex AB is  AB B A AB K c c c = , and the 
molar extinction coefficient of the complex AB is  B A AB ε ε ε + = . The assumption has 
been made here that the partial specific volume v of the complex AB can be calculated   71
from the respective weight fractions of reactants A and B,  B
AB
B
A
AB
A
AB v
M
M
v
M
M
v + = , and 
thus  B b A b AB b M M M , , , + =  (Lebowitz et al., 2002). 
 
4.1.3.2 Data analysis 
 
It is important to choose the right rotor speed to perform the sedimentation equilibrium 
experiment, because if the speed is too slow then the curvature of the a(r) data is not 
adequate for curve fitting, and if the speed is too fast then the majority of the solute 
molecules will sediment to the bottom of the cell. For a certain sample, sedimentation 
equilibrium needs to be performed at three or four different speeds and at several 
different concentrations of the solute (Figure 4.5 a), in order to find the optimum speed 
and concentration for calculation of the molecular weight M (Perkins et al., 2005). For a 
homogeneous solute with a typical protein v  value of about 0.74 cm
3/g and a molar 
mass of M, the recommended lowest speed is  M 1 10 4
6 × , and the higher speeds are 
increased 1.2-fold to 1.5-fold between each speed. Before using the observed 
absorbance, interference or fluorescence data, the baseline offset δ has to be subtracted. 
This can be achieved by increasing the rotor speed to 40,000 r.p.m at the end of the 
experiment to pellet the solutes and then using the final a(r) data as the offset δ. Another 
way is to treating the baseline offset as a fitting parameter when a(r) data is fitted by 
various programmes (Cole et al., 2008). 
 
The method used in this thesis for analysing the sedimentation equilibrium data is the 
nonlinear least squares analysis. The fitting programmes such as SEDPHAT directly fit 
the experimental data into the equations of certain models such as single component 
model, self-association of a single component model and heterogeneous interaction 
system model, to determine the molar mass M of the solute molecules. In SEDPHAT, 
the scan data can be loaded as single sedimentation equilibrium files or multi-speed 
equilibrium file. For a single component system, the buoyant molar mass Mb can be 
readily obtained, since only one exponential distribution is present in the system. If the 
value of the partial specific volume v  is known, then the molar mass of the solute M 
can be easily calculated.  For a self-association system, an association model should be 
selected, and a global nonlinear regression fitting of multiple scans at different  72
 
 
Figure 4.5 Analyses of sedimentation equilibrium data. (a) Sedimentation equilibrium 
analysis of the single-chain Fv fragment MFE-23.  The curves were obtained at three 
concentrations of 1.1, 2.2 and 3.0 mg/ml, and three angular velocities of 11,000, 15,000 
and 19,000 r.p.m. The continuous white line is the result of the simultaneous fit using 
non-linear least-squares regression analysis (adapted from Perkins  et al., 2005). (b) 
Residuals from desired fit. The patterns of residuals indicate good fit in the left panel, 
aggregation in the middle panel, and nonideality in the right panel (adapted from 
Beckman Model XL-A/XL-I Analytical Ultracentrifuge OptimaTM Series Training 
Guide, 1998). 
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concentrations and different rotor speeds should be performed to determine the M of the 
monomer, the association constant Kn, and the stoichimetries n of the best fitted 
association model. For heterogeneous interactions, the buoyant molar mass of the 
reactants Mb,A and Mb,B can be determined in advance by performing sedimentation 
equilibrium experiments on reactants A and B seperately, and a heterogeneous 
interaction model and a global fitting are needed for scans required at multiple 
concentrations and rotor speeds. If the difference between the molar mass of the 
reactant A and B is less than 20% or more than a factor of 5, it is very difficult to fit the 
data. However, if A and B have significant distinguishable absorbance properties (eg. a 
protein-DNA interaction), an absorbance optical system which allows for multi-
wavelength scans can make the analysis possible. In addition, if the total concentration 
of the solute remains the same during the course of the sedimentation equilibrium 
experiments, the data fitting of self-association model and heterogeneous interaction 
model can be easier (Lebowitz et al., 2002; Cole et al., 2008).  
 
The residual plot is very sensitive to the goodness of model fit, and it can also indicate 
possible alternative models. The difference between each experimental data point and 
the corresponding point on the curve calculated from the model equation is the residual. 
After curve fitting, the residuals should be examined by plotting these as a function of 
radius (Figure 4.5 b). For a good fit, the residuals should be randomly distributed near 
the zero (McRorie & Voelker, 1993; Beckman Model XL-A/XL-I Analytical 
Ultracentrifuge Optima
TM Series Training Guide, 1998). 
 
4.1.4 AUC in constrained modelling 
 
Like solution scattering (see below: Section 4.2), a unique structure for the 
macromolecule cannot be determined by analytical ultracentrifugation in that the 
orientations of the macromolecule in solution are random. In addition, only a single 
parameter is fitted. Therefore, the constrained scattering modelling approach is 
applicable to model s
o
20,w values. The best-fit structures with s
o
20,w values within an 
acceptable error range are selected by performing an automated trial-and-error fit 
procedure (Section 4.2.5.4; Perkins et al., 2005). 
 
   74
4.2 Solution scattering 
 
Solution scattering is a low resolution diffraction technique suitable for studying the 
overall structure features of biological macromolecules in solution state in random 
orientations (Glatter & Kratky, 1982; Perkins, 1988). It can complement high-resolution 
techniques such as crystallography and nuclear magnetic resonance (NMR). 
 
4.2.1 Theoretical aspects 
 
4.2.1.1 Physical principles of solution scattering 
 
X-rays are diffracted by electrons and neutrons are diffracted by nuclei, but the physical 
principles are the same. A macromolecular sample is irradiated with a collimated, 
monochromatic beam of X-rays or neutrons. All of the electrons (or nuclei) in a 
molecule scatter Xrays or neutrons as waves which can constructively or destructively 
interfere with each other (Figure 4.6 a). If the waves scattered from two electrons (or 
nuclei) are out of phase by nπ while n is zero or an even integer, the interference is 
constructive. If n is an odd integer, the interference is destructive. At very small angles 
longe range structure is probed, which at low resolution, allows in many cases the 
precise details of the atomic coordinates to be ignored, and regions of locally uniform 
scattering density to be considered instead. Equations can be derived for the small angle 
scattering of, for example, spheres, cylinders or Gaussian coils of uniform scattering 
density. Some universal equations appear such as the Guinier Law for the form of the 
small Q (scattering vector) scattering for any shape of dilute object. The larger the 
object the faster the scattering falls off in the scattering vector Q. 
 
As a result of all the interference, a circularly-symmetric diffraction pattern is observed 
on a two dimensional (2D) area detector placed behind the sample (Figure 4.6 b). The 
radically averaged intensities I(Q) are measured in a small angular range as a function 
of the magnitude of the scattering vector Q, where Q=4π sinθ/λ (2θ is the scattering 
angle and λ the wavelength). The I(Q) decreases as the Q increases. Radial integration 
of this two-dimensional pattern yields the scattering curve I(Q) in one dimension. 
Classical solution scattering views structures at a low structural resolution about 2-4 nm 
from data obtained in a Q range between 0.05 to over 2 nm
-1. Analyses of    75
 
Figure 4.6 Schematic diagram of a complete scattering experiment (taken from Perkins 
et al., 2009). (a) Scattering from two electrons (or nuclei) in a globular molecule to an 
angle 2θ which have a scattering angle of 2θ and a path difference of 1λ. (b) The 
diffraction pattern of a sample of macromolecules at random orientations in solution is 
recorded on a 2D detector. The scattering vector is  i s k k q − = , and Q is the magnitude 
of the scattering vector  λ θ π sin 4 = = q Q . The diffraction pattern gives the scattering 
curve  I(Q) in reciprocal space, and transforming I(Q) into the real space gives the 
distance distribution P(r).    76
I(Q) lead to the overall molecular weight, the degree of oligomerization, the radius of 
gyration RG  (and in certain cases, those of the cross-section and the thickness), the 
dimension and the shape of the macromolecules (Perkins, 1994; Perkins, 2001a; Perkins 
et al., 2005). The Fourier transformation of I(Q) from the reciprocal space into the real 
space gives the distance distribution P(r) which provides the maximum dimension and 
information about the shape of the particles. A powerful method of constrained solution 
scattering has been developed, in which automated curve fit procedures based on known 
crystal structures are able to extract structural information to a precision of 0.5-1.0 nm, 
corresponding to medium resolution structures (Perkins, 2001a; Perkins, 1998). 
 
4.2.1.2 Comparison between X-ray scattering and neutron scattering 
 
X-rays are diffracted by electrons. The intensity of scattering I(Q) by an electron is 
proportional to the X-ray scattering length f of the electron, which has a value of 2.81 
fm. The X-ray scattering length for small angle scattering studies of an atom is the 
atomic number multiplied by the electron scattering length (Table 4.1 a). Therefore, the 
hydrogen isotopes, 
1H and 
2H, both have the scattering length of an electron of 2.81 fm 
(Perkins, 1988). The scattering intensity I(Q) of a sample of molecules at random 
orientations in solution can be described by the Debye equation, when the value of Q is 
not zero: 
( ) ∑∑ =
pq
q p rQ
rQ
f f Q I
sin
) ( 
where p and q are two different points within a molecule, r is the distance between 
them, and fp and fp  are the scattering length of the electrons at the point p and q 
respectively.  
 
The physical principles of neutron scattering are the same as for X-ray scattering. 
However, there are some significant differences between those two types of scattering 
experiments. Unlike X-rays which are scattered by electrons, neutrons are scattered by 
the nuclei of atoms. The nuclear atomic scattering length b, which is equivalent to and 
replaces the X-ray scattering length f in the Debye equation, is usually positive and 
similar between different nuclei. There is an important exception in that the 
1H isotope, 
has a large, negative b value of –3.742 fm (Table 4.1 a). Some other atoms or isotopes 
have negative scattering lengths but 
1H is the most important. The large difference in   77
 
 
 (a) Scattering lengths of biological important nuclei (adapted from Perkins, 1988) 
    Atomic number  f (2θ=0˚) (fm)  b (fm) 
1H 1  2.81  -3.742  Hydrogen 
2H 1  2.81  6.671 
Carbon 
12C 6  16.9  6.651 
Nitrogen 
14N 7  19.7  9.40 
Oxygen 
16O 8  22.5  5.804 
Phosphorus 
31P 15  42.3  5.1 
 
(b) Scattering densities of solvents and macromolecules (adapted from Perkins, 1988) 
 X-ray  (e.nm
-3)  Neutrons (%  
2H2O) 
H2O 334  0 
2H2O 334  100 
50% (w/w) sucrose in H2O 402  13 
Lipids 310-340  10-14 
Detergents 300-430  6-23 
Proteins 410-450  40-45 
Carbohydrates 490  47 
DNA 590  65 
RNA 600  72 
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the neutron scattering properties of the two hydrogen isotopes is very important in 
neutron scattering experiments, as this made the contrast variation experiments possible 
to study the internal structure of the macromolecule, if it is heterogeneous in its 
scattering properties (Perkins, 2001a). The scattering density ρ is the total of scattering 
lengths, f for X-ray scattering and b for neutron scattering, within the molecule divided 
by the molecular volume. The contrast ∆ρ is defined as the difference between the mean 
scattering density of the macromolecule ρv and that of its buffer ρs:  s v ρ ρ ρ − = ∆  
(Perkins, 1988). Since different biological macromolecules have different proportion of
 
non-exchangeable protons, different macromolecules such as lipids, proteins, 
carbohydrates and nucleic acids possess distinct neutron scattering densities which fall 
between the very different neutron scattering densities of H2O and 
2H2O (Table 4.1 b). 
Variation of the ratio of H2O and 
2H2O in neutron scattering experiments alters the 
contrast  ∆ρ, and thus reveals the internal structure of the components within the 
macromolecules such as protein-RNA and protein-lipid complexes. In principle, 
1H- 
2H 
exchange processes will mean that there will be internal regions where the 
macromolecule appears to be hollow (∆ρ=0). The contrast ∆ρ variation in X-ray 
scattering can be achieved by varying the percentage of sucrose, but the scattering 
density range is limited (Perkins, 2001a). 
 
Another difference between X-ray scattering and neutron scattering is that the hydration 
shell surrounding the macromolecules such as protein and carbohydrate is visible by X-
ray scattering but much less so by neutron scattering in 
2H2O. In solution, a 
macromolecule has a surrounding hydration shell which has an electron density similar 
to that of protein and higher than that of bulk water, and therefore hydration shells are 
visualised as part of the macromolecular structures by X-ray scattering. The dynamic 
properties of these hydrated structures can be studied in sedimentation velocity 
experiments by analytical ultracentrifugation. In the case of neutron scattering, the 
hydration shells are not significant in 
2H2O. At other neutron contrasts the water shell 
may be more visible than that in 
2H2O. Glycoproteins in solution are assumed to have 
0.3 g H2O / g protein of hydration shell which contributes approximately 33% of the 
total structure volume. Another difference is that neutron scattering does not cause 
radiation damages to the proteins which happen frequently in X-ray scattering 
experiments (Perkins, 2001b).    79
 
Solution scattering is usually applied to proteins that are bigger than 10 kDa in size 
including glycosylated proteins. Nucleic acids such as DNA and RNA are difficult to 
study by solution scattering due to their extended polyelectrolyte structure and their less 
optimal scattering density. Biological complexes such as protein-protein, protein-
nucleic acid and protein-lipid complexes can also be studied. Since protein-protein 
complexes have scattering densities that are uniform throughout complex molecules, 
they are suitable to be studied by both X-ray and neutron scattering. Neutron scattering 
has advantages in studying protein-nucleic acid and protein-lipid complexes, because 
the scattering densities of the complexes vary significantly between the protein, nucleic 
acids and lipid components (Perkins et al., 2008).   
 
4.2.3 Instrumentation 
 
A scattering camera is designed to irradiate a solution which has a path thickness of 1-2 
mm with a collimated, monochromatized beam of X-ray photons or neutrons, and to 
record the resulting circularly-symmetric scattering pattern by using a two-dimensional 
area detector interfaced to a computer (Perkins, 2001a). The use of high-flux sources 
such as the European Synchrotron Radiation Facility (ESRF), the Institut Laue-
Langevin (ILL) both based in Grenoble, France, and Diamond (Oxfordshire, UK) 
greatly facilities the study of biological samples (Perkins et al., 2008). 
 
4.2.3.1 Instruments for X-ray scattering 
 
There are about 70 X-ray synchrotron sources in the world, of which the most powerful 
ones are currently the ‘third-generation’ machines such as the 6 gigaelectronvolt (GeV) 
ESRF in France, the 8 GeV Super Photon Ring (Spring8) in Japan, and the 7 GeV 
Advanced Photon Source (APS) in America (Perkins, 2001a). At ESRF, electrons are 
emitted by an electron gun. Then electrons are accelerated in a linear accelerator (linac), 
and transmitted to a booster synchrotron which is a circular accelerator to be accelerated 
to 6 GeV energies. The 6 GeV electrons are then injected into the main storage ring 
where they circulate in vacuum at a constant energy for many hours. The storage ring is 
refilled several times a day, as the lifetime of the electron beam is 12 to 24 hours. 
Electrons circulating in the storage ring emit white radiation tangentially into various   80
beamlines which contains all the wavelengths including X-rays from the storage ring 
(Figure 4.7 a). There are 49 different beamlines at ESRF that are designed for different 
purposes. A typical beamline consists of an optics cabin which contains the optical 
systems used to select and optimise the radiation to the desired properties (eg. X-ray 
wavelength), an experimental cabin where samples and the detector are housed and the 
interactions between samples and the X-ray beam are recorded, and a control cabin 
where scientists control the experiments and collect the data (Figure 4.7 b). The 
beamline ID02 at the ESRF was designed for small-angle X-ray scattering (SAXS) 
combined with wide-angle X-ray scattering (WAXS) and ultra-small-angle scattering 
(USAXS), using a highly monochromatic beam with very low divergence and small 
cross-section. The emitted white beam provides a high photon flux with a low 
divergence. The high photon flux then passes through the ID02 optical system. The 
optical system consists of a cryogenic crystal Si-111 monochromator which provides a 
monochromatic X-ray beam with a wavelength of 0.1 nm, a toroidal focusing mirror to 
focus the X-ray beam, and the primary, secondary and guard slits to collimate the beam 
to a cross section of 0.2 mm x 0.4 mm. There are two experimental cameras inside the 
ID02 beamline, namely a Bonse-Hart camera for USAXS and a pin-hole camera for 
SAXS and WAXS (Figure 4.8 a). The pin-hole camera is located in Experimental hutch 
2. In the pin-hole camera, two guard slits are located directly before the sample holder. 
After the sample holder, there is an image-intensified charged coupled device (CCD) 
detector inside a 12-m-long detector tube in a vacuum which is movable and is 
responsible for recording SAXS curves. The sample-detector distance for this detector 
can be varied between 1 m to 10 m and therefore the Q range for this detector is 
between 0.006 nm
-1 and 6 nm
-1. Outside this 12 m detector tube, there is a second 
detector which records the WAXS curves. This second detector covers a Q range 
between 5 nm
-1 and 60 nm
-1 ( Figure 4.8 b). Thus, by combining the two different 
detectors in the pin-hole camera, both SAXS and WAXS curves in a broad Q range, 
0.006 nm
-1 to 60 nm
-1, can be recorded. The Bonse-Hart camera is located in 
Experimental hutch 1, and is used to perform USAXS experiments. The Bonse-Hart 
camera is composed of one Si-220 triple-bounce crystal before the sample holder as a 
conditioning monochromator, another Si-220 triple-bounce crystal after the sample 
holder as a horizontal analyzer, a Si-111 double reflection vertical analyzer, and an 
avalanche photo diode detector (Figure 4.8 a). The Bonse-Hart camera can extend the 
low Q limit to 0.0008 nm
-1. At ID02 beamline, the operating energy is 12.4 KeV, and   81
 
Figure 4.7 Schematic layout of the ESRF, Grenoble. (a) How synchrotron light is 
produced. Electrons emitted from an electron gun are accelerated in the linac first, then 
in the booster synchrotron, and then transmitted into the storage ring where they 
circulate and emit synchrotron light beams into various beamlines (taken from 
http://www.esrf.eu). (b) layout of a typical beamline at the ESRF (taken from 
http://www.esrf.eu).   82
 
 
 
Figure 4.8 Composition of the beamline ID02 at the ESRF, Grenoble. (a) Schematic 
layout of the beamline ID02 which contains two cameras, the Bonse-Hart camera and 
the pin-hole camera (taken from Perkins et al., 2008). (b) A front view of the combined 
SAXS/WAXS detection configuration of the pin-hole camera in Experimental hutch 2 
(taken from http://www.esrf.eu).    83
the frame rate can reach 10 images per second (http://www.esrf.eu). Typical photon flux 
routinely obtained at the sample position is nearly 10
13 photons/s (Narayanan & 
Bosecke, 2001). The optimum sample thickness is 1 mm for dilute protein solutions. In 
order to reduce the radiation damage to protein solutions, a 1-mm-wide quartz capillary 
is used as a flow cell which allows each protein solution to pass through the capillary at 
a controlled speed, and therefore the X-ray beam always pass across a fresh protein 
solution. The exposure time of the sample to the beam is also monitored to minimise the 
radiation damage, and it can be as short as 0.001 sec (Perkins et al., 2008).  
 
4.2.3.2 Instruments for neutron scattering 
 
There are about 35-40 neutron sources in the world. Most of them are reactor sources, 
but five of them are spallation sources. A neutron reactor is a category of nuclear 
devices which initiate, control and substain a nuclear chain reaction called nuclear 
fission. In a nuclear fission event, a neutron is absorbed by a 
235U atom which then 
becomes a heavy 
236U atom. The heavy atom then splits into two lighter atoms, and 
release free neutrons and other fission products. The released neutrons can be absorbed 
by other 
235U atoms to initiate more nuclear reactions which can release more neutrons. 
A neutron spallation source is a device in which a particle accelerator is used to 
generate a beam of neutrons. A highly accelerated beam of protons hit onto a target 
composed of heavy metal such as mercury or tantalum. As a result, 20 to 30 neutrons 
are expelled from a heavy metal nucleus hit by a proton. Presently, the most powerful 
reactor source is the 58 MW High Flux Reactor at the ILL in Grenoble, and the most 
powerful spallation source is that of the Spallation Neutron Source (SNS) in Oak Ridge, 
Tennessee, USA (Perkins, 2001a). The new station TS2 at ISIS near Oxford in the UK, 
offers world-class facilities. 
 
The most powerful instrument used for neutron scattering at the ILL with a high-flux 
reactor in Grenoble is the camera D22. The camera D22 is designed to maximize the 
incident flux at a sample by the use of physical large designs and large samples. The 
fission of 
235U in a specially-designed reactor core produces fast high-energy neutrons. 
A cold source (liquid 
2H2) moderates the neutrons and enhances the number of neutrons 
in a wavelength range of 0.1-1 nm. A velocity selector based on a rotating drum with a 
helical slot is used for beam monochromatization. The wavelengths of the neutrons that   84
can pass the velocity selector range between 0.45 nm to 4 nm. The suitable wavelength 
for biological samples is 1.0 nm. A beam collimation employs a series of movable 
segments of beam guides. An aperture defines the beam size. A two dimensional 
3He 
detector which has a size of 102 cm x 100 cm with 128 × 128 cells can be moved within 
a 20-m-long evacuated tube, which makes the sample-detector distance ranges between 
1.35 m and 18 m (Figure 4.9 a). This detector can be moved sideways in order to access 
bigger Q. The accessible Q range is between 0.004 nm
-1 to 4.4 nm
-1.  The progress of 
the experiments, data collection and storage are controlled by computers (Perkins, 
2001a; Perkins et al., 2008). 
 
At the spallation neutron source at ISIS, Rutherford Appleton Laboratory, a 200 mA, 
800 MeV, proton synchrotron is used to accelerate a proton beam to strike a target made 
of depleted uranium or tantalum which then emits 50 pulses/sec of neutron beams, 
rather than a continuous beam as with a reactor source. A cold source (liquid H2) is used 
again to make each neutron pulse contains wavelengths between 0.2 nm and 1.0 nm. 
The camera LOQ is designed for small angle neutron scattering (SANS). Inside LOQ, a 
spinning double-disk chopper is used to remove every other pulse to prevent frame 
overlapping between consecutive pulses. Two apertures define the size of the beam. The 
sample holder is an automatic sample changer which can house 20 different samples in 
quartz cells. Unlike the ILL, both the collimation and the sample-detector distance on 
the LOQ camera are fixed. The sample-detector distance is fixed at 4.1 m. 
Monochromatization of the neutron beam is achieved by time-of-flight techniques 
which are based on the time required for each pulse travels from the uranium target to 
the two dimensional ORDELA detector. The size of the ORDELA detector is 64 cm x 
64 cm (Figure 4.9 b). The major advantage of the LOQ camera design is that the entire 
scattering curve in the Q range of 0.06-2.2 nm
-1 can be measured simultaneously, and 
this is ideal for P(r) calculation and kinetic experiments (Perkins, 1988; Perkins, 2001a; 
Perkins et al., 2008). Recently, a new camera SANS2D has been commissioned at ISIS 
and offer even higher performance.  
 
4.2.4 Data collection 
 
Before the scattering experiments are performed, a proper Q range must be chosen for 
the sample. The minimum Q required for a RG determination of protein molecule with a    85
 
 
 
Figure 4.9 Examples of SANS cameras. (a) Schematic layout of the neutron camera 
D22 at the ILL (taken from Perkins et al., 2008). (b) Schematic layout of the neutron 
camera LOQ at ISIS (taken from Perkins et al., 2008). 
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dimension L can be decided by using the relationship (Perkins, 1988): 
π ≤ L Qmin . 
The value of L can be estimated in advance from electron microscopy or calculated 
from the sedimentation coefficient from analytical ultracentrifugation experiments 
assuming that the shape of the molecule is a rigid rod (Perkins, 1988). The variation of 
the Q range can be achieved by altering the sample-detector distance. The longer the 
sample-detector distance is, the smaller the Qmin and Qmax values will be 
(http://www.esrf.eu). However, the counting rates must be taken into consideration, 
because they decrease proportionally as the square value of sample-detector distance 
increase.  
 
For X-ray scattering, radiation damage of the protein sample caused by the interactions 
with X-ray is shown as a systematic increase or in some cases decrease of I(Q) at low Q 
as a result of the exposure to X-rays. Thus, radiation damage has to be eliminated to 
obtain reliable I(Q) curves. At the ESRF, X-ray beams with reduced intensity such as 
single-bunch mode beam with a current of 16 mA or 16-bunch mode beam with a 
current of 90 mA are used for the work in this thesis, instead of the uniform fill mode at 
200 mA which is more suited for stopped-flow work. In addition, a flow sample cell 
connected with a motorised syringe which can push fresh sample solution across the X-
ray at a controlled speed causes the X-ray beam to continuously interact with fresh 
sample that have not been irradiated. Radiation damage tests must be perform before 
data collection, by exposing the sample to X-rays for 0.1 – 2 sec and choosing the 
maximum exposure time that does not cause systematic change of the I(Q) curve 
(Perkins et al., 2008).  
 
To avoid the effect of time-dependent changes of the sample cell such as accumulation 
of protein on the capillary wall, it is necessary to check the overlapping of the I(Q) 
curves of the same buffer throughout the beamtime. If the latter I(Q) curve of the buffer 
is higher in intensity than the curve of the same buffer at the beginning of the beamtime, 
then the capillary cell needs to be cleaned. Buffers must be measured immediately 
before the corresponding samples, and the I(Q) curves of the sample must be subtracted 
with the buffer curve just before the sample run, to minimise the effects from the time-
dependent changes of the sample cell. For sample preparations, sufficient buffer   87
exchange is needed, and concentration series are important to detect any concentration-
dependent change of the I(Q) curves. 
 
4.2.5 Data analyses 
 
4.2.5.1 Guinier analyses  
 
At sufficiently low Q values, Guinier analyses (Figure 4.10 a, b) of the scattering curves 
In I(Q) as a function of Q
2 give the radius of gyration, RG, and the forward scattered 
intensity I(0): 
In I(Q) = In I(0) – RG
2Q
2/3 
RG characterizes the degree of structural elongation, and corresponds to the mean square 
distance of scattering elements from their centre of gravity. RG should be measured in a 
Q range in which  5 . 0 min ≥ ⋅ G R Q  and  5 . 1 max ≤ ⋅ G R Q . The anisotropy ratio is 
determined by RG / RO, where RO is the RG of the sphere of volume equal to that of the 
protein, to show the degree to which the shape deviates from that of a perfect sphere. 
The anisotropy ratio of globular protein molecules is about 1.28. I(0) is the intensity at 
zero Q which is determined by the intercept of the linear plot with the Y axis. I(0) is 
proportional to Mr
2, where Mr represents the relative molecular mass. I(0)/c (c = sample 
concentration in mg/ml) is proportional to Mr. Mr values can be deduced from I(0)/c, 
either as relative values from the X-ray scattering data, or as absolute values from 
neutron data by referencing I(0) to the incoherent scattering of water as a standard. 
Thus, concentration-dependent change of the Mr value of the sample can be checked by 
plotting I(0)/c as a function of concentration c (Perkins, 1988; Perkins, 1994; Perkins, 
2001a).  
 
For elongated macromolecules such as rod-like macromolecules, the corresponding 
cross-sectional radius of gyration, RXS, and the cross-sectional intensity at zero angle 
[I(0)Q]Q→0 are obtained from curve analyses in a Q range which is larger than and does 
not overlap with the one used for the RG determination (Figure 4.10 c,d) (Perkins, 1988; 
Perkins, 1994; Perkins, 2001a) : 
In [I(Q)Q]= In [I(0)Q]Q→0 – RXS
2Q
2/2 
The combination of the RG and RXS analyses gives an estimate of the macromolecular    88
 
Figure 4.10 X-ray and neutron data analyses for human secretory component (SC) 
(adapted from Bonner et al., 2007). (a to d) Guinier RG (a, b) and RXS (c, d) fits of X-ray 
(a, c) and neutron (b, d) data for SC. Filled circles between the Q·RG and Q·RXS ranges 
show the data points used to determine the RG and RXS values. (e,f) Distance distribution 
functions P(r) of X-ray (e) and neutron data (f) for SC.  
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dimension L assuming the structure of the molecule is an elliptical cylinder (Perkins, 
2001a): 
) ( 12
2 2
XS G R R L − ⋅ =  and  [ ] 0 ) ( / ) 0 ( → ⋅ ⋅ = Q Q Q I I L π  
 
In neutron scattering experiments in which the solute-solvent contrast ∆ρ is varied, the 
RG depends on ∆ρ, if the macromolecules that are measured do not have uniform 
scattering densities within the molecule (Perkins, 1988). Stuhrmann analyses (Ibel & 
Stuhrmann, 1975) of the RG
2 as a function of ∆ρ
-1 give information about the internal 
structure of the macromolecule: 
RG
2 = RC
2 + α· ∆ρ
–1– β· ∆ρ
–2 
RC is the RG at infinite contrast (∆ρ
–1 = 0). The term α is the radial distribution of 
scattering density fluctuations within the macromolecule. The term β is the curvature of 
the Stuhrmann parabola, and measures the effect on RG from the ∆ρ dependent change 
of the centre of gravity (Perkins, 1988). A similar analysis can be made using the RXS
2 
values. For protein-protein complexes and two-component centro-symmetric complexes 
with two different scattering densities, β is negligible, and therefore the Stuhrmann 
analyses should give linear RG
2 plots as a function of ∆ρ
–1, and the slope of the plots can 
give the valued of α. For macromolecules which have two asymmetrically distributed 
centres of scattering densities, such as macromolecules with two asymmetrically 
distributed components, one of which has been heavily deuterated, the Stuhrmann plot 
is a parabola, and β, the curvature, provides the distance between those two centres of 
gravity (Perkins, 2001a). 
 
4.2.5.2 Distance distribution function analyses 
 
The scattering curve I(Q) represents the macromolecular structure in reciprocal space. 
By using Fourier transformation over 0 ≤  Q ≤  ∞, the scattering curve I (Q) can be 
converted into the distance distribution function P(r) (Figure 4.10 e, f), which reveals 
the particle shape in real space: 
(Qr)dQ   I(Q)Qr    
2
1
  =   P(r)
0
2 sin ∫
∞
π
 
where  P(r) corresponds to the distribution of distances r between any two volume 
elements within one particle weighted by the product of their respective  scattering   90
densities. In general, P(r) termination errors occur, because data points are missing at 
low Q values because of the beam stop, or are truncated at large Q at the edge of the 
detector. This problem can be dealt with by using the Indirect Transform Procedure 
which fits the experimental curve to B-splines that are then transformed to give P(r). 
This was performed using the GNOM program which does this semi-automatically 
(Semenyuk & Svergun, 1991). 
 
Several important results can be obtained from P(r) analyses. First of all, P(r) analyses 
give an alternative calculation of the RG and I(0) values based on the whole scattering 
curve, which complements the Guinier analyses made at low Q values. Secondly, at the 
point at which the P(r) becomes zero, the r value gives the dimension L of the 
macromolecule. Thirdly, the r value of one or more maxima M corresponds to the most 
common distance between any two volume elements within the macromolecule.  
 
Experimentally, P(r) curves are finalized according to several criteria: Firstly, the P(r) 
curve should exhibit positive values. Secondly, the RG value from the P(r) curves 
should agree with the RG value from Guinier analyses. Thirdly, when r is zero, P(r) 
should be zero. Fourthly, P(r) should be stable for different experimental I(Q) curves 
when the trial L value is varied over a reasonable range (Perkins, 1988; Perkins, 1994; 
Perkins, 2001a). 
 
4.2.6 Modelling of scattering curves 
 
4.2.6.1 Generation of atomic coordinates 
 
To generate trial structures for a multi-domain protein, first of all, atomic models for 
each domain are created. A search for any known atomic structures from 
crystallography or NMR deposited in PDB is needed.  If there is an atomic structure 
available for the domains of the protein, this atomic structure provides the basis for the 
models created by the automated modelling procedures. The structures from 
crystallography and NMR for individual domains provide the main constraint for the 
sphere modelling. If there is not any, the individual domains are modelled using the 
known sequences and structures of similar domains as templates to create homology 
models, and these homology modelling can be done by using a package such as   91
MODELLER. For glycosylated proteins, all the oligosaccharide chains need to be added 
onto the glycosylation sites on the atomic structures. Secondly, if the domains are 
connected by flexible linker peptide, then a library contains thousands randomised 
conformations is generated for each linker by using molecular dynamic methods. 
Finally, a full unhydrated trial atomic coordinate for the protein molecule is created by 
joining one of the randomised conformations of each linker with atomic structures of 
the domains. A large number of these unhydrated trial coordinates, typically in a range 
of 2,000 -10,000, are generated to be able to produce best-fit models for the 
experimental data. The generation of random trial coordinates, the “search”, can be 
carried out in other different ways such as translational search and rotational search. A 
translational search does not change the domains’ rotational position, but optimise the 
relative distances between each domain. On the contrary, a rotational search keeps the 
inter-domain distance constant, but optimises the rotational position of each domain 
(Chamberlain et al., 1998; Perkins et al., 2009). 
 
4.2.6.2 Generation of sphere models 
 
The full trial atomic structure of the protein molecule is then converted into a sphere 
model which consists of hundreds of spheres of the same total volume as the original 
atomic model. Spheres are less power demanding for the processors than atoms. To do 
this, the coordinates of an atomic model are converted to spheres by putting the full 
coordinates in a three-dimensional grid of cubes of side about 0.55 nm in length, which 
is much less in length than the resolution 2π/Qmax of the scattering curves (Figure 4.11). 
A cube was included as a sphere in a model if it contained sufficient coordinates above 
a self-defined cut-off value, so that the total volume of all the cubes included in the 
model was close to the unhydrated volume calculated for the protein. The unhydrated 
sphere models can be used for neutron scattering curve calculations. X-ray scattering 
curves require hydrated models because of the hydration shell (Section 4.2.1.2). To 
create hydrated models, the hydration shell of a protein is added by assuming a 
hydration of 0.3 g water/g protein and an electrostricted volume of 0.0245 nm
3 per 
bound water molecule, and spheres corresponding to water molecules are added over 
the surface of the unhydrated sphere. The duplicated and excess water spheres are 
removed to match the calculated hydrated volume of the spheres with that calculated 
from the sequence (Perkins, 1998; Perkins, 2001b).  
9
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4.2.6.3 Generation of theoretical scattering curves 
 
The next step is to generate theoretical scattering curves of thousands of the sphere 
models. The scattering curve I(Q) is calculated using Debye’s Law adapted to spheres, 
by computing all the distances r from each sphere to the remaining spheres and 
summing the results. For macromolecules of a single density:  
⎟
⎟
⎠
⎞
⎜
⎜
⎝
⎛
+ = ∑
=
− −
m
j j
j
j Qr
Qr
A n n Q g
I
Q I
1
2 1 sin
2 ) (
) 0 (
) (
 
( ) ( )
6 6 2 / cos sin 3 ) ( R Q QR QR QR Q g − =  
where g(Q) is the squared form factor for the sphere of radius R, n is the number of 
spheres filling the body, Aj is the number of distances rj for that value of j, rj is the 
distance between the spheres and m is the number of different distances rj. This 
equation is suitable for proteins and for glycoproteins with low carbohydrate contents, if 
equally good scattering curve fits to the same model can be obtained with the X-ray data 
in positive contrasts and the neutron data in negative contrasts (Perkins, 2001a). If not, 
the equation has to be adapted for different densities (eg: protein-DNA complex). 
 
4.2.6.4 Identification of best-fit models 
 
The 2,000 – 10,000 theoretical scattering curves from the sphere models are then 
compared with the best experimental scattering curve (Figure 4.11). The unhydrated 
sphere models should be fitted to neutron scattering curves, whereas the hydrated sphere 
models should be fitted to X-ray scattering curves. The models are then selected by a 
trial-and-error process which uses three generous filters to remove unsatisfactory full 
models: Firstly, sterical overlap between the subunits can result during the creation of 
models. So the number of spheres in each model was compared to that expected from 
the volume calculated from the molecular sequence and composition. The model was 
retained if it has at least 95% of the total spheres expected. Secondly, the scattering 
parameters RG and RXS are calculated from each theoretical scattering curve. Models 
were retained if the modelled RG and RXS values were within 5% or ±0.3 nm from the 
experimental values. Thirdly, models were then assessed using a goodness-of-fit R-
factor ( ∑ ∑ − ⋅ exp exp ) ( ) ( ) ( 100 Q I Q I Q I cal ) to measure the agreement between 
calculated and observed scattering curves. If I(0) is set as 1000, good R-factor values   94
are less than 10%, and preferably less than 5%. A comparison between R-factor and RG 
values should show that the sphere models that give the lowest R-factors also give RG 
values close to the experimental RG value (Perkins, 2001a; Perkins, 2005). The 
identified best-fit models are double-checked by comparing the experimental 
sedimentation coefficient value with the calculated values from the models by using the 
HYDRO and HYDROPRO programme (Section 4.1.4). The difference between the 
experimental sedimentation coefficient value and the calculated values from the best-fit 
models should be within 0.21 S (Perkins et al., 2009). 
 
4.2.7 Advantages of solution scattering 
 
There are two essential advantages of solution scattering. Firstly, it can describe a 
protein structure in near-physiological conditions, for comparison with the structures 
seen in high or low salt obtained by crystallography. Secondly, using known atomic 
structure, modelling of the scattering curves can be largely constrained to produce 
structures that are deposited in PDB and can be visualised. Compared to X-ray 
crystallography, solution scattering can provide information about large-scale 
conformational changes of macromolecular interactions and the oligomerization of the 
macromolecule. It can also study macromolecules which cannot be crystallized. Unlike 
2D-NMR spectroscopy which has a macromolecular size limitation about 25,000 Da, 
solution scattering can study macromolecules of mass 10,000 Da upwards (Perkins, 
2001a). To sum up, solution scattering is a multi-parameter diffraction method which 
can provide very useful information about the overall structure of biological 
macromolecules. 
  
4.3 Surface plasmon resonance 
 
4.3.1 Principles underlying surface plasmon resonance 
 
Surface plasmon resonance (SPR) is a phenomenon based on the excitation of surface 
plasmons (electromagnetic waves which propagates along the interface between media 
of different refractive indexes such as a dielectric and a metal) by incident light 
(Homola, 2003). The electromagnetic field of surface plasmons is confined at the 
interface and deceases exponentially with the distance from the interface. The effective   95
penetration depth is about 20% of the wavelength of the incident light. The Biacore
TM, 
manufactured by GE Healthcare, is the most widely used SPR-based system which 
exploits the SPR phenomenon to monitor interactions between molecules in real time. A 
SPR sensor chip in a Biacore
TM system contains a glass surface covered with a thin gold 
film. In Biacore
TM systems, the excitation of surface plasmons is achieved by means of 
prism coupling (Figure 4.12 a). Light waves (wavelength about 800 nm for Biacore
TM) 
with a range of incidence angles pass through a high refractive index prism, and are 
then reflected at the interface between the glass and the gold film. The incident light can 
excite surface plasmons along the interface between the gold film and the glass only at a 
certain combination of incidence angle and wavelength of the light (Homola, 2003). As 
a result, the intensity of reflected light waves drops at certain angle which is called the 
“SPR angle” (Figure 4.12 b). At the SPR angle, the energy of the incident light is 
absorbed to generate electromagnetic waves. The changes to the refractive index of the 
solution at the surface of the sensor chip within the effective penetration depth (150 nm 
for Biacore
TM system) of the electromagnetic field can lead to the shifts of the SPR 
angle which are detected in real time by the Biacore
TM system. Therefore the refractive 
index on the sensor chip surface is monitored in real time (Biacore® Sensor Surface 
Handbook, 2003). 
 
The interactions between two different molecules are monitored by attaching one 
molecule onto the sensor chip surface, and passing the other molecule in solution over 
the sensor chip surface. In SPR assays, the reactant immobilised on the sensor chip 
surface is termed as the ligand, whereas the reactant in solution is termed as the analyte. 
The interaction between the ligand and the analyte leads to changes in mass in the 
aqueous layer (150 nm in thickness) close to the sensor chip surface, which then leads 
to changes in the refractive index that are detected by the Biacore
TM system (Figure 4.12 
b) (Torreri et al., 2005).  
 
4.3.2 Sensorgram 
 
In Biacore
TM systems, the sample solution which contains analyte is injected over the 
sensor chip surface in a continuous, pulse-free fashion at a controlled speed. The mass 
close to the sensor chip surface increases when the analytes bind to the ligands 
immobilised on the surface, and decreases when the analytes disassociate from the   96
 
 
Figure 4.12 Surface plasmon resonance principles (Adapted from An introduction to 
Biacore®’s SPR technology, 2002). (a) Excitation of surface plasmons. (b) At the SPR 
angle, the intensity of the reflected light drops. The change of mass close to the sensor 
chip surface leads to the shift of the SPR angle.   97
ligands. A SPR signal response caused by the surface mass change is proportional to the 
concentration of bound analytes, and is measured in resonance units (RU). One RU 
represents approximately 1 pg of bound protein /mm
2 ( Van der Merwe, 2001). A 
sensorgram shows the change of the response as a function of time which shows the 
progress of the interaction. The sensorgram of an SPR assay is generated in real time 
and directly displayed on the computer screen during the course of the experiment. A 
typical SPR assay contains five different stages (Figure 4.13). At the first stage, the 
running buffer is flowing over the sensor chip surface, and the response value at this 
stage is considered to be the baseline. The baseline should be stable to obtain reliable 
measurements. The second stage is the sample injection which shows the association 
phase of the interaction. During the sample injection, the observed upward slope of the 
sensorgram shows that the association rate is bigger than the dissociation rate. The 
binding rate decreases as more ligand sites are occupied by the analyte. If the sample 
injection stage lasts long enough, a steady state of the sensorgram should be reached 
when the association rate is equal to the dissociation rate. The next stage after sample 
injection is when the sample solution is replaced by the running buffer flowing over the 
sensor chip surface. At this stage, the slope of the sensorgram is downward, as the 
analyte disassociate from the ligand and are washed away by the continuous flow of the 
running buffer. At the fourth stage, the regeneration buffer is flowed over the surface to 
disassociate any remaining analyte on the sensor chip surface. At the final stage after 
regeneration, the regeneration buffer is replaced by the running buffer, and the response 
should be back to the baseline if the regeneration is successful 
(http://www.biacore.com; Torreri et al., 2005). 
 
4.3.3 Applications 
 
SPR assays have been used to study many biosystems: proteins, oligonucleotides, 
oligosaccharides, lipids, small molecules (as small as 100 Da), phage, viral particles and 
cells (Rich & Myszka, 2000). There are three types of SPR assays including binding 
analysis, equilibrium analysis and concentration analysis that can be performed 
depending on what characters of the interactions need to be determined.  
   98
 
 
Figure 4.13 Typical sensorgram of a surface plasmon resonance assay (Adapted from 
An introduction to Biacore®’s SPR technology, 2002).   99
4.3.3.1 Binding analysis 
 
The easiest SPR assay is the binding analysis which is used to characterise the 
specificity of biomolecular interactions, and measure the degree of binding between 
different molecules. The results from such analyses are evaluated by using maximum 
binding report point values or bar charts, and the information from the association and 
dissociation phase of the interaction is not needed. A typical example of the binding 
analysis application is to evaluate the correct folding of recombinant proteins. The 
binding site of a protein molecule to its natural ligand involves multiple residues that 
are usually far apart in the sequence. Therefore, if a recombinant protein molecule is 
correctly folded to have the same structure as its native counterpart, then it should be 
able to bind to its natural ligands. The binding of recombinant protein to its natural 
ligands or to the monoclonal antibodies of its native counterpart can be easily checked 
by performing binding analyses in the Biacore
TM system (Van der Merwe, 2001; 
Biacore® Sensor Surface Handbook, 2003).   
 
4.3.3.2 Equilibrium analysis 
 
An equilibrium analysis is used to determine the kinetics and affinity of an interaction, 
by interpreting the sensorgrams of sequential injections of an analyte at different 
concentrations in terms of molecular interaction models. Each concentration of the 
analyte is run in a separate cycle, and the analyte should be completely removed from 
the sensor chip surface after the regeneration stage in each cycle. The dissociation 
constant  KD of an interaction can be determined from the steady state affinity 
measurements and from the kinetic rate constants. The change of steady-state response 
(Req) is plotted as a function of the analyte concentrations (C). In the Biacore X100 
evaluation software (version 1.1), this function is fitted into a model of a 1:1 interaction 
which can be expressed in the equation: 
RI
C K
CR
R
D
eq +
+
=
max  
where Rmax is the maximum binding capacity of the sensor chip, and RI is the bulk 
refractive index which represents the contribution of buffer to the signal. Other use-
defined models can also be used. For the KD values determined from the steady-state 
affinity measurements to be reliable, most of the sequential sensorgrams should reach   100
the steady state, and the response value should be measured at or close to steady-state 
binding levels. The concentration range of the analyte needs to be wide enough to give a 
good curve fitting. Ideally, the highest concentration of analyte should be higher than 
twice of the KD value (Biacore
TM X100 Handbook, 2008).    
 
The KD value can also be derived from the kinetic constants which describe how fast the 
ligand and analyte associate and dissociate. The association rate constant (M
-1s
-1) is 
defined as ka, and the dissociation rate constant (s
-1) is defined as kd. The value of KD 
can be determined by a d D k k K = . In the Biacore X100 evaluation software (version 
1.1), there are several predefined mathematical models used to interpret the sensorgram 
of an interaction. The default model is the 1:1 interaction model:  AB B A ↔ +  in which 
the association of the reactants can be expressed by 
] [ ] [
] [
B A k
dt
AB d
a ⋅ ⋅ = , 
and the disassociation of the complex can be expressed by 
] [
] [
AB k
dt
AB d
d ⋅ =
−
. 
Therefore the concentration changes in the interaction can be described in the equation: 
] [ ] [ ] [
] [
AB k B A k
dt
AB d
d a ⋅ − ⋅ ⋅ =  
The concentration of the complex [AB] is given by the response value R. The 
concentration of the free analyte [A] over the surface is known and is constant in each 
cycle. The [A] is expressed as C here. The concentration of the free ligand [B] can not 
be measured directly, but can be expressed as R R − max . The equation above can be 
transformed as: 
R k R R C k
dt
dR
d a − − = ) ( max . 
In the disassociation phase in a sensorgram, since the free analyte is washed away by 
the running buffer, the value of C is zero, and therefore 
R k
dt
dR
d = . 
The values of ka and kd, and thus KD, can derived from analysing the association phase 
and the disassociation phase in a sensorgram. Global fitting of sequential sensorgrams 
of different analyte concentrations gives more reliable kinetic constants values.   101
However, if the interaction associates and dissociates so fast that the ka value is outside 
the range of 3 x 10
2 M
-1s
-1 to 3 x 10
7 M
-1s
-1 and the kd value is outside the range of 10
-5 
s
-1 to 10
-1 s
-1, then the kinetic rate constants cannot be measured accurately (Biacore
TM 
X100 Handbook, 2008).  
 
4.3.3.3 Concentration analysis 
 
Concentration analysis is used to determine the concentration of specific molecules 
present in a sample, by comparing the observed response value with a calibration curve 
of known samples. The calibration curves may be linear or curved. Compared with the 
conventional interaction-based methods such as ELISA which only provide end-point 
measurements, the concentration analysis by using Biacore monitors the binding in real 
time, and therefore can provide both rate-based and end-point measurements. In 
addition, there is no need to use labels for the detection (Biacore® Concentration 
Analysis Handbook Version AA, 2001).  
 
4.3.4 Sensor surface 
 
As mentioned in Section 4.3.1, a sensor chip in Biacore
TM system contains a glass 
surface covered with a thin layer of gold. The unmodified gold surface is not suitable 
for interaction in biosystems, and therefore the gold surface of most of the Biacore 
sensor chips is coated with a layer of molecules that are covalently bound. This extra 
molecule layer prevents the biomolecules from contacting the gold, and can be designed 
to suit different ligand-immobilisation chemistry.  
 
CM-series sensor chips have gold layers covalently bound with a matrix of 
carboxymethylated dextran. The CM-series sensor chips are designed for covalent 
attachment of biomolecules used as the ligands to the surface by using a variety of 
chemical methods exploiting amino groups, aldehyde groups of the ligands, or thio-
disulfide exchanges between the ligands and the surface matrix. The carboxymethylated 
dextran matrix provides a hydrophilic environment for the attached molecules, and 
preserves them in a non-denaturated state. In addition, the flexibility of the matrix 
allows relatively free movements of the attached ligands. The sensor chip CM5 used in 
Chapter 7 is the most common used chip for general purposes. It has a   102
carboxymethylated dextran layer that extends about 100 nm from the gold surface in 
physiological buffer conditions, and provides a high capacity for immobilisation of a 
wide variety of biomolecules. The sensor chip CM4 also used in Chapter 7 is similar to 
CM5 chip but has only 30% of the degree of carboxymethylation, which leads to 
reduced immobilisation capacity and surface charge density. The non-specific binding 
of positive charged molecules to the surface is reduced as a result of the lower surface 
charge density (Biacore® Sensor Surface Handbook, 2003).  
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Chapter Five 
 
Implications of the progressive self-association of heterozygous human factor H for 
complement regulation and disease    104
5.1 Introduction 
 
In the human innate immune defence system, the central complement component C3 is 
activated to C3b by the cleavage and removal of the small anaphylatoxin C3a to initiate the 
alternative pathway in serum. C3b is regulated by factor H (FH) in order to prevent 
complement-mediated host cell damage, in which FH acts as a cofactor for factor I 
cleavage of C3b to form iC3b, accelerating the decay of the C3 convertase C3bBb, and 
competing with factor B for binding to C3b (Whaley & Ruddy, 1976; Weiler et al., 1976; 
Pangburn et al., 1977; Farries et al., 1990; Law & Reid, 1995).
 FH is comprised of 20 short 
complement regulator (SCR) domains, each of length about 61 residues. SCR domains, 
also known as short consensus repeats, Sushi or complement control protein domains 
(Soares and Barlow, 2005), constitute the most abundant domain type in complement 
proteins. There are multiple binding sites for C3b within the 20 SCR domains (Sharma & 
Pangburn, 1996; Jokiranta et al., 2000), and likewise there are multiple binding sites for 
heparin (Blackmore et al., 1996; Blackmore et al., 1998; Ormsby et al., 2006; Prosser et 
al., 2007). FH regulates surface-bound C3b activity by recognising charge (anionic) 
clusters on the surfaces of host cells that are mimicked by heparin. The initial contact with 
host cells is made through its C-terminal end, which is followed by N-terminal regulatory 
activity (Oppermann et al., 2006; Ferreira et al., 2006). Polymorphisms and mutations in 
FH have been associated with age-related macular degeneration (AMD) (Klein et al., 2005; 
Haines et al., 2005; Edwards et al., 2005; Hageman et al., Saunders et al., 2007), the most 
common cause of blindness in the elderly in the Western world, and also with atypical 
haemolytic uraemic syndrome (aHUS) (Saunders et al., 2007; Dragon-Durey & Frémeaux-
Bacchi, 2005), a rare disease leading to renal failure that affects all ages but primarily 
children and young adults (http://www.fh-hus.org). The involvement of FH indicates that 
complement activation and regulation in the retina and the kidney endothelium has been 
impaired.  
 
Intact FH has not been crystallised to date for reason of its size, glycosylation and inter-
SCR flexibility. Thus solution scattering and electron microscopy methods have been 
applied to show that the FH SCR domain structure is not fully extended in solution (Perkins   105
et al., 1991; DiScipio, 1992; Aslam and Perkins, 2001). X-ray scattering and 
ultracentrifugation data in combination with constrained scattering modelling is a powerful 
approach that resulted in the first molecular structures for FH and its SCR-6/8, SCR-1/5 
and SCR-16/20 fragments (Perkins et al., 1998; Aslam & Perkins, 2001; Fernando et al., 
2007; Perkins et al., 2008; Okemefuna et al., 2008). Homology models for the SCR 
domains provided many of the first structural explanations for AMD and aHUS (Aslam & 
Perkins, 2001; Perkins & Goodship, 2002; Saunders et al., 2006). AMD was associated 
with a common Tyr402His polymorphism which is located at the surface of SCR-7 and 
close to a heparin binding site. The aHUS related mutations cluster at the surface of SCR-
20 and to a lesser degree in SCR-16 to SCR-19, and are associated with another heparin 
binding site. The distribution of over 100 genetic alterations (http://www.fh-hus.org) 
showed that the observed clinical phenotype is correlated with their structural location 
(Saunders et al., 2007). NMR and crystal structures, starting with those for SCR-5 and 
SCR-15/16, and more recently extended to those for SCR-6/8 and SCR-19/20, have 
confirmed and extended these predictions (Soares & Barlow, 2005; Prosser et al., 2007; 
Barlow et al., 1992; Barlow et al., 1993; Jokiranta et al., 2006; Herbert et al., 2007). Even 
with these structures, there are no clear indications of a molecular mechanism involving FH 
that leads to AMD. 
 
One of the hallmarks of AMD is the appearance of drusen, an amyloid plaque-like 
deposition in Bruch’s membrane, a layer interposed between the retinal pigment epithelium 
and the choroidal vasculature (Bird, 1992; Bird, 1995). These deposits contain oxidized 
lipids and many aggregated proteins including FH (Hageman  et al., 2001). The self-
association properties of FH are thus relevant to drusen formation. FH was originally 
shown to be monomeric by ultracentrifugation (Sim & DiScipio, 1982). Dimeric FH was 
demonstrated by scattering, but this observation could not be subsequently replicated 
(Perkins  et al., 1991;  Aslam & Perkins, 2001). Partial FH SCR-15/18 and SCR-15/20 
dimers were however observed by non-reducing SDS-PAGE, and SCR-1/7 was observed to 
interact with SCR-1/20 by surface plasmon resonance (Jokiranta et al., 2000; Oppermann et 
al., 2006). Ultracentrifugation and scattering studies showed that SCR-6/8 and SCR-16/20 
(but not SCR-1/5) exhibit weak monomer-dimer associations (Fernando  et al., 2007;   106
Okemefuna et al., 2008). These studies indicate at least two potential dimerisation sites in 
FH. In combination, the two sites would constitute a mechanism for its continual self-
association that would lead ultimately to aggregate formation. In this chapter, the re-
investigation of the oligomerisation properties of native heterozygous FH is explained. Due 
to the use of improved scattering and ultracentrifugation instrumentation and analyses, a 
monomer-dimer equilibrium of heterozygous FH at physiological concentrations and 
multiple oligomers of heterozygous FH at higher concentrations have been observed. The 
implications of this result for complement regulation and AMD is also discussed in this 
chapter. This chapter is a preliminary study which sets up the basis for the studies in 
Chapter 6, 7 and 8.  
 
5.2 Results and discussion 
 
5.2.1 X-ray scattering of FH oligomers 
 
The X-ray scattering radius of gyration (RG) of FH monitors its degree of elongation.  FH 
prepared two days beforehand was studied on Instrument ID02 at the ESRF in eight 
concentrations between 8.7 mg/ml to 0.43 mg/ml in HEPES buffer (Figure 5.1) (Narayanan 
& Bosecke, 2001). Here improved Guinier RG fits were obtained at lower Q values 
compared to the previous X-ray measurements at the SRS at Daresbury (Q = 4π sin θ /λ  
where 2θ = scattering angle, and λ = wavelength) (Perkins et al., 1991; Aslam & Perkins, 
2001). Due to the higher beam intensities at ESRF, improved signal-noise ratios were 
obtained (Figure 5.1 a, b). There is better control of radiation damage on Instrument ID02 
as this is monitored on-line during data acquisition. The Guinier RG and its cross-sectional 
radius of gyration RXS-1 parameters but not its RXS-2 parameter and the associated intensity 
I(0)/c parameters showed small but visible concentration dependences (Figure 5.2 a, b, c, 
d). The RXS-2 parameter differs from SCR protein to protein, and generally monitors the 
averaged short-range degree of bend between two or three adjacent SCR domains along the 
length of the protein (Aslam & Perkins, 2001). An additional medium-range proximity 
relationship between non-neighbouring SCR domains that are further apart in the sequence 
leads to the observation of the RXS-1 region (Aslam & Perkins, 2001). This weak   107
 
 
 
 
Figure 5.1 Guinier analyses for heterozygous FH at a series of concentrations. 
 
(a) Guinier RG plots of ln I(Q) vs. Q
2 at low Q values for heterozygous FH at concentrations 
of 8.69 mg/ml, 6.08 mg/ml, 4.34 mg/ml, 2.61 mg/ml and 0.87 mg/ml. The Q fit range was 
0.06 - 0.13 nm
-1 The filled circles correspond to the I(Q) data used to determine the RG 
values, and the straight line correspond to the best fit through those points. The Q.RG  
ranges used in the fits are arrowed.   
 
(b) The corresponding Guinier cross-sectional RXS-1 fits of ln I(Q).Q vs. Q
2 for the same 
five scattering curves in a Q range of 0.16 - 0.26 nm
-1 are shown  The RXS-2 fits in a Q range 
of 0.4 - 0.8 nm
-1  are not shown.   108
 
Figure 5.2 Dependence of Guinier parameters on FH concentrations. Concentration 
dependence of the RG in (a), I(0)/c in (b) RXS-1 values in (c) and RXS-2 values in (d) (O). Each 
value was measured in quadruplicate and averaged. Statistical error bars are shown where 
visible. These data were fitted by linear regression. The open triangles (∆) correspond to 
the RG and I(0)/c parameters from the distance distribution function. The filled triangles 
(▲) correspond to data measured in PBS buffer.  
    109
concentration dependence showed that FH oligomerisation had occurred. Data obtained 
using phosphate buffered saline (PBS: 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 
1.15 mM KH2PO4, pH 7.4) were consistent with the HEPES data (Figure 5.2 a, c). The RG 
value extrapolated to zero concentration is 8.90 (± 0.19) nm, while RXS-1 is 2.51 (± 0.06) nm 
and RXS-2 is 1.79 (± 0.01) nm. If the slope of the I(0)/c parameter as a function of FH 
concentration (Figure 5.2 b) corresponds to a monomer-dimer equilibrium, the resulting 
dissociation constant KD is estimated to be about 100 µM. This is comparable with the KD 
values of 40 µM and 16 µM observed for the SCR-6/8 and SCR-16/20 fragments 
respectively (Fernando et al., 2007; Okemefuna et al., 2008). 
 
The present RG values for FH are lower than previous. This was shown by comparisons of 
Figure 5.1 here with Figure 3 of the 2001 analysis (Aslam & Perkins, 2001) and Figure 2 of 
the 1991 analysis (Perkins et al., 1991). From 2001, the apparent RG value was 11.4 (± 0.4) 
nm, RXS-1 was 4.4 (± 0.2) nm and RXS-2 was 1.7 (± 0.1) nm. From 1991, the apparent RG 
value was 12.4 (± 0.4) nm, RXS-1 was 3.6 (± 0.4) nm and RXS-2 was 1.8 (± 0.3) nm. These 
earlier values were confirmed by reanalyses of the earlier data files retrieved from archives. 
The difference is attributed to the presence of minor aggregation in 2001 and a greater level 
of aggregation in 1991, together with worsened signal-noise ratios in 2001 and 1991. These 
issues may have masked the presently observed concentration dependence in FH. 
Previously it was thought that alkaline pH values would cause FH to self-associate (Aslam 
& Perkins, 2001). This was not confirmed after sample dialysis for 2 days at pH 11.9, 
followed by X-ray measurement.  
 
The P(r) function summarises all the distances between pairs of atoms within FH, and gives 
an independent calculation of the RG and I(0) values that is based on the full scattering 
curve, and gives the maximum length of FH, denoted L. The P(r) RG and I(0)/c values were 
in good agreement with the Guinier RG values (Figure 5.2 a, b). The eight P(r) curves show 
a concentration-independent peak M1 at r = 4.8 ± 0.3 nm. A second peak M2 was observed 
at r = 10.2 ± 0.6 nm, and, as the concentration increased, peak M2 increases in its relative 
intensity. L increased from 32 nm at 0.9 mg/ml to 38 nm at 8.7 mg/ml (Figure 5.3).  These 
changes are attributed to oligomer formation in FH. The value of L between 32-38 nm is   110
 
 
 
Figure 5.3 Dependence of distance distribution P(r) analyses on FH concentrations. The 
four P(r) curves correspond to concentrations of 0.87 mg/ml (green), 2.61 mg/ml (red), 
6.08 mg/ml (blue), and 8.69 mg/ml (cyan). The peaks in the P(r) curves are denoted as M1 
at 4.9 nm and M2 at 10.3 nm. The maximum length L was determined to be 32 nm, 35 nm 
and 38 nm (numbered 1, 2 and 3). The intensities of the four P(r) curves are normalised 
using the peak M1 in order to show the concentration dependence of peak M2 and L more 
clearly.  The dashed line corresponds to the P(r) curve obtained in 2001 for FH at 3.56 
mg/ml in Tris-HCl buffer (Aslam & Perkins, 2001), for which L was determined to be 40 
nm (numbered 4).   111
about half the length of 73 nm expected if the 20 SCR domains in FH are in a fully 
extended arrangement. When compared with the P(r) curve from 2001 at 3.6 mg/ml in 25 
mM Tris-HCl, 140 mM NaCl, 0.5 mM EDTA buffer, pH 7.4, the intensity of peak M2 is 
now greater than M1, and L is 40 nm (Figure 5.2 d) (Aslam & Perkins, 2001). This 
difference is consistent with the presence of minor aggregation in FH from 2001. The 
superimposition of the I(Q) curves from 1991 and 2001 upon the current ones shows 
increased intensities at low Q that are consistent with aggregation (Figure 5.4).  The P(r) 
curves show that the SCR domains in FH are bent or folded back upon themselves in 
solution, both for the monomer and its oligomeric and aggregated forms (Figure 5.3). 
 
5.2.2 Sedimentation equilibrium of FH oligomers 
  
Sedimentation equilibrium experiments were performed on heterozygous FH samples in 
HEPES buffer prepared 16 days beforehand. Data were acquired at 4°C, 20°C and 37°C at 
concentrations between 0.07 mg/ml to 7.11 mg/ml and four rotor speeds between 8k r.p.m. 
and 20k r.p.m. Data were fitted using SEDPHAT v4.10b software both individually and 
globally (Schuck, 2003). Similar fit outcomes were obtained with the data at three different 
temperatures. In the individual fits, the fitting of a monomer-dimer model to the 11k data at 
1.32 mg/ml gave a reduced χ
2 value of 3.7 compared to that of 34.8 from a monomer model 
using the same data. In global fits up to 1.32 mg/ml, and based on a fixed molecular weight 
of 145 kDa, the monomer-dimer model (reduced χ
2 of 11) gave significantly improved fits 
compared to a monomer model that gave a high molecular weight of 187 kDa and an 
increased reduced χ
2 of 22. Low random residuals were obtained (upper nine fits in Figure 
5.5). This showed that a monomer-dimer equilibrium existed in a physiological 
concentration range. 
 
At higher FH concentrations, the formation of higher oligomers was detected. Between 
2.86 – 7.11 mg/ml, the monomer-dimer model did not result in good fits. Large deviations 
in the residuals were consistent with aggregate formation (lowest three fits in Figure 5.5) 
(McRorie & Voelker, 1993). Tests with other fit models based on the inclusion of trimers 
or tetramers gave no improvement in the residuals or reduced χ
2 values. The reduced χ
2   112
 
Figure 5.4 Comparison of current and previous X-ray scattering data of heterozygous FH. 
The X-ray scattering curves for FH used in this chapter (Section 5.2.1; Nan et al., 2008) are 
compared with the previous published X-ray scattering curves in 1991 (Perkins et al., 1991) 
and in 2001 (Aslam & Perkins, 2001). Both the previous mesurements were done at the 
Daresbury synchrotron, and the concentrations of heterozygous FH used were 2.0 mg/ml in 
1991 and 3.6 mg/ml in 2001. The X-ray scattering curve in this chapter was obtained at the 
ESRF synchrotron, and the concentration was 4.3 mg/ml. The continuous line corresponds 
to the distance distribution function P(r) fitted curve in this chapter, which is then 
compared with the 1991 and 2001 curves. The Q ranges used to report the RG, RXS-1 and 
RXS-2 values from the scattering data are indicated as arrowed.  
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Figure 5.5 Sedimentation equilibrium of heterozygous FH. The upper nine panels show the 
outcome of a global fit using SEDPHAT when the equilibrium curves of five 
concentrations between 0.07 mg/ml to 1.32 mg/ml of FH at 20
oC were fitted to the 
“monomer-dimer self-association” model using the “M and s” fitting routine. The fit 
residuals are shown above each panel. The lower three panels show the poor fits to the 
monomer-dimer self-association model when higher concentrations of FH (2.86 mg/ml, 
7.11 mg/ml) were fitted.    114
values of between 269 to 980 for these fits at higher concentrations showed that neither 
monomer-dimer, monomer-dimer-trimer or monomer-dimer-tetramer self-association 
models would fit. Hence these data do not correspond to an equilibrium between monomers 
and higher oligomers.  
 
5.2.3 SDS-PAGE and size-exclusion gel filtration of FH oligomers 
 
Non-reducing SDS-PAGE of the samples at three concentrations including 0.16 mg/ml, 
1.42 mg/ml and 2.74 mg/ml after ultracentrifugation showed that a dimer band was 
observed at the higher concentrations used, and fainter bands corresponding approximately 
to trimers and tetramers could be observed (Figure 5.6 b). There are no unpaired Cys 
residues in FH that would explain this. The size-exclusion gel filtration of heterozygous FH 
in the original purification showed the single homogenous peak between 65 ml and 75 ml 
of FH and a small peak at about 80 ml corresponds to residual human serum albumin which 
was then removed (Figure 5.6 a). The size-exclusion gel filtration of the equilibrium FH 
samples 78 days after their original purification showed that the single homogenous peak of 
FH between 65 ml and 75 ml was supplemented by additional peaks that eluted between 50 
ml and 65 ml (Figure 5.6 a). This showed that oligomers had formed during the 
ultracentrifugation experiment and the subsequent sample storage at 4°C.  
 
5.2.4 Sedimentation velocity of FH oligomers 
 
The sedimentation coefficient s 20,w monitors macromolecular elongation, and provides an 
independent monitor of the scattering data through its ability to detect sample 
polydispersity. Sedimentation velocity experiments were performed at four rotor speeds 
between 25k r.p.m. and 60k r.p.m. using three FH preparations at nine concentrations 
between 0.07-5.9 mg/ml in HEPES buffer and between 0.05-0.35 mg/ml in PBS buffer. 
Data analyses utilised size-distribution c(s) analyses in SEDFIT v9.3b in order to identify 
species other than monomeric FH (Schuck, 1998; Schuck, 2000). At all concentrations, 
monomeric FH was observed to sediment at s 20,w = 5.65 (± 0.05) S. This is in good 
agreement with previous determinations of the s 20,w value of 5.5 S to 5.6 S and 5.3 ± 0.1 S    115
 
 
Figure 5.6 Size-exclusion gel filtration and non-reducing SDS-PAGE analyses of 
heterozygous FH.  
 
(a) FH samples at 3 mg/ml were loaded onto a Superose
TM 6 prep grade XK 16/60 column 
following purification (black) and 78 days after purification (red). The elution positions of 
three molecular mass standards are shown.  
 
(b) Non-reducing SDS-PAGE analyses of FH after ultracentrifugation. Lane A: Himark
TM 
Prestained High Molecular Weight Standard, labelled to the left; Lane B: 0.16 mg/ml FH; 
Lane C: 1.42 mg/ml FH; Lane D: 2.74 mg/ml FH. The higher molecular weight bands seen 
in FH are labelled on the right by 1, 2, 3 and 4 to denote monomer, dimer, trimer and 
tetramer.  116
(Whaley & Ruddy, 1976; Aslam & Perkins, 2001; Fernando et al., 2007).
  
 
A concentration dependence of the c(s) distributions was observed. At 0.17 mg/ml, the 
shape of the sedimentation boundaries indicated a predominantly single sedimentation 
species (Figure 5.7 b). For 0.17 mg/ml and 0.63 mg/ml of heterozygous FH in either 
HEPES or PBS buffer, a second peak was observed in the c(s) analyses at 9.2 ± 0.5 S and 
its relative intensity increased with concentration (Figure 5.7 c). The c(M) size distribution 
plots showed that the major peak at 5.56 S corresponds to a molecular weight of 142 ± 2 
kDa. This is consistent with the global fit of the sedimentation equilibrium data (Figure 
5.5). At higher FH concentrations and using a one-day old FH preparation, the 
sedimentation boundaries of heterozygous FH at 5.92 mg/ml indicated a more complex 
sedimentation profile (Figure 5.7 a), and the peak at about 7.3 S is 7% of the intensity of 
the major peak at 5.56 S. As the concentration of FH increased from 1.53 mg/ml to 5.92 
mg/ml, six smaller sedimentation species were consistently observed at s values of 7.3 (± 
0.2) S, 9.2 (± 0.2) S, 11.3 (± 0.4) S, 13.4 (± 0.06) S, 15.4 (± 0.2) S and 17.2 (± 0.4) S at 50k 
r.p.m. This suggested that FH formed not only dimers but also trimeric to heptameric 
oligomers in small but significant amounts of about 15% in total.  
 
This interpretation was verified starting from the four best-fit glycosylated FH models 
previously generated by constrained scattering modelling done in 2001 (Aslam & Perkins, 
2001). The present RG value of 8.9 nm for monomeric FH (Figure 5.2 c), meant that these 
previous models with a RG value of 9.9 nm in 2001 were now too elongated. Thus linkers in 
one of the previous four best-fit FH models were adjusted in order to generate a more 
compact SCR arrangement. In satisfactory agreement with the experimental s value of 5.65 
S, a s 20,w value of 5.2 S was obtained from this glycosylated model using HYDROPRO v7c 
(Garcia de la Torre et al., 2000), using the default value of 0.31 nm for the atomic element 
radius for all atoms in order to represent the hydration shell. The s 20,w calculations were 
insensitive to the presence or absence of six biantennary oligosaccharide chains at Asn511, 
Asn784, Asn804, Asn864, Asn893 and Asn1011 (mature protein numbering) (Aslam & 
Perkins, 2001). If a FH monomer became spherical in its shape, the maximum possible s20,w 
value would be 9.4 S. Hence postulating the occurrence of conformational changes in    117
 
Figure 5.7 Sedimentation velocity of heterozygous FH.  
 
(a) The 200 scan boundaries for FH at 5.92 mg/ml at 50k r.p.m. were fitted using Lamm 
equation fits with SEDFIT. Only every tenth scan is shown for reason of clarity.  
 
(b) The corresponding boundary fits are shown for FH at 0.17 mg/ml at 40k r.p.m.. Other 
details follow (a).  
 
(c) In the five c(s) size-distribution analyses, the major sedimentation species at 5.56 S is 
labelled as 1. Its intensity was normalised in all five analyses for clarity. From bottom to 
top, the FH concentrations were 0.17 mg/ml, 0.63 mg/ml, 1.53 mg/ml, 2.99 mg/ml and 5.92 
mg/ml. The oligomeric FH peaks in increasing order of S values are labelled from 2 to 7. 
The five analyses are displaced by 10% of the intensity of peak 1.   118
monomeric FH is unable to explain the discrete peaks seen at the larger s values in the c(s) 
analyses for heterozygous FH at concentrations above 1.53 mg/ml (Figure 5.7 c).  
 
Modelling to account for oligomer formation was arbitrarily created from dimerisation sites 
at opposite ends of the FH monomer model. Oligomers were created using INSIGHT II 
98.0 molecular graphics software (Accelrys, San Diego, CA, USA) on Silicon Graphics 
OCTANE Workstations (Figure 5.8). The predicted s 20,w value for a dimer model in an 
extended conformation was 7.5 S, in good agreement with the observed peak at 7.3 S. The 
addition of a third monomer to this dimer model resulted in a predicted s 20,w values of 9.2 S, 
in good agreement with the observed peak at 9.2 S. Starting with the tetramer, it was found 
necessary to add further monomers in a more compact arrangement to give models with 
predicted s 20,w values that agreed within error of the experimental values. The movement of 
monomer 1 in the tetrameric model towards the centre of the model gave a predicted value 
of 11.3 S, in good agreement with the observed peak at 11.3 S. The pentamer, hexamer and 
heptamer models gave predicted values of 13.5 S, 15.2 S and 16.9 S respectively, which 
agreed well with the experimental values of 13.4 S, 15.4 S and 17.2 S respectively. These 
agreements support the assignment of the six additional peaks at high S values in the c(s) 
plots to a series of FH oligomers. 
 
5.3 Material and Methods 
 
5.3.1 Protein purification 
 
The purification of heterozygous FH for X-ray scattering and analytical ultracentrifugation 
experiments utilised a 3 litre pool of just-outdated anonymised human plasma from the 
Royal Free Hospital Blood Bank with an anti-FH monoclonal antibody Sepharose MRC-
OX23 column as described (Aslam & Perkins, 2001; Sim et al., 1993). About 50ml of 
mixed human plasma, made 5 mM with EDTA, was made 0.5 mM with protease inhibitor 
Pefabloc-SC
70, and then dialysed against Tris buffer (25 mM Tris-HCl, 140 mM NaCl, 0.5 
mM EDTA, pH 7.4).  To deplete proteins which bind to Sepharose or to IgG, the plasma 
was passed through a column of non-immune IgG immobilized on Sepharose.    119
 
 
Figure 5.8 Schematic models for FH oligomers observed in the sedimentation coefficient 
distribution analyses for sedimentation velocity data. Six schematic models for oligomers 
of FH are shown that yield the predicted s20,w values shown in brackets. The monomers are 
denoted by different colours and numbered. Monomers 2 and 3 are viewed in the same 
orientation in all the models except for the dimer.    120
Plasminogen/plasmin was then removed by passing the plasma through a lysine-sepharose 
column. After that, the plasma was passed through a monoclonal antibody column, MRC 
OX23-Sepharose specific for FH, at a rate less than 1ml/min. FH was then eluted with 
about 40ml of the chaotrope, 3 M MgCl2, pH 6.9. The material was dialysed against 
HEPES buffer (10 mM HEPES, 137 mM NaCl, pH 7.4) in the presence of 0.5 mM EDTA. 
The material was then passed through Hitrap Protein G HP column to remove any 
contaminant IgG. The FH concentration step at 4°C employed a gentle centrifugation 
approach without stirring (Amicon® Ultra-15 centrifugal filter devices with a molecular 
weight cut-off of 50 kDa at 2500 g). Non-specific aggregates of FH and human serum 
albumin were removed by gel-filtration on a Superose
TM 6 prep grade XK 16/60 column, at 
a flow rate of 1 ml/min and the HEPES buffer with 0.5 mM EDTA as the running buffer. 
The purified FH sample was reconcentrated by centrifugation. All FH samples were 
checked using SDS-PAGE before and after scattering and ultracentrifugation experiments. 
The electrophoresis was performed by using NuPAGE® Novex 3-8% Tris-Acetate Mini 
Gel and the standard protocol. An absorption coefficient of 16.7 (1%, 280 nm, 1 cm path 
length) was used to determine concentrations (Aslam & Perkins, 2001). Note that this value 
will be revised in Chapter 7 and 8 below.   
 
5.3.2 X-ray scattering data collection and analysis 
 
X-ray scattering data were obtained in three beam time sessions on the Beamline ID02 at 
the European Synchrotron Radiation Facility (ESRF), Grenoble, France operating with a 
ring energy of 6.0 GeV (Sim et al., 1993). Storage ring currents ranged from 63 mA to 65 
mA and 66 mA to 91 mA (two sessions in 16-bunch mode) and from 170 mA to 172 mA 
(one beam session in uniform fill mode). Samples were measured in flow cells to reduce 
radiation damage by moving the sample continuously during beam exposure in 10 time 
frames of duration 0.1 sec or 0.2 sec each (uniform fill mode), or 1.0 or 2.0 sec each (16-
bunch mode), together with on-line checks for the absence of radiation damage, after which 
the frames were averaged. Heterozygous FH prepared two days beforehand was studied at 
eight concentrations including 0.43 mg/ml, 0.87 mg/ml, 1.74 mg/ml, 2.6 mg/ml, 4.3 mg/ml, 
6.1 mg/ml, 7.8 mg/ml and 8.7 mg/ml in HEPES buffer. The Guinier analyses were   121
performed to obtain the values of RG, RXS-1 and RXS-2 using a PERL script program SCTPL7 
(J. T. Eaton & S. J. Perkins, unpublished software) on Silicon Graphics O2 Workstations. 
The indirect transformation of the scattering data I(Q) in reciprocal space in the Q range 
between 0.08 nm
-1 to 2.1 nm
-1 into real space gives the distance distribution function P(r). 
Other details about data collection and Guinier and P(r) analyses are described in Section 
4.2.4 and 4.2.5. 
 
5.3.3 Sedimentation equilibrium data collection and analysis 
 
Analytical ultracentrifugation experiments were performed on two Beckman XL-I 
instruments using an eight-hole rotor AnTi50 and a six-hole rotor AnTi60. Sedimentation 
equilibrium experiments were conducted using six-sector cells with solution column 
heights of 2 mm at rotor speeds of 8k r.p.m., 11k r.p.m., 15k r.p.m. and 20k r.p.m. and 
temperatures of 4 °C, 20 °C and 37 °C on heterozygous FH samples at 20 concentrations 
between 0.07 mg/ml and 7.1 mg/ml. Both absorbance and interference optical systems were 
used. Absorbance data at 280 nm above 0.7 mg/ml were not fitted because of the saturation 
of the optics, thus interference data were fitted. Data at 20 °C were fitted using SEDPHAT 
v4.10b software initially using individual fits of 80 equilibrium curves, and subsequently 
followed by global fits of between nine to 20 curves (Schuck, 2003). Both a monomer 
model and a “monomer-dimer self-association” model were used. The global fitting of the 
interference data at concentrations between 0.07 mg/ml to 1.32 mg/ml utilised the 
“monomer-dimer self-association” model with the “M and s” fitting routine. In this fitting, 
the molecular weight of FH monomer was fixed at 145 kDa, while the baseline and the 
dissociation constant KD were floated. Other details about sedimentation equilibrium 
experiments are explained in Section 4.1.3. 
 
5.3.4 Sedimentation velocity data collection and analysis 
 
Sedimentation velocity experiments were performed at 20 °C for heterozygous FH at 
various concentrations in HEPES buffer and PBS buffer at rotor speeds of 25k r.p.m., 40k 
r.p.m, 50k r.p.m and 60k r.p.m. on two Beckman XL-L analytical ultracentrifuges equipped   122
with AnTi60 rotors and two-sector cells with a column height of 12 mm. The sedimentation 
coefficient distribution c(s) analyses of the data were performed using the programme 
SEDFIT (version 9.3b) (Schuck, 1998; Schuck, 2000). The fits were based on a resolution 
of 200 and a fixed frictional coefficient ratio f/fo of 1.78, while allowing both the meniscus 
and the cell bottom to float within a narrow range of 0.01 cm until the overall root mean 
square deviation (r.m.s.d) and fitting residuals were satisfactory. Other details about c(s) 
analyses are explained in Section 4.1.2. 
 
5.4 Conclusions 
 
Knowledge of the oligomeric state of FH is crucial for understanding its immunological 
function in complement regulation and its likely roles in AMD and aHUS disease. The new 
data collection in this study clarified that heterozygous FH exhibits oligomeric forms after 
all, as originally proposed (Perkins  et al., 1991). A monomer-dimer equilibrium was 
identified at the lowest concentrations. Partial FH dimerisation has been reported by two 
other laboratories (Jokiranta et al., 2000; Jokiranta et al., 2006; Oppermann et al., 2006). 
As the concentration increases, higher oligomeric structures that can be as large as 
heptamers and are not in equilibrium with each other were identified. The studies of 
heterozygous FH in 2001 and 1991 had reported RG values that were stated to be 
approximate for reason of the need to access the lowest Q values, which is difficult to 
measure with highly elongated proteins. Under these conditions, the aggregation of a highly 
elongated protein can be hard to identify. Here, the use of freshly-purified FH resulted in a 
lower RG value of 8.90 nm in place of the apparent RG values of 11.4 nm and 12.4 nm 
before. The sequence-calculated molecular weight of FH is 150,000 Da assuming six N-
linked oligosaccharides. In 2001, the molecular weight of FH was determined as 148,000-
182,000 Da, as the result of which FH was deduced to be monomeric (Aslam & Perkins, 
2001). In 1991, its molecular weight was determined to be 250,000-320,000 Da, leading to 
the deduction that FH was dimeric (Perkins et al., 1991). The new data suggest that the 
1991 result is best explained in terms of the presence of monomeric FH together with 
sufficient FH oligomers to double its averaged observed molecular weight. Oligomerisation   123
in the 1991 study was favoured by the higher FH concentrations that were necessary for the 
X-ray data collection.  
 
This study of FH oligomerisation resulted from the unexpected observation of weak 
monomer-dimer equilibria for two fragments of FH. One for the SCR-6/8 fragment of FH 
has a KD of about 40 µM. Detailed ultracentrifugation equilibrium and velocity 
measurements were required to establish this, as the compact structure of this SCR-6/8 
dimer meant that dimerisation was not readily detected by X-ray scattering (Fernando et al., 
2007). However the presence of the SCR-6/8 dimer was requisite for good X-ray modelling 
fits to its structure. The second weak monomer-dimer equilibrium with a KD of 16 µM for 
the SCR-16/20 fragment was readily detected by both X-ray scattering and 
ultracentrifugation because this dimer has an extended structure (Okemefuna et al., 2008). 
Both these KD values are comparable with that of 28 µM for heterozygous FH from the 
SEDPHAT global fits below 1.36 mg/ml (Figure 5.5). This suggests that the dimerisation 
of SCR-6/8 and SCR-16/20 is physiologically relevant, even though both were recombinant 
proteins. FH concentrations range between 0.235-0.810 mg/ml in blood (Saunders et al., 
2007). Therefore so long as no other factors require consideration, this KD value of 28 µM 
indicates that about 5% to 15% of FH in blood will be dimeric. The complement regulatory 
function of FH will be affected by dimer formation in serum. Thus ligands may be 
sterically blocked from approaching their binding sites if they are proximate to either of the 
two presumed FH dimer sites, or may not bind because of aggregate formation. 
Alternatively ligand binding may be enhanced if their binding sites are distant from the FH 
dimer sites, because in that case FH would become multivalent. Future studies of FH-ligand 
binding will be complicated by the observation of dimerisation. Thus FH-ligand binding 
studies that disregard dimerisation are open to misinterpretation, as exemplified by a recent 
SEDPHAT sedimentation equilibrium study of SCR-6/8 (Prosser et al., 2007). Alternative 
approaches are required to establish 1:1 complex formation with ligands in the presence of 
dimers, such as that described in Figure 3 of the original ultracentrifugation study of the 
SCR-6/8 complex with heparin, where titrations with a range of heparin-protein ratios were 
analysed using SEDFIT c(s) size distribution plots (Fernando et al., 2007). 
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A mechanistic pathway for oligomer formation is suggested from this work. At higher 
concentrations, the existence of two different weak self-association sites in FH suggests 
that FH can self-associate continuously by intermolecular contacts that occur alternately 
through both these sites to form large oligomers. These higher oligomers were indeed 
directly observed above 2 mg/ml in fresh FH samples by velocity experiments (Figure 5.7). 
At low FH concentrations, the modelling of the species observed in the c(s) analyses 
suggests that extended dimer structures were formed, which would explain its reversibility. 
At higher concentrations, the formation of higher oligomers is predicted to involve more 
compact associations of the monomer (Figure 5.8), and this would explain its lack of 
reversibility (Figure 5.5). The storage of FH samples may facilitate the formation of more 
stable higher oligomers. Further studies of this are in progress. These results suggest that 
the use of freshly gel-filtrated FH samples stored below 1 mg/ml concentrations may be 
required for complement regulatory functional studies. The aggregation of FH is relevant 
for AMD, for which a risk factor is the observation of drusen deposits at the retinal surface. 
Currently there is no detailed knowledge of the mechanism of drusen formation in AMD. It 
is possible that the localised accumulation of higher FH concentrations within the eye may 
facilitate the slow formation of protein precipitates within drusen during the course of a 
lifetime. For such a mechanism to operate, any FH precipitation in drusen would appear to 
necessitate much higher concentrations of FH than those seen physiologically in serum, and 
this would occur in the presence of a number of other components that are present. The 
latter would alter the kinetics and thermodynamics of deposit formation when compared to 
a mechanism based only on FH self-association. In this context, it is intriguing that the 
His402 genetic polymorphism that is a risk factor for AMD showed a slightly higher 
propensity to self-associate than the lower-risk Tyr402 form when the SCR-6/8 fragment 
was studied by X-ray scattering and ultracentrifugation (Fernando et al., 2007). 
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Chapter Six 
 
Uncontrolled zinc- and copper-induced oligomerisation of heterozygous human 
factor H and its possible implications for function and disease  
   126
6.1 Introduction 
 
In the innate immune response, C3 is activated to C3b by the cleavage of the small 
anaphylatoxin C3a, thereby initiating the alternative complement pathway. To prevent 
complement-mediated host cell damage, C3b is regulated by factor H (FH) amongst 
other proteins, in which FH acts as a cofactor for the factor I-mediated cleavage of C3b 
to form iC3b, C3c and C3dg (Law & Reid, 1995; Whaley & Ruddy, 1976; Pangburn et 
al., 1977). FH also accelerates the decay of the C3 convertase C3bBb and competes 
with factor B for binding to C3b (Whaley & Ruddy, 1976; Weiler et al., 1976; Farries et 
al., 1990). FH is comprised of a linear arrangement of 20 short complement regulator 
(SCR) domains, each of length about 61 residues, and 19 linkers between the domains 
(Soares & Barlow, 2005). FH possesses multiple binding sites for C3b and heparin, the 
latter being an analogue of heparan sulphate that is found on host cell surfaces, and FH 
also binds to other proteins such as C-reactive protein (Ormsby et al., 2006; Sharma & 
Pangburn., 1996; Jokiranta et al., 2000). FH protects host cells by binding to heparin-
like negatively-charged clusters on their surfaces through its C-terminal end, which is 
then followed by N-terminal regulatory activity against C3b (Oppermann et al., 2006; 
Ferreira et al., 2006). FH involvement in uncontrolled inflammation is associated with 
disease, namely atypical haemolytic uraemic syndrome (aHUS) and 
membranoproliferative glomerulonephritis type II (MPGN)
  and age-related macular 
degeneration (AMD) (Saunders et al., 2007; Klein et al., 2005; Haines et al., 2005; 
Edwards  et al., 2005; Hageman et al., 2005). AMD is the most common cause of 
blindness in the elderly in the Western world. In several groups identified a Tyr402His 
FH polymorphism that increased the risk of developing AMD over seven-fold (Klein et 
al., 2005; Haines et al., 2005; Edwards et al., 2005; Hageman et al., 2005). Since then, 
other FH variants have been shown to modify the risk for AMD (Li et al., 2006; Maller 
et al., 2006; Hughes et al., 2006). Even with the analysis of over 100 genetic alterations 
in FH, no clear molecular mechanism for diseases based on the involvement of 
defective forms of FH has been proposed so far (Saunders et al., 2007).  
 
An early hallmark of AMD is the appearance of sub-retinal pigment epithelial deposits 
(sRPEds) that can be focal (drusen) or diffuse (basal linear and laminar). These deposits 
contain oxidized lipids and over 120 aggregated proteins including FH and other   127
complement components that are secreted by RPE cells or delivered by the choroidal 
blood circulation (Crabb et al., 2002; Hageman et al., 2001). These deposits develop 
within Bruch’s membrane, an extracellular matrix layer interposed between the retinal 
pigment epithelium (RPE) and the choroidal vasculature (Bird, 1992; Bird et al., 1995). 
Recently, millimolar concentrations of zinc have been found in sRPEds and Bruch’s 
membrane, suggesting that the pathological release of zinc from surrounding tissues like 
the zinc-rich RPE choroid complex might be involved in sRPEd formation (Galin et al., 
1962; Lengyel et al., 2007). In the context of AMD the presence of FH and zinc in 
sRPEd is of interest, firstly because zinc inhibits the factor I-mediated cleavage of C3b 
leading to uncontrolled inflammation, and secondly an initial X-ray scattering study 
showed that FH aggregates in the presence of high zinc concentrations (Crossley & 
Porter, 1980; Perkins et al., 1991).  
 
The molecular basis of the self-associative interaction between FH and zinc is unknown. 
The overall structure of native FH is not straightforward to characterise by methods 
such as crystallisation or NMR for reason of its large size, glycosylation and inter-SCR 
flexibility between its 20 domains, although several crystal and NMR structures have 
been published for small domain fragments of FH (Section 2.1.2). Solution structural 
methods such as X-ray and neutron scattering and analytical ultracentrifugation have 
been applied to demonstrate that native FH possesses a partially-folded back SCR 
structure in solution (Perkins et al., 2008; Cole et al., 2008). Recently we showed that 
native FH is predominantly monomeric and partly dimeric at physiological 
concentrations in serum, and forms higher oligomers as its concentration increases if no 
other factors require consideration (Chapter Five; Nan et al., 2008a). The original X-ray 
scattering study of FH-zinc complexes was limited by a requirement for relatively high 
FH concentrations at that time, consequently only Guinier analyses at low scattering 
angles were measured, and the resulting averaged FH structure was mostly dimeric 
(Perkins  et al., 1991). Since that time, the availability of monomeric FH at low 
concentrations and improvements in X-ray scattering instrumentation at the ESRF 
synchrotron facility permits a more detailed investigation of the role of zinc and FH in a 
physiological concentration range (Chapter Five; Nan et al., 2008a). Following the 
study of the self-association properties of heterozygous FH in Chapter Five, in this 
chapter, by performing quantitative titration studies of FH with a range of different   128
metals by X-ray scattering, supplemented by analytical ultracentrifugation, aggregations 
of heterozygous FH in the presence of zinc was observed. Other transition metals such 
as copper induce different degrees of uncontrolled FH oligomer formation. The 
aggregation of heterozygous FH in the presence of zinc and copper correlated with the 
reduction of FH activity. Whether the high zinc concentrations associated with Bruch’s 
membrane may drive the aggregation of FH in the environment of the retina, and the 
molecular implications of our results for complement regulation and sRPEd formation 
are discussed in this chapter. 
 
6.2 Results and Discussion  
 
6.2.1 Guinier X-ray scattering analyses of FH-metal complexes  
 
Freshly-purified heterozygous FH for scattering and ultracentrifugation studies resulted 
in a homogeneous peak by gel-filtration, and the purity of FH was verified by SDS-
PAGE (Figure 5.6 in  Chapter Five; Nan et al., 2008a). FH concentrations were 
generally maintained at 1 mg/ml or less with storage at 4
oC to avoid irreversible 
oligomer formation, and studied at this concentration or less to be comparable with 
physiological FH concentrations between 0.235-0.810 mg/ml in serum (Saunder et al., 
2007). The effect of metals on FH was studied by synchrotron X-ray scattering and 
analytical ultracentrifugation in HEPES buffer (Section 6.3.1). Phosphate buffer was not 
used because zinc precipitates with phosphate.  
 
Solution scattering enabled the overall structure and size of FH to be studied (Section 
4.2; Perkins et al., 2008). FH samples at 0.42 mg/ml (2.8 µM) and 1.05 mg/ml (7.0 µM) 
were titrated with 0 µM, 0.2 µM, 0.6 µM, 2 µM, 6 µM, 20 µM, 60 µM and 200 µM 
ZnSO4. Excellent signal-noise ratios were obtained with the improved instrument at 
ESRF, and no detectable effect was observed from radiation damage. Linear Guinier 
analyses at low Q values (where Q = 4π sin θ /λ; 2θ = scattering angle; λ = wavelength) 
gave the radius of gyration RG in satisfactory Q.RG ranges below 1.1 (Figure 6.1). The 
data obtained at 0.42 mg/ml FH was relatively nosier than that at 1.05 mg/ml. The RG of 
FH corresponds to its degree of elongation. For heterozygous FH without zinc, the mean 
RG value was 8.45 (± 0.14) nm at 1.05 mg/ml and 8.28 (± 1.18) nm at 0.42 mg/ml. Both  129
 
 
Figure 6.1 Guinier analyses for heterozygous FH titrated with zinc. The filled symbols 
correspond to the Q range used to determine the RG and RXS values. The symbols ○, ∆, 
□, ∇, ◊ represent [Zn] of 2 µM, 6 µM, 20 µM, 60 µM and 200 µM in that order. The 
filled symbols represent the data points used to determine RG or RXS values, and the 
straight lines represent the best linear fits through those data points. The Q.RG  and 
Q.RXS fit ranges are arrowed. 
 
(a) RG plots of ln I(Q) vs. Q
2 for 1.05 mg/ml heterozygous FH using a Q range of 0.06 - 
0.13 nm
-1. 
 
(b,c) The corresponding cross-sectional RXS-1 and RXS-2 plots of ln I(Q).Q vs. Q
2 for the 
same five scattering curves in a Q range of 0.16 - 0.26 nm
-1 and 0.4 - 0.8 nm
-1 are 
shown. In (c), the five curves are successively displaced in steps of 0.5 ln units for 
reason of clarity.   130
values were consistent with the recently determined RG value of 8.89 (± 0.19) nm for 
heterozygous FH monomers (Chapter Five; Nan et al., 2008a). The present RG values 
starting from a monodisperse preparation of FH were consistently lower than the old RG 
values for FH which had partially self-aggregated (Perkins et al., 1991). Here, the RG 
values stayed stable when [Zn] ≤ 6 µM, and increased significantly when [Zn] ≥ 20 µM 
(Figure 6.1 a and Figure 6.2 a). The associated intensity I(0)/c parameters which are 
derived from RG fits, are proportional to relative molecular weights Mr of the FH 
macromolecules. The I(0)/c value of heterozygous FH also showed a large increase at 
[Zn]  ≥ 20 µM (Figure 6.2 b). Hence these changes are attributable to strong FH 
oligomer formation previously seen for dimeric FH (Perkins et al., 1991). To investigate 
the effects of SO4
-2 on FH, heterozygous FH prepared two days beforehand at 0.93 
mg/ml added with 200 µM ZnSO4 or ZnCl2 in HEPES buffer was studied using 
synchrotron X-ray scattering. No significant difference in the Guinier parameters has 
been observed, hence ruling out any anion effects on the oligomerisation of FH induced 
by zinc. The present experiments extend the previous X-ray work by demonstrating that 
zinc chloride causes monomeric FH to aggregate (Perkins et al., 1991).  
 
The cross-sectional Guinier analyses monitor the structural proximity relationships 
between non-neighbouring SCR domains (RXS-1) and neighbouring SCR domains (RXS-2) 
(Aslam & Perkins, 2001). Linear fits for both parameters were obtained within 
satisfactory Q.RXS ranges (Figure 6.1 b, c). Without zinc, the RXS-1 value of heterozygous 
FH was determined to be 2.68 (± 0.08) nm at 1.04 mg/ml and 2.40 (± 0.16) nm at 0.42 
mg/ml, in good agreement with the previously determined RXS-1 value of 2.51 (± 0.06) 
nm for the heterozygous FH monomer (Chapter Five; Nan et al., 2008a). The RG and 
RXS-1 values without the presence of zinc were consistent with the fact that heterozygous 
FH is mainly monomer (85% to 95%) in physiological concentration range (Nan et al., 
2008). The RXS-1 values significantly increased when [Zn] was 20 µM or greater (Figure 
6.2 c). This change showed that the FH oligomers associated in a side-by-side manner, 
and not end-to-end. Without zinc, the RXS-2 value was determined to be 1.78 (± 0.03) 
nm, in good agreement with the previous value of 1.79 (± 0.01) nm (Perkins et al., 
1991; Chapter Five; Nan et al., 2008a; Aslam & Perkins, 2001). When zinc was added, 
the  RXS-2 value did not alter significantly (Figure 6.2 d), indicating that the linear 
arrangement of neighbouring SCR domains was unchanged.    131
 
 
Figure 6.2 Dependence of the Guinier parameters of heterozygous FH on the ZnSO4 
concentration. Each value was measured in quadruplicate and averaged. The two 
titrations correspond to 1.05 mg/ml FH titrated with ZnSO4 (○, solid line), and 0.42 
mg/ml FH titrated with ZnSO4 (●, dashed line). The RG and I(0)/c values calculated 
from the distance distribution function are denoted as ∆ in (a) and (b). (a,c) The data 
were fitted to a three-parameter function ) ln( 0 0 x x a y y − + = . (b) The lines correspond 
to a two-parameter function ) ln( bx a y + = . (d) A straight line indicates the averaged 
RXS-2 values for FH at 0.42 mg/ml, with statistical error bars shown where visible. In (a, 
b and c), the Guinier values of heterozygous FH at 0.93 mg/ml titrated with 200 µM 
ZnCl2 are denoted as blue squares.    132
The effect of copper on the oligomerisation of heterozygous FH was studied by 
synchrotron X-ray scattering (see Materials and Methods). Copper had not previously 
been tested (Crossley & Porter, 1980; Perkins et al., 1991). Freshly prepared 
heterozygous FH was studied at 0.93 mg/ml in HEPES buffer, and titrated with 0.2 µM 
to 200 µM copper sulphate. For heterozygous FH at 0.93 mg/ml without copper, a 
similar RG value of 9.00 (± 0.23) nm, RXS-1 value of 2.76 (± 0.13) nm, and RXS-2 value of 
1.78 (± 0.01) nm were obtained. The values of RG, I(0)/c,  RXS-1 parameters of FH 
showed a significant concentration dependence of copper. Different from the effect of 
zinc, the large increases of the RG, RXS-1 and I(0)/c parameters were observed after the 
concentration of copper reached 60 µM (Figure 6.3 a, b, c). No concentration 
dependence of copper has been observed for the RXS-2 parameter of FH (Figure 6.3 d).  
 
The reversibility of complex formations with zinc and copper were tested by studying 
the 0.93 mg/ml FH samples with 200 µM ZnSO4 or ZnCl2 which were diluted two folds 
by addition of 1.5 mM EDTA using X-ray scattering. After adding with EDTA, the RG, 
RXS-1 and I(0)/c parameters decreased to the values agreeable with those of  the FH at 
0.93 mg/ml without any metals. Thus, the complex formations of FH with zinc and 
copper were reversible. 
 
Control experiments with other metals were performed with 200 µM CaCl2, MgCl2, 
NiCl2, CdCl2 and FeSO4 with FH at 0.93 mg/ml. No change was detected for CaCl2 and 
MgCl2. Small increases in the RG,  RXS-1 and I(0)/c values compared to zinc were 
observed for NiCl2, CdCl2 or FeSO4 (Table 6.1). The result for nickel was unexpected, 
as previously 100 µM Ni
2+ had showed no effect, and the difference is attributed to the 
improved signal-noise ratio available at ESRF (Perkins et al., 1991).  
 
6.2.2 X-ray distance distribution function FH-metal complexes  
 
The distance distribution function P(r) is calculated from the full scattering curve and 
reports the distances between all pairs of atoms within FH. The calculation of the RG 
and I(0) values from the P(r) curve agreed well with the Guinier RG and I(0) values 
above, showing that the scattering curve is self-consistent across the observed Q range 
(Figure 6.2 a, b and Figure 6.3 a, b). The intensity of the P(r) curve increased  133
 
Figure 6.3 Dependence of the Guinier parameters of heterozygous FH on the copper 
concentration. Each value was measured in quadruplicate and averaged. The Guinier 
parameters of 0.93 mg/ml FH titrated with copper are denoted as squares in (a), (b), (c) 
and (d), and the RG and I(0)/c values calculated from the distance distribution function 
are denoted as triangles in (a) and (b). (a,c) The data were fitted to a three-parameter 
function ) ln( 0 0 x x a y y − + = . (b) The lines correspond to a two-parameter 
function ) ln( bx a y + = . (d) A straight line indicates the averaged RXS-2 values for 
heterozygous FH. Statistical error bars are shown where visible.  
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significantly with increase in [Zn] (Figure 6.4 a). The maximum dimension L is determined 
when P(r) = 0 at large r. For 1.05 mg/ml heterozygous FH, when [Zn] was between 0 µM 
and 2 µM, the L value of FH was 32 nm, in good agreement with previous for metal-free 
heterozygous FH (Chapter Five; Nan et al., 2008a). When [Zn] increased from 2 µM to 200 
µM, L increased to 50 nm (Figure 6.4 a, b). The r value of the maximum M in the P(r) curve 
gives the most commonly occurring distance within the macromolecule. Peak M1 at r = 5.2 ± 
0.6 nm was observed for [Zn] up to 6 µM, which agrees with the previous M1 determination 
of 4.8 ± 0.3 nm for metal-free heterozygous FH (Figure 5.3 in Chapter Five; Nan et al., 
2008a). Peak M2 was previously observed for metal-free heterozygous FH at 10.2 ± 0.6 nm 
(Figure 5.3 in Chapter Five; Nan et al., 2008a), but here its position shifted from a starting 
value of 10.8 nm at [Zn] = 6 µM up to 17.0 nm at [Zn] = 200 µM (Figure 6.4 b). The changes 
in the P(r) curves with increase in [Zn] showed that zinc formed relatively compact FH 
oligomers with maximum dimensions not much larger than that for monomeric metal-free 
FH. No difference between the P(r) curves for heterozygous FH added with 200 µM ZnSO4 
and with 200 µM ZnCl2 has been observed, which ruled out the effects any anion effects. For 
heterozygous FH at 0.93 mg/ml titrated with 0.2 µM to 200 µM copper, the changes of P(r) 
curve differed from those seen with zinc. The intensity of the P(r) curve increased 
significantly with [Cu] ≥ 60 µM (Figure 6.5 a), which indicates the copper induced 
oligomerisation of heterozygous FH. The L value of FH was 32 nm with 0.2 µM to 20 µM 
copper, and increased to 62 nm when the [Cu] increased to 200 µM (Figure 6.5 a, b). The 
position of M2 shifted to 26 nm when [Cu] increased to 200 µM (Figure 6.5 a, b). The P(r) 
curves of heterozygous FH with 200 µM zinc or copper reverted to the metal-free P(r) curve 
after being diluted two folds by addition 1.5 mM EDTA was added, and the L value 
decreased to 30 nm after adding EDTA (Figure 6.6). 
 
Other metals showed divergent effects. The addition of CaCl2 and MgCl2 had no effect 
(Figure 6.7). The P(r) intensities increased in the presence of 200 µM NiCl2, CdCl2, FeSO4, 
CuSO4 and ZnSO4 in that order. The L values however increased in the presence of 200 µM 
FeSO4, CdCl2, NiCl2, ZnSO4 and CuSO4 in that order, which is different and showing that 
different metals caused different structural effects on FH.   136
 
 
 
Figure 6.4 Dependence of the distance distribution function P(r) on zinc.  
 
(a) The unnormalised P(r) curves were calculated from the five scattering curves in Figure 
6.1. From bottom to top, [Zn] are 2 µM, 6 µM, 20 µM, 60 µM and 200 µM, represented by 
alternate solid and dashed lines in grey and black. The two maxima occur at M1 and M2. The 
maximum length L was determined to be 32 nm, 35 nm, 38 nm, 42 nm and 50 nm (numbered 
1, 2, 3, 4 and 5) with increase in [Zn].  
 
(b) The five P(r) curves in (a) are normalised to 100 to show that M1 is unchanged at 5.2 ± 
0.6 nm while M2 increases from 10.8 nm to 17.0 nm with increase in [Zn]. The alternate solid 
and dashed lines correspond to those in (a).  137
 
 
 
 
Figure 6.5 Dependence of the distance distribution function P(r) on copper.  
 
(a)  The unnormalised P(r) curves were calculated from the five scattering curves of 0.93 
mg/ml of heterozygous FH titrated with 2 µM to 200 µM copper. From bottom to top, [Cu] 
are 2 µM, 6 µM, 20 µM, 60 µM and 200 µM, represented by alternate solid and dashed lines 
in grey and black. The two maxima occur at M1 and M2. The maximum length L of 
heterozygous FH was determined to be 32 nm (numbered 1) with [Cu] of 2 µM, 6 µM and 20 
µM, 38 nm (numbered 2) with [Cu] of 60 µM, and 62 nm (numbered 3) with [Cu] of 200 µM. 
  
(b) The five P(r) curves in (a) are normalised to 100 to show the increase of M2 with [Cu] ≥ 
60 µM. The alternate solid and dashed lines correspond to those in (a).  138
 
 
Figure 6.6 Effects of EDTA on the distance distribution function P(r) of heterozygous FH 
added with zinc or copper. The P(r) curve of heterozygous FH added with 200 mM zinc is 
denoted as solid black line, and that of the same sample after being added EDTA is denoted 
as dashed black line. The corresponding P(r) curves for heterozygous FH with copper are 
denoted in grey. 
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Figure 6.7 Eight P(r) curves for 0.93 mg/ml FH in the presence of seven metals at 200 µM. 
The M2 and L values are arrowed for each curve. The L values were 32 nm (no metal, Mg, 
Ca), 37 nm (Fe, blue), 39 nm (Cd, green), 47 nm (Ni, cyan), 50 nm (Zn, black) and 62 nm 
(Cu, red).  140
 
6.2.3 Sedimentation velocity analyses of FH-metal complexes  
 
Sedimentation velocity experiments by analytical ultracentrifugation follow the 
sedimentation behaviour of FH on subjecting this to a high centrifugal force (Section 4.1; 
Cole et al., 2008). The sedimentation coefficient s20,w monitors macromolecular elongation, 
and is analogous to the RG value. Velocity experiments were performed at four rotor speeds 
up to 60,000 r.p.m. for FH at 0.35 mg/ml and 0.87 mg/ml, each titrated with zinc at eight 
concentrations between 0 µM to 200 µM. In comparison to the run at 6 µM zinc, rapidly-
sedimenting species were observed at 60 µM of zinc, and even more so at 200 µM zinc 
(Figures 6.8 a, b, c). The observed sedimentation boundaries were fitted using size-
distribution analyses c(s) in which the frictional ratio f/fo was held fixed (Materials and 
Methods), and good fits were obtained in all cases (Figures 6.8 a, b, c).  
 
The sedimentation coefficient distribution c(s) analyses revealed the presence of distinct FH 
oligomers through the appearance of resolved stable multiple peaks (Figures 6.9 a, b). At all 
zinc concentrations, a FH monomer peak was observed at s 20,w = 5.57 (± 0.12) S (Figure 6.9 
b). A c(M) mass distribution plot showed that this corresponded to a molecular weight of 138 
± 7 kDa. This value agreed well with the sequence-determined molecular mass of 155 kDa 
and also with previous s20,w determinations of 5.65 (± 0.12) S and 5.3 ± 0.1 S, and mass 
determinations of 142 ± 2 kDa by c(M) size distribution analyses and 145 kDa by 
sedimentation equilibrium experiments for FH monomers (Chapter Five; Nan et al., 2008a; 
Aslam & Perkins, 2001). At all zinc concentrations, the c(s) distributions showed additional 
peaks that correspond to larger FH oligomers as [Zn] increased. For [Zn] between 0 µM and 
20 µM, dimers were visible at a s 20,w value of 7.7 (± 0.3) S. In addition, smaller amounts of 
trimers to nonamers of FH were consistently observed at s 20,w values of 10.0 (± 0.6) S, 11.8 (± 
0.7) S, 14.2 (± 0.7) S, 16.1 (± 0.8) S, 18.5 (± 0.9) S, 22.6 (± 1.5) S and 27.0 (± 0.5) S (Figure 
6.9 b), and this agrees with the progressive self-association properties of FH observed 
previously (Chapter Five; Nan et al., 2008a). At 0 µM zinc, 12% oligomers were seen in 
agreement with previous observation (Chapter Five; Nan et al., 2008a). At [Zn] = 60 µM, 
sizeable amounts of larger FH oligomers with s 20,w values up to 50 S and increased intensities  141
 
Figure 6.8 Fittings of sedimentation boundaries of heterozygous FH titrated with zinc by size-
distribution analyses c(s). The [Zn] values in µM are denoted by red numbers. The 
experimental runs were performed at 50k r.p.m. with 0.87 mg/ml FH (black), and the 
boundary fits are shown in red. (a) Every sixth scan boundary for 200 µM zinc was fitted; (b) 
Every fifteenth scan boundary for 60 µM zinc was fitted; (c) Every sixth scan boundary for 6 
µM zinc was fitted.   142
 
 
Figure 6.9 Size-distribution c(s) analyses for heterozygous FH titrated with zinc. The [Zn] 
values in µM are denoted by red numbers.  
 
(a)  The c(s) size-distribution analyses for 20 µM, 60 µM and 200 µM zinc are shown. Here 
and in (b), the intensity of the monomer peak at 5.57 S was set to 100 for clarity. 
 
(b) The c(s) size-distribution analyses for 0 µM, 0.2 µM, 2 µM, 6 µM, 20 µM, and 60 µM 
zinc are shown. The FH oligomers are numbered from 2 to 9 in increasing order of S values 
(Chapter Five; Nan et al., 2008a).The six analyses are displaced vertically in steps of 0.7 
units for reason of clarity.   143
were observed in the c(s) distribution (Figures 6.9 a, b). At [Zn] = 200 µM, the size of the FH 
oligomers reached 100 S, together with a significant increase in their intensities (Figure 6.9 
b). 
 
The effect of copper on heterozygous FH was also investigated by performing sedimentation 
velocity experiments on 0.81 mg/ml heterozygous FH titrated with 0.2 µM to 200 µM CuSO4 
(Materials and Methods). Similar to the heterozygous FH titrated with zinc, the sedimentation 
coefficient distribution c(s) revealed that small amount of oligomers was observed for 
heterozygous FH with 0.2 µM to 20 µM copper, and rapidly-sedimenting species were 
observed at 60 µM of copper, and even more so at 200 µM copper (Figures 6.10 a, b, c and 
Figure 6.11). However, the sedimentation boundaries and therefore the c(s) analyses for 
heterozygous FH with 200 µM copper were different from those for 200 µM zinc (Figure 
6.10 a and Figure 6.11).  
 
To gain a quantitive understanding of the effect of zinc concentration change on the 
oligomerisation of heterozygous FH in sedimentation velocity experiments, the integration 
function for c(s) size-distribution analyses were used to determine the percentages of FH 
monomer and oligomers (Materials and Methods). For heterozygous FH at 0.35 mg/ml and 
0.87 mg/ml, the percentage of monomer decreased while the percentage of oligomers 
increased, as a result of increasing of zinc concentration (Figure 6.12). Here, 50% oligomer 
formation occurred with approximately 35 µM zinc for 0.35 mg/ml FH, and with 50 µM zinc 
for 0.87 mg/ml FH (Figure 6.12). The slight difference is attributed to the larger zinc:FH ratio 
at the lower FH concentration, meaning that more FH oligomers were formed at 0.35 mg/ml 
FH for a given zinc concentration. The effect of 0.2 µM to 200 µM CuSO4 on 0.81 mg/ml FH 
caused significant oligomer formation to take place, for which 50% oligomer formation 
occurred at approximately 150 µM [Cu] (Figure 6.12).   
 
To test the reversibility of the oligomerisation of heterozygous FH induced by zinc, 
sedimentation velocity experiments were performed on the sample of 0.87 mg/ml FH with 
120 µM zinc which was diluted four folds by the addition of 1.5 mM EDTA. The c(s) 
distribution analyses showed that after added with EDTA, the oligomeric species with high 
s20,w decreased significantly both in intensities and the number of species (Figure 6.13  a, b),  144
 
Figure 6.10 Fittings of sedimentation boundaries of heterozygous FH titrated with copper by 
size-distribution analyses c(s). The [Cu] values in µM are denoted in each panel. The 
experimental runs were performed at 50k r.p.m. for 200 µM and 6 µM copper and at 60k 
r.p.m. for 60 µM copper with 0.81 mg/ml FH (black), and the boundary fits are shown in red. 
(a) Every eighth scan boundary for 200 µM copper was fitted; (b) Every tenth scan boundary 
for 60 µM copper was fitted; (c) Every eighth scan boundary for 6 µM copper was fitted.   145
 
 
Figure 6.11 Size-distribution c(s) analyses for heterozygous FH titrated with copper. The 
[Cu] values in µM are denoted near the corresponding c(s) analysis. The c(s) size-distribution 
analyses for 20 µM, 60 µM and 200 µM copper are shown. The intensity of the monomer 
peak at 5.57 S was set to 100 for clarity. 
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Figure 6.12 Comparison of the proportion of heterozygous FH monomer and oligomers in 
titrations with zinc and copper.  The percentages were derived by integration of the c(s) 
analyses, and correspond to the mean value obtained at 50,000 r.p.m. and 60,000 r.p.m.. 
Monomers are denoted by filled symbols and oligomers by open symbols (0.87 mg/ml FH 
with zinc, black ●, ○; 0.35 mg/ml FH with zinc, black ■, □; 0.81 mg/ml FH with copper, red 
▲, ∆).   147
 
Figure 6.13  Effects of EDTA on the sedimentation coefficient distribution c(s) of 
heterozygous FH added with zinc. The sedimentation velocity data was obtained at 50,000 
r.p.m.. The oligomer peaks are labelled from 2 to 9 to follow Figure 6.9. 
 
(a) The c(s) distribution analyses for 0.87 mg/ml FH with 120 µM zinc. The inserted panel 
shows the 10 times zoomed in view of the c(s) distribution from 7 S to 50 S. 
 
(b) The c(s) distribution analyses after the addition of EDTA to a final concentration of 0.22 
mg/ml FH, 30 µM zinc and 1.5 mM EDTA. The inserted panel shows the 20 times zoomed in 
view of the c(s) distribution from 7 S to 30 S.  148
and the c(s) plot was identical to that of 0.87 mg/ml FH without zinc. After adding of EDTA, 
the percentage of oligomers decreased from 62% to 16% which is very near to that of 0.87 
mg/ml FH without zinc. These changes indicate that the oligomerisation of heterozygous FH 
induced by zinc is reversible.  
 
Control experiments were performed. The comparison of 200 µM ZnSO4 and ZnCl2 on 0.93 
mg/ml FH showed no difference in the c(s) distributions, hence oligomer formation is not 
dependent on the anion. FH at 0.93 mg/ml was also studied with 200 µM CaCl2, MgCl2, 
NiCl2, CdCl2, FeSO4, CuSO4 and ZnSO4. The c(s) plots for NiCl2, CdCl2 or FeSO4 showed an 
increase in oligomer formation from 12% to 20% when compared with that of FH alone or 
with CaCl2 or MgCl2 (Figures 6.14 a, b). Oligomer formation increased even further with 
CuSO4 and ZnSO4 (Figure 6.14 b).   
 
6.2.4 Fluid-phase activity assays of FH-metal complexes  
 
In order to test whether the formation of heterozygous FH oligomers is correlated with the 
regulatory cofactor role of heterozygous FH, assays of fluid-phase ammonium-inactivated C3 
cleavage by factor I were performed in the presence and absence of metals (Crossley & 
Porter, 1980). As mentioned in Section 2.3.5, complement functional assays routinely 
employed heterozygous FH concentrations that were significantly lower than the 0.235-0.81 
mg/ml (1.6–5.4 µΜ) observed in vivo (e.g. 45 µg/ml, 3 µg/ml, 31 µg/ml and 0.31 µg/ml) 
(Crossley & Porter, 1980; Day & Sim, 1986; Blom et al., 2003; Tsiftsoglou & Sim, 2004). 
Accordingly assays in this thesis were performed at 0.3 mg/ml FH (2 µM) for direct 
comparison with the AUC data and to be more comparable with serum levels. SDS-PAGE 
showed that the α-chain of haemolytically inactive C3 was cleaved by factor I in the presence 
of heterozygous FH to produce two major degradation fragments at apparent sizes of 45 kDa 
and 75 kDa (Figure 6.15 a and Figure 6.16 a). The influence of zinc or copper on this reaction 
was investigated at concentrations of 0 µM, 2 µM, 20 µM, 60 µM, 120 µM and 200 µM. The 
cleavage rate was decreased by both metals, and this became noticeable with zinc at 120 µM 
and 200 µM (Figure 6.15 b, c and Figure 6.17 a) and to a lesser extent with copper at 200 µM 
(Figure 6.16 b, c and Figure 6.17 b). This matched the growth of oligomers in Figure 6.12, 
indicating that the oligomerisation of FH is able to account for the decrease of activity of FH  149
 
Figure 6.14 Comparative effects of different metals on heterozygous FH oligomerisation. The 
sedimentation velocity data was obtained at 50,000 r.p.m.. The intensity of the monomer peak 
at 5.57 S was set to 100 for clarity. The oligomer peaks are labelled from 2 to 9 to follow 
Figure 6.9. (a) The c(s) distribution analyses for 0.93 mg/ml FH for five metals at 200 µM 
(labelled). (b) Proportion of FH monomer and oligomer in the presence of different metals at 
a concentration of 200 µM. The hatched columns correspond to FH monomer, and the solid 
columns correspond to FH oligomers.  150
 
 
Figure 6.15 Cleavage of fluid phase inactive C3 (C3u) in the presence of zinc. (a) Reducing 
SDS-PAGE analysis of C3u cleavage in 20 µM zinc (lanes 4 – 15 correspond to the reaction 
times in min as labelled). Lane 1, 0.3 mg/ml C3u; Lane 2, 0.3 mg/ml C3u and 0.3 mg/ml FH; 
Lane 3, 0.3 mg/ml C3u, 0.3 mg/ml FH and zinc. FH, C3 α-chain and C3 β-chain are arrowed 
on the left, and the C3 α-chain cleavage products are arrowed on the right. Reducing SDS-
PAGE analysis of C3u cleavage in 120 µM zinc is shown in (b) and that in 200 µM zinc is 
shown in (c). Other details in (b,c) follow (a).      151
 
 
 
Figure 6.16 Cleavage of fluid phase inactive C3 (C3u) in the presence of copper. Reducing 
SDS-PAGE analysis of C3u cleavage by FI and heterozygous FH with 20 µM Copper in (a), 
with 120 µM Copper in (b), and with 200 µM Copper in (c). Other details follow Figure 6.15 
except the metal used here is copper.  152
 
 
Figure 6.17 Quantification of the cleavage of fluid phase inactive C3 (C3u) in the presence of 
zinc (Figure 6.15) or copper (Figure 6.16).  
 
(a) The percentage cleavage of C3 α-chain is shown as a function of [Zn], with their values 
shown as labels (0 µM, ●; 2 µM, ○; 20 µM, ▲; 60 µM, ∆; 120 µM, ■; 200 µM, □).  
 
(b)  As for (a) except that copper is used instead of zinc.   153
by blocking FH access to C3u and/or factor I. Factor I activity is unaffected by zinc, while 
C3b binds to zinc with little change in activity (Day & Sim, 1986; Blom et al., 2003; 
Tsiftsoglou & Sim, 2004). 
 
6.3 Materials and Methods  
 
6.3.1 Protein purification  
 
Heterozygous FH and factor I were purified from a 3 litre pool of just-outdated anonymised 
human plasma from the Royal Free Hospital Blood Bank, using an anti-FH monoclonal 
antibody MRC-OX23 Sepharose column, and an anti-FI monoclonal antibody MRC-OX21 
Sepharose column (Aslam & Perkins, 2001; Sim et al., 1993). Both monoclonal antibody 
columns were kindly provided by Dr R. B. Sim in Oxford University. About 50 ml of mixed 
human plasma with 5 mM EDTA and protease inhibitor Pefabloc-SC
70, was first dialysed 
into Tris buffer (25 mM Tris-HCl, 140 mM NaCl, 0.5 mM EDTA, pH 7.4). After the dialysis, 
the plasma was passed through a Sepharose column immobilised with non-immune IgG to 
remove the proteins that bind to Sepharose or IgG, then a lysine-sepharose column to remove 
plasminogen/plasmin. After these two columns, the plasma was passed through the MRC-
OX23 column specific for FH, and then through the MRC-OX21 column specific for FI. 
Repeating passing the plasma through these two monoclonal antibody columns significantly 
improved the yields of FH and FI. Bound FH and factor I were each eluted from the column 
using 3 M MgCl2, pH 6.9, then each was dialysed into HEPES buffer (10 mM HEPES, 137 
mM NaCl, pH 7.4) in the presence of 0.5 mM EDTA to remove Mg
2+, then each was passed 
through a Hitrap Protein G HP column to remove contaminant IgG. Non-specific aggregates 
and human serum albumin were removed using Superose
TM 6 gel filtration (Section 5.3.1).  
 
Native C3 was purified from the author’s own fresh plasma using slightly modified methods 
described previously (Dodds et al., 1993). 20 ml fresh plasma made 5% with polyethylene 
glycol (PEG) 3500 MWCO was centrifuged, and the supernatant then made 12% with PEG 
3500 MWCO was centrifuged again. The final pellet was resuspended in the starting buffer 
(20 mM HEPES, 50 mM NaCl, 50 mM ε-aminocaproic acid, 5 mM EDTA, 0.5 mM 
Pefabloc-SC, pH 7.5) for ion-exchange chromatography. The suspension was then filtered 
before loading onto a 20 ml Q-Sepharose
TM fast flow anion-exchange column (Amersham 
Biosciences, GE Healthcare, Uppsala, Sweden). The Q-Sepharose
TM fast flow column was  154
then washed with the washing buffer (20 mM HEPES, 100 mM NaCl, 50 mM ε-
aminocaproic acid, 5 mM EDTA, 0.5 mM Pefabloc-SC, pH 7.5) to remove the unbound 
proteins, and then a linear salt gradient to 300 mM NaCl was used to elute C3 which was 
eluted with about 210 mM NaCl to 240 mM NaCl. The elution fractions were checked by 
reducing SDS-PAGE. The C3 fractions were pooled together and then diluted to reduce the 
salt concentration to 100 mM NaCl, and then loaded onto a MonoQ 5/50 GL column 
(Pharmacia GE Healthcare, Uppsala, Sweden) to improve the purity of C3. The MonoQ 5/50 
GL column is also an anion-exchange column but with better resolution. Using a linear salt 
gradient to 300 mM NaCl, and the C3 was eluted with about 210 mM NaCl to 240 mM NaCl. 
The purity of the eluted C3 was checked again by using SDS-PAGE. Haemolytically inactive 
C3 (C3u) was prepared by incubating native C3 in 200 mM hydrazine at 37°C for 1 h (Dodds 
et al., 1993).  
 
The purified FH, FI and C3u were dialysed into HEPES buffer (10 mM HEPES, 137 mM 
NaCl, pH 7.4). Protein concentrations were determined from absorption coefficients of 16.7 
for FH, 12 for FI and 9.4 for C3u (1%, 280 nm, 1 cm path length) which were calculated 
from protein compositions (Perkins & Sim, 1986; Ullman et al., 1998; Aslam & Perkins, 
2001; Li et al., 2010). The absorption coefficient value for FH will be revised in Chapter 
Seven and Chapter Eight. The protein concentration preps utilised a gentle centrifugation 
approach with Amicon® Ultra-15 centrifugal filter devices. Protein integrities were routinely 
checked by SDS-PAGE before and after scattering, ultracentrifugation and assays.  
 
6.3.2 X-ray scattering data collection and analysis 
 
X-ray scattering is a diffraction method used to study solution structures of macromolecules 
in random orientations (Section 4.2; Perkins et al., 2008). The X-ray data I(Q) as a function 
of the scattering vector Q were acquired in two beam sessions on Beamline ID02 at the 
European Synchrotron Radiation Facility (Grenoble, France) with a ring energy of 6.0 GeV 
and operating in 4-bunch and 16-bunch modes to reduce the incident flux. Storage ring 
currents ranged from 22 mA to 41 mA (4-bunch mode), and from 67 mA to 92 mA (16-bunch 
mode). Potential radiation damage was eliminated by continuous movement of the sample in 
a flow cell during beam exposure, the use of 10 time frames of duration 0.2 sec or 0.5 sec 
each during each acquisition, and on-line checks for the absence of radiation damage at low 
Q. FH was studied at concentrations of 1.05 mg/ml (7.0 µM) and 0.42 mg/ml (2.8 µM)  155
respectively with ZnSO4 concentrations between 0 µM to 200 µM, and 0.93 mg/ml (6.2 µM) 
with CuSO4 in the same concentration range as well as 200 µM of ZnCl2, CaCl2, MgCl2, 
NiCl2, CdCl2 and FeSO4. Other details including the data reduction are described elsewhere 
(Section 4.2.4; Fernando et al., 2007; Okemefuna et al., 2008).  
 
In a given solute-solvent contrast, Guinier analyses of ln I(Q) vs Q
2 at low Q give the radius 
of gyration RG and the forward scattering at zero angle I(0) (Section 4.2.5):  
In I(Q) = In I(0) – RG
2Q
2/3 
The RG is the root mean square radius of scattering density, and I(0)/c (c = concentration) is a 
measure of its molecular weight. For elongated structures, the cross-sectional radius of 
gyration RXS and cross-sectional intensity at zero angle [I(Q).Q]Q→0 is obtained from analyses 
at larger Q ranges: 
ln [I(Q)Q] = ln [I(Q)Q]Q→0 - RXS
2Q
2/2. 
These provide information on the structural relationship between adjacent SCR domains. 
Indirect transformation of the scattering data I(Q) in reciprocal space to give the distance 
distribution function P(r) in real space was carried out using GNOM (Section 4.2.5): 
(Qr)dQ   I(Q)Qr    
2
1
  =   P(r)
0
2 sin ∫
∞
π
 
 The P(r) curve reports the distribution of distances r between all volume elements within the 
protein. This offers an alternative calculation of the RG and I(0) values that is based on the 
full scattering curve I(Q), and not that at low Q. It also gives the maximum dimension of the 
macromolecule L. The X-ray curve utilised up to 211 data points for Q between 0.06 nm
-1 and 
1.50 nm
-1 for 0.42 mg/ml FH, 309 data points for Q between 0.06 nm
-1 and 2.10 nm
-1 for 1.05 
mg/ml FH, and up to 599 data points for Q between 0.09 nm
-1 and 2.10 nm
-1 for 0.93 mg/ml 
FH. Other details are described elsewhere (Nan  et al., 2008a; Aslam & Perkins, 2001; 
Fernando et al., 2007; Okemefuna et al., 2008). 
 
 
6.3.3 Sedimentation velocity data collection and analyses 
 
Analytical ultracentrifugation studies the sedimentation behaviour of macromolecules on 
subjecting these to a high centrifugal force in order to determine their sizes and shapes (Cole 
et al.,2008).
 Data were obtained on a Beckman XL-I instrument using AnTi50 or AnTi60 
rotors at 20
oC. Sedimentation velocity experiments were performed at rotor speeds up to  156
60,000 r.p.m. in two-sector cells with column heights of 12 mm. for 0.87 mg/ml and 0.35 
mg/ml FH titrated with ZnSO4 at eight concentrations between 0 µM and 200 µM, 0.81 
mg/ml FH titrated with CuSO4 at eight concentrations from 0 µM to 200 µM, and 0.93 mg/ml 
FH with 200 µM of ZnCl2, CaCl2, MgCl2, NiCl2, CdCl2 and FeSO4. Data analyses were 
performed using SEDFIT (version 9.4). The size-distribution analyses c(s) that provided size 
and shape data were based on a fixed resolution of 200 and frictional ratio f/fo of 1.78, and 
floated the meniscus, the bottom of the cell, and the baseline until the overall root mean 
square deviation and fits between the observed and calculated sedimentation boundaries were 
satisfactory. The percentage fraction of oligomers in the total loading concentration was 
derived using the c(s) integration function. Other details are described elsewhere (Section 
4.1.2; Nan et al., 2008a; Okemefuna et al., 2008). 
 
6.3.4 Fluid-phase activity assays  
 
The reaction mixtures contained 0.3 mg/ml FH, 0.3 mg/ml C3u and 0.003 mg/ml factor I in 
six concentrations of ZnSO4 or CuSO4 (0 µM, 2 µM, 20 µM, 60 µM, 120 µM and 200 µM) 
and were incubated in a water bath at 37 °C.  At timed intervals, 5 µl aliquots were removed 
for reducing SDS-PAGE analyses. Three controls were used, namely 0.3 mg/ml C3u; 0.3 
mg/ml C3u and 0.3 mg/ml FH; and 0.3 mg/ml C3u, 0.3 mg/ml FH and zinc or copper. The 
C3 α-chain band densities from SDS-PAGE were measured using the gel analysis system 
SYNGENE (Synoptics Ltd., Cambridge, UK). The C3 α-chain cleavage was referenced to 
the averaged density of the uncleaved bands in the controls. Electrophoresis was performed 
by using NuPAGE® Novex® 4-12% Bis-Tris Mini Gel according to manufacturer’s standard 
protocol.  
 
6.4 Conclusions  
 
Metals have not generally been considered as FH ligands. In distinction to the original study 
of the interaction between heterozygous FH with zinc (Perkins et al., 1991), the study in this 
thesis has shown that five transition metals cause monomeric heterozygous FH to form large 
oligomers at the FH concentration seen in human serum. By performing X-ray solution 
scattering and analytical ultracentrifugation experiments, heterozygous FH at 2.8 − 7.0 µM 
was shown to be unaffected with [Zn] ≤ 20 µM, but formed a series of large oligomers with  157
[Zn] ≥ 60 µM. Structurally distinct large oligomers were also observed for Cu, while Ni, Cd 
and Fe showed low amounts of oligomers, and Mg and Ca showed no changes. The increased 
oligomer formation of heterozygous FH induced by zinc or copper matched with reduced FH 
activities shown by fluid-phase assays. Therefore zinc and copper should be considered as 
newly-identified inhibitory FH ligands at pathological metal concentrations above 60 µM. 
Not only do zinc and copper promote uncontrolled oligomer formation of heterozygous FH, 
but the pre-formed oligomers can be disassembled by chelation using EDTA.  
 
FH is a major complement regulator in blood, and is expressed and secreted by many 
different cell types including the RPE (An  et al., 2006). Many functional studies of FH 
binding to its major ligand C3b, and to others such as heparin and C-reactive protein, have 
been performed. In distinction, surprisingly little attention has been paid to FH self-
association and its effect on its regulatory function. The originally-reported inhibition of C3b 
cleavage in 1000 µM zinc could be explained in terms of the non-specific aggregation of FH 
first reported by X-ray scattering, because the protein aggregates would block the 
accessibility to the functionally-active regions in FH (Crossley & Porter, 1980; Perkins et al., 
1991). While FH is often considered to be monomeric, several groups have reported its 
ability to dimerise (Jokiranta et al., 2000; Oppermann et al., 2006; Jokiranta et al., 2006). 
There are two dimerisation sites that have been located within the FH SCR-6/8 and SCR-
16/20 fragments with KD values of about 40 µM and 16 µM respectively (Fernando et al., 
2007; Okemefuna et al., 2008). Ultracentrifugation showed that heterozygous FH exists in a 
reversible monomer-dimer equilibrium with a KD of 28 µM up to 1.36 mg/ml, indicating that 
about 5% to 15% of FH in serum is reversibly dimeric, and that nonreversible higher 
oligomers form at higher concentrations, presumably through a alternating chain of 
dimerisation events at the two dimer sites (Chapter Five; Nan et al., 2008a). The effect of 
dimerisation on regulatory function is not known. Here, using physiological concentrations of 
heterozygous FH from pooled serum, our scattering data showed the formation of large but 
compact oligomers of heterozygous FH in the presence of zinc and copper, while our 
ultracentrifugation data show that heterozygous FH is 85% oligomeric in 200 µM zinc and 
50% oligomeric in 200 µM copper. FH activity was proportionately reduced by oligomer 
formation (Figure 6.17). 
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In a physiological scenario, because this metal binding is weak, the zinc- (or copper-) induced 
uncontrolled oligomerisation of FH can only occur in tissues where a sufficient amount of 
zinc (or copper) is present. For example, the total zinc concentration of 12.5 µM in serum is 
clearly too low to induce FH oligomerisation according to our data (Figure 6.2 and Figure 
6.12). This level remains low at 14.7 µM even after a daily diet supplement with 80 mg zinc 
in the AREDS trials (AREDS Research Group, 2001b; AREDS Research Group, 2002). Few 
tissues have high enough total zinc concentrations to release biologically reactive zinc in the 
range of 20-200 µM (Frederickson et al., 2006).
 The retina appears to be an exception, as this 
has the highest concentration of zinc per gram of tissue (Ugarte & Osborne, 2001). Retinal 
zinc is concentrated mostly in the RPE-choroidal complex, where sRPEds are formed, bound 
to melanin, metallothionein and other zinc binding proteins (Galin et al., 1962; Newsome et 
al., 1992). Cellular damage to the RPE which may occur through stress factors such as 
excessive light, smoking, or oxidative processes during ageing, is one of the first pathological 
events that lead to AMD. Damage to RPE cells may trigger the release of pathological levels 
of zinc from protein complexes into extracellular regions, and the local bioavailable zinc 
level may reach >60 µM which will be sufficient to initiate FH oligomerisation (Figure 6.2 
and Figure 6.12) and its precipitation into sRPEds (Frederickson et al., 2006). The concept 
that zinc might be involved in the initiation of AMD appears to contradict the clinical 
observation that zinc supplements are able to slow the development of blindness in patients 
(AREDS Research Group, 2001b; AREDS Research Group, 2002). However, AMD is a 
progressive disease, and decades elapse between the appearance of sRPEds and the 
degeneration that eventually lead to blindness. Therefore, it is possible that too much bio-
available zinc in the early stages of the disease can trigger the problem by facilitating the 
formation of sRPEds, while decades later zinc supplementation can be beneficial if most of 
the zinc in the tissues is trapped in sRPEds and the surrounding tissues are relatively depleted 
(Lengyel & Peto, 2008). 
 
At present, there is no simple mechanistic understanding of the formation of sRPEds and the 
slow progression to AMD over several decades of a lifespan. In the absence of metal, FH 
self-association involving probably SCR-7 and SCR-20 may lead to the formation of higher 
oligomers of FH through a set of alternating dimeric interactions between FH molecules 
(Chapter Five; Nan et al., 2008a; Fernando et al., 2007; Okemefuna et al., 2008). It is 
intriguing that the SCR-6/8 fragment with the His402 allotype that is a risk factor for AMD  159
shows a slightly higher propensity to self-associate than the wild-type Tyr402 allotype 
(Fernando et al., 2007), and this by itself could enhance the deposition of FH into sRPEds 
over several decades. A detailed comparison of the self-association properties between the 
Tyr402 and His402 allotype of FH is explained in Chapter Seven. However, if the alternative 
pathway is involved in AMD, as suggested from the involvement of FH polymorphisms 
(Klein et al., 2005; Haines et al., 2005; Edwards et al., 2005; Hageman et al., 2005) (and not 
the classical pathway which is regulated by membrane-bound regulators including membrane 
cofactor protein and decay-acceleration factor), and if FH-metal complexes contribute to the 
onset of AMD, a pathway for zinc-induced oligomer formation is suggested by the results in 
this chapter. Zinc is tetrahedrally coordinated in proteins (Auld, 2001). Given that zinc 
ligands at protein interfaces often include pairs of surface Asp and His residues, and Tyr402 
is exposed at the surface of SCR-7 (Fernando et al., 2007), it is also intriguing that the AMD-
risk Tyr402His polymorphism involves the introduction of a His residue (Klein et al., 2005; 
Haines et al., 2005; Edwards et al., 2005; Hageman et al., 2005). This raises the possibility 
that an Asp-His pair on the surface of an SCR domain forms half a zinc binding site, and zinc 
may pair these two SCR domains together in a symmetric arrangement. The comparison of 
the zinc-binding properties of the Tyr402 and His402 allotypes of FH and the prediction of 
possible zinc-binding sites within FH are reported in Chapter Eight. Other scenarios based on 
other metal coordinations are possible. Irrespective of whether zinc interacts with specific 
residues on the surface of SCR domains, or whether zinc promotes the previously-observed 
self-association dimer sites in SCR-6/8 and SCR-16/20, it is clear that, in the presence of 
zinc, FH will form indefinite oligomers more readily than in its absence. Different metals will 
cause different oligomerisation properties, depending on their relative affinity for different 
self-association sites. For example, the more compact zinc-promoted oligomers (Figure 6.7) 
may be formed through a stronger pairing of two central SCR domains of FH, while the more 
extended copper-induced oligomers may result from a stronger pairing of SCR domains at 
one end of FH (Figure 6.18). As zinc is more abundant in sRPEds than any other metal (Flinn 
et al., 2008; Scholl et al., 2008), a compact association mechanism might be more relevant. 
While such an aggregation mechanism may be directly relevant to AMD, it is not known 
whether this proposed aggregation mechanism may act as a trigger for sRPEd formation, or 
facilitates the growth of sRPEd into larger and clinically relevant sizes over several decades 
of a lifespan. An aggregation mechanism will be distinct from that in which excessive 
complement activation and uncontrolled inflammation caused by reduced FH regulation will 
generate the slow build-up of protein and lipids after complement attack of host cells (Klein  160
 
 
Figure 6.18 Hypothetical cartoon of the differential effect of metals on FH oligomerisation.   
 
(a) A partially folded-back FH monomer structure is depicted, with SCR-7 and SCR-20 
highlighted in black as possible dimerisation sites in native FH. It is stressed that the FH 
monomer is more compact in its folded-back structure than that shown, which is drawn for 
reason of clarity. 
 
(b) A putative compact oligomer is formed, initially as a dimer through contacts in the region 
near SCR-20. The presence of zinc promotes further dimerisation in a central region of FH 
near to but not necessarily at SCR-7, and this leads to a set of compact oligomers (Figure 
6.7).  
 
(c) More extended oligomers can be formed if a different metal promotes a different pattern 
of oligomer formation. In the schematic view shown, dimers are initially formed near SCR-7, 
and the presence of copper leads to further dimerisation near to one end of FH, not necessarly 
at SCR-20. More extended oligomers are formed in the presence of copper (Figure 6.7).  
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et al., 2005; Haines et al., 2005; Edwards et al., 2005; Hageman et al., 2005; Lengyel et al., 
2004).  
 
The molecular effect of dimerisation on FH function is not presently known, but Figure 6.17 
indicated that complement regulation by FH will be diminished by oligomer formation. The 
C3b or factor I ligands may be sterically blocked from interaction with FH aggregates by 
zinc. Alternatively, or simultaneously, zinc may enhance the deposition of FH-binding 
proteins, together with FH, into sRPEds contributing to the accelerated protein built up in the 
Bruch’s membrane. This process might be slow, given that it could be triggered by the 
gradual decline of RPE cells that may happen without relevant visual impairment of the 
peripheral retina (Jager  et al., 2008). However, the process might be accelerated by the 
several environmental, cellular and genetic factors associated with AMD, especially when the 
damage affects the macula (Wills et al., 2008). If FH-metal complexes contribute to the onset 
of AMD, a pathway for zinc-induced oligomer formation is suggested by analogy with the 
two FH dimerisation site, SCR-6/8 and SCR-16/20 (Fernando et al., 2007; Okemefuna et al., 
2008). By this, two weak dimer sites will initiate FH dimer formation at either site. As shown 
in Figure 6.18 a, these are arbitrarily postulated to be in the vicinity of SCR-7 and SCR-20. In 
the absence of metal, these sites will lead to higher oligomers of FH at high concentration 
through a set of alternating dimeric interactions between FH molecules (Chapter Five; Nan et 
al., 2008a). If the process of self-association at two dimer sites is enhanced by the presence of 
zinc (not necessarily at SCR-7 and SCR-20), FH will form indefinite oligomers more readily 
(Figure 6.18 b). The varied effect of different transition metals on the FH oligomer structure 
is explained schematically in Figure 6.18 depending on which of the two dimer sites is more 
strongly promoted by metal. For example, the more compact zinc-promoted oligomers of 
Figure 6.7 may be formed through a stronger dimerisation effect at a central SCR domain of 
FH (Figure 6.18 b), while the more extended copper-induced oligomers may result from a 
stronger effect at a C-terminal region of FH (Figure 6.18 c). Note that zinc is more abundant 
in the retina than copper (Flinn et al., 2008; Wills et al., 2008). While such an aggregation 
mechanism for FH may be directly relevant to AMD, it is possible that the high 
bioavailability of zinc in the retina may exert a pathogenic effect by this route. Given that 
zinc ligands at protein interfaces often include surface Asp and His residues, and Tyr402 is 
exposed at the surface of SCR-7 (Fernando et al., 2007), it is also intriguing that the AMD-
risk polymorphism in FH replaces Tyr402 with His402 (Klein et al., 2005; Haines et al., 
2005; Edwards et al., 2005; Hageman et al., 2005).   162
 
Given the unambiguous association between complement activation and AMD, the presence 
of FH and other complement related proteins in sRPEds (Hageman et al., 2001), and the 
indication that FH plays a role in the age-related thickening of the Bruch’s membrane (Coffey 
et al., 2007), an improved understanding of the role for FH may lead to novel therapies for 
AMD. For example, if a metal-induced aggregation mechanism or metal-induced 
complement dysregulation proves to be significant, the reversibility of FH oligomerisation 
with EDTA offers the possibility to capture this oligomerisation before the irreversible cross 
linking of proteins with photo-oxidised lipids takes place (Crabb  et al., 2002). Similar 
arguments may be relevant to other deposit-forming diseases in which trace metals are 
involved, such as Alzheimer’s disease in which a zinc buffering compound is already in 
clinical trials (Ritchie et al., 2003).  
 
 
  163
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Seven 
 
Self-association and folded-back solution structure of the wild-type Tyr402 and the 
disease-related His402 allotypes of homozygous complement factor H  
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7.1 Introduction 
 
The alternative complement pathway is a crucial component of the innate immune 
system. Its activation is initiated by the spontaneous hydrolysis of C3 to form C3u, also 
known as C3(H2O), which leads to a positive-feedback amplification of C3 cleavage to 
form the activated form C3b which is deposited on pathogenic cell surfaces. To prevent 
complement-mediated host cell damage, complement factor H (FH) regulates the 
alternative pathway by acting as a cofactor for factor I (FI) to cleave C3b (Law & Reid, 
1995; Whaley & Ruddy, 1976; Pangburn et al., 1977), competing with factor B to 
interfere with the formation of the C3 convertase C3bBb (Farries et al., 1990), and 
accelerating the decay of the C3bBb complex (Whaley & Ruddy, 1976; Weiler et al., 
1976). FH is genetically associated through a common Tyr402His polymorphism with 
age-related macular degeneration (AMD), the most common cause of blindness in the 
elderly in the Western population (Klein et al., 2005; Haines et al., 2005; Edwards et 
al., 2005; Hageman et al., 2005). FH is also involved with kidney diseases including 
atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis 
type II, and with dementia, including Alzheimer's disease (Strohmeyer et al., 2002; 
Saunders  et al., 2007; Zetterberg et al., 2008). Even with the analysis of over 100 
genetic alterations in FH (Saunders et al., 2007), molecular mechanisms leading to these 
four diseases based on the involvement of altered forms of FH are still not clear. In the 
context of AMD, the early stages of this disease involve the appearance of sub-retinal 
pigment epithelial deposits that develop in the extracellular matrix interposed between the 
retinal pigment epithelium (RPE) and the choroidal vasculature, called Bruch’s membrane 
(Bird, 2010). Sub-RPE deposits have been long recognized as a hallmark of AMD. They 
contain oxidized lipids, carbohydrates, cellular materials and over 200 proteins 
including FH and other complement components (Hageman et al., 2005; Crabb et al., 
2002; Bok, 2005).  Based on these co-localizations, complement activation-related 
inflammation was proposed to be associated with sub-RPE deposit formation (Hageman 
et al., 2005; Anderson et al., 2002). The studies in Chapter Five and Chapter Six 
proposed that the propensity of heterozygous FH to form oligomers may contribute to 
sub-RPE deposits (Nan et al., 2008a; Nan et al., 2008b), thus it becomes necessary to 
understand how the individual homozygous FH allotypes form oligomers.  
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FH is constructed from 20 short complement regulator (SCR) domains, each of length 
about 61 residues, with 19 linkers of lengths composed of three to eight residues 
between the domains (Soares & Barlow, 2005). There are nine potential N-
glycosylation sites in FH, of which eight are occupied by biantennary disialylated 
glycans (Fenaille  et al., 2007). FH binds to three major physiological ligands via 
comparatively weak interactions at multiple sites (Perkins et al., 2010a; Perkins et al., 
2010b). Three binding sites have been proposed for C3b, including SCR-1/4 that binds 
to intact C3b, SCR-6/10 that binds to the C3c fragment of C3b and SCR-16/20 that 
binds to the C3d fragment (Sharma & Pangburn, 1996; Jokiranta et al., 2000; Schmidt 
et al., 2008b). At least two binding sites for heparin have been proposed at SCR-7 and 
SCR-20, where heparin is an analogue of heparan sulphate that coats the host cell 
surface (Blackmore et al., 1996; Blackmore et al., 1998; Ormsby et al., 2006). At least 
two major binding sites have been proposed for C-reactive protein (CRP) at SCR-7 and 
SCR-8/11, and also at SCR-16/20 (Okemefuna et al., 2010). The FH-CRP interaction 
has been controversial for reason of the strong affinity of denatured CRP for FH which 
complicated earlier analyses (Hakobyan et al., 2008), however the most recent study 
reconciled observations based on inappropriate buffers and denatured CRP to confirm 
that native CRP interacts with FH at two different sites (Okemefuna et al., 2010). The 
FH Tyr402His polymorphism was recognized as a risk factor for AMD (Klein et al., 
2005; Haines et al., 2005; Edwards et al., 2005; Hageman et al., 2005), and residue 402 
is located in SCR-7 which interacts with heparin and CRP. The SCR-6/8 His402 
allotype exhibits reduced binding to CRP than the Tyr402 allotype (Okemefuna et al., 
2010), while variable results have been obtained in binding studies of FH to heparin 
(Clark et al., 2006). The Val62Ile polymorphism is protective against AMD (Hageman 
et al., 2005; Hocking et al., 2008), and this is located in SCR-1 which interacts with 
C3b. FH also forms oligomers through self-association sites at each of SCR-6/8 and 
SCR-16/20 (Chapter Five; Nan et al., 2008a; Fernando et al., 2007; Okemefuna et al., 
2008). Dimer formation at SCR-7 may affect FH-ligand interactions that involve SCR-
7.  
 
To date, the structure of full-length FH has not been determined by crystallography or 
NMR methods for reason of its large size and the glycosylation of its 20 domains. 
Crystal and NMR structures have been published for small domain fragments of FH 
(Hocking et al., 2008; Wu et al., 2009; Schmidt et al., 2010; Okemefuna et al., 2009).  166
FH self-association is not always considered in these crystal and NMR studies. FH 
dimers in solution at high concentrations were reported by X-ray and neutron scattering 
(Perkins et al., 1991), while other studies showed that heterozygous FH possesses a 
partially folded-back and largely monomeric domain structure in solution that is 
affected by ionic strength (Okemefuna et al., 2009; DiScipio, 1992; Aslam & Perkins, 
2001). The recombinant SCR-6/8 and SCR-16/20 fragments of FH each showed dimeric 
properties (Fernando  et al., 2007; Okemefuna et al., 2008). The sequential daisy-
chaining of these dimer sites in FH would lead to the formation of a series of FH 
oligomers, and this hypothesis was verified by ultracentrifugation of heterozygous FH 
(Chapter Five; Nan et al., 2008a; Okemefuna et al., 2009). Given the involvement of the 
Tyr402His polymorphism at one of the two dimerisation sites with AMD, more detailed 
knowledge of how dimers and higher oligomers are formed in the two homozygous FH 
allotypes is essential to understand the relation of FH to AMD. Previously, 
ultracentrifugation suggested that the His402 allotype of SCR-6/8 showed a greater self-
association than the Tyr402 allotype (Fernando et al., 2007). Following the study in 
Chapter Five, the self-association of the Tyr402 and His402 allotypes of full-length 
homozygous FH and its SCR-6/8 fragment are characterised in this chapter. The study 
in this chapter shows that the His402 allotype of SCR-6/8 exhibits significantly greater 
self-association than the Tyr402 allotype when immobilised at surfaces, and that both 
forms of full-length FH self-associate by similar amounts to form oligomers. Improved 
similar folded-back solution structures are determined for both FH allotypes by 
constrained scattering modelling, and two different mechanisms for FH self-association 
are proposed. The implications of these results for complement regulation and the 
formation of protein aggregates in the development of AMD are also discussed in this 
chapter. 
 
7.2 Results and discussion  
 
7.2.1 Surface plasmon resonance of the two FH allotypes and FH SCR-6/8 
 
Both the full-length FH Tyr402 and FH His402 allotypes were purified from the plasma 
of genotyped healthy volunteers without known eye disease (Table 7.1) from the major 
peak in size-exclusion chromatography. Both gave clean single bands by SDS-PAGE as 
in Figure 5.6 b (Chapter Five; Nan et al., 2008a). The seven Tyr402 samples were  167
Table 7.1 Genotyped FH samples used in this chapter. 
 
FH source  Tyr402His  Ile62Val  Experiment 
a 
002CW  Tyr402  heterozygous  Gel filtration; AUC 
004EE  Tyr402  heterozygous  Gel filtration; AUC 
026II  Tyr402  Ile62  Gel filtration; AUC 
020FM Tyr402  heterozygous  AUC; SAXS; Modelling 
022LM  Tyr402  Val62  AUC; SAXS; Modelling 
013HH Tyr402  Val62  MS 
018DK Tyr402  heterozygous  SPR 
      
011KY  His402  Val62  Gel filtration; AUC 
027BA  His402  Val62  Gel filtration; AUC 
023SK His402  Val62  AUC 
028EL  His402  Val62  AUC; SAXS; Modelling 
032KO  His402  Val62  AUC; SAXS; Modelling 
015LT His402  Val62  MS 
030TJ His402 Val62  SPR 
 
a Abbreviations: AUC, analytical ultracentrifugation; SAXS, small angle X-ray 
scattering; Modelling, constrained scattering modelling; MS, mass spectrometry; SPR, 
surface plasmon resonance.  168
  homozygous or heterozygous for the Ile62Val polymorphism (Table 7.1), another 
AMD-asscoiated polymorphism. All seven AMD-risk His402 samples were 
homozygous for the Val62 polymorphism. Fluid-phase activity assays using C3u and 
factor I with both FH allotypes showed that both demonstrated similar C3u cleavage 
rates (Nan et al., 2008b). 
 
Surface plasmon resonance (SPR) studies of protein in the solution phase binding to an 
immobilised protein surface enabled FH self-association to be studied in terms of the 
Tyr402His polymorphism and their dissociation constant KD values (Tanious  et al., 
2008). A total of 150 RU (resonance unit) of heterozygous FH was immobilised on a 
CM5 chip.  Equilibrium experiments were performed by flowing FH Tyr402 over the 
chip at concentrations between 0.1-1.5 mg/ml (0.65-9.74 µM) (Figure 7.1 a), and FH 
His402 over the chip at concentrations between 0.1-1.8 mg/ml (0.65-11.69 µM) in 
HEPES buffer (Figure 7.1 b). The binding of both FH allotypes to heterozygous 
immobilised FH was observed at all concentrations (Figure 7.1 a, b), indicating that FH 
oligomerisation proceeded in physiological relevant conditions. In equilibrium analyses, 
the individual sensorgrams could not be fitted to a 1:1 binding kinetic model, suggesting 
that FH binding is more complicated that that provided by a 1:1 model, in agreement 
with the conclusion from ultracentrifugation that at least two self-association sites exist 
on FH (Chapter Five; Nan et al., 2008a). However, the maximum binding response 
from each sensorgram can be well fitted to a steady state affinity model which assuming 
the binding is 1:1. Therefore if assuming 1:1 binding, a KD value of 8.04 µM with a χ
2 
value of 2.58 RU
2 was determined for FH Tyr402, while a similar KD value of 6.72 µM 
with a  χ
2 value of 6.53 RU
2 was determined for FH His402 from a steady state affinity 
model (Figure 7.1 c). Both these KD values were smaller than the KD value of 28 µM 
determined for heterozygous FH in solution by sedimentation equilibrium 
ultracentrifugation (Nan et al., 2008a). The stronger self-association of FH seen by SPR 
than by ultracentrifugation may result from its immobilisation on a surface, at which 
local concentration effects will amplify the strength of binding. Overall, these 
experiments with one pair of FH allotypes show that the binding of FH His402 and FH 
Tyr402 to immobilised FH are similar.  
 
Earlier analytical ultracentrifugation experiments showed that the His402 allotype of FH 
SCR-6/8 self-associated slightly more than the Tyr402 allotype in solution (Fernando et  169
 
 
 
Figure 7.1 Surface plasmon resonance analysis of the FH self-association. 150 RU of 
wild-type heterozygous FH was immobilised on a CM5 chip; The Tyr402 allotype is 
denoted by blue; the His402 allotype is denoted by red. 
 
(a) A FH Tyr402 sample 018DK was analysed at seven concentrations of 0 µM 
(measured twice), 0.65 µM, 1.95 µM (twice), 3.90 µM, 5.84 µM, 7.79 µM and 9.74 µM 
(twice) from bottom to top;  
 
(b) A FH His402 sample 030TJ was analysed at eight concentrations of 0 µM, 0.65 µM, 
1.95 µM, 3.90 µM, 5.84 µM, 7.79 µM, 9.74 µM and 11.69 µM from bottom to top, each 
measured in duplicate;  
 
(c) Binding affinities were fitted using the maximum response values in (a) and (b). The 
KD values were determined as 8.04 µM (Tyr402) with a χ
2 value of 2.58 RU
2 and 6.72 
µM (His402) with a χ
2 value of 6.53 RU
2 (vertical dashed straight lines).   170
 al., 2007). Accordingly further SPR studies were made using both allotypes of the FH 
SCR-6/8 fragment. Each allotype was separately successfully immobilised to a CM4 
chip up to a total response of 150 RU (Figure 7.2), and the His402 allotype was also 
immobilised up to 400 RU on a third chip (Figure 7.3). The binding of FH SCR-6/8 
Tyr402 was studied at concentrations between 0.04-0.8 mg/ml (2-40 µM) over CM4 
chips immobilised with either FH SCR-6/8 Tyr402 (Figure 7.2 a) or FH SCR-6/8 
His402 respectively (Figure 7.3 a). The binding of FH SCR-6/8 His402 was studied at 
concentrations between 0.04-0.6 mg/ml (2-28 µM) over CM4 chips immobilised with 
either FH SCR-6/8 Tyr402 (Figure 7.2 b) or FH SCR-6/8 His402 (Figure 7.3 b) 
respectively. Binding was observed in all cases, and therefore both allotypes of FH 
SCR-6/8 self-associate with each other. The two allotypes of FH SCR-6/8 showed the 
same binding affinities on the surface immobilised with FH SCR-6/8 Tyr402 allotype 
(Figure 7.2 c), and this indicates that the affinity of the self-association of FH SCR-6/8 
Tyr402 allotype is similar to that of the self-association of the heterozygous FH SCR-
6/8. On the other hand, the FH SCR-6/8 His402 allotype showed significantly higher 
binding affinity than the Tyr402 allotype did to the surface immobilised with the His402 
allotype (Figure 7.3 c), and this indicates that the affinity of the self-assocation of FH 
SCR-6/8 His402 allotype is higher than that of the heterozygous FH SCR-6/8. From the 
two comparions, one can derive that the FH SCR-6/8 His402 allotype self-associates 
more than the FH SCR-6/8 Tyr402 allotype does, and the His402 residue is participating 
in the binding. The KD values could not be determined from steady state affinity fits 
because both KD values were larger than 40 µM, which indicate that the binding is 
weak. This is consistent with the KD value of approximately 40 µM determined by 
ultracentrifugation for the His402 allotype (Fernando et al., 2007). Given that the self-
association of the two FH SCR-6/8 allotypes is weaker than the self-association of the 
two full-length FH allotypes, for which the KD value is 28 µM for heterozygous full-
length FH in solution (Chapter Five; Nan et al., 2008a) and 7-8 µM by SPR above for 
the full-length FH allotypes, this also indicates that other self-association sites exist in 
FH as well as that in SCR-6/8. 
  171
 
 
Figure 7.2 Surface plasmon resonance analysis of the FH SCR-6/8 self-association with 
150 RU of the Tyr402 allotype of FH SCR-6/8 immobilised on a CM4 chip. The Tyr402 
allotype is denoted by blue; the His402 allotype is denoted by red. 
 
(a) A FH SCR-6/8 Tyr402 sample was analysed at six concentrations of 0 µM (twice), 5 
µM, 10 µM (twice), 19 µM, 29 µM (twice) and 37 µM from bottom to top;  
 
(b) A FH SCR-6/8 His402 sample was analysed at six concentrations of 0 µM, 5 µM, 9 
µM, 14 µM, 22 µM and 28 µM from bottom to top, each measured in duplicate;  
 
(c) Binding affinities were fitted using the maximum response values in (a) and (b), 
however no KD values were determined because these are greater than 40 µM.  
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Figure 7.3 Surface plasmon resonance analysis of the FH SCR-6/8 self-association with 
400 RU of the His402 allotype of FH SCR-6/8 immobilised on a CM4 chip. The Tyr402 
allotype is denoted by blue; the His402 allotype is denoted by red. 
 
(a) A FH SCR-6/8 Tyr402 sample was analysed at concentrations of 0 µM (twice), 2 
µM (twice), 5 µM (twice), 8 µM, 11 µM (twice) and 15.1 µM from bottom to top;  
 
(b) A FH SCR-6/8 His402 sample was analysed at six concentrations of 0 µM (twice), 2 
µM (twice), 5 µM (twice), 8 µM, 11 µM (twice) and 13.6 µM from bottom to top;  
 
(c) Binding affinities were fitted (open circles) using the maximum response values in 
(a) and (b), however no KD values were determined because these are greater than 40 
µM. A second experiment with 150 RU of FH SCR-6/8 His402 immobilised on a CM4 
chip using six concentrations of His402 at 0 µM, 5 µM, 10 µM, 15 µM, 20 µM and 22 
µM and six concentrations of Tyr402 at 0 µM, 5 µM, 10 µM, 20 µM, 30 µM and 40 µM 
are also shown (filled circles).  173
7.2.2 Sedimentation velocity analyses of the two FH allotypes  
 
Analytical ultracentrifugation studies the sedimentation behaviour of macromolecules 
on subjecting these to a high centrifugal force in order to determine their sizes and 
shapes (Section 4.1; Cole et al., 2008). The oligomers previously observed for 
heterozygous FH (Chapter Five;  Nan  et al., 2008a) were now evaluated using 
sedimentation velocity experiments on five FH Tyr402 and five FH His402 allotypes 
from ten genotyped donors at three concentrations between 0.5-2.1 mg/ml in HEPES 
buffers (10 mM HEPES, 137 mM NaCl, pH 7.4). Similar sedimentation boundary 
profiles were observed for the two allotypes (Figure 7.4, upper panels), and these were 
fitted using size-distribution analyses c(s). Good fits with low residuals were obtained in 
all cases. The mean sedimentation coefficient s20,w of monomeric FH (Tyr402) at a rotor 
speed of 50,000 r.p.m was 5.69 (± 0.03) S, and that for FH (His402) was identical at 
5.67 (± 0.04) S (peak 1 in Figures 7.4 a, b). Both values (Table 7.2) agree well with 
previous s20,w values of 5.3 (± 0.1) S and 5.65 (± 0.05) S for heterozygous monomeric 
FH in 137 mM NaCl (Chapter Five;  Nan  et al., 2008a; Aslam & Perkins, 2001). 
Conversion of the c(s) distribution to mass distribution plots c(M) showed that the major 
peak 1 corresponded to a molecular mass of 147 (± 10) kDa for the FH (Tyr402) 
allotype and 147 (± 11) kDa for FH (His402). Both values agreed with the sequence-
calculated molecular mass of 154 kDa for both allotypes, and previous c(M) mass 
determinations of 142 (± 2)  kDa for heterozygous FH (Chapter Five; Nan et al., 2008a). 
Integration of the c(s) peaks showed that dimer and trimer comprised 4.0 (± 1.9) % and 
2.1 (± 0.7) % respectively for FH Tyr402 samples, and 5.7 (± 1.5) % and 2.5 (± 0.6) % 
respectively for FH His402 samples at 1.1 mg/ml. Thus the averaged c(s) distributions 
showed similar dimer and trimer formation for the two allotypes (peaks 2 and 3 in 
Figure 7.4 c). The mean s20,w value of dimeric FH Tyr402 was 7.57 (± 0.36) S, and that 
for dimeric FH His402 was similar at 7.69 (± 0.40) S (peak 2 in Figure 7.4 a, b). The 
mean s20,w value of trimeric FH Tyr402 was 9.3 (± 0.7) S, and that for trimeric FH 
His402 was similar at 9.4 (± 0.8) S (peak 3 in Figure 7.4 a, b). These values also agree 
well with previous values of 7.3 ± 0.2 S and 9.2 ± 0.2 S for heterozygous FH dimers and 
trimers respectively (Chapter Five;  Nan  et al., 2008a). These dimer peaks were 
reproducibly seen for heterozygous FH in a range of NaCl concentrations and pH 
values, and their size increases with increase in FH concentration (Okemefuna et al., 
2009). The present study now shows that these reversible peaks also exist in   174
 
Figure 7.4 Sedimentation velocity c(s) size-distribution analyses for the two FH 
allotypes. All analyses correspond to 1.1 mg/ml FH. In the upper panels, the 
sedimentation boundary fits corresponding to the FH Tyr402 (blue) and FH His402 
(red) allotypes are shown in the upper panels, where only every tenth scan is shown for 
reason of clarity. In the lower panels, the intensity of the major monomer peak at 
approximately 5.7 S is normalised to 100 for reason of clarity. 
 
(a) The c(s) analyses are shown for five Tyr402 FH samples ( , 002CW;  , 
004EE;  , 026II;  , 020FM;  , 022LM);  
 
(b) The c(s) analyses are shown for five His402 FH samples ( , 011KY;  , 
023SK;  , 027BA;  , 028EL;  , 032KO).  
 
(c) The averaged c(s) plots for Tyr402 FH (blue) and His402 FH (red) from (a,b) are 
overlaid for comparison.   
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homozygous FH. Reaction boundaries are c(s) peaks that correspond to the co-
sedimentation of two different species, and exhibit well-defined sedimentation 
coefficients between the values of the two different species (Dam & Schuck, 2005). The 
dimer and trimer peaks do not correspond to reaction boundaries because these are 
separately observed from that of the FH monomer peak, thus they correspond to slow 
equilibria between the monomer, dimer and trimer on the timescale of sedimentation. 
 
In heterozygous FH, variable amounts of further oligomers from tetramers to nonamers 
with lower intensities have been observed (Chapter Five; Nan et al., 2008a; Okemefuna 
et al., 2009). For the FH Tyr402 allotype, the s20,w values of peaks 4-9 (Figure 7.5 a) 
were 11.9 (± 1.0) S, 14.7 (± 0.8) S, 17.1 (± 0.7) S, 19.4 (± 1.0) S, 22.1 (± 1.0) S and 
25.0 (± 0.7) S in that order. For the FH His402 allotype, the s20,w values of peaks 4-9 
(Figure 7.5 b) were in close agreement at 11.9 (± 0.9) S, 14.3 (± 0.5) S, 16.7 (± 0.4) S, 
18.7 (± 0.6) S, 21.3 (± 0.5) S and 24.8 (± 0.7) S in that same order. The percentages of 
the FH Tyr402 and His402 oligomers at concentrations from 0.5 to 2.1 mg/ml were 
derived by integration of the peaks 2-9 between 6.8 S to 28 S in the five c(s) analyses 
for each allotype (Figure 7.5 c). A mean value of 11.7 (± 2.0) % of oligomers was seen 
for FH Tyr402 while a mean of 12.8 (± 2.7) % of oligomers were seen for FH His402 
FH. Both percentages agree well with that of 12% observed for heterozygous FH at 1 
mg/ml, and are comparable with an estimate of 17% of dimer predicted from a simple 
reversible monomer-dimer self-association KD value of 28 µM (Chapter Five; Nan et 
al., 2008a). The variability in quantifying the proportion of higher FH oligomers is 
attributable to two factors. First, the amount of higher oligomers is not consistently 
observed in all cases, as exemplified by the NaCl concentration and pH study of 
heterozygous FH (Okemefuna  et al., 2009). Second, slight misalignments of the 
ultracentrifugation cells in the rotor relative to the centre of rotation can result in the 
observation of pseudo-oligomeric peaks (Arthur  et al., 2009). Overall, larger FH 
oligomers appear to form irreversibly by a different mechanism to that for the FH dimer 
and trimer. 
 
7.2.3 Mass spectrometry of the two FH allotypes  
 
Because the direct evidence for discrete FH oligomers in solution has been observed up 
to now only by analytical ultracentrifugation, mass spectrometry of homozygous FH  177
 
 
Figure 7.5 Integration of the homozygous FH oligomers in c(s) analyses. FH samples 
were analysed by sedimentation velocity at rotor speeds up to 60,000 r.p.m.  (a,b) 
Representative analyses of the Tyr402 and His402 allotypes are shown at 50,000 r.p.m., 
where the numbers represent the FH oligomers starting with monomer (peak 1) and 
dimer (peak 2) and extending to nonamers (peak 9). (c) The proportion of oligomers 
present was derived by integration of the c(s) analyses for peaks 2-9 for the five 
different samples of each FH allotype (Tyr402, blue; His402, red) at concentrations of 
approximately 0.5 mg/ml, 1.1 mg/ml and 2.1 mg/ml. Statistical error bars are shown 
where visible. The mean proportion of oligomers is shown as a straight line.  178
was employed as a further means of detecting oligomers. Mass spectrometry is able to 
observe macromolecular assemblies and determine their stoichiometry (Benesch & 
Robinson, 2009). Caution in data interpretation is required because the presence of 
oligomeric forms may not reflect the solution composition, but instead result from non-
specific protein-protein interactions formed during the electrospray process during the 
evaporation of nanodroplets inside the instrument (Lane et al., 2009). One pair of the 
FH Tyr402 and His402 allotypes was studied shortly after concentration to about 4 
mg/ml in order to promote the formation of reversible oligomers. Buffers with either 
140 mM or 1 M ammonium acetate (pH 7.0) were used in order to evaluate two ionic 
strengths, given the known decrease of oligomer formation with increase in NaCl 
concentration (Okemefuna et al., 2009). Ammonium acetate was used because this is 
volatile in the gas phase used for measurements, unlike the HEPES buffer used for SPR 
and ultracentrifugation. The mass spectrometry experiments were performed by Dr. 
Adam MacKay in the Department of Chemistry at UCL. In all four cases, a major signal 
with five to six components were seen at mass/charge (m/z) ratios that corresponded to 
the monomer of FH with different charge states of +23 to +27 (Figure 7.6). For the FH 
Tyr402 allotype, the monomer molecular masses were determined to be 150 kDa in 140 
mM ammonium acetate and 157 kDa in 1 M ammonium acetate (Figure 7.6 a, b). These 
results were replicated for the FH His402 allotype, where the masses were determined 
to be 156 kDa in 140 mM ammonium acetate, and 150 kDa in 1 M ammonium acetate 
(Figure 7.6 c, d). These masses agree well with those masses obtained from 
sedimentation velocity analyses for both FH allotypes (Figure 7.4), and for 
heterozygous FH (Chapter Five; Nan et al., 2008a; Okemefuna et al., 2009). The masses 
also agree well with the sequence-calculated value of 154 kDa for FH that was based on 
the glycosylation of eight of the nine sites in FH determined by mass spectrometry of 
FH peptides (Fenaile et al., 2007). The variability of the individual mass determinations 
is attributed to the relatively large peak width that results from the comparatively high 
level of glycosylation in FH at eight locations (Fenaile et al., 2007). 
 
Dimer and trimer forms of FH were also observed in the spectra (Figure 7.6). For the 
FH Tyr402 allotype, the dimer and small amounts of the trimer were observed in 140 
mM ammonium acetate, while only the dimer was observed in 1 M ammonium acetate. 
Their molecular masses were determined to be 307 kDa and 457 kDa, and 309 kDa 
respectively (Figure 7.6 a, b). The FH His402 allotype showed similar masses of 306  179
 
Figure 7.6 Mass spectrometry of the Tyr402 and His402 FH allotypes.  The FH 
monomer, dimer and trimer peaks are marked by M, D and T followed by the measured 
molecular weight. (a) FH Tyr402 sample 013HH at 3.9 mg/ml (25.3 µM) in 140 mM 
ammonium acetate buffer pH 7.0. (b) FH Tyr402 sample 013HH at 4.4mg/ml (28.6 µM) 
in 1 M ammonium acetate buffer pH 7.0. (c) FH His402 sample 015LT at 3.9 mg/ml 
(25.3 µM) in 140 mM ammonium acetate buffer pH 7.0. (d) FH His402 sample 015LT 
at 3.6 mg/ml (23.4 µM) in 1 M ammonium acetate buffer pH 7.0.   180
 kDa and 455 kDa in 140 mM ammonium acetate, and 299 kDa in 1 M ammonium 
acetate (Figure 7.6 c, d). Peak integrations showed that the proportions of monomer, 
dimer and trimer were comparable at 73%, 24% and 4% for FH Tyr402 and 76%, 17% 
and 6% for FH His402 in 140 mM ammonium acetate (Figure 7.6 a, c). At 4 mg/ml, a 
comparable amount of 37% dimer formation is predicted from the monomer-dimer KD 
value of 28 µM in 137 mM NaCl HEPES buffer. The proportions of monomer and 
dimer were altered to 90% and 10% for FH Tyr402 and 98% and 2% for FH His402 in 1 
M ammonium acetate (Figure 7.6 b, d). The relative reduction of dimer and the 
disappearance of trimer in 1 M ammonium acetate are consistent with the reduced FH 
self-association when the NaCl concentration is increased (Okemefuna et al., 2009). No 
significant difference was detectable between the two allotypes, and higher oligomers 
beyond trimers were not detectable. In conclusion, the observation of dimer and trimer 
by mass spectrometry confirm the reversible existence of discrete monomer, dimer and 
trimer species of FH in solution, even with the concerns over possible non-specific 
interactions by mess spectrometry (Lane et al., 2009).  
 
7.2.4 Size-exclusion gel filtration of the two FH allotypes  
 
Ultracentrifugation showed that heterozygous FH that was exposed to concentrations 
above 2 mg/ml forms irreversible high oligomers (Chapter Five; Nan et al., 2008a). In 
order to evaluate FH oligomer formation with the homozygous proteins, size-exclusion 
chromatography was performed at the end of sedimentation velocity experiments after 
the proteins had sedimented to the bottom of the ultracentrifuge cell. The FH allotypes 
were resuspended into solution by gentle shaking. Size-exclusion chromatography on 
resuspended FH showed that the single homogenous FH peak between 65-75 ml was 
supplemented by additional peaks corresponding to FH oligomers that eluted earlier 
between 55-65 ml in all cases (Figure 7.7), and this is similar to the previous elution 
profile of heterozygous FH (Figure 5.6 a). Similar elution profiles were obtained at FH 
concentrations of 1.7 mg/ml (Figure 7.7 a) decreasing to 0.3 mg/ml (Figure 7.7 d). The 
main monomer peak was eluted at the same position in each case, indicating that no 
structural differences between allotypes were detectable by size-exclusion 
chromatography. The early elution between 55-65 ml showed that both FH allotypes 
formed oligomers. Even though the His402 allotype eluted slightly earlier in three 
loading concentrations (Figure 7.7 a, b, c), and the Tyr402 allotype eluted earlier in only  181
 
Figure 7.7 Size-exclusion gel filtration of nine homozygous FH preparations. Purified 
samples of the Tyr402 and His402 allotypes of FH at different concentrations were 
loaded onto a Superose
TM 6 prep grade XK 16/60 column after sedimentation velocity 
experiments. Pairs of elution profiles for the two allotypes are overlaid at the same 
concentration of (a) 1.7 mg/ml; (b) 0.9 mg/ml; (c) 0.2 mg/ml; and (d) 0.3 mg/ml. The 
homozygous FH samples were identified by five-letter codes adjacent to their elution 
profiles (Table 7.1), and corresponded to the ultracentrifugation samples. The Tyr402 
allotype is shown in blue and the His402 allotype is shown in red.   182
one loading concentration (Figure 7.7 d), the differences are too small to be significant. 
This approach also showed that both FH allotypes form similar amounts of oligomers. 
 
7.2.5 X-ray scattering of the two FH allotypes  
 
X-ray scattering is a diffraction method used to determine solution structures of 
macromolecules in random orientations (Section 4.2;  Perkins  et al., 2008). Here, 
scattering was used to compare the overall structures of FH Tyr402 and FH His402. 
Two pairs of FH Tyr402 and FH His402 (Table 7.1) were freshly prepared and studied 
in two different beam sessions at the ESRF in five concentrations between 0.4 mg/ml 
(2.6 µM) and 3.3 mg/ml (21.4 µM) in HEPES buffer. Excellent signal-noise ratios were 
obtained with no detectable effect from radiation damage. Linear Guinier fits at low Q 
values (where Q = 4π sin θ /λ; 2θ = scattering angle; λ = wavelength) gave the radius of 
gyration RG in satisfactory Q.RG ranges below 1.1 (Figure 7.8 a). RG is the root mean 
square radius of scattering density. At larger Q values, the cross-sectional Guinier RXS 
fits monitor the structural proximity between non-neighbouring SCR domains (denoted 
as RXS-1) and neighbouring SCR domains (denoted as RXS-2) (Aslam & Perkins, 2001). 
Both the RXS-1 and RXS-2 parameters were likewise obtained from linear fits within 
satisfactory Q.RXS ranges (Figure 7.8 b, c). This permitted comparative data analyses 
with errors for the four FH Tyr402 and FH His402 samples. In Guinier analyses, At 0.4 
mg/ml, the RG values were 7.54 nm and 7.97 nm for the two FH Tyr402 samples, and 
were 7.45 nm and 7.91 nm for the two FH His402 samples (Table 7.2). The RXS-1 values 
were 2.35 nm and 2.36 nm for FH Tyr402, and 2.15 nm and 2.25 nm for FH His402. 
The RXS-2 values were 1.77 nm and 1.76 nm for FH Tyr402, and 1.77 nm and 1.75 nm 
for FH His402. In conclusion, these comparisons showed that the RG, RXS-1 and RXS-2 
parameters at 0.4 mg/ml were similar for both allotypes, thus no conformational 
changes between the allotypes were detectable.  
 
Both FH Tyr402 and FH His402 showed concentration dependences which were similar 
for the Guinier I(0)/c, RG and RXS-1 parameters, but no dependence was seen for the RXS-2 
parameter (Figure 7.9). These concentration dependences showed that reversible 
oligomerisation had occurred for both FH allotypes, the extent of which was similar to 
heterozygous FH. The I(0)/c value is proportional to molecular mass for protein samples 
measured within a single beam time session. If the slopes in the linear fits of the I(0)/c   183
 
 
Figure 7.8 Guinier analyses for the X-ray scattering data of the FH Tyr402 and His402 
allotypes. In the RG and RXS Guinier analyses, the open symbols represent the I(Q) data, 
the filled symbols correspond to the I(Q) data used to determine the RG or RXS values, 
and the straight line correspond to the best fit through those points. The fit ranges are 
arrowed. Data are shown for one Tyr402 allotype (020FM – blue) and one His402 
allotype (028EL – red).   
 
(a) RG plots of ln I(Q) vs. Q
2 at low Q values for FH at concentrations of 1.1 mg/ml (O), 
2.2 mg/ml (∆) and 3.2 mg/ml (□). The Q fit range was 0.09 - 0.13 nm
-1.  
 
(b) The corresponding cross-sectional RXS-1 fits of ln I(Q).Q vs. Q
2 are shown using a  Q 
fit range of 0.16 - 0.26 nm
-1. 
 
(c) The RXS-2 fits of ln I(Q).Q vs. Q
2 are shown using a Q range of 0.4 - 0.8 nm
-1.  
  184
 
 
Figure 7.9 Concentration dependence of the Guinier parameters for the FH Tyr402 and 
His402 allotypes. The I(0)/c, RG, RXS-1, and RXS-2 data are shown for two different pairs 
of each of two allotypes of FH from 0.4 mg/ml to 3.3 mg/ml (Tyr402, 020FM ● and 
022LM  ▲; His402, 028EL ● and 032KO ▲). Each value was measured in 
quadruplicate, then averaged and fitted by linear regression except for panel (d) when 
the mean values were shown. Statistical error bars are shown where visible. In (a), the 
pairs of I(0)/c intensities were measured in two beam sessions, resulting in two different 
pairs of lines.  In (b), the RG values at zero concentration were 7.39 ± 0.25 nm and 7.35 
± 0.13 nm (Tyr402), and 7.22 ± 0.15 nm and 7.77 ± 0.27 nm (His402). In (c), the RXS-1 
values at zero concentration were 2.21 ± 0.06 nm and 2.27 ± 0.06 nm (Tyr402), and 
2.02 ± 0.06 nm and 2.15 ± 0.06 nm (His402). In (d), the averaged RXS-2 values were 1.77 
nm and 1.77 nm (Tyr402), and 1.76 nm and 1.75 nm (His402).   185
parameters are assumed to reflect a monomer-dimer equilibrium  (Figure 7.9 a), the 
resulting KD values were estimated to be 16 (± 4) µM and 18 (± 2) µM for the two FH 
Tyr402 samples, and 11 (± 3) µM and 22 (± 8) µM for the two FH His402 samples. 
These  KD values are comparable with that of 28 µM for heterozygous FH from 
sedimentation equilibrium (Chapter Five; Nan et al., 2008a), and the KD values of 8 µM 
and 7 µM respectively for FH Tyr402 and FH His402 binding to heterozygous 
immobilised FH (Figure 7.1). Because the KD values from scattering and 
ultracentrifugation are higher than those determined by SPR, this suggests that full-
length FH dimerises more weakly when free in solution than when immobilised on a 
surface. The extrapolation of the RG values to zero concentration resulted in RG values 
of 7.22-7.77 nm for the allotypes (Figure 7.9 b). These values were lower than that of 
8.90 ± 0.19 nm for heterozygous FH when extrapolated to zero concentration (Chapter 
Five; Nan et al., 2008a). The RXS-1 values at zero concentration were 2.02-2.27 nm, 
which is lower when compared to the previous extrapolated RXS-1 value of 2.51 ± 0.06 
nm for heterozygous FH (Chapter Five; Nan et al., 2008a). The mean RXS-2 value is 
1.75-1.77 nm which is similar to the previous mean RXS-2 value of 1.79 ± 0.01 nm for 
heterozygous FH (Chapter Five; Nan et al., 2008a). The further reduction in RG is 
attributed to reduced oligomerisation in the homozygous FH preparations; this most 
probably resulted from improved protein handling, and the use of a slightly increased Q 
range of fit to reduce the contribution of FH oligomers. The new RG values are even 
lower than the originally-reported high RG value of 11.1-11.3 nm for heterozygous FH, 
where the high values are attributed to the presence of aggregated FH (Aslam & 
Perkins, 2001). Overall, the lower RG value of 7.22-7.77 nm for the two allotypes 
indicated that FH is even more folded-back in its SCR domain arrangement than 
previously thought.  
 
The distance distribution function P(r) is calculated from the full scattering curve I(Q) 
and reports the distances between all pairs of atoms within full-length FH (Figure 7.10; 
Section 4.2.5.2). The P(r) curves gave another calculation of the RG and I(0) values for 
full-length FH Tyr402 and FH His402 (Table 7.2) for comparison with the Guinier 
analyses at low Q. At 0.4 mg/ml, the Guinier and P(r)  RG values showed good 
agreement, indicating self-consistency of the scattering curve across the measured Q 
range. The maximum dimension L of FH is deduced from the intercept of the P(r) 
curves with zero at large r. The r value of the maximum M in the P(r) curve gives the  186
 
Figure 7.10 Distance distribution function P(r) analyses for the X-ray scattering data of 
the FH Tyr402 and His402 allotypes. The P(r) analyses are shown for one Tyr402 
allotype (020FM – blue) and one His402 allotype (028EL – red) at five concentrations 
of 0.4 mg/ml, 0.7 mg/ml, 1.1 mg/ml, 2.2 mg/ml and 3.3 mg/ml from bottom to top.  187
most commonly occurring distance within the macromolecule. The two allotypes of FH 
between 0.4 mg/ml and 3.3 mg/ml showed similar concentration dependences in the 
appearances of their P(r) curves and L values (Figure 7.10). These appearances were 
comparable with that for heterozygous FH shown in Figure 5.3 (Chapter Five; Nan et 
al., 2008a), and indicated the similar solution structures of the two allotypes. For the FH 
Tyr402 allotype, the P(r) curves show a concentration-independent peak M1 at r = 5.3 ± 
0.7 nm, and a concentration-dependent second peak M2 which was observed at r = 11 
nm at 3.3 mg/ml. For the FH His402 allotype, M1 was unchanged at 4.9 ± 0.4 nm and 
M2 was likewise unchanged at 11 nm at 3.3 mg/ml. The dependence of peak M2 on 
concentration showed that M2 corresponds to FH oligomer formation. At 0.4 mg/ml, the 
L values were 28 nm and 29 nm for FH Tyr402, and 28 nm and 26 nm for FH His402 
(Table 7.2). These L values were lower than that of 32 nm determined previously for 
heterozygous FH at 0.9 mg/ml in Figure 5.3 (Chapter Five; Nan et al., 2008a), and this 
is attributable to a reduced level of FH oligomerisation at the lower concentrations. In 
conclusion, the P(r) curves confirm the reversible formation of FH oligomers in the 
concentration range up to 3.3 mg/ml, and that these oligomers were significantly 
reduced at 0.4 mg/ml.  
 
7.2.6 Constrained scattering modelling of the two FH allotypes  
 
Solution structures for the FH Tyr402 and FH His402 allotypes in 137 mM NaCl were 
determined by constrained scattering modelling. This procedure optimises the 
arrangement of 20 SCR domains joined by 19 conformationally-randomised linkers 
against the X-ray scattering curve. To be consistent, the same randomly generated 5,000 
FH models used previously to model ionic strength effects on the FH conformation 
(Okemefuna et al., 2009) were used here to evaluate the FH allotypes. This FH library 
was based on nine SCR homology models and 11 crystal or NMR structures for the 
SCR domains, which were linked together by randomised peptide linker conformations 
(Materials and Methods). Best-fit monomer conformations for FH Tyr402 and FH 
His402 were identified from trial-and-error searches of these 5,000 structures. The 
experimental X-ray curves used for fits corresponded to the lowest measured 
concentration of 0.4 mg/ml in order to reduce the estimated proportion of dimer to 8% 
(KD = 28 µM). The comparisons of the RG values with the R-factor (goodness of curve 
fit) (Figure 7.11) and RXS-1 values (Figure 7.12) using two experimental curves for each  188
 
 
Figure 7.11 Constrained modelling searches to determine the solution structures of the 
FH Tyr402 and His402 allotypes by comparing of the 5,000 R–factor goodness-of-fit 
values with the RG values. For each structure of 5,000 conformationally-randomised FH 
models, a RG value was calculated, and a R-factor was generated by fitting the structure 
to two scattering curves for each of the Tyr402 (020FM, ○; 022LM, ∆; blue) and 
His402 (028EL, ○; 032KO, ∆; red) allotypes measured at 0.4 mg/ml. The vertical 
dashed line shows the averaged experimental RG value. The fittings of the four best-fit 
models at the bottom are shown using filled symbols (Model 1, ●; Model 2, ▲; Model 
3,  ; Model 4, ■; Red for Tyr402 and blue for His402 allotype). These best-fit models 
are shown in more detail in the magnified view at the upper right corner.  189
 
 
 
 
Figure 7.12 Constrained modelling searches to determine the solution structures of the 
FH Tyr402 and His402 allotypes by comparing of the 5,000 RXS-1 and RG values. For 
each structure of 5,000 conformationally-randomised FH models, a RG value and a RXS-1 
value was calculated (denoted by cyan open symbol). The vertical dashed line indicates 
the average experimental RG value, and the horizontal dashed line indicates the average 
experimental RXS-1 value measured at 0.4 mg/ml. The four best-fit models (Model 1, ●; 
Model 2, ▲; Model 3,  ; Model 4, ■) are high-lighted in black.   190
FH allotype showed that the 5,000 models satisfactorily encompassed the mean 
experimental P(r) RG of 7.90 nm and the mean Guinier RXS-1 value of 2.28 nm (Table 
7.2). The final best-fit structures for each FH experimental curve were selected using 
the criteria that they were within 10% of the experimental RG and R XS-1 values, and 
showed the lowest R-factor values. A family of eight best-fit structures were identified 
for each of the four FH curves (Table 7.2). Interestingly, four of these FH models 
occurred in all four fit analyses (Figure 7.13). The close similarity of the four best-fit 
families showed that the solution structures of the FH Tyr402 and FH His402 allotypes 
were indistinguishable.  
 
The four best-fit models were all partially folded-back and bent in appearance. It is 
stressed that the best-fit models correspond to structures in which the 20 SCR domains 
are free to reorientate themselves. Because the method does not correspond to high 
resolution structure determinations, no specific inter-SCR proximity arrangements can 
be deduced. Unlike the 2001 fits (Aslam & Perkins, 2001) which revealed 31 best-fit 
structures with R-factors of 19 ± 3% and the 2009 fits (Okemefuna et al., 2009) which 
revealed 17 best-fit with R-factors between 4.5-9.6%, the four best-fit structures now 
exhibited even lower R-factors between 2.8-4.7%. This reduction was attributed to 
improvements in experimental data acquisitions and a reduced level of FH 
oligomerisation. The RG values of the four best-fit models were slightly lower than the 
observed RG values. This difference is attributed to the effect of trace amount of FH 
dimer in the curve fit procedure that assumed a fully monomeric structure (Figure 7.11). 
The visual comparison between the experimental I(Q) curves for the best-fit Model 1 
showed excellent visual agreements out to a Q value up to 1.5 nm
-1 ( Figure 7.13). 
Likewise the P(r) curves showed maxima M and maximum dimensions L that were in 
excellent agreements with the experimental values (Figure 7.13). These visual 
agreements were improved over the curve fitting of heterozygous FH in 2001 and 2009 
(Figure 7.14) (Aslam & Perkins, 2001; Okemefuna et al., 2009).  
 
The sº20,w values of the four best-fit FH models were calculated using HYDROPRO as 
an independent check of the scattering modelling (Table 7.2). The calculated sº20,w 
values for the four common best fitting models (Figure 7.13) ranged between 5.38-5.54 
S, where Model 1 gave a calculated sº20,w values of 5.45 S. The calculated values agree 
well with the experimental values of 5.67 S, 5.66 S, 5.71 S, and 5.69 S for the two  191
 
 
Figure 7.13 Four best-fit FH models for the X-ray scattering curve fit analyses. The left 
panel shows the X-ray scattering curve modelling fits, with the modelled curves in black 
and the experimental data in blue or red. The central panels compare the modelled P(r) 
curve (black) with the experimental P(r) curves (blue; red). The right panels show 
ribbon views of the four best-fit FH models that fit the curves for both allotypes and 
correspond to those highlighted in Figure 7.11 (Model 1, ●; Model 2, ▲; Model 3,  ; 
Model 4, ■). The oligosaccharides are shown in orange. (a) Tyr402 FH at 0.4 mg/ml 
(upper, 020FM; lower, 022LM). (b) His402 FH at 0.4 mg/ml (upper, 028EL; lower, 
032KO). The modelled curves in black in (a, b) are all calculated from Model 1.  192
 
 
 
Figure 7.14 Comparison of the visual agreements between the experimental I(Q) curves 
for the best-fit model in the analyses for heterozygous FH in 2001 (a) (Aslam & 
Perkins, 2001), in 2009 (b) (Okemefuna et al., 2009), and for homozygous FH from 
Figure 7.13 b (His402 FH sample 028EL at 0.4 mg/ml).  193
 allotypes  (Table 7.2). This agreement is acceptable given that the mean difference 
between the modelled and experimental values should be ± 0.21 S (Perkins et al., 2009). 
The discrepancy between the calculated and experimental values is much reduced 
compared to the 2001 best-fit model that gave predicted sº20,w values of 5.0 ± 0.1 S 
(Aslam & Perkins, 2001) and the 2009 fits that gave predicted sº20,w values of 4.85–5.18 
S (Okemefuna et al., 2009). This better agreement is attributable to the reduced level of 
FH oligomers in the experimental X-ray scattering curves. The resulting scattering 
curve fits identified more compact FH models, which in turn resulted in the calculation 
of larger sº20,w values that agreed better with experiment.  
 
The improved FH monomer models permitted the sedimentation modelling of the 
dimer, trimer and tetramer forms of FH (Figure 7.15). Previous sº20,w models for the FH 
oligomers had been based on too elongated a FH monomer model from the analyses in 
2001 (Aslam & Perkins, 2001), and conformational changes in this model had been 
required in order to achieve agreement between the experimental and modelled sº20,w 
values (Figure 5.8;  Nan  et al., 2008a). Here, sº20,w models were prepared from the 
Model 1 structure of Figure 7.13, in which the putative locations of SCR-7 and SCR-20 
were assumed to comprise dimerisation sites (Fernando et al., 2007; Okemefuna et al., 
2008). The KD of 16 µM for SCR-16/20 self-association corresponds to stronger binding 
than the KD of 40 µM for SCR-6/8 self-association, hence full-length FH is expected to 
dimerise at SCR-20 before SCR-7. The association of two SCR-20 domains gave a 
dimer with a modelled sº20,w value of 7.60 S in good agreement with the experimental 
values of 7.57 S (Tyr402) and 7.69 S (His402), and no conformational change in the 
monomer structure was required (Figure 7.15). The addition of further 
conformationally-unmodified FH monomers at SCR-7 to this dimer gave trimer and 
tetramer models with modelled sº20,w values of 9.42 S and 11.2 S respectively. These 
agreed well with the experimental values of 9.35 S (Tyr402) and 9.45 S (His402) for the 
trimer, and with the experimental values of 11.9 S (Tyr402) and 11.2 S (His402) for the 
tetramer (although the tetramer is less readily observed in Figure 7.5 a, b). These 
agreements support the observation of reversible FH equilibria that involve the SCR-6/8 
and SCR-16/20 fragments.  
 
Sedimentation modelling also supported the deduction of irreversible oligomer forms of 
FH (Figure 7.16). The addition of further reversibly-bound FH monomers at SCR-7 and  194
 
Figure 7.15 Sedimentation modelling of FH dimer, trimer and tetramer. The models 
were based on Model 1 from Figure 7.13. The reversible association of FH monomers is 
depicted, first to form the dimer by contacts at two SCR-20 domains (red), then 
followed by trimer and tetramer formation by contacts at two SCR-7 domains 
(orange/yellow). The experimental and modelled sedimentation coefficient values are 
shown to the right.  
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Figure 7.16 Sedimentation modelling of the irreversible higher oligomers of FH. The 
models were based on Model 1 from Figure 7.13. The irreversible association of FH 
monomers is depicted in side-by-side models that show more extensive contacts 
between the FH monomers (alternating cyan and purple). The experimental and 
modelled sedimentation coefficient values are tabulated at the centre.   196
 SCR-20 to the models of Figure 7.15 gave models with sº20,w values of 12–15 S that 
were too low compared to the observed values of 15–22 S. These “reversible” models 
were too elongated in shape. If irreversibility is the result of extra contacts between FH 
monomers, the FH oligomers are expected to become more compact in shape when 
forming aggregates. Modelling with conformationally-unmodified monomer structures 
that are arranged side-by-side to form aggregated structures resulted in modelled sº20,w 
values of 8.9 S and 11.2 S for compact dimer and trimer structures respectively, up to 
19.9 S for a compact octamer structure (Figure 7.16). This showed that the compact 
dimer and trimer peaks overlap with the reversible trimer and tetramer peaks 
respectively, and this would account for the intensity increase between 9-11 S in Figure 
7.5 a, b. At larger S values, the peaks become more clearly resolved (Chapter Five; Nan 
et al., 2008a; Okemefuna et al., 2009). Given that the error in the experimental sº20,w 
values are as large as 1 S, the agreement to within 1 S between the experimental and 
modelled values is considered to be satisfactory. 
 
7.2.7 Fluid-phase activity assay of the two FH allotypes  
 
In order compare the regulatory role of Tyr402 and His402 allotype of FH in solution, 
assays of fluid-phase haemolytically inactive C3 (C3u) cleavage by factor I and two 
allotypes of FH were performed (Section 6.2.4; Nan et al., 2008b; Crossley & Porter, 
1980). As mentioned in Section 2.3.5, previous fluid-phase activity assays were 
performed at significantly lower concentrations of FH than the 0.235-0.81 mg/ml (1.5–
5.3 µΜ) observed in vivo (Crossley & Porter, 1980; Day & Sim, 1986; Bloom et al., 
2003; Tsiftsoglou & Sim, 2004). The assays in this chapter were performed with both 
allotypes of FH at a concentration of 0.3 mg/ml (1.9 µΜ) which is comparable with the 
physiological concentration and the concentration of heterozygous native FH used for 
previous activity assays (Section 6.2.4; Nan et al., 2008b). The α-chain of C3u was 
cleaved by factor I in the presence of 0.3 mg/ml of each FH allotype to produce two 
major degradation fragments at apparent sizes of 45 kDa and 75 kDa (Figure 7.17 a). 
The cleavage rates of inactive C3 were not distinguishable between the Tyr402 and 
His402 allotypes of FH (Figure 7.17 b), and were similar to that of heterozygous FH 
(Figure 6.17). Therefore, the Tyr402His polymorphism does not affect the C3u cleavage 
function of FH in fluid phase. This result agrees well with the previous observation by  197
                     
Figure 7.17 Cleavage of fluid phase C3u by FI and the two FH allotypes. (a) Reducing 
SDS-PAGE analysis of C3u cleavage by FI and FH Tyr402 allotype (013 HH). Lane 1, 
High Mark
TM Prestained High Molecular Weight Standard; Lane 2, 0.3 mg/ml C3u as a 
control; Lane 3, 0.3 mg/ml C3u added with 0.3 mg/ml of FH Tyr402 allotype as another 
control; Lane 4-15 correspond to the reaction mixture that contains 0.3 mg/ml C3u, 0.3 
mg/ml of FH Tyr402 allotype and 0.003mg/ml FI with the reaction time labelled. FH 
and the α-chain and β-chain of C3u are arrowed on the left, whereas the cleavage 
products of the C3u α-chain are arrowed on the right. (b) Comparison of the C3u α-
chain cleavage rate by 0.003 mg/ml FI and 0.3 mg/ml FH Tyr402 allotype or His402 
allotype. The percentage cleavage is shown as a function of time. The FH Tyr402 
allotype (013HH) (Table 7.1) is denoted in blue, and the His402 allotype (015LT) 
(Table 7.1) is denoted in red.   198
SPR of the similar weak affinities to C3b for the two allotypes of FH SCR-6/8 (Schmidt 
et al., 2008b), and the observation by ELISA of the similar bindings to C3b for the two 
allotypes of FH and FHL1 (Skerka et al., 2007). 
 
7.3 Materials and Methods  
 
7.3.1 Protein purifications 
 
Human blood was obtained from 48 genotyped healthy volunteers following ethical 
approval. The common Tyr402His and Ile62Val FH polymorphisms were genotyped by 
direct DNA sequencing of their PCR product by Dr Naushin Waseem and Prof. Shomi 
Bhattacharya. The PCR was performed with Extensor Hi-Fidelity PCR® Master Mix 
from ABgene following the manufacturer’s protocol. Bidirectional sequencing of the 
PCR product was carried out with Big Dye Terminator v3.1 on a 3730 DNA Analyzer 
(Applied Biosystems, Cheshire, UK) at the UCL Institute of Ophthalmology. A total of 
seven homozygous FH Tyr402 and seven FH His402 allotypes were purified from 
appropriate genotyped plasma (Table 7.1), while wild-type FI was purified from a pool 
of just-outdated anonymised human plasma. Purifications utilised monoclonal affinity 
chromatography with MRC-OX23 Sepharose columns for FH and MRC-OX21 
Sepharose columns for FI (Section 6.3.1; Nan et al., 2008; Sim et al., 1993). Bound 
homozygous FH and native FI were each eluted from the column using 3 M MgCl2, pH 
6.9, then each was dialysed into HEPES buffer (10 mM HEPES, 137 mM NaCl, pH 7.4) 
in the presence of 0.5 mM EDTA to remove Mg
2+. To avoid cross-contamination 
between different FH samples, the MRC-OX23 column was washed with guanidine (0.2 
M Tris, 4 M guanidine-HCl, pH 8.0) between each preparation. Each FH and FI sample 
was passed through a Hitrap
TM Protein G HP column to remove residual IgG 
contaminant. Non-specific aggregates and human serum albumin were removed by gel 
filtration on a Superose
TM 6 prep grade XK 16/60 column. Protein concentrations were 
determined using absorption coefficients of 16.2 for FH (Tyr402) and 16.1 for FH 
(His402) (1%, 280 nm, 1 cm path length), revised in the light of its known glycosylation 
(Okemefuna  et al., 2009), and that of 12 for FI (Ullman  et al., 1998). After 
sedimentation velocity experiments on the purified FH allotypes, the proteins were re-
passed through the Superose
TM 6 prep grade XK 16/60 column in order to analyse the 
presence of FH oligomers (Figure 7.1).   199
 
Native C3 was purifed from fresh plasma from the author using slightly modified 
methods described previously (Dodds et al., 1993). The purification utilised a 20 ml Q-
Sepharose
TM fast flow anion-exchange column (Amersham Biosciences, GE Healthcare, 
Uppsala, Sweden), followed by a MonoQ 5/50 GL anion-exchange column (Pharmacia 
GE Healthcare, Uppsala, Sweden) with better resolution. Haemolytically inactive C3 
(C3u) was obtained by incubating native C3 in 200 mM hydrazinc at 37°C for 1 h 
(Section 6.3.1; Dodds et al., 1993). The purity of C3u was checked by using reducing 
SDS-PAGE (Figure 7.17 a), and the protein concentration was determined using the 
absorption coefficient of 9.4 for C3u (1%, 280 nm, 1 cm path length) (Li et al., 2010).  
 
FH SCR-6/8 was expressed and purified following previous procedures (Fernando et 
al., 2007) (A. Miller and S. J. Perkins, unpublished data). The recombinant SCR-6/8 
Tyr402 was expressed in BL21 (DE3) E. coli cells using a pET21ab vector system, 
while SCR-6/8 His402 was expressed in BL21 (DE3)pLysS E. coli cells using a 
pET14b vector system. The protein was extracted from inclusion bodies and solubilised, 
and the refolded protein was passed through a Hitrap
TM 5 ml Heparin HP column 
equilibrated in Tris buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 7.4). The 
bound protein was washed with Tris buffer and was eluted with up to 1 M NaCl in Tris 
buffer. The protein concentration of FH SCR-6/8 was determined using absorption 
coefficients of 22.7 for SCR-6/8 Tyr402, and 22.1 for SCR-6/8 His402 (1%, 280 nm, 1 
cm path length). Proteins were dialysed into HEPES buffer for experiments, and their 
integrity was routinely checked by SDS-PAGE before and after scattering and 
ultracentrifugation.  
 
7.3.2 Surface plasmon resonance data 
 
The binding of one pair of FH Tyr402 and His402 allotypes (Table 7.1) to immobilised 
heterozygous FH and of the FH SCR-6/8 Tyr402 and His402 allotypes to immobilised 
FH SCR-6/8 were performed using a Biacore X100 instrument with version 1.1 of its 
evaluation software (GE Healthcare, Uppsala, Sweden). Heterozygous FH was coupled 
to a carboxymethylated dextran (CM5) research grade sensor chip (Okemefuna et al., 
2010). Each of the FH SCR-6/8 allotypes were coupled to a carboxymethylated dextran 
(CM4) research grade sensor chip with a lower degree of carboxymethylation. Both  200
procedures utilised a standard amine coupling procedure according to the 
manufacturer’s protocol. Heterozygous FH (20 µg/ml) or FH SCR-6/8 (10 µg/ml) in 10 
mM acetate buffer, pH 5.5 (FH) was injected over flow cell 2 to reach a maximum 
response of 150 or 400 resonance units (RU) immobilised on the surface. A control 
surface cell was prepared identically on flow cell 1 but without protein immobilisation. 
Equilibrium analyses were performed at 25º C using the appropriate Biacore X100 
wizards at a flow rate of 30 µl/min. The running buffer was HEPES buffer. FH Tyr402 
was injected for 180 sec at six concentrations between 0.1-1.5 mg/ml (0.65-9.74 µM). 
FH His402 was injected at six concentrations between 0.1-1.8 mg/ml (0.65-11.69 µM). 
FH SCR-6/8 Tyr402 was injected for 150 sec over the CM4 chip immobilised with 150 
RU of either the Tyr402 or the His402 allotype at concentrations of 0.1-0.8 mg/ml (5-40 
µM), and over the CM4 chip bound with 400 RU of His402 at concentrations of 0.04-
0.32 mg/ml (5-15 µM). FH SCR-6/8 His402 was injected over the Tyr402 CM4 chip at 
concentrations of 0.1-0.6 mg/ml (5-28 µM), and over the CM4 chip immobilised with 
150 RU His402 at concentrations of 0.1-0.5 mg/ml (5-22 µM), and over the CM4 chip 
with 400 RU His402 at 0.04-0.32 mg/ml (2-14 µM). For the FH SCR-6/8 analyses, the 
CM4 chips were used with 0.3 mg/ml non-specific binding (NSB) reducer added to each 
sample to reduce the non-specific binding to dextran surfaces. Regeneration after each 
run was achieved by pulsing with 10 mM sodium acetate buffer, 5 M NaCl, 0.05 mM 
EDTA, pH 7.0 across both flow cells twice for 45 sec. The maximum binding response 
value in each run was fitted to a steady state 1:1 affinity model.   
 
7.3.3 Sedimentation velocity data  
 
FH data were obtained on two Beckman XL-I instruments equipped with AnTi50 and 
AnTi60 rotors. Sedimentation velocity experiments were performed at 20
oC at rotor 
speeds of at rotor speeds of 50,000 r.p.m and 60,000 r.p.m. in two-sector cells with 
column heights of 12 mm for five FH Tyr402 samples at 0.5 mg/ml, 1.1 mg/ml and 2.1 
mg/ml (3.2-13.6 µM), and again for five FH His402 samples, all in HEPES buffer 
(Table 7.1). Data analyses were performed using SEDFIT (version 11.71) (Schuck, 
1998; Schuck, 2000). The size-distribution analyses c(s) that provided shape and size 
data were performed using direct boundary Lamm fits of up to 300 scans using a fixed 
resolution of 200, and floated the meniscus, the bottom of the cell, the baseline and the 
average frictional ratio f/fo (initial value 1.781), until the overall root mean square  201
deviation and agreement between the observed and calculated sedimentation boundaries 
were satisfactory (Figure 7.2). The percentage fraction of oligomers in the total loading 
concentration was derived using the c(s)  integration function. Other details are 
described elsewhere (Section 4.1.2; Nan et al., 2008; Okemefuna et al., 2009).  
 
7.3.4 Mass spectrometry data  
 
Mass spectra were acquired on a LCT orthogonal time-of-flight instrument modified for 
high mass operation and equipped with a Z-spray nanoflow source (Waters, 
Manchester, UK). The following instrumental parameters were used: capillary voltage 
1.7 kV, cone voltage 80 – 120 V, cone gas 100 L/h. Mass spectra were analysed using 
Mass Lynx and Data-Explorer software. Purified FH samples were concentrated to a 
final concentration of about 4 mg/ml (26 µM), and then dialysed overnight into 140 mM 
or 1 M ammonium acetate at pH 7.0 for measurement the next day. One pair of FH 
Tyr402 and one FH His402 allotype (Table 7.1) were analysed in both buffers. These 
mass spectrometry experiments were performed by Dr Adam MacKay in the 
Department of Chemistry at UCL. 
 
7.3.5 X-ray scattering data  
 
X-ray scattering data were acquired in two beam sessions on Instrument ID02 
(Narayanan & Bosecke, 2001) at the European Synchrotron Radiation Facility 
(Grenoble, France) with a ring energy of 6.0 GeV and operating in four-bunch mode. 
Storage ring currents were 30-44 mA and 68-89 mA. The sample-detector distances 
were 2 m and 3 m respectively. Potential radiation damage was eliminated by the 
continuous movement of the sample in its capillary flow cell during beam exposure, the 
use of 10 time frames of duration between 0.1 sec and 0.5 sec each during each 
acquisition, and on-line checks for the absence of radiation damage at low Q. Two FH 
Tyr402 and two FH His402 allotypes were each studied at five concentrations between 
0.4 mg/ml (2.6 µM) and 3.3 mg/ml (21.4 µM) to compare their self-association 
properties. All measurements were done in HEPES buffer. Other details including the 
data reduction are described elsewhere (Section 4.2; Fernando et al., 2007; Okemefuna 
et al., 2008).  
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In a given solute-solvent contrast, the radius of gyration RG is the root mean square 
radius of scattering density if the internal inhomogeneity of scattering densities within 
the protein has no effect. Guinier analyses at low Q gives the RG, and the forward 
scattering at zero angle I(0) (Glatter & Kratky, 1982):  
ln I(Q) = ln I(0) - RG
2 Q
2/3. 
This expression is valid in a Q.RG range up to 1.5. If the structure is elongated, the mean 
radius of gyration of cross-sectional structure RXS and the mean cross-sectional intensity 
at zero angle [I(Q)Q]Q→0 is obtained from: 
ln [I(Q)Q] = ln [I(Q)Q]Q→0 - RXS
2Q
2/2. 
The RG and RXS analyses lead to the triaxial dimensions of the macromolecule if the 
structure can be represented by an elliptical cylinder, where  ) ( 12
2 2
XS G R R L − ⋅ =  and L 
is its length (Glatter & Kratky, 1982). The RG and RXS analyses were performed using 
an interactive PERL script program SCTPL7 (J. T. Eaton and S. J. Perkins, unpublished 
software) on Silicon Graphics OCTANE Workstations. Indirect transformation of the 
scattering data I(Q) in reciprocal space into real space to give the distance distribution 
function P(r) was carried out using the program GNOM (Semenyuk & Svergun, 1991):  
P(r) corresponds to the distribution of distances r between volume elements. For this, 
the X-ray I(Q) curve utilised up to 207 data points for Q between 0.06 nm
-1 and 1.50 
nm
-1 for 0.4 mg/ml FH, and increasing up to 308 data points for Q between 0.06 nm
-1 
and 2.10 nm
-1 for 3.3 mg/ml FH. Other details are described elsewhere (Nan et al., 
2008; Fernando et al., 2007; Okemefuna et al.,2008; Aslam & Perkins, 2001).  
 
7.3.6 Constrained modelling procedure 
 
The original constrained modelling of the 20 SCR domains in FH used NMR structures 
for three SCR domains and homology models for the remaining 17 SCR domains 
(Aslam & Perkins, 2001). Here the remodelling of FH for this study and its 
accompanying study was based on NMR and crystal structures for 11 SCR domains and 
9 improved SCR homology models for the remainder. NMR structures were used for 
SCR-5 (Barlow, et al., 1992), SCR-15 (PDB codes 1hfi), SCR-16 (PDB codes 1hcc) 
dQ   (Qr)   Qr   I(Q)    
2
1
  =   P(r)
o
2 sin ∫
∞
π
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(Barlow, et al., 1993) and SCR-1/3 (PDB codes 2rlp and 2rlq) (Hocking, et al., 2008). 
Crystal structures were used for SCR-19/20 (PDB code 2g7i) (Jokiranta, et al., 2006) 
and SCR-6/8 (PDB code 2uwn) (Prosser, et al., 2007). The homology models for the 
remaining SCR domains were taken from the website http://www.fh-hus.org (Saunders, 
et al., 2006). The FH sequence numbering starts from the N-terminus of the 18-residue 
signal peptide, and not that of the mature protein. Eight biantennary disialylated glycans 
were added to Asn529 in SCR-9, Asn719 in SCR-12, Asn802 in SCR-13, Asn822 in 
SCR-14, Asn882 and Asn911 in SCR-15, Asn1029 in SCR-17 and Asn1095 in SCR-19 
(Fenaille et al., 2007). Libraries of 1,000 randomised conformations were generated in 
extended β-strand conformations for each of the twenty peptides that corresponded to 
the N-terminus (19-ED-20) and the 19 inter-SCR linkers using INSIGHT II 98.0 
molecular graphics software (Accelrys, San Diego, CA, USA) on Silicon Graphics 
OCTANE Workstations. This procedure followed Randomized-3 search in the original 
constrained modelling of FH which gave satisfactory results (Aslam & Perkins, 2001). 
One conformation was randomly selected from each library for each linker in order to 
join the 20 SCR domains to assemble 5,000 full FH models. Further details are given 
elsewhere (Aslam & Perkins, 2001; Gilbert et al., 2005).  
 
Each full FH molecular model was used to calculate its X-ray scattering curve for 
comparison with two different experimental curves for each FH allotype (Table 7.1). A 
cube side length of 0.498 nm in combination with a cutoff of 3 atoms was used to 
convert the coordinates into Debye sphere models with 1554 spheres that corresponded 
to the unhydrated structure, and the addition of the hydration shell gave an optimal total 
of 2074 hydrated spheres. The X-ray scattering curve I(Q) was calculated using the 
Debye equation adapted to spheres. Details are given elsewhere (Okemefuna  et al., 
2009). Steric overlap between the SCR domains in the models was used to filter out 
unacceptable models, where models showing less than 95% of the required total N of 
1554 unhydrated spheres and 2074 hydrated spheres were discarded. Next, the X-ray RG 
and RXS-1 values calculated from the modelled curves in the same Q ranges used for the 
experimental Guinier fits were used to select models that were within 10% of the 
experimental RG and RXS-1 parameters. Models that passed the N, RG and RXS-1 filters 
were then ranked using a goodness-of-fit R factor defined by analogy with protein 
crystallography. Sedimentation coefficients s
0
20,w were calculated directly from the 
atomic coordinates in the HYDROPRO shell modelling program using the default value  204
of 0.31 nm for the atomic element radius for all atoms to represent the hydration shell 
(Garcia de la Torre et al., 2000).  
 
7.3.7 Protein Data Bank accession number 
 
The four best-fit FH models have been deposited in the Protein Data Bank with the 
accession codes 3n0j.  
 
7.3.8 Fluid-phase activity assays  
 
The reaction mixtures contained 0.3 mg/ml of Tyr402 or His402 allotype of FH, 0.3 
mg/ml C3u and 0.003 mg/ml factor I were incubated in a water bath at 37 °C.  The 
functions of one FH Tyr402 allotype sample (013HH) and one FH His402 allotype 
sample (015LT) were tested. At timed intervals, 5 µl aliquots were removed for 
reducing SDS-PAGE analyses using NuPAGE® Novex® 4-12% Bis-Tris Mini Gel. 
Two controls were used, namely 0.3 mg/ml C3u; and 0.3 mg/ml C3u and 0.3 mg/ml FH. 
The C3 α-chain band densities from SDS-PAGE were measured using the gel analysis 
system SYNGENE (Synoptics Ltd., Cambridge, UK). The C3 α-chain cleavage was 
referenced to the averaged density of the uncleaved bands in the controls. 
 
7.4 Conclusions 
 
A functional understanding of FH is complicated by its multivalency, its relative 
abundance in serum, and its weak interactions with ligands (Perkins  et al., 2010a; 
Perkins et al., 2010b). The major human physiological and pathophysiological ligands 
of FH include (i) its self-association properties, and its interactions with (ii) C3b and 
C3d, (iii) heparin, (iv) CRP, and (v) zinc. The unravelling of these five interactions 
requires knowledge of the KD values in combination with the use of appropriate buffers 
and protein concentrations. The study in Chapter Seven clarifies the self-association 
properties of FH using purified homozygous proteins (Table 7.1). This study showed 
that the full-length FH Tyr402 and FH His402 allotypes show similar self-association 
properties both at surfaces and in solution, and indistinguishable structures in solution. 
However surface-immobilized SCR-6/8 His402 shows a higher level of self association  205
than SCR-6/8 Tyr402. There is no indication that the Ile62Val polymorphism (Table 
7.1), another AMD-associated polymorphism in SCR-1, is relevant for self-association 
or the FH structure. The formation of FH dimer and trimer is shown to be reversible, 
together with the presence of irreversible higher oligomers. The folded-back FH 
solution structure of its monomer is more compact than previously believed, as the 
maximum length of monomeric FH was determined to be 28 nm. A relatively inflexible 
monomer structure is able to account for the FH oligomers seen by ultracentrifugation. 
The biological meaning of FH self-association in terms of sub-RPE deposit formation 
and AMD is discussed below. For example, an understanding of FH self-association 
was essential to show that heterozygous FH and native CRP interacted with each other. 
Ultracentrifugation showed that the FH oligomers were eliminated when native CRP 
was added (Okemefuna et al., 2010). In the present study, the KD value of 7-8 µM 
measured for the self-association of the two FH allotypes by SPR is larger than the 
corresponding KD value of 4.2 µM for the FH-CRP interaction by SPR (Okemefuna et 
al., 2010). This difference confirms that the FH-CRP interaction is stronger and will 
block FH oligomer formation. 
 
FH oligomer formation is relevant for a proper interpretation of functional assays and 
the physiological role of FH. The weak self-association of FH is now established 
through a series of investigations. The dimerisation of heterozygous FH was originally 
proposed from molecular weights of 250-320 kDa that were determined by X-ray and 
neutron scattering Guinier fits at high 1-11 mg/ml concentrations, although these 
Guinier analyses were approximate ones (Perkins  et al., 1991). Initial electron 
microscopy, gel filtration and ultracentrifugation studies suggested that FH is only 
monomeric (DiScipio, 1992). Further X-ray and neutron scattering of heterozygous FH 
showed that this was largely monomeric and its folded-back solution structure could be 
modelled by constrained scattering modelling, although the final Q range of the curve fit 
was quite limited (Figure 7.14) (Aslam & Perkins, 2001). However FH fragments 
revealed dimeric bands by SDS-PAGE, and FH self-interactions were observed by SPR 
(Jokiranta et al., 2000; Oppermann et al., 2006). In addition, ultracentrifugation showed 
that the SCR-6/8 and SCR-16/20 fragments displayed monomer-dimer equilibria with 
KD values of 40 µM for SCR-6/8 His402 and 16 µM for SCR-16/20 (Fernando et al., 
2007; Okemefuna et al., 2008). The presence of at least two different dimer sites within 
FH suggested that FH molecules could form “daisy-chains” at alternating pairs of dimer  206
sites at high concentrations (Figure 7.15). This hypothesis was initially verified by 
ultracentrifugation and scattering studies of heterozygous FH, when oligomers that 
contained 2-9 subunits were observed in c(s) distribution analyses at high FH 
concentrations (Chapter Five; Nan et al., 2008a). In the present study, the availability of 
homozygous FH Tyr402 and FH His402 showed that FH oligomers with 2-9 subunits 
existed for each of these by ultracentrifugation, and did not depend on Tyr402His or 
Ile62Val, the two major AMD-associated polymorphisms (Figure 7.5 a). The existence 
of FH dimer and trimer forms was supported independently by mass spectrometry 
(Figure 7.6). Given the reversibility of the dimer and trimer forms of FH with its 
monomer (Chapter Five; Nan et al., 2008a), their sedimentation coefficients could be 
modelled on the basis of previously-observed reversible associations at SCR-7 and 
SCR-20 (Figure 7.15). The observation of small amounts of irreversible higher 
oligomers is best explained by the indefinite compact self-association of FH monomers 
(Figure 7.16).  
 
The AMD-risk Tyr402His polymorphism corresponds to a surface residue located in the 
SCR-7 domain. Previously, ultracentrifugation showed that FH SCR-6/8 His402 
dimerises slightly more than FH SCR-6/8 Tyr402 (Fernando et al., 2007), and this result 
was confirmed in this chapter by SPR (Figure 7.3). This difference indicates that the 
SCR-6/8 dimerisation site is close to residue 402. Because SCR-7 also possesses the 
heparin and CRP binding sites in FH, the Tyr402His polymorphism is implicated with 
these FH interactions. For the full-length FH allotypes, four different comparisons 
consistently indicated no significant difference in their self-association. This lack of 
difference in full-length FH is explained by the somewhat greater strength of dimer 
formation at SCR-20 and not at SCR-7 (Fernando et al., 2007; Okemefuna et al., 2008). 
For the two FH allotypes, the KD values for a monomer-dimer equilibrium model were 
7-8 µM by SPR, and 11-22 µM by scattering. The lower KD values by SPR than by 
scattering indicated a strengthened self-association for immobilised FH, presumably for 
reason of local concentration effects and a more complex self-association process than 
that represented by a monomer-dimer equilibrium. Given that FH occurs in serum at 
0.235-0.810 mg/ml (Saunders et al., 2006), the scattering KD values indicate that 8-21% 
of the FH allotypes in serum will be dimeric if no other factors are involved. These 
percentages correspond well to the observed oligomerisation of 12-13% at 1.1 mg/ml 
and 23-28% at ca. 4 mg/ml of the FH allotypes seen by sedimentation velocity and mass  207
spectrometry respectively (Figures 7.5 b and Figure 7.6), and 5-14% calculated from the 
KD of 28 µM for heterozygous FH from sedimentation equilibrium (Chapter Five; Nan 
et al., 2008a). A more detailed comparison between full-length FH and the SCR-6/8 
fragment is instructive. Because SPR and ultracentrifugation revealed a clearer 
difference between the His402 and Tyr402 allotypes for only the fragment and not for 
full-length FH, the effect of this will only become biologically significant under 
relevant conditions. For example, if FH is immobilised on cell surfaces through SCR-20 
and reaches a sufficient density, the closer packing of FH molecules will provide more 
opportunities for SCR-6/8 to interact, and SCR-6/8 dimerisation may become more 
important. This aspect may be important for RPE surface-bound FH and the 
development of sub-RPE deposits in Bruch’s membrane in the early stages of AMD. 
The resulting impairment of C3b control may facilitate the early stages of AMD. If 
comparative fluorescent microscopy studies of full length FH Tyr402 and FH His402 
binding to RPE cell surfaces are performed (Hageman et al., 2005), controls will be 
required to show that any observed differential binding of the two allotypes is 
independent of potential FH self-association effects.  
 
Indistinguishable solution structures for FH Tyr402 and FH His402 were determined by 
constrained modelling. The replacement of neutral Tyr402 by a positively charged 
His402 residue increases the predicted isoelectric point of the SCR-7 domain from 9.04 
to 9.14. The Tyr402His replacement did not lead to an altered FH domain arrangement, 
and this was confirmed by the similarity of the RXS-1 values within error (Table 7.2) and 
by the similar curve fits for the two allotypes  (Figure 7.13). The similarity of the 
structures for the full-length FH allotypes complements the similar solution structures of 
the two SCR-6/8 allotypes and the subsequent similar crystal structure of SCR-6/8 
His402 (Clark et al., 2006; Prosser et al., 2007). The NMR structures for SCR-7 Tyr402 
and SCR-7 His402 in 20 mM sodium acetate at pH 5.2 are also similar (Herbert et al., 
2007). All these structures show that, even though Tyr402His is solvent exposed at the 
SCR-7 surface, the residue change has no effect. The lack of structural change in full-
length FH by the Tyr402His substitution suggests that the domain arrangement in full-
length FH may be less flexible than previously thought. The view that the FH structure 
possesses limited inter-SCR flexibility is suggested also by the sedimentation modelling 
of the FH dimer, trimer and tetramer that started from a FH monomer without  208
conformational change in this (Figure 7.15). Overall it can be concluded that the 
reduced binding affinity of FH His402 to ligands such as CRP (Okemefuna et al., 2010) 
is attributable to the residue change itself, and not through changes in the similar overall 
FH structures. 
 
In summary, we found that while the overall structure and self-association of the two 
full-length FH allotypes are not affected by the Tyr402His polymorphism, there is a 
measurable increase in self-association involving the SCR-6/8 His402 allotype, 
especially when this is surface bound. FH accumulates at surfaces such as that of the 
basal membrane of the RPE (Hageman et al., 2005), therefore this process might be 
relevant in vivo. The consequence of FH enrichment at surfaces has been associated 
with increased sub-RPE deposit formation in the Bruch’s membrane and inflammation 
(Hageman et al., 2005) that may lead to AMD. Several decades elapse between early 
deposit formation and the development of blindness, a slow process perhaps explained 
by the low affinity interactions described above. Sub-RPE deposit formation is part of a 
natural ageing process and yet how sub-RPE deposit formation accelerates and leads to 
AMD is not understood. Together with the previous study on the FH-CRP interaction 
(Okemefuna et al., 2010), this study provides evidence for a mechanistic model for how 
the Tyr402His polymorphism in FH might connect sub-RPE deposit formation with 
inflammatory processes and the development of blindness in AMD. 
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Chapter Eight 
 
Localisation of zinc binding sites in the wild-type Tyr402 and disease-related 
His402 allotypes of homozygous complement factor H: implications for age-related 
macular degeneration  
  210
8.1 Introduction 
 
The complement system of the innate immune system is activated by the alternative 
pathway through the low level spontaneous hydrolysis of C3 to form C3u (also known 
as C3H2O), which leads to a positive-feedback amplification of C3 cleavage to form 
activated C3b (Law & Reid, 1995; Walport, 2001). While complement is targeted 
against pathogenic bacteria, complement-mediated host cell damage is prevented by the 
complement regulator factor H, which acts as a cofactor for factor I to cleave C3b, 
competes with factor B to inhibit the formation of the C3 convertase C3bBb, and 
accelerates the decay of C3bBb (Ferreira et al., 2010). FH is constructed from 20 short 
complement regulator (SCR) domains, each of length about 61 residues (Soares & 
Barlow, 2005). The SCR domains in heterozygous and homozygous FH form a 
partially-folded back structure in solution (Aslam & Perkins, 2001; Okemefuna et al., 
2009; Chapter Seven). FH binds to glycosaminoglycans on the host cell surface through 
its C-terminal region and to SCR-7, and this is followed by the decay accelerating and 
co-factor activity of FH against C3b through the N-terminal region (Sharma & 
Pangburn, 1996; Pangburn, 2000; Oppermann et al., 2006). FH binds to C3b at SCR-1/4 
and SCR-19/20 (Schmidt et al., 2008b). FH also binds to other ligands such as C-
reactive protein, M-protein of Streptococci bacterium, and FH binding protein of 
Neisseria meningitides (Okemefuna et al., 2010; Horstmann et al., 1988; Giannakis et 
al., 2003; Schneider et al., 2009). FH also self-associates to form dimer, trimer and 
higher oligomers (Fernando et al., 2007; Okemefuna et al., 2008; Nan et al., 2008a, 
Chapter Seven). FH oligomerisation is strongly promoted by transition metals, of which 
zinc has the strongest effect, followed by copper (Perkins et al., 1991; Chapter Six; Nan 
et al., 2008b). X-ray scattering and analytical ultracentrifugation (AUC) experiments 
showed that pooled heterozygous FH aggregates strongly in the presence of ≥ 20 µM of 
zinc or copper, and this is matched by the decrease of  fluid-phase activity of 
heterozygous FH (Chapter Six; Nan et al., 2008b).  
 
FH is genetically associated with age-related macular degeneration (AMD), the most 
common cause of blindness in the elderly in the Western population (Hageman et al., 
2001; Klein et al., 2005; Haines et al., 2005; Edwards et al., 2005; Hageman et al., 
2005). FH is also involved with atypical haemolytic uraemic syndrome (aHUS), 
membranoproliferative glomerulonephritis type II (MPGN), and Alzheimer's disease  211
(AD) (Strohmeyer et al., 2002; Saunders et al., 2007; Zetterberg et al., 2008). Even with 
the analysis of over 100 genetic alterations, the molecular role of FH in these diseases is 
still unclear (Saunders  et al., 2007). This lack of knowledge is attributed to the 
multivalent weak affinities of FH for its ligands, which makes experimental studies 
difficult (Perkins et al., 2010a; Perkins et al., 2010b). A hallmark of early AMD is the 
drusen deposits that develop within Bruch’s membrane, an extracellular matrix layer 
interposed between the retinal pigment epithelium (RPE) and the choroidal vasculature 
(Bird, 1992; Bird et al., 1995; Guymer & Bird, 1998). Drusen contains oxidized lipids, 
carbohydrates, cellular materials and over 200 aggregated proteins including FH and 
other complement components. FH is secreted by RPE cells or is delivered by the 
choroidal blood circulation (Hageman et al., 2001; Crabb et al., 2002; Hageman et al., 
2005; Bok, 2005). Complement activation-related inflammation has been linked with 
the formation of drusen (Hageman et al, 2001; Anderson et al., 2002; Hageman et al., 
2005). A Tyr402His polymorphism in FH SCR-7 is associated with 50% of AMD cases 
(Klein et al., 2005; Haines et al., 2005; Edwards et al., 2005; Hageman et al., 2005). 
The SCR-6/8 His402 allotype shows slightly greater self-association than the Tyr402 
allotype (Fernando et al., 2007; Section 7.2.1). While the binding of C-reactive protein 
to FH was recently disputed, the most recent study confirmed that the proteins interact 
with each other, and that the SCR-6/8 His402 allotype binds more weakly to C-reactive 
protein than the Tyr402 allotype (Okemefuna et al., 2010; Perkins et al., 2010b; Ferreira 
et al., 2010). The two FH allotypes showed similar cofactor activity in C3b degradation 
(Skerka et al., 2007; Schmidt et al., 2008b). However the effect of glycosaminoglycans 
on these two FH allotypes presently remains unclear (Clark et al., 2006).  
 
Zinc is abundant in human retina (Galin et al., 1962). It is vital for retinal cell survival, 
and the functioning of antioxidant enzymes and the visual cycle, while an excess of zinc 
can be detrimental and exacerbate neuronal damage (Ugarte & Osborne, 2001). Under 
oxidative stress during light exposure, the secretion of zinc from the zinc-rich RPE cells 
is elevated (Ugarte & Osborne, 2001). Millimolar concentrations of zinc have been 
found in sRPEds and Bruch’s membrane, suggesting that the pathological release of 
zinc from surrounding tissues like the RPE-choroid complex might be involved in 
sRPEd formation (Galin et al., 1962; Lengyel et al., 2007). Studies of the effect of zinc 
supplements on reducing the development of AMD gave different results. Based on the 
premise that zinc is an antioxidant, the large Age-Related Eye Disease Study (AREDS)  212
indicated that supplements with zinc alone or with zinc together with vitamins C and E 
and β carotene reduces the risk for progression to advanced AMD (AREDS Research 
Group, 2001a; AREDS Research Group, 2001b). Interestingly, a follow-up study found 
that the treatment response to the AREDS-recommended zinc supplement was 
influenced by the Tyr402His FH polymorphism. A smaller reduction in the progression 
to AMD to advanced stage disease was found in patients with the FH His402 allotype 
than in those with the FH Tyr402 allotype (Klein  et al., 2008). Zinc binding sites 
between two protein surfaces show a tetrahedral coordination geometry at which the 
binding site is often formed from surface His, Asp, Glu and Cys residues (Auld, 2001). 
The Tyr402His polymorphism is of great interest because this potentially provides a 
new His zinc-binding ligand. In this chapter, to clarify whether the two allotypes exhibit 
different zinc binding properties, the homozygous FH Tyr402 and His402 allotypes and 
the two allotypes of recombinant SCR-6/8 in zinc titrations were studied. By analytical 
ultracentrifugation and synchrotron X-ray scattering, this study showed that zinc 
interacts with the two homozygous allotypes of FH, hence ruling out heterogeneity 
effects, and the major zinc binding sites are most likely to be within the SCR-6/8 
fragment. The analyses were confirmed by bioinformatics predictive strategies which 
were performed by Miss Irene Farabella and Mr Felix F. Schumacher. The molecular 
implications of these results for complement regulation and sRPEd formation in AMD 
are discussed in this chapter. 
 
8.2 Results and discussion 
 
8.2.1 Sedimentation velocity of the complexes of the two FH and SCR-6/8 allotypes with 
zinc 
 
Homozygous FH and recombinant SCR-6/8 were purified (Materials and Methods). The 
two homozygous FH allotypes were studied at 0.9 mg/ml (5.8 µM) in order to be 
comparable in concentration with the physiological FH range of 0.235-0.810 mg/ml in 
serum (Saunders et al., 2007). The SCR-6/8 allotypes were studied at 0.2-0.3 mg/ml 
(9.7-14.6 µM) which was the lowest concentration that produced analysable data. Both 
proteins were studied in Hepes buffer (Materials and Methods). PBS buffer was not 
used, in order to avoid the precipitation of zinc with phosphate. Both were titrated with  213
0-600 µM ZnSO4 in ultracentrifugation (section 8.2.1) and scattering experiments 
(Section 8.2.2). 
 
Analytical ultracentrifugation studies the sedimentation behaviour of macromolecules 
on subjecting these to a high centrifugal force in order to determine their sizes and 
shapes (Section 4.1;  Cole  et al., 2008). Sedimentation velocity experiments were 
performed using speeds up to 60,000 r.p.m on two Tyr402 and two His402 FH allotypes 
at concentrations of 0.7-0.8 mg/ml, each being titrated with zinc from 0.2 µM to 200 
µM. Similar sets of rapidly-moving sedimentation boundaries were observed for both 
allotypes when [Zn] increased. Good fits to the sedimentation boundaries were obtained 
in all cases using sedimentation coefficient distribution analyses c(s) (Figures 8.1). At 
all [Zn] values, the FH monomer was observed at a mean value of 5.67 ± 0.05 S for the 
Tyr402 allotype, and at 5.74 ± 0.07 S for the His402 allotype at 50,000 r.p.m. These 
values agree well with the previous determined values for homozygous FH monomer 
(Section 7.2.2). This indicated the presence of zinc-free FH even with a 40-fold excess 
of zinc, meaning that the binding of zinc is weak. For both allotypes with [Zn] between 
0.2-20 µM, additional peaks that corresponded to similar small amounts of oligomers 
from dimers to nonamers were visible from 7 S to 30 S that resembled those for zinc-
free FH (Chapter Five; Nan et al., 2008a; Okemefuna et al., 2009; Chapter seven). For 
both allotypes with [Zn] between 60-200 µM, sizeable amounts of rapidly sedimenting 
species were observed with increased s  20,w values up to 100 in the c(s) distributions 
(Figure 8.2). The proportions of oligomers of the Tyr402 and His402 allotypes were 
derived by integration of the c(s) size-distribution analyses. No differences in 
proportions were seen between the allotypes. Like heterozygous pooled native FH 
(Chapter Six; Nan et al., 2008b), both the Tyr402 and His402 allotypes form heavy 
oligomers with zinc and share similar dependences on [Zn] (Figure 8.3).  
 
The sedimentation boundaries showed that differential amounts of zinc-induced FH 
oligomers were formed with the two allotypes. For the Tyr402 allotype, the oligomers 
ranged in S values in excess of 100 S, indicating a larger proportion of more compact or 
high molecular mass species (Figure 8.2 a). For the His402 allotype, the oligomers 
peaked in the region of 20-80 S, indicating a larger proportion of more extended or 
lower molecular mass oligomers (Figure 8.2 b). These differences were reflected in 
Figure 8.1, where the upper part of the boundaries sedimented more rapidly for the   214
 
Figure 8.1 Sedimentation boundary fits of the two FH allotypes titrated with zinc. Both 
allotypes were studied at 0.7 mg/ml. Only every tenth scan is shown for clarity. (a, b, c, 
d) The fits corresponding to the FH Tyr402 allotype (026II; blue) was titrated with zinc 
concentrations of 20 µM, 60 µM, 120 µM and 200 µM in that order. (e, f, g, h) The fits 
corresponding to the FH His402 allotype (027BA; red) was titrated with the same zinc 
concentrations.    215
 
 
Figure 8.2 c(s) sedimentation coefficient distribution analyses of the two FH allotypes 
titrated with zinc. (a) c(s) analyses for FH Tyr402 titrated with 20 µM, 60 µM, 120 µM 
and 200 µM zinc from the boundary fits in Figure 8.1 a, b, c, d; (b) corresponding c(s) 
analyses for FH His402 with zinc from the boundary fits in Figure 8.1 e, f, g, h. The 
height of the FH monomer peak at 5.7 S is normalised to 100 for clarity. The zinc 
concentrations (µM) are denoted numerically. The sedimentation boundary fits of the 
same homozygous FH samples are shown in Figure 8.1.  216
 
 
 
Figure 8.3 Dependence of the monomer and oligomers of homozygous FH on zinc 
concentrations. The values from c(s) integrations correspond to the averages obtained at 
50,000 r.p.m. and 60,000 r.p.m. The oligomer data were fitted to a two-parameter power 
function y=a*(1 + x)
b, and the monomer data were fitted to the function f=y0+a*x
b. 
Oligomers are denoted by filled symbols and monomers by open symbols for four 
experiments with two FH Tyr402 (026II, 022LM, blue, ●, ○, ▲, ∆) and two FH His402 
(027BA, 032KO, red, ●, ○, ▲, ∆) allotypes.   217
Tyr402 allotype compared to the His402 allotype at all zinc concentrations. These 
features were not reproducible for another pair of the two FH allotypes, although 
differential effects were again observed (data not shown). Therefore, the difference 
between the zinc-induced oligomers of FH Tyr402 allotype and that of His402 allotype 
shown in Figure 8.2 is not considered significant. In addition, even with the 
homozygous FH proteins whose heterogeneity is much reduced compared to the pooled 
FH used in earlier studies, the c(s) peaks show no sequence of peaks with well-resolved 
progression of S values similar to the peaks 2-9 seen in zinc-free FH (Chapter Five; Nan 
et al., 2008a; Okemefuna et al., 2009; Chapter Seven). Overall, these observations 
suggested that a range of zinc-induced FH oligomers of different sizes had formed 
through the cross-linking of different weak zinc-binding sites at the surface of FH.  
 
In order to clarify the molecular basis for zinc-induced FH oligomers, sedimentation 
velocity experiments were performed at 50,000 r.p.m on the Tyr402 and His402 
allotypes of the SCR-6/8 fragment at 0.3 mg/ml (14.6 µM) titrated with zinc from 0.2 
µM to 600 µM. Similar sedimentation boundaries were observed for the two allotypes 
of SCR-6/8 at each [Zn] (Figure 8.4 a, b, c, d). In contrast to full-length FH, no rapidly 
sedimenting larger species were detected in the size distribution c(s) fits at any [Zn]. 
The c(s) analyses consistently showed a major monomer peak at 2.12 ± 0.09 S and a 
minor dimer peak at 4.03 ± 0.20 S for the Tyr402 allotype, and likewise two peaks at 
2.19 ± 0.08 S and 3.95 ± 0.16 S for the His402 allotype (Figure 8.4 e). This agrees with 
the previous observation of SCR-6/8 monomer and dimer by sedimentation velocity 
(Fernando et al., 2007). However, with [Zn] above 60 µM, the signal intensity of the 
monomer peak for both allotypes decreased significantly with increase in [Zn] (Figure 
8.4 e; Figure 8.5). This indicates that, at [Zn] above 60 µM, zinc induced the formation 
of aggregated SCR-6/8 which were sufficiently large to precipitate and sediment to the 
bottom of the sample cell before the first boundary scan was recorded. While the 
His402 allotype showed slightly greater precipitation than the Tyr402 allotype, this may 
result from experimental variability in quantifying the different sedimenting species. 
Overall, it was noteworthy that SCR-6/8 precipitated at the same [Zn] value that caused 
large FH oligomers to form. This indicated that the major binding sites for zinc in full-
length FH were located within SCR-6/8.   218
 
 
 
 
Figure 8.4 Sedimentation velocity analyses of the two SCR-6/8 allotypes titrated with 
zinc. Both allotypes were studied at 0.3 mg/ml. In the sedimentation boundary fits, only 
every tenth scan is shown for clarity. (a,b) The fits for the SCR-6/8 Tyr402 allotype 
(blue) titrated with zinc at 6 µM and 200 µM. (c,d) The fits for the SCR-6/8 His402 
allotype (red) titrated with zinc at 6 µM and 200 µM. (e) The c(s) sedimentation 
coefficient distribution analyses for the Tyr402 allotype with 6 µM (blue) and 200 µM 
(cyan) zinc, and the His402 allotype with 6 µM (red) and 200 µM (pink) zinc. The c(s) 
distributions are labelled with their zinc concentration values (µM). The peak at about 
2.1 S corresponds to the monomer, and that at about 4.0 S is the dimer. 
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Figure 8.5 Dependence of the monomer and oligomers of FH and SCR-6/8 on zinc 
concentrations. The signal intensities of the monomer of SCR-6/8 fragment titrated with 
zinc are obtained from the integration function of the c(s) analyses (Tyr402 allotype, 
blue; His402 allotype, red).  220
The reversibility of the zinc-induced precipitation of the SCR-6/8 allotypes was studied 
by adding 2 mM EDTA to the ultracentrifuge cell contains 0.3 mg/ml SCR-6/8 and 300 
µM of zinc. After mixing, the sedimentation velocity experiment was immediately re-
run at 50,000 r.p.m on this cell again. Even though the size distribution c(s) analyses 
showed that the monomer peak for both allotypes of SCR-6/8 with 300 µM of zinc was 
much reduced, the addition of EDTA caused a significant increase of the monomer peak 
intensity for both allotypes (Figure 8.6). This showed that the zinc-induced precipitation 
of SCR-6/8 was reversible, in good agreement with the reversibility of the zinc-induced 
oligomers of heterozygous pooled FH by adding EDTA (Chapter Six;  Nan  et al., 
2008b).  
 
Additional ultracentrifugation experiments with the SCR-1/5 and SCR-16/20 fragments 
in the presence of zinc were performed as controls of the SCR-6/8 experiments. The 
control experiments were performed by Mr Felix F. Schumacher and Miss Irene 
Farabella. SCR-1/5 is less soluble at 0.2 mg/ml when expressed, compared to SCR-6/8 
and SCR-16/20. As [Zn] increased, SCR-1/5 precipitated in the same manner as SCR-
6/8 at a similar [Zn] value to that for SCR-6/8. This was visible from both the reduced 
intensities of the fringes as [Zn] increased and the marked reduction of the monomer 
peak intensity in the c(s) plot (Figure 8.7 a, b, c, d). In contrast to this, SCR-16/20 is 
more soluble than SCR-1/5 and SCR-6/8, and SCR-16/20 remained in solution as [Zn] 
increased with a smaller reduction in the number of observed fringes at 600 µM. Here, 
the c(s) plot showed a smaller reduction in the sizes of the monomer and dimer peaks, 
while at the same time as many as three other species were observed (Figure 8.7 e, f, g, 
h). These experiments showed that other different types of zinc-induced oligomers 
formed at other regions of FH. Unlike SCR-6/8, both SCR-1/5 and SCR-16/20 
possessed His6-tags which may comprise potential zinc binding sites (Okemefuna et al., 
2008). This was evaluated by further zinc titrations in which a 2:1 molar ratio of nickel 
(17 µM) was present to saturate its binding site at the His6-tag, to which nickel binds 
more tightly with a dissociation constant of 1 µM (Nieba et al., 1997). The resulting c(s) 
plots showed that no SCR-1/5 or SCR-16/20 precipitated, and that only the monomer or 
monomer/dimer peaks were seen similar to those observed for zinc-free protein. These 
control experiments indicate either that the His6-tag represented an oligomeric zinc-
binding site which is eliminated by the stronger binding of nickel, or that nickel 
competes with zinc for weak interaction sites in FH. The first explanation is preferred,  221
 
 
Figure 8.6 Effects of EDTA on the interactions between the SCR-6/8 allotypes and zinc 
using sedimentation velocity.   
 
(a) The c(s) distribution analyses are shown for the Tyr402 allotype in the presence of 
0.2 µM zinc (blue solid line), 300 µM zinc (cyan solid line), and 300 µM zinc and 2 
mM EDTA (cyan dashed line).  
 
(b) The c(s) distribution analyses are shown for the His402 allotype in the presence of 
0.2 µM zinc (red solid line), 300 µM zinc (pink solid line), and 300 µM zinc and 2 mM 
EDTA (pink dashed line).  222
 
Figure 8.7  Sedimentation velocity analysis of SCR-1/5 and SCR-16/20 titrated with 
zinc. Red numbers indicate zinc concentrations (µΜ) (adapted from Rotation 1 report of 
Mr Felix F. Schumacher, 2009). (a-c) For SCR-1/5, the boundary fits at three zinc 
concentrations are shown for only every 24
th scan out of 480 for reason of clarity. (d) 
Size-distribution c(s) analyses for SCR-1/5 at seven zinc concentrations are shown. M 
indicates the monomer position, and two weak emerging zinc-induced signals are 
denoted by 1 and 2. The graphs were displaced vertically in units of 0.5 for reason of 
clarity. (e-g) For SCR-16/20, the boundary fits at three zinc concentrations are shown 
for only every 22
nd scan out of 440. (h) Size-distribution c(s) analyses for SCR-16/20 at 
seven zinc concentrations are shown. M and D indicates the monomer and dimer peaks. 
Weak emerging signals are denoted by 1, 2 and 3. Graphs are displaced vertically in 
units of 0.5 for reason of clarity.  223
because nickel has no strong effect on FH oligomer formation (Chapter Six; Nan et al., 
2008b). Control experiments with full-length FH in the presence of 200 µM zinc and 20 
µM nickel were performed to complete these studies. These experiments showed that 
zinc still causes FH to aggregate, indicating that while other possible zinc-binding sites 
in FH apart from those in SCR-6/8 may require consideration, no major sites were 
detected within SCR-1/5 and SCR-16/20. 
 
8.2.2 X-ray scattering of the two allotypes of FH and SCR-6/8 with zinc 
 
X-ray scattering is a diffraction method used to study solution structures of 
macromolecules in random orientations (Perkins et al., 2008). The effect of zinc on the 
structures of freshly-purified two Tyr402 and two His402 allotypes of full-length FH 
and the two allotypes of FH fragment SCR-6/8 were investigated by synchrotron X-ray 
scattering. FH was studied at 0.9 mg/ml (5.8 µM) in order to be comparable with 
physiological FH concentrations, while SCR-6/8 was studied at 0.2 mg/ml (9.7 µM), 
this being the lowest concentration of SCR-6/8 that produced analysable data. Each FH 
or SCR-6/8 sample was titrated with 0 µM to 600 µM ZnSO4. The scattering data I(Q) 
showed excellent signal-noise ratios and no detectable effect from radiation damage.  
 
Guinier fits at low Q values (where Q  = 4π sin θ / λ; 2θ = scattering angle; λ = 
wavelength) gives the radius of gyration (RG) which monitors the degree of elongation 
of the protein, and the I(0)/c value which is proportional to the relative molecular mass 
(Figure 8.8 a, b) (Glatter & Kratky, 1982; Perkins et al., 2008). At larger Q values, 
Guinier fits give the cross-sectional radius of gyration RXS which monitors the structural 
proximity relationships between non-neighbouring SCR domains (RXS-1) and 
neighbouring SCR domains (RXS-2) (Figure 8.8 c, d, e, f) (Aslam & Perkins, 2001). In 
our previous study of heterozygous and homozygous FH, the presence of oligomers 
caused concentration-dependent increases in the values of RG and RXS-1 (Chapter Five; 
Nan et al., 2008a; Chapter Six). Here, at the lowest zinc concentration of 0.2 µM, the 
mean RG and RXS-1 values were 8.91 ± 0.17 nm and 3.03 ± 0.17 nm respectively for the 
Tyr402 FH allotype, and 9.23 ± 0.72 nm and 3.15 ± 0.39 nm respectively for the His402 
FH allotype (Figure 8.9 b, c). Both the RG and RXS-1 values were similar to those for 
heterozygous FH at 0.9 mg/ml without zinc (Figure 5.2 a, c) (Nan et al., 2008a). Both  224
 
  
 
Figure 8.8 X-ray Guinier analyses of the two full-length FH allotypes titrated with zinc. 
In all panels, the open symbols correspond to the experimental data and the filled 
symbols correspond to those used for the RG and RXS straight line fits. Data correspond 
to one FH Tyr402 allotype (018DK) in (a,c,e) and one FH His402 allotype (030TJ) in 
(b,d,f), both at 0.9 mg/ml. Data for the Tyr402 allotype of FH are shown in blue from 
0.2 µM to 120 µM of ZnSO4, and in cyan from 200 µM to 600 µM of ZnSO4. Data for 
the His402 allotype of are shown in red from 0.2 µM to 120 µM of ZnSO4, and in pink 
from 200 µM to 600 µM of ZnSO4.  
 
(a,b) Guinier RG plots of ln I(Q) vs. Q
2 for FH Tyr402 and FH His402 allotypes titrated 
with ZnSO4 concentrations of 0.2 µM (O), 2 µM (□), 6 µM (∆), 20 µM ( ), 60 µM (
), 120 µM ( ), 200 µM (O) and 600 µM (∆). The Q fit range was 0.08 - 0.13 nm
-1 for 
0.2 µM to 120 µM ZnSO4, and 0.03 - 0.16 nm
-1 for 200 µM to 600 µM ZnSO4. The zinc 
concentrations are numerically labelled as shown. 
 
(c,d) The corresponding Guinier cross-sectional RXS-1 fits of ln I(Q).Q vs. Q
2 for the two 
FH allotypes with zinc using a Q range of 0.16 - 0.26 nm
-1.  
 
(d,e) The corresponding Guinier cross-sectional RXS-2 fits for the two FH allotypes with 
zinc using a Q range of 0.4 - 0.8 nm
-1.  225
 
 
Figure 8.9 Dependence of the I(0)/c, RG and RXS values of the two allotypes of FH on 
the zinc concentration. In all cases, the Tyr402 allotype is shown in blue and the His402 
allotype is shown in red. Each value was measured in quadruplicate and averaged, and 
statistical error bars are shown where visible. The four titrations correspond to two pairs 
of FH Tyr402 allotypes (018DK, ● with solid line; 016CC, ○ with dashed line) and FH 
His402 allotypes (030TJ, ● with solid line; 033NV, ○ with dashed line) at 0.9 mg/ml 
titrated with zinc from 0.2 to 600 µM.   226
RG and RXS-1 values were the same within error of the corresponding values for zinc-free 
homozygous FH at 1.1 mg/ml (Figure 7.9). When both the Tyr402 and His402 FH 
allotypes were titrated with zinc up to 6 µM, the scattering curves I(Q) remained 
unchanged (Figure 8.8 a, b), and the Guinier values remained unchanged (Figure 8.9). 
For [Zn] from 20 µM to 600 µM, the I(Q) intensities increased significantly at low Q 
and decreased at high Q as the result of oligomer formation (Figure 8.8). The Guinier 
I(0)/c and RG values increased significantly (Figure 8.9 a, b), although the RXS-1 and RXS-
2 valued decreased at [Zn] above 200 µM as the result of the decrease in the intensity of 
I(Q) in the Q ranges used for the RXS determinations (Figures 8.8 c, d, e, f and Figure 8.9 
c, d). The changes for both homozygous FH allotypes are comparable with previous 
observations for heterozygous native FH (Figure 6.2) (Nan et al., 2008b), indicating 
again that FH heterogeneity is not responsible for these observations. For [Zn] between 
20 µM and 120 µM, the two His402 allotypes showed slightly higher Guinier I(0)/c, RG 
and RXS-1 values than the two Tyr402 allotype (Figure 8.9 a, b, c), which if true would 
indicate that the His402 allotype formed more oligomers than the Tyr402 allotype, 
however the difference is not considered to be significant.   
 
To test whether the Tyr402 and His402 allotypes of SCR-6/8 formed zinc-induced 
oligomers, both were titrated with [Zn] from 0.2 to 600 µM. For SCR-6/8 at 0.2 mg/ml 
with 0.2 µM zinc, the Guinier RG and RXS values were 2.63 ± 0.46 nm and 0.88 ± 0.29 
nm respectively for the Tyr402 allotype, which were similar to values of 2.79 ± 0.47 nm 
and 1.00 ± 0.27 nm for the His402 allotype. Those Guinier values are slightly less but 
within error of the experimental RG and RXS values of 3.26-3.35 nm and 1.04 nm 
respectively for the zinc-free Tyr402 allotype, and 3.12-3.21 nm and 1.15 nm (± 0.06-
0.20 nm) for the zinc-free His402 allotype (Fernando et al., 2007). For [Zn] between 0.2 
µM to 6 µM, the scattering curves I(Q) were unchanged for both allotypes (Figure 8.10 
a, b and Figure 8.11).  At 20 µM [Zn], the I(Q) curves of both allotypes underwent 
dramatic changes in which the intensities sharply increased at low Q and decreased 
rapidly at large Q (Figure 8.10 c, d), and these changes resulted in much increased 
Guinier I(0)/c and RG values (Figure 8.11 a, b). Above 20 µM [Zn], the I(Q) intensities 
continued to rise at very low Q (Figure 8.10 a, b). The Guinier I(0)/c and RG values 
peaked at [Zn] of 60 µM and declined at higher [Zn] values (Figure 8.11 a, b). These 
changes showed that both allotypes of SCR-6/8 interacted with zinc starting from 20  227
 
 
 
Figure 8.10 X-ray Guinier analyses of the two SCR-6/8 allotypes titrated with zinc. In 
all panels, the open symbols correspond to the experimental data and the filled symbols 
correspond to those used for the RG and RXS straight line fits. Data correspond to SCR-
6/8 Tyr402 (g,i) and SCR-6/8 His402 (h,j), both at 0.2 mg/ml. Data for the SCR-6/8 
Tyr402 are shown in blue from 0.2 µM to 120 µM of ZnSO4, and in cyan from 200 µM 
to 600 µM of ZnSO4. Data for SCR-6/8 His402 are shown in red from 0.2 µM to 120 
µM of ZnSO4, and in pink from 200 µM to 600 µM of ZnSO4.  
 
 (a, b) Guinier RG plots for the SCR-6/8 Tyr402 and His402 allotypes at 0.2 mg/ml 
titrated with ZnSO4 at concentrations of 0 µM (O), 2 µM (□), 6 µM (∆), 20 µM ( ), 60 
µM ( ), 120 µM ( ), 200 µM (O), 300 µM (□) and 600 µM (∆). The Q fit range was 
0.16 - 0.5 nm
-1 for 0.2 µM to 120 µM ZnSO4, and 0.06 - 0.11 nm
-1 for 200 µM to 600 
µM ZnSO4. 
 
(c, d) The corresponding Guinier cross-sectional RXS fits for the SCR-6/8 allotypes using 
a Q range of 0.55 – 1.0 nm
-1.   228
 
 
 
Figure 8.11  Dependence of the I(0)/c,  RG and RXS values of SCR-6/8 on the zinc 
concentration. The titrations correspond to the two SCR-6/8 allotypes titrated with the 
same zinc concentration range from 0.2 to 600 µM. The Tyr402 allotype is shown in 
blue and the His402 allotype is shown in red. Each value was measured in quadruplicate 
and averaged, and statistical error bars are shown where visible.   229
µM, which is the same starting concentration as the FH interaction with zinc. Unlike the 
FH-zinc oligomers which remained in solution, the changes observed for SCR-6/8 
caused this to precipitate, and this accounted for the apparent decline in the I(0)/c and 
RG above 60 µM. Like full-length FH, no significant difference was observed for the 
zinc-induced oligomerisation of the Tyr402 and His402 allotypes.  
 
The distance distribution function P(r) of the two FH allotypes provided shape 
information in real space on the zinc-induced FH oligomers. The P(r) curve summarises 
the distances between all pairs of atoms within FH, and gives the most frequently 
occurring distance M from the position of the peak maximum, the maximum length L 
from the point at which P(r) becomes zero at large Q, and an independent calculation of 
the RG and I(0) values for comparison with the Guinier determinations (Perkins et al., 
2008). At [Zn] up to 6 µM, the shape of the P(r) curves remained unchanged with 
increase in [Zn], and was indistinguishable between the Tyr402 and His402 FH 
allotypes (Figure 8.12). The length L of both allotypes was 32 nm, and the maximum M 
was at 5.36 ± 0.11 nm and 5.20 ± 0.11 nm for the Tyr402 and His402 allotypes. These 
values are in good agreement with previous observations for heterozygous FH with zinc 
(Section 6.2.2; Nan et al., 2008b). Also similar to previous, the intensity of the P(r) 
curves and the L and M values for both allotypes increased with increase in [Zn] above 
6 µM, which indicates that zinc-induced oligomerisation occurred with both the Tyr402 
and His402 allotypes and was not dependent on heterogeneity (Figure 8.12). For [Zn] at 
20 µM, 60 µM and 120 µM, the shapes of the P(r) curves were similar between the two 
allotypes, indicating that similar-sized oligomers had formed under these conditions 
(Figure 8.12). The P(r) intensities and M values were slightly higher for the His402 
allotype than the Tyr402 allotype, which is consistent with the Guinier analyses, 
however the difference is not considered to be significant (Figure 8.12). When the P(r) 
analyses were repeated for the SCR-6/8 allotypes with [Zn] up to 6 µM,  L was 
determined to be 9 nm for both allotypes, and the curves were indistinguishable between 
the two allotypes. The P(r) curves were similar in appearance to those for SCR-6/8 
without zinc (Fernando et al., 2007). Above 6 µM zinc, the precipitation of SCR-6/8 
made further P(r) impossible. The lack of difference between the SCR-6/8 allotypes 
indicated that His402 had no effect on zinc-induced oligomerisation compared to 
Tyr402.   230
 
Figure 8.12 Dependence of the distance distribution function P(r) of the FH allotypes on 
zinc concentration. The P(r) curves were calculated from the scattering curves of the 
two FH Tyr402 allotypes (018DK, 016CC; blue) and two FH His402 allotypes (030TJ, 
033NV; red). From bottom to top, the zinc concentrations were 6 µM, 20 µM, 60 µM 
and 120 µM (labelled). The average value of the most frequently occurring distance M 
for each allotype at each zinc concentration is marked by vertical straight lines.   231
8.2.3 Fluid-phase activity assays of the two allotypes of FH complexes with zinc  
 
In order to test the impact of zinc on the regulatory role of the Tyr402 and His402 FH 
allotypes, assays of fluid-phase ammonium-inactivated C3 (C3u) cleavage by factor I 
and two allotypes of FH were performed by zinc titration (Crossley & Porter, 1980). As 
mentioned in Section 2.3.5, previous fluid-phase activity assays had been performed at 
significantly lower FH concentrations that included 45 µg/ml (Crossley & Porter, 1980), 
3 µg/ml (Day & Sim, 1986), 30  µg/ml (Blom et al., 2003) and 0.3  µg/ml (Tsiftsoglou 
& Sim, 2004) than the 0.235-0.81 mg/ml (1.5–5.3 µΜ) observed in vivo. Our assays 
with the FH allotypes were performed at 0.3 mg/ml (1.9 µΜ) which is comparable with 
both its physiological range and the heterozygous FH concentrations used previously 
(Chapter Six; Nan et al., 2008b). Thus the α-chain of C3u was cleaved by factor I in the 
presence of the FH Tyr402 allotype without zinc to produce two major degradation 
fragments at apparent sizes of 45 kDa and 75 kDa (Figure 8.13 a), and the cleavage rate 
was significantly reduced in the presence of 200 µM zinc (Figure 8.13 b). The influence 
of zinc on this reaction for both FH allotypes was investigated at concentrations of 0 
µM, 120 µM and 200 µM (Figure 8.14). This revealed that the C3u cleavage rate was 
decreased by zinc, in good agreement with the decrease seen previously for 
heterozygous FH (Chapter Six; Nan et al., 2008b). No difference between the Tyr402 
and His402 allotypes was seen (Figure 8.14). If similar levels of FH oligomerisation 
with both allotypes accounted for the decrease of FH activity by blocking FH access to 
C3u and/or factor I (Chapter Six;  Nan  et al., 2008b), this would account for the 
observed reduced rate of C3u cleavage.  
 
8.2.4 Bioinformatics prediction of zinc-binding sites on full-length FH 
 
Two bioinformatics strategies were developed in order to assess potential zinc-binding 
sites in FH. The first approach utilised a distance-dependent knowledge-based method 
that was based on known zinc-binding sites, and was performed by Miss Irene 
Farabella. A total of 3705 proteins with Zn-binding sites were identified in the Protein 
Data Bank, which were screened to identify the residues that were within 0.3 nm of the 
metal site. Zinc binding sites at the interface between two protein surfaces generally 
contain Asp, His and Glu sidechains as zinc-coordination sites (Auld, 2001). Cys  232
 
 
Figure 8.13 Comparison of the reducing SDS-PAGE analyses of C3u cleaved by FI and 
the FH Tyr402 allotype in the absence and the presence of zinc.  
 
(a) Reducing SDS-PAGE of C3u cleavage by FI and the FH Tyr402 allotype (013HH) 
in the absence of zinc (from Figure 7.17 a). Lane 1, High Mark
TM Prestained High 
Molecular Weight Standard; Lane 2, 0.3 mg/ml C3u; Lane 3, 0.3 mg/ml C3u and 0.3 
mg/ml FH; Lanes 4-15 correspond to Lane 3 with 0.003 mg/ml factor I added with the 
reaction times in min as labelled. FH and the α-chain and β-chain of C3u are arrowed 
on the left, and the α-chain cleavage products are arrowed on the right.  
 
(b) Reducing SDS-PAGE of C3u cleavage by FI and the FH Tyr402 allotype (013HH) 
with 200 µM zinc. Lane 1, 0.3 mg/ml C3u; Lane 2, 0.3 mg/ml C3u and 0.3 mg/ml FH; 
Lane 3, 0.3 mg/ml C3u, 0.3 mg/ml FH and 200 µM of zinc; Lanes 4 – 15 correspond to 
Lane 3 with the reaction times in min as labelled.  233
 
 
Figure 8.14 Quantification of the cleavage of fluid phase C3u by FI and the two FH 
allotypes in the presence of zinc. The percentage cleavages of the C3 α-chain are shown 
as a function of reaction time. The [Zn] values are labelled as shown. The Tyr402 
allotypes are in blue (013HH, ●; 022LM, ▲) and the His402 allotypes are in red 
(015LT, ○; 032KO, ∆).  234
residues were not included in this survey, because there are no exposed Cys residues in 
full-length FH. Accordingly a total of 830 zinc-binding sites composed of His, Glu and 
/or Asp residues only were indentified and classified into 33 subgroups based on their 
compositions. A contact matrix was defined for each subgroup that is based on the mean 
separation ± standard deviation between the α-carbon atoms and that between the β-
carbon atoms (Materials & Methods). This matrix was used to screen the FH domains in 
order to predict potential interface zinc-binding sites. For this, crystal and NMR 
structures for 11 SCR domains and nine homology-modelled structures available at the 
time of this work were used (Table 8.1) (Barlow et al., 1993; Jokiranta et al., 2006; 
Saunders et al., 2007; Prosser et al., 2007; Hocking et al., 2008). A total of 202 possible 
zinc binding sites were identified as residue pairs or triplets that could act as one-half of 
a zinc-interface binding site. In some cases, a pair or triplet of residues could form a 
partial zinc binding site with more than one coordination geometry (Table 8.2). In order 
of probability, 31% of these sites were identified in SCR-6 which had 62.5 sites, 
followed by 12% in SCR-3, 10% in SCR-16, 7% sites in SCR-2 and 7% sites in SCR-
14. Two or less predicted zinc–binding sites were found in five SCR domains (Table 
8.1). All the triplets were located in SCR-6 or between SCR-6 and SCR-7 (Table 8.2). 
The predicted highest number of zinc binding sites in SCR-6 agrees with the similar 
effect of zinc on the aggregation of full-length FH and SCR-6/8. The predicted 
involvement of SCR-2, SCR-3 and SCR-16 concurs with the ultracentrifugation 
experiments with SCR-1/5 and SCR-16/20 that suggest that other weak binding sites 
may be present. Even though the disease-related His402 residue may be a potential zinc-
binding residue, His402 occurred in only two out of the 202 zinc binding sites predicted 
in FH. The His402 polymorphism thus has a low probability of altering the interaction 
with zinc, and this agrees with the observed lack of difference between the Tyr402 and 
His402 allotypes of FH and SCR-6/8. 
 
The second bioinformatics approach was based on submitting the 20 crystal, NMR and 
homology SCR structures to web servers that predict metal binding sites in proteins 
(Materials and Methods). The second approach was performed by Mr Felix F. 
Schumacher. METSITE was developed using relative residue position and does not 
require side-chain atoms to be present, therefore this is applicable to low resolution 
structures (Sodhi  et al., 2004). It has a high sensitivity of 94.6% and a medium 
selectivity of 47.8% for zinc. This detected all residues containing a main chain atom 
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Table 8.2 Possible predicted zinc binding sites in the FH SCR-6/8 fragment (adapted 
from Rotation 1 report of Miss Irene Farabella, 2009). 
a 
Residues  Location  Possible zinc coordination 
D326-D329 SCR-6  DDH,  DDHH   
D329-H332  SCR-6  DDHH, DHHH  
H332-D358 SCR-6  DDDH,  DDHH, DEHH, DH, DHH, DHHH 
H332-D358-E359 SCR-6 DEHH 
H332-D358H360 SCR-6  DDHH,  DEHH, DHH, DHHH   
H332-D358-E362  SCR-6  DDHH, DEHH   
H332-E359  SCR-6  EH, EHH, EHHH   
H332-H360 SCR-6  DDHH,  DEHH,  DHH, DHHH, EHH, HH, HHH 
H332-H360-E362 SCR-6 DEHH   
H332-H360-E433 SCR-6/7 DEHH   
H332-E362  SCR-6  DEHH, EHH, EHHH  
H332-E433  SCR-6/7  EHHH, DEH, DEHH  
H337-E338 SCR-6  EH,  EHHH   
D358-E359 SCR-6  DE   
D358-H360  SCR-6  DDHH, DH, DHH, DHHH  
D358-H360-E362 SCR-6 DEHH   
H360-E362  SCR-6  DEHH, EEEH, EEHH, EH, EHHH  
H360-E433  SCR-6/7  EHH, DEHH, EHHH 
D370-H371  SCR-6  DDHH, DEHH, DHH 
D370-H371-H373  SCR-6  DDHH, DHH, DHHH 
D370-H373  SCR-6  DDHH, DHH, DHHH  
H371-H373  SCR-6  DHHH, EEHH, EHH, HHH, HHHH 
H373-D377 SCR-6  DHHH,  DDHH 
E395-H402 SCR-7  EHH,  EHHH 
E395-H417  SCR-7   DEHH, EHH,EHHH  
D454-E456 SCR-8    DDH,  DDE 
 
 
a His402 occurred in 2 of the 76 possible zinc coordinations in SCR-6/8. Zinc 
coordinations that contain two or three residues also contain two or one H2O molecules 
respectively to form the required tetrahedral geometry with zinc.  237
within 0.7 nm or 0.4 nm of a putative zinc atom position as a seed, then this calculated 
the residue solvent accessibility in order to achieve the prediction. Using a 0.4 nm 
threshold, METSITE predicted that a total of 26 out of 175 His, Asp and Glu residues in 
FH are candidates for 13 predicted interaction sites with zinc. SCR-6 with five residues 
gave the highest total among the 20 SCR domains, followed by SCR-15 and SCR-20 
with three each. A ranking based on the number of residues per zinc binding site 
(between 1.3 to 1.4) showed that SCR-6, SCR-7, SCR-8, SCR-15 and SCR-20 were the 
most likely to contain zinc binding sites. Given this outcome, the crystal structure of 
SCR-6/8 (PDB code 2UWN) was used to create 195 possible homodimeric structures 
for SCR-6/8 using four different protein docking servers (Materials and Methods). All 
195 dimeric structures were subjected to zinc binding site prediction using the web 
servers METSITE and CHED (Materials and Methods). METSITE identified possible 
zinc binding sites in 193 out of 195 structures, while CHED with no activated filters 
identified possible zinc binding sites in 91 structures. The difference is attributed to the 
higher sensitivity but lower selectivity of METSITE compared to CHED (Sodhi et al., 
2004; Babor et al., 2008). The ten most frequent possible zinc binding site residues in 
the 195 dimeric structures were Glu359, His360, His371, Asp370, Asp485, His332, 
His417, Glu462, Glu487 and Asp497 in order of frequency. Interestingly, His402 was 
not included in those ten residues, which is consistent with the experimental 
observations of no difference seen between the two SCR-6/8 allotypes in the presence 
of zinc. In order to rationalise the outcome of these searches, the 195 putative dimeric 
structures were submitted to RMSDCLUST (Materials and Methods) to group together 
the most similar structures. Nine different zinc binding sites were found in seven 
clusters that each contained 18, 15, 4, 2, 3, 4 and 5 SCR-6/8 dimer structures, together 
with a single outlier that did not belong to any cluster. Only two out of the nine possible 
zinc binding sites possessed all the residues identified as the ten most frequent possible 
zinc binding residues. One of these binding sites involved Glu359 and His360 on each 
of two SCR-6/8 monomers (Figure 8.15 a), and the other involved His371 on one SCR-
6/8 monomer and Asp485 and Glu487 on the other monomer (Figure 8.15 b). If zinc 
cross-links pairs of SCR domains, the predictions of Figure 8.15 leads to a schematic 
cross-linking cartoon in which adjacent pairs of two SCR-6 domains or SCR-6 and 
SCR-8 domains form contact with each other. The indefinite self-association suggested 
in  Figure 8.16 shows how zinc may cross link SCR-6/8 molecules to form large 
aggregates that precipitate. As a control of this predictive approach, the same procedure  238
 
 
Figure 8.15 Two most likely predicted zinc binding sites to FH SCR-6/8 (taken from 
Rotation 2 report of Mr Felix F. Schumacher, 2009).  
 
(a) One of the two sites is composed of two Glu359 and His360 sidechains at the 
surface interface between two SCR-6 domains in the docked dimer. The left panel 
shows a close-up view of the zinc binding residues, whilst the right panel shows the 
overall structure of the putative dimer. The distances between each zinc ligand atom 
(nitrogen or oxygen) are displayed in nm. 
 
(b) The other site is composed of a His371 sidechain in SCR-6 of the first SCR-6/8 
monomer and the Asp485 and Glu487 sidechains in SCR-8 of the second SCR-6/8 
monomer. Other details follow (a).   239
 
 
 
 
 
 
 
Figure 8.16 Cartoon of the putative zinc-induced SCR-6/8 aggregation. The mechanistic 
model for the zinc-induced aggregation of SCR-6/8 based on the two possible zinc 
binding sites shown in Figure 8.15 a, b shows how the two zinc sites may form a daisy-
chain of SCR-6/8 that leads to aggregation and precipitation.   240
was performed with three protein structures with known zinc binding sites (Materials 
and Methods). All the known zinc binding residues were included in the top ten most 
frequently occurring residues in the three known protein structures; this outcome 
supports the credibility of this predictive method. 
 
8.3 Materials and Methods 
 
8.3.1 Protein purification  
 
Human blood was obtained from 48 anonymous genotyped healthy volunteers following 
ethical approval. Direct DNA sequencing of the PCR product of the FH gene was used 
to identify the Tyr402His and Val62Ile FH polymorphisms in each volunteer (Table 
7.1). Four homozygous FH Tyr402 allotypes (coded 026II, 022LM, 018DK and 
016CC), and four FH His402 allotypes (coded 027BA, 032KO, 030TJ and 033NV) 
were purified using monoclonal affinity chromatography with an MRC-OX23 
Sepharose column (Section 6.3.1; Sim et al., 1993; Nan et al., 2008b). The four Tyr402 
allotypes were homozygous for Ile62, homozygous for Val62, heterozygous for 
Val62/Ile62, and homozygous for Val62 in that order, while all four His402 allotypes 
were homozygous for Val62. Native FI was purified from a pool of just-outdated 
anonymised human plasma using another monoclonal affinity MRC-OX21 Sepharose 
column for FI (Section 6.3.1; Sim et al., 1993; Nan et al., 2008b). Bound homozygous 
FH and native FI were each eluted from the columns using 3 M MgCl2, pH 6.9, then 
each was dialysed into HEPES buffer (10 mM HEPES, 137 mM NaCl, pH 7.4) in the 
presence of 0.5 mM EDTA to remove Mg
2+. The MRC-OX23 column was washed with 
guanidine (0.2 M Tris, 4 M guanidine-HCl, pH 8.0) after each FH preparation to avoid 
allotype cross-contamination. IgG contaminants were removed by passing the FH and 
FI purifications through a Hitrap
TM Protein G HP. Non-specific aggregates and human 
serum albumin were removed by gel filtration on a Superose
TM 6 prep grade XK 16/60 
size-exclusive column. Native C3 was purified from fresh plasma by ion-exchange 
chromatography, and haemolytically inactive C3 in which the reactive thioester is 
hydrolysed (C3u) was prepared by incubating native C3 in 200 mM hydrazine at 37 °C 
for 1 h (Section 6.3.1; Dodds, 1993). The DNA constructs for FH SCR-6/8 Tyr402 and 
His402 allotypes were kindly provided by Miss Ami Miller. The recombinant FH 
fragment SCR-6/8 Tyr402 was expressed in BL21 (DE3) E. coli cells using a pET21ab  241
vector system, while SCR-6/8 His402 was expressed in BL21 (DE3)pLysS E. coli cells 
using a pET14b vector system. SCR-6/8 was extracted from inclusion bodies, 
solubilised and refolded. The refolded SCR-6/8 was purified by using ion-exchange 
chromatography with a Hitrap
TM 5 ml Heparin HP column (Fernando et al., 2007; A. 
Miller and S. J. Perkins, unpublished data). The purification of FH SCR-1/5 and SCR-
16/20 fragments were performed by Mr Felix F. Schumacher and Miss Irene Farabella. 
The fragments FH SCR-1/5 and SCR-16/20 were expressed in the yeast strain P. 
pastoris, and then purified using a 5 ml nickel affinity columns (Amersham 
Biosciences), according to the previously described methods (Okemefuna et al., 2008). 
Both the recombinant fragments FH SCR-1/5 and SCR-16/20 were designed to contain 
His6-tag at the C-terminal. 
 
Proteins were dialysed into HEPES buffer for zinc experiments because HEPES does 
not interact with zinc. Protein concentrations were determined from absorption 
coefficients of 16.2 for full-length FH Tyr402, 16.1 for full-length FH His402, 12 for 
FI, 9.4 for C3u, 22.7 for SCR-6/8 Tyr402, 22.1 for SCR-6/8 His402, 17.2 for SCR-1/5, 
and 15.7 for SCR-16/20 (1%, 280 nm, 1 cm path length) (Perkins & Sim, 1986; Ullman 
et al., 1998; Aslam & Perkins, 2001; Okemefuna et al., 2009). The integrity of protein 
samples were routinely checked by SDS-PAGE before and after scattering and 
ultracentrifugation experiments.  
 
8.3.2 Sedimentation velocity data collection and analyses 
 
Analytical ultracentrifugation data were obtained on two Beckman XL-I instruments 
equipped with AnTi50 or AnTi60 rotors, using two-sector cells with column heights of 
12 mm at rotor speeds of 50,000 r.p.m and 60,000 r.p.m. Sedimentation velocity 
experiments at 20
oC were performed for the two FH allotypes Tyr402 (026II and 
022LM) and the two His402 allotypes (027BA and 032KO) at 0.7 – 0.8 mg/ml which 
were titrated with ZnSO4 at concentrations of 0.2 µM, 2 µM, 6 µM, 20 µM, 60 µM, 120 
µM and 200 µM,. The Tyr402 and His402 allotypes of SCR-6/8 at 0.3 mg/ml were 
titrated with ZnSO4 at concentrations of 0.2 µM, 2 µM, 6 µM, 20 µM, 60 µM, 200 µM, 
300 µM and 600 µM. FH SCR-1/5 at 0.3 mg/ml was titrated with of 0 µM, 2 µM, 6 µM, 
20 µM, 60 µM, 200 µM and 600 µM zinc, and FH SCR-16/20 at 0.1 mg/ml was titrated  242
with 0 µM, 2 µM, 20 µM, 200 µM and 600 µM zinc. Data analyses were performed 
using SEDFIT software (version 11.71) (Schuck, 1998; Schuck, 2000). The distribution 
analyses  c(s) provided size and shape data by directly fitting the boundary Lamn 
equation to 350 scans for FH, 480 scans for SCR-1/5, 440 scans for SCR-16/20, and 640 
scans for SCR-6/8. The c(s) analyses were based on a fixed resolution of 200, and 
floated the meniscus, the bottom of the cell, the baseline and the average frictional ratio 
f/fo starting from 1.781 for FH and from 1.200 for SCR-6/8, until the overall root mean 
square deviation and fits between the observed and calculated sedimentation boundaries 
were satisfactory. The frictional ratio f/fo values were kept un-floated at 1.45 for SCR-
1/5, 1.35 for SCR-16/20 monomer, and 1.58 for SCR-16/20 dimer (Okemefuna et al., 
2008). Monomer and oligomers were quantitated using the integration function in the 
c(s) analyses. The percentage fraction of monomer and oligomers of FH was derived by 
assuming that the sum of the signal intensities of monomer and oligomer was 100%. 
Other details are described elsewhere (Section 4.1.2; Nan et al., 2008a; Okemefuna et 
al., 2008). 
 
8.3.3 X-ray scattering data collection and analysis 
 
X-ray scattering data was acquired for the FH allotypes in one beam session, and for the 
SCR-6/8 allotypes in a second beam session on Beamline ID02 at the European 
Synchrotron Radiation Facility (Grenoble, France) operating with a ring energy of 6.0 
GeV in 4-bunch mode and 16-bunch mode in the two beam session respectively to 
reduce the incident flux (Narayanan & Bosecke, 2001). Storage ring currents were 29 - 
43 mA in the first beam session, and 56 - 91 mA in the second beam session. The 
sample-detector distance was 3 m for the first beam session, and 1.5 m for the second 
beam session. Potential radiation damage was eliminated by the continuous movement 
of the sample in a flow cell during beam exposure, the use of 10 time frames of duration 
between 0.1 sec and 0.25 sec each during each acquisition, and on-line checks for the 
absence of radiation damage at low Q. In the first beam session, the FH Tyr402 
allotypes 018DK and 016CC and the His402 allotypes 030TJ and 033NV were studied 
at 0.9 mg/ml (5.8 µM) with ZnSO4 at concentrations of 0.2 µM, 2 µM, 6 µM, 20 µM, 60 
µM, 120 µM, 200 µM and 600 µM. In the second beam session, the Tyr402 and His402 
allotypes of SCR-6/8 were studied at 0.2 mg/ml (9.7 µM) with ZnSO4 at concentrations 
of 0.2 µM, 2 µM, 6 µM, 20 µM, 60 µM, 120 µM, 200 µM, 300 µM and 600 µM. All the  243
measurements were done in HEPES buffer (10mM HEPES, 137mM NaCl, pH 7.4). 
Other details including data reduction are described elsewhere (Section 4.2; Fernando et 
al., 2007; Okemefuna et al., 2008).  
 
In a given solute-solvent contrast, the radius of gyration RG corresponds to the mean 
square distance of scattering elements from their centre of gravity, and is a measure of 
structural elongation. Guinier analyses at low Q gives the RG value and the forward 
scattering at zero angle I(0) from the expression (Glatter & Kratky, 1986): 
ln I(Q) = ln I(0) - RG
2 Q
2/3. 
This expression is valid in a Q.RG range up to 1.5. The I(0)/c value (c is the protein 
concentration in mg/ml) is proportional is the relative molecular mass Mr. If the 
structure is elongated, the mean cross-sectional radius of gyration RXS and the cross-
sectional intensity at zero angle [I(Q)Q]Q→0 are determined from Guinier analyses in a 
Q range larger than that used for the RG determination (Glatter & Kratky, 1986): 
ln [I(Q)Q] = ln [I(Q)Q]Q→0 - RXS
2Q
2/2. 
The Guinier analyses were performed using an interactive PERL script program 
SCTPL7 (J. T. Eaton and S. J. Perkins, unpublished software) on Silicon Graphics 
OCTANE Workstations.  
 
Indirect transformation of the I(Q) curve measured in reciprocal space into real space 
gives the distance distribution function P(r) and was carried out using the program 
GNOM (Semenyuk & Svergun, 1991): 
P(r) corresponds to the distribution of distances r between volume elements. This offers 
an alternative calculation of the RG and I(0) values that is based on the full scattering 
curve I(Q), and not that at low Q. It also gives the most frequently occurring distance M 
and the maximum dimension of the macromolecule L. For FH at 0.9 mg/ml titrated with 
zinc, the X-ray curves utilised up to 344 data points for Q between 0.08 nm
-1 and 1.60 
nm
-1. Other details are described elsewhere (Section 4.2; Nan et al., 2008a; Aslam & 
Perkins, 2001; Fernando et al., 2007; Okemefuna et al., 2008).  
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8.3.4 Fluid-phase activity assays  
 
To determine activities, the reaction mixtures containing 0.3 mg/ml FH, 0.3 mg/ml C3u 
and 0.003 mg/ml factor I were incubated in a water bath at 37 °C in three concentrations 
of ZnSO4 (0 µM, 120 µM and 200 µM).  The functions of two pairs of the two allotypes 
of FH were tested. The FH Tyr402 allotype 013HH and the FH His402 allotype 015LT 
were tested with 0 µM and 200 µM of zinc, and the FH Tyr402 allotype 022LM and the 
His402 allotype 032KO were tested with 120 µM of zinc. At timed intervals, 5 µl 
aliquots were removed for reducing SDS-PAGE analyses. Three blank controls were 
used, namely 0.3 mg/ml C3u; 0.3 mg/ml C3u and 0.3 mg/ml FH; and 0.3 mg/ml C3u, 
0.3 mg/ml FH and zinc. The C3 α-chain band densities from SDS-PAGE were 
measured using the gel analysis system SYNGENE (Synoptics Ltd., Cambridge, UK). 
The C3 α-chain cleavage was referenced to the averaged density of the uncleaved bands 
in the controls. 
 
8.3.5 Molecular prediction of surface zinc binding sites  
 
Structural database analyses were used to predict protein-interface-type zinc binding 
sites on protein surfaces. A dataset of 3705 Zn-binding protein crystal structures with 
resolutions better than 0.3 nm was identified from the Protein Data Bank. Residues that 
were located within 0.3 nm distance of the zinc atom were assigned as putative zinc 
coordinating residues using a PERL script to scan the Protein Data Bank. Of the 4883 
putative zinc binding sites that were identified, a total of 830 zinc-binding sites 
composed of His, Glu and /or Asp as zinc coordination residues were analysed and 
classified into 33 subgroups based on the amino acid composition of each site. In each 
subgroup, the distance x between the Cα atoms and that between the Cβ atoms of each 
zinc-coordinating residue j were calculated as a residue pair type (x,j), and stored in a 
contact matrix CM. For each residue pair in CM, the average distancex and its standard 
deviation  σ was calculated. An algorithm was implemented to screen each protein 
structure of interest for residues that form putative partial Zn binding sites. For a given 
protein structure, solvent-exposed Asp, His and Glu side-chains were identified. A 
residue is considered exposed if its side-chain has a relative surface accessibility greater 
than 20%. The geometric distances between pairs and triplets of Cα atoms and Cβ atoms  245
of the putative zinc-coordinating residues were calculated. If these distances fall within 
the distance cut-off  σ ± x , then the pair or triplet of residues became considered as 
possible zinc coordinating residues. Using this algorithm, 11 experimental SCR crystal 
or NMR structures for SCR-1/2, SCR-2/3, SCR-5, SCR-6/8, SCR-15/16 and SCR-19/20 
(Barlow et al., 1993; Jokiranta et al., 2006; Saunders et al., 2007; Prosser et al., 2007), 
and nine homology-modelled SCR structures for SCR-4, SCR-9, SCR-10, SCR-11, 
SCR-12, SCR-13, SCR-14, SCR-17 and SCR-18 (Saunders et al., 2007) were screened. 
This bioinformatics analysis was done by Miss Irene Farabella. 
 
Further predictions of metal binding sites in FH were carried out using web servers. 
First, the 20 experimental and homology SCR structures in FH were evaluated using 
METSITE (http://bioinf.cs.ucl.ac.uk/metsite) (Sodhi et al., 2004) which uses a set of 
neural network classifiers trained to identify potential cation sites. Second, to form FH 
dimer structures, the SCR-6/8 His402 crystal structure (PDB code 2UWN) was docked 
using four different docking approaches available as web servers including CLUSPRO 
(http://cluspro.bu.edu/login.php), HEX (http://www.csd.abdn.ac.uk/hex_sever/), 
PATCHDOCK (http://bioinfo3d.cs.tau.ac.il/PatchDock/) and ROSETTADOCK 
(http://rosettadock.graylab.jhu.edu/) (Comeau et al., 2003; Gray et al., 2003; Ritchie, 
2003; Schneiderman-Duhovny et al., 2005; Gray, 2006). These four docking programs 
were selected according to their performance in the Critical Assessment of Predicted 
Interactions surveys (Mendez et al., 2005; Lyskov and Gray, 2008). Third, the possible 
biological relevant dimeric structures were tested again by METSITE and another web 
server CHED (Babor et al., 2008) to detect the possible zinc binding sites at the protein 
interface of the dimeric structures. The CHED web server searches for Cys, His, Glu 
and Asp residues with atoms within several specified distances to each other and a 0.27 
nm distance to the putative zinc atom position, and if the distances do not match, a 
independent rotamer library was used to find an appropriate fit configuration. The sites 
found in CHED are filtered by a decision tree and a support vector machine to verify 
their suitability. Fourth, the dimeric structures that possess zinc binding sites predicted 
by METSITE and CHED were clustered by using the program RMSDCLUST to group 
similar structures. RMSDCLUST computes the centre of gravity of every dimeric 
structure and finds the lowest root mean square deviation (r.m.s.d) between each 
structure, and the clusters are formed by the structures within a r.m.s.d limit of 0.6 nm. 
To validate the methods, the same predictions were performed with three zinc binding  246
structures as benchmarks, namely human interferon-β (PDB code 1AU1), human 
growth hormone (PDB code 1BP3) and thermophilic cytochrome P450 from S. 
solfataricus (PDB code 1F4T) (Karpusas et al., 1997; Somers et al.; Yano et al., 2000). 
 
8.4 Conclusions 
 
Even though metals have not generally been considered as FH ligands, the study in 
Chapter Six showed that heterozygous FH aggregated strongly in the presence of zinc, 
and that five transition metals caused FH to aggregate at physiological FH 
concentrations and pathophysiological zinc and copper concentrations of ≥ 20 µM 
(Perkins et al., 1991; Nan et al 2008b; Lengyel et al., 2007). Zinc has the strongest 
effect on FH. In this study, using ultracentrifugation and X-ray scattering, we have 
shown that this aggregation occurs for the major homozygous forms of FH with either 
Tyr402 or the disease-related His402 allotypes, and including the Val62 or Ile62 
allotypes. This provides the key result that zinc-induced aggregation does not result 
from FH heterogeneity. We have also identified SCR-6/8 as a major locus for this 
process from ultracentrifugation and scattering studies that showed that SCR-6/8 
precipitated with zinc. Bioinformatics modelling predictions confirmed that SCR-6/8 
has the highest propensity to form partial zinc binding sites at its surface, which become 
indefinitely cross-linked in the presence of zinc (Figure 8.16). Control experiments with 
SCR-1/5 and SCR-16/20 showed that SCR-1/5 also precipitated with zinc, while SCR-
16/20 remained soluble but formed some oligomers with zinc. The bioinformatics 
predictions indicated that additional weak zinc binding sites may be present in SCR-1/5 
and SCR-16/20, although the involvement of the His6-tag on our two recombinant 
fragments in facilitating zinc binding cannot be ruled out. Overall, this work now 
explains the zinc-induced formation of large compact FH oligomers in terms of multiple 
weak surface zinc-binding sites, primarily within the SCR-6/8 region. Interestingly, the 
Tyr402 or His402 allotypes have no significant influence on zinc-induced aggregation, 
even though His402 might be considered as a zinc-chelating residue.  
 
FH is a major complement regulator in blood, and is expressed and secreted by many 
different cell types including the RPE (An et al., 2006). The major physiological ligands 
of FH include C3b and its C3d fragment, heparin and other glycososaminoglycans, C- 247
reactive protein and FH self-association, in addition to zinc binding (Perkins et al., 
2010a; Perkins et al., 2010b). All these ligands bind weakly to FH with µM affinities, 
and this is consistent with the relative abundance of FH in serum. The FH-zinc 
interaction has already been discussed previously (Chapter Six;  Nan  et al., 2008b). 
Recent studies show that C3b and C3d bind with KD values of 3.5-14 µM and 2.6 µM 
respectively (Schmidt et al., 2008; Okemefuna et al 2009), C-reactive protein binds with 
a KD value of 4-15 µM (Okemefuna et al., 2010), and FH dimerises with a KD value of 
28 µM (Chapter Five; Nan et al., 2008a). If FH is found at 0.6 mg/ml in serum, this 
means that 11% of FH exists as dimers. If C3b is found at 1 mg/ml, this means that 29% 
of FH is bound to C3b if the KD value is 3.5 µM. If C-reactive protein is at the acute-
phase level of 0.4 mg/ml, this means that 32% of FH is bound to C-reactive protein if 
the  KD value is 4.2 µM. This calculation assumes that no other factors in serum 
influence these equilibria, and that the three equilibria are considered separately from 
each other for purpose of illustration here. In comparison to these physiological 
interactions, the pathophysiological interaction between FH and zinc is characterised by 
comparable KD values in the region of 6-20 µM, implying that FH will be 50% bound to 
zinc if bioavailable zinc is present at 13 µM. This concentration agrees with the total 
serum zinc concentration of 12.5 µM (AREDS Research Group, 2002). However most 
of the zinc in plasma is bound to proteins such as serum albumin, and only 2-8% of this 
zinc is bioavailable (Lu et al., 2008). The zinc level remains low at 14.7 µM even after a 
daily diet supplement with 80 mg zinc in the AREDS trials (AREDS Research Group, 
2002). Therefore, normal zinc levels in plasma are too low to induce FH 
oligomerisation. Interestingly, because two of the most frequently predicted zinc 
binding residues His360 and His371 have been implicated in glycosaminoglycan 
binding to FH (Prosser et al., 2007), it is possible that zinc binding to FH can perturb 
the binding of glycosaminoglycans to FH.  
 
Human ocular tissues contain unusually high concentrations of zinc, where the zinc 
concentration is 472 µg/g of dry tissue in the RPE-choroid complex, and 464 µg/g in the 
neurosensory retina (Galin et al., 1962). Zinc in the RPE-choroidal complex is mostly 
bound to melanin, metallothionein and other zinc binding proteins, and it has been 
proposed that 10% of zinc in retina is free or chelatable (Galin et al., 1962; Ugarte & 
Osborne, 2001; Newsome et al., 1992). Zinc is essential for the normal function of the  248
retina, being suggested to act as an antioxidant. Zinc appears to be essential for the 
normal function of the retina, but its exact role is not clear (Section 3.2.2). RPE cells 
can accumulate zinc following oral supplementation and retain it longer than any other 
tissues in the body (Newsome et al., 1992). This zinc might be released through photo 
oxidative damage but the mechanism for this is not known (Ugarte & Osborne, 2001; 
Lengyel et al., 2007).  High millimolar concentrations of zinc are present in drusen 
(Lengyel  et al., 2007). Even if a small fraction of the zinc in drusen becomes 
bioavailable, this level will be sufficient to induce the localised aggregation of FH. The 
above comparison with the KD values for FH interactions with its other ligands (above) 
shows that the regulatory balance of FH activity in terms of interactions with C3b, 
heparin and C-reactive protein can be disturbed. The likelihood that zinc mostly 
interacts with the SCR-6/8 regions, which is a locus for heparin and C-reactive protein 
interactions, indicates that FH function can be perturbed if sufficient excess zinc is 
available. Such a mechanism can contribute to both the formation of drusen deposits 
and the inhibition of the regulatory function of FH to cause host cell damage. Daily 
supplements with 80 mg zinc, 2 mg copper, vitamins C and E, and β carotene are 
recommended by AREDS as a means of reducing the risk for progression to advanced 
AMD (AREDS Research Group, 2001a; AREDS Research Group, 2001b). 
Interestingly, the AREDS-recommended zinc supplements with antioxidants correlated 
with a greater reduction in progression to advanced AMD in patients (34% of cases) 
who are homozygous for the FH Tyr402 allotype compared to patients (11% of cases) 
who are homozygous for the FH His402 allotype (Klein et al., 2008). Our current study 
offers no direct explanation for this observation because no significant difference in 
zinc-induced FH aggregation was seen between the Tyr402 and His402 allotypes of FH 
and SCR-6/8.  
 
The most common coordination geometry of zinc binding sites is tetrahedral (Auld, 
2001). Here, the bioinformatics analyses indicated the availability of 3705 zinc binding 
co-ordinations in the Protein Data Bank for evaluation. Protein interface zinc binding 
sites are primarily supplied by His, Glu and Asp residues, but sites containing Cys are 
also found (not relevant to FH), and β-sheet secondary structures predominately 
contribute to zinc binding sites. Zinc binding is able to induce protein self-association or 
link two different proteins (Auld, 2001). The previous discussion of potential FH zinc 
binding sites (Figure 6.18) (Nan et al., 2008b) is now clarified by the abundance of  249
potential zinc sites that were predicted using a distance-based algorithm, suggesting that 
multiple weak zinc binding sites exist in FH. This outcome predicts that a range of 
different zinc-induced oligomers will form, which is in good agreement with the 
observation of many overlapping peaks in the ultracentrifugation c(s) size distribution 
analyses (i.e. the opposite of the formation of fewer well-resolved signals such as those 
observed for FH alone (Figure 5.7 and Figure 7.5) and also with the formation of 
indefinite oligomers at high zinc concentrations. The prediction of multiple sites also 
explains better why different types of FH oligomers were observed with different metals 
such as copper (Chapter Six; Nan et al., 2008b). Finally the predictions were also 
informative in that they explained the lack of difference seen between the SCR-6/8 
Tyr402 and His402 allotypes, because His402 was not predicted to be a significant zinc-
binding ligand. These analyses provide insight into the weak binding of zinc to other 
plasma proteins. It is possible that the outcome of this FH-zinc study will be applicable 
to other plasma proteins. For example, the zinc-induced oligomer formation in C3 has 
been observed (K. Li & S. J. Perkins, unpublished data).  
 
 
 
 
 
  
   250
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Nine 
 
Conclusions   251
9.1 Prologue 
 
In the innate immune system, factor H (FH) is a major regulator of complement 
alternative pathway activation. It is composed of 20 short complement regulator (SCR) 
domains arranged in tandem, and 19 peptide linkers between the SCR domains. Over 
the years, high resolution structures have been resolved for small SCR domain 
fragments (Section 2.1.2), and homology structures have been generated for the 
remainder (Section 2.1.3). A high resolution structure for full-length FH has never been 
determined due to its large size, flexibility and glycosylation, and the conformation of 
full-length FH cannot be obtained by joining the known SCR domains structures 
together. The combination of constrained X-ray solution scattering modelling and 
analytical ultracentrifugation offers an approach to reveal the medium-resolution folded 
back structure of full-length FH in solution. However, the self-association properties of 
FH have complicated the modelling curve fits (Figure 7.14). In this thesis, an improved 
solution structure for full-length FH was obtained in which self-association issues were 
minimized (Chapter Seven).  
 
FH binds to multiple ligands such as C3b, heparin and C-reactive protein, and the 
binding sites for different ligands are located in different SCR domains (Section 2.3). 
The studies of the affinities between FH and its ligands showed micromolar KD values 
which indicate weak binding. Although some dimerisation of FH fragments has been 
observed before (Section 2.3.4), the self-association properties of full-length FH have 
not previously been analysed, and most of the previous studies of FH are based on the 
assumption that FH is monomeric in solution. In this thesis, the weak self-association of 
full-length FH has been clarified systematically by using improved X-ray solution 
scattering and analytical ultracentrifugation analyses (Chapter Five; Chapter Seven). 
This process needs to be taken into account for interpreting the physiological interaction 
of FH. Metals have not been generally considered as FH ligands. Previous studies 
showed that zinc causes FH to aggregate, and this inhibits the regulatory function of FH 
in the fluid-phase (Section 2.3.5). The KD of zinc binding and the domain interaction 
sites have now been clarified by the work in this thesis (Chapter Six; Chapter Eight). 
 
FH is genetically related to several human diseases (Section 2.5). For example, it is 
related to age-related macular degeneration (AMD), a leading cause of blindness in the   252
elderly in the western world, through a Tyr402His polymorphism in domain SCR-7 
where binding sites for multiple ligands locate. Many studies have been done on 
comparing the binding affinities of the wild-type Tyr402 allotype and the disease-
related His402 allotype of FH with ligands such as heparin, C3b and C-reactive protein. 
Few studies have been focussed on the self-association properties of FH and its metal 
binding. Millimolar concentrations of zinc are found in drusen which is a hallmark of 
early AMD (Section 3.3.1). The work in this thesis presented a detailed comparison of 
these properties of the two allotypes of FH, and characterised the similar weak self-
association and zinc-induced oligomerisation of the two allotypes.  
 
9.2 Solution structure of FH 
 
In this thesis, in relation to FH solution structures, X-ray scattering showed that the 
maximum length is 28 nm for both monomeric FH Tyr402 and His402 allotypes. 
Constrained scattering modelling fits gave similar best-fit structures of monomeric FH 
for the two allotypes, with an improved goodness-of-fit than the previous models for 
heterozygous FH monomer (Figure 7.13; Figure 7.14). These new results were due to 
the improvements in X-ray scattering instrumentation and a minimised level of FH 
oligomerisation. These best-fit structures were more folded-back than those previously 
determined, and have calculated sedimentation coefficient values that agreed well with 
the experimental values obtained by ultracentrifugation. The Tyr402His polymorphism 
is solvent exposed on the surface of SCR-7, where the previously determined solution 
structures for SCR-6/8 and the NMR structures for SCR-7 are similar between the 
Tyr402 allotype and His402 allotype. In this thesis, the similarity between the structures 
of the two allotypes of full-length FH monomer complements the structures for these 
fragments to show that the polymorphism has no effect on the overall FH structure even 
through it changes the surface charge of SCR-7. This result suggests that the inter-SCR 
flexibility of FH is limited, and that the reduced binding affinity of FH His402 to 
ligands such as CRP is due to the residue change itself rather than an altered FH 
structure.  
 
9.3 Self-association of FH 
 
Prior to this thesis, FH was known to form dimers, however the basis for these   253
observations was unclear (Section 2.3.4). In this thesis, the study of self-association 
properties of FH started with a combination of solution X-ray scattering and analytical 
ultracentrifugation analyses of heterozygous FH (Chapter Five). The dimerisation of FH 
had firstly been reported in a previous X-ray scattering study of FH at high 
concentrations that was necessary for data collection at that time (Section 2.3.4). The 
updated X-ray scattering study presented in Chapter Five utilised heterozygous FH at 
lower concentrations with improved signal-noise ratios, and revealed clear dependences 
of the Guinier parameters RG,  I(0)/c and RXS-1 values on FH concentration that 
corresponded to the weak self-association of FH (Figure 5.2). From sedimentation 
equilibrium analyses, the self-association of heterozygous FH below 1.36 mg/ml can be 
best fitted to a reversible monomer-dimer equilibrium with a dissociation constant KD 
value of 28 µM. Less reversible higher oligomers formed at increased concentrations 
(Figure 5.5). At physiological concentrations of FH (0.235 – 0.810 mg/ml) in serum, the 
KD value of 28 µM suggests that 85% to 95 % of FH will be monomeric in serum 
without considering other factors that might affect this ratio. This KD value is 
comparable with that of 40 µM for the dimerisation of the SCR-6/8 His402 allotype, 
and that of 16 µM for the dimerisation of SCR-16/20 previously determined by 
ultracentrifugation (Section 2.3.4). Sedimentation coefficient distribution analyses in 
sedimentation velocity experiments revealed that monomeric FH was the major species, 
together with small amount of as many as six different higher oligomeric forms of FH 
(Figure 5.7). These observations suggest a progressive mechanism for FH self-
association. 
 
A previous study showed that the disease-related His402 allotype of FH SCR-6/8 
exhibits slightly higher self-association than the lower-risk Tyr402 allotype of FH SCR-
6/8 (Fernando et al., 2007). This observation triggered the study in this thesis of the 
self-association properties of the two homozygous allotypes of full-length FH (Chapter 
Seven). In this study, surface plasmon resonance analyses confirmed that the SCR-6/8 
His402 self-associates more than SCR-6/8 Tyr402 does (Figure 7.3). However, the two 
allotypes of full-length FH showed similar 12 % amounts of oligomeric forms in surface 
plasmon resonance and analytical ultracentrifugation analyses (Figure 7.5). The similar 
self-associations of the two allotypes of full-length FH were confirmed in mass 
spectrometry analyses which indicated that both FH allotypes exhibited monomer,   254
dimer and possibly trimer forms, and X-ray scattering analyses which showed that 
similar concentration dependences of the Guinier parameters. The observed FH dimer, 
trimer and tetramer in sedimentation-coefficient distribution analyses can be well 
explained by the “daisy-chains” oligomer formation of FH best-fit monomeric structure 
by alternating dimerisation sites at SCR-7 and SCR-20. Since the bindings of FH with 
ligands such as CRP and C3b are weak interactions with micromolar level KD values, 
the self-association properties may compete with these physiological interactions of FH. 
 
9.4 Zinc-induced oligomerisation of FH 
 
Prior to this thesis, FH was known to aggregate strongly with zinc (Section 2.3.5). In 
this thesis, the interaction between FH and zinc was first investigated using 
heterozygous FH using a more quantitative approach (Chapter Six). Heterozygous FH at 
2.8 − 7.0 µM was titrated with 0.2 – 200 µM of zinc. By performing X-ray scattering 
experiments, heterozygous FH was shown to be unaffected by [Zn] lower than 20 µM. 
With [Zn] ≥ 20 µM, the Guinier parameters RG,  I(0)/c and RXS-1 values showed 
significant increases as [Zn] increased (Figure 6.2), which indicates the formation of 
large oligomers of FH with a KD of about 20 µM. The distance distribution analyses of 
the scattering data showed that the maximum dimension of FH increased from 32 nm to 
50 nm, indicating that the large oligomers of FH are compact in conformation. In the 
sedimentation coefficient distribution analyses of the sedimentation velocity 
experiments, monomeric FH at 5.57 S was the major species at [Zn] up to 60 µM. A 
series of large oligomers in solution with sedimentation coefficient value up to 100 S 
were observed at [Zn] above 60 µM (Figure 6.9). These zinc-induced oligomers of FH 
can be disassembled by chelation using EDTA. Control experiments were performed 
with other metals. Copper can induce FH to form structurally distinct oligomers, while 
Ni, Cd and Fe exhibited small amounts of oligomers, and Ca and Mg showed no effects 
(Figure 6.14). The oligomerisation of heterozygous FH induced by zinc and copper was 
matched with reduced FH regulatory functions in fluid-phase. Therefore, zinc and 
copper should be considered as inhibitory ligands of FH when the metal concentrations 
are high enough to trigger the oligomerisation of FH.  
   255
The locations of the zinc binding sites in FH were unknown prior to this thesis. The 
common residues for zinc binding at protein interface include His, Asp, Glu and Cys 
residues, and the most frequently observed coordination geometry is tetrahedral 
(Section 2.3.5). The AMD-related polymorphism Tyr402His in SCR-7 introduces a 
solvent-exposed His402 side chain that may leads to increased zinc binding. This raised 
the question of whether the zinc interactions with FH Tyr402 allotype and FH His402 
allotype are different (Chapter Eight). Similar to heterozygous FH, large amounts of 
oligomers were formed by each of the Tyr402 and His402 allotypes of full-length FH in 
the presence of zinc observed by analytical ultracentrifugation. By X-ray scattering, the 
Guinier parameters RG, I(0)/c and RXS-1 values for both two allotypes of full-length FH 
showed the same dependences on [Zn] as for heterozygous FH. The same experiments 
were performed on the two allotypes of FH SCR-6/8, and the two SCR-6/8 allotypes 
strongly precipitated in a similar manner with zinc at [Zn] ≥ 20 µM. Thus the 
Tyr402His polymorphism does not lead to different interactions with zinc. Since the 
zinc-binding properties of full-length FH and that of SCR-6/8 share similar KD values 
(about 20 µM), the main interacting domains within FH are most likely located in SCR-
6/8 (Figure 8.9; Figure 8.11). Bioinformatics predictions of zinc binding sites revealed 
multiple zinc binding sites at several SCR domains, of which the most abundant were 
within SCR-6/8. These predictions agreed well with the experimental results. 
Interestingly, multiple binding sites for FH ligands such as CRP and heparin are located 
in SCR-7, thus the binding of zinc may inhibit other ligands binding where [Zn] is 
sufficient and affect the regulatory role of FH.  
 
9.5 Implications for AMD 
 
In serum, the physiological [Zn] is 12.7 µM, however only 2-8 % of zinc is bio-
available. Therefore [Zn] is too low to induce the formation of FH oligomers in serum. 
However in the RPE-choroid complex, [Zn] is unusually high (472 µg/g). As in serum, 
most of zinc in the RPE-choroid complex is bound to proteins. Under conditions such as 
light stimuli, zinc can be released from the RPE, and become bio-available in the 
extracellular space (Section 3.2). High millimolar concentrations of zinc are present in 
drusen (Section 3.3). Even only 10 % of zinc in drusen is bio-available, [Zn] would be 
sufficient to induce the strong oligomerisation of FH locally. FH was found in drusen,   256
and complement activation-related inflammation has been suggested in relation to 
drusen formation. The RPE is a local source for FH (Section 2.5.3). Thus the interaction 
between zinc and FH may play a role in the formation of drusen, through a metal-
induced aggregation mechanism or a metal-induced complement mis-regulation 
mechanism. The AREDS trials found that a supplement with zinc alone, or with zinc 
together with vitamins C and E and β carotene reduces the risk for progression to 
advanced AMD. Interestingly, a follow-up study suggested that this treatment has a 
much weaker response in patients with FH His402 allotype than in those with FH 
Tyr402 allotype (Section 3.3.2). Because the results from this thesis showed very 
similar zinc binding of the two FH allotypes (Chapter Eight), the different responses to 
zinc supplementation are not due to direct effects of the Tyr402His polymorphism on 
the interactions between FH and zinc. 
    257
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Factor H (FH) is a major regulator of complement alternative pathway
activation. It is composed of 20 short complement regulator (SCR) domains
and is genetically associated as a risk factor for age-related macular degen-
eration. Previous studies on FH suggested that it existed in monomeric and
dimeric forms. Improved X-ray scattering and analytical ultracentrifugation
methodology for wild-type FH permitted a clarification of these oligomeric
properties. Data at lower concentrations revealed a dependence of the X-ray
radius of gyration values on concentration that corresponded to the weak
self-association of FH. Global sedimentation equilibrium fits indicated that
a monomer–dimer equilibrium best described the data up to 1.3 mg/ml
with a fitted dissociation constant KD of 28 μM and that higher oligomers
formed at increased concentrations. The KD showed that about 85–95%
of serum FH will be monomeric in the absence of other factors. Size-
distribution analyses in sedimentation velocity experiments showed that
monomeric FH was the major species but that as many as six oligomeric
forms co-existed with it. The data were explained in terms of two weak
dimerisation sites recently identified in the SCR-6/8 and SCR-16/20 frag-
ments of FH with similar KD values. These observations indicate a mecha-
nism for the progressive self-association of FH and may be relevant for
complement regulation and the formation of drusen deposits that are
associated with age-related macular degeneration.
© 2007 Elsevier Ltd. All rights reserved.
Edited by R. Huber
Keywords: factor H; oligomerisation; X-ray scattering; analytical ultracen-
trifugation; age-related macular degeneration
In the human innate immune defence system, the
central complement component C3 is activated to
C3b by the cleavage and removal of the small
anaphylatoxin C3a to initiate the alternative path-
way in serum. C3b is regulated by factor H (FH) in
order to prevent complement-mediated host cell
damage, in which FH acts as a co-factor for factor I
cleavage of C3b to form iC3b,
1–3 accelerating the
decay of the C3 convertase C3bBb
2,4 and competing
with factor B for binding to C3b.
5 FH is composed of
20 short complement regulator (SCR) domains, each
of about 61 residues in length. SCR domains, also
known as short consensus repeats, Sushi or comple-
ment control protein domains,
6 constitute the most
abundant domain type in complement proteins.
There are multiple binding sites for C3b within the
20 SCR domains,
7,8 and likewise there are multiple
binding sites for heparin.
9–12 FH regulates surface-
bound C3b activity by recognising charge (anionic)
clusters on the surfaces of host cells that are
mimicked by heparin. The initial contact with host
cells is made through its C-terminal end, which is
followed by N-terminal regulatory activity.
13,14
Polymorphisms and mutations in FH have been
associated with age-related macular degeneration
(AMD),
15–19 the most common cause of blindness in
the elderly in the Western world, and with atypical
haemolytic uraemic syndrome (aHUS),
19,20 a rare
*Corresponding author. E-mail address:
s.perkins@medsch.ucl.ac.uk.
Abbreviations used: FH, factor H; SCR, short
complement regulator; RG, radius of gyration; AMD,
age-related macular degeneration; aHUS, atypical
haemolytic uraemic syndrome.
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duals of all ages but primarily children and young
adults†. The involvement of FH indicates that
complement activation and regulation in the retina
and the kidney endothelium have been impaired.
Intact FH has not been crystallised to date for
reasons of its size, glycosylation and inter-SCR flexi-
bility. Thus, solution scattering and electron micro-
scopymethodshavebeenappliedtoshowthattheFH
SCR domain structure is not fully extended in
solution.
21–23X-rayscatteringandultracentrifugation,
incombinationwithconstrainedscatteringmodelling,
are powerful approaches
24,25 that resulted in the first
molecularstructuresforFHanditsSCR-6/8,SCR-1/5
and SCR-16/20 fragments.
23,26,27 Homology models
for the SCR domains provided many of the first
structural explanations for AMD and aHUS.
23,28,29
Thus, AMD was associated with a common Tyr402-
His polymorphism, which is located at the surface of
SCR-7 and close to a heparin binding site. The aHUS-
related mutations cluster at the surface of SCR-20 and
to a lesser degree in SCR-16 to SCR-19, and they are
associated with another heparin binding site. The
distribution of more than 100 genetic alterations†
showed that the observed clinical phenotype is
correlated with their structural location.
19 NMR and
crystal structures, starting with those for SCR-5 and
SCR-15/16 and more recently extended to those for
SCR-6/8 and SCR-19/20, have confirmed and
extended these predictions.
6,12,30–33 Even with these
structures, there is no clear indication of a molecular
mechanism involving FH that leads to AMD.
One of the hallmarks of AMD is the appearance
of drusen, an amyloid plaque-like deposition in
Bruch's membrane, a layer interposed between the
retinal pigment epithelium and the choroidal vas-
culature.34,35 The deposits contain oxidized lipids
and many aggregated proteins, including FH.
36 The
self-association properties of FH are thus relevant
to drusen formation. FH was originally shown to
be monomeric by ultracentrifugation.
37 Dimeric FH
was demonstrated by scattering, but this observa-
tion could not be subsequently replicated.
21,23
Partial FH SCR-15/18 and SCR-15/20 dimers were
however observed by non-reducing SDS-PAGE, and
SCR-1/7 was observed to interact with SCR-1/20 by
surface plasmon resonance.
8,13 Our recent ultracen-
trifugation and scattering studies showed that SCR-
6/8 and SCR-16/20 (but not SCR-1/5) exhibit weak
monomer–dimer associations.
26,27 These studies
indicate at least two potential dimerisation sites in
FH. In combination, the two sites would constitute a
mechanism for the continual self-association of
FH that would lead ultimately to aggregate forma-
tion. In this study, we re-investigated the oligomer-
isation properties of native FH. Through the use of
improved scattering and ultracentrifugation instru-
mentation and analyses, we found and here show
that FH exhibits a monomer–dimer equilibrium at
physiological concentrations and multiple oligo-
mers at higher concentrations. We discuss the impli-
cations of this result for complement regulation and
AMD.
X-ray scattering of FH oligomers
The purification of wild-type FH for X-ray
scattering and analytical ultracentrifugation experi-
ments utilised a 3-l pool of just-outdated anony-
mised human plasma from the Royal Free Hospital
Blood Bank with an anti-FH monoclonal antibody
Sepharose MRC-OX23 column as previously
described.
23,38 The final column eluate in 3 M
MgCl2 was dialysed into Hepes buffer [10 mM
Hepes, 137 mM NaCl and 0.5 mM ethylenediami-
netetraacetic acid (EDTA), pH 7.4]. The FH concen-
tration step at 4 °C employed a gentle centrifugation
approach without stirring (Amicon
® Ultra-15 cen-
trifugal filter devices with a molecular-mass cutoff
of 50 kDa at 2500g). Non-specific aggregates of FH
and human serum albumin were removed by gel
filtration on a Superose™ 6 prep grade XK 16/60
column, and the sample was re-concentrated by cen-
trifugation. All FH samples were checked using
SDS-PAGE before and after scattering and ultracen-
trifugation experiments. An absorption coefficient
of 16.7 (1%, 280 nm, 1-cm path length) was used to
determine concentrations.23
The X-ray scattering radius of gyration (RG)o fF H
monitors its degree of elongation. FH prepared
2 days beforehand was studied on Instrument ID02
at the European Synchrotron Radiation Facility
39 in
eight concentrations between 8.7 and 0.43 mg/ml
in Hepes buffer (Fig. 1). Improved Guinier RG fits
were obtained at lower Q values compared with the
previous X-ray measurements at the Synchrotron
Radiation Source at Daresbury (Q=4π sin θ/λ,
2θ=scatteringangle,λ=wavelength).
21,23Forreason
of the higher beam intensities at the European
Synchrotron Radiation Facility, improved signal–
noise ratios were obtained (Fig. 1a and b). There is
better control of radiation damage on Instrument
ID02 as this is monitored online during data acqui-
sition. The Guinier RG and its cross-sectional radius
of gyration (RXS-1) parameters (but not its RXS-2
parameter: not shown) and the associated intensity I
(0)/c parameters showed small but visible concen-
tration dependences (Fig. 1c–e). The RXS-2 parameter
differs from SCR protein to protein and generally
monitors the averaged short-range degree of bend
between two or among three adjacent SCR domains
along the length of the protein.
23 An additional
medium-range proximity relationship between non-
neighbouring SCR domains that are further apart in
the sequence leads to the observation of the RXS-1
region.23 This weak concentration dependence
showed that FH oligomerisation had occurred.
Data obtained using phosphate-buffered saline
(PBS: 137 mM NaCl, 2.7 mM KCl, 8.1 mM
Na2HPO4 and 1.15 mM KH2PO4, pH 7.4) were
consistentwiththeHepesdata(Fig.1cande).TheRG
value extrapolated to zero concentration is 8.90±
0.19 nm, while RXS-1 is 2.51±0.06 nm and RXS-2 is
1.79±0.01 nm. If the slope in Fig. 1d corresponds to a †http://www.fh-hus.org
892 Self-association of Factor HFig. 1. X-ray scattering analyses of wild-type FH. (a) Guinier RG plots of ln I(Q) versus Q
2 at low Q values for wild-type
FH at concentrations of 8.69, 6.08, 4.34, 2.61 and 0.87 mg/ml. The Q fit range was 0.06–0.13 nm
−1. The filled circles
correspond to the I(Q) data used to determine the RG values, and the straight line corresponds to the best fit through those
points. The Q·RG ranges used in the fits are arrowed. (b) The corresponding Guinier cross-sectional RXS-1 fits of ln I(Q)·Q
versus Q
2 for the same five scattering curves in a Q range of 0.16–0.26 nm
−1 are shown. The RXS-2 fits in a Q range of
0.4–0.8 nm
−1 are not shown. (c–e) Concentration dependence of the RG, I(0)/c and RXS-1 values (open circles). Each value
was measured in quadruplicate and averaged. Statistical error bars are shown where visible. These data were fitted by
linear regression. The open triangles correspond to the RG and I(0)/c parameters from (f). The filled triangles correspond
to data measured in PBS. (f) Distance distribution function P(r) analyses. The four P(r) curves correspond to
concentrations of 0.87 mg/ml (green), 2.61 mg/ml (red), 6.08 mg/ml (blue) and 8.69 mg/ml (cyan). The peaks in the P(r)
curves are denoted as M1 at 4.9 nm and as M2 at 10.3 nm. The maximum length L was determined to be 32, 35 and 38 nm
(numbered 1, 2 and 3, respectively). The intensities of the four P(r) curves are normalised using the peak M1 in order to
show the concentration dependence of peak M2 and L more clearly. The dashed line corresponds to the P(r) curve
obtained in 2001 for FH at 3.56 mg/ml in Tris–HCl buffer,
23 for which L was determined to be 40 nm (numbered 4). X-ray
scattering data were obtained in three beam time sessions on the Beamline ID02 at the European Synchrotron Radiation
Facility (Grenoble, France) operating with a ring energy of 6.0 GeV.
38 Storage ring currents ranged from 63 to 65 mA and
66 to 91 mA (two sessions in 16-bunch mode) and from 170 to 172 mA (one beam session in uniform fill mode). Samples
were measured in flow cells to reduce radiation damage by moving the sample continuously during beam exposure in 10
time frames of 0.1- or 0.2-s duration each for the uniform fill mode and those of 1.0- or 2.0-s duration each for the 16-bunch
mode, together with online checks for the absence of radiation damage, after which the frames were averaged. Other
details, including the data reduction procedure and the Guinier and P(r) analyses, are described elsewhere.26,27
893 Self-association of Factor Hmonomer–dimer equilibrium, then the resulting
dissociation constant KD is estimated to be 100 μM.
This is comparable with the KD values of 40 and
16 μM observed for the SCR-6/8 and SCR-16/20
fragments, respectively.
26,27
The present RG values for FH are lower than
previous ones. This was shown by comparisons of
Fig. 1 here with Fig. 3 of Ref. 23, reporting a 2001
analysis, and Fig. 2 of Ref. 21, reporting a 1991
analysis. In the 2001 analysis, the apparent RG
value was 11.4±0.4 nm, RXS-1 was 4.4±0.2 nm and
RXS-2 was 1.7±0.1 nm. In the 1991 analysis, the
apparent RG value was 12.4±0.4 nm, RXS-1 was 3.6
±0.4 nm and RXS-2 was 1.8±0.3 nm. These earlier
values were confirmed by re-analyses of the earlier
data files retrieved from archives. The difference is
attributed to the presence of minor aggregation in
2001 and to a greater level of aggregation in 1991,
together with worsened signal–noise ratios in 2001
and 1991 (data not shown). These issues may have
masked the presently observed concentration
dependence in FH. Previously, it was thought
that alkaline pH values would cause FH to self-
associate.
23 This was not confirmed after sample
dialysis for 2 days at pH 11.9, followed by X-ray
measurement.
The indirect transformation of the scattering data
I(Q) in reciprocal space in the Q range between 0.08
and 2.1 nm
−1 into real space gives the distance dis-
tribution function P(r). This summarises all the
distances between pairs of atoms within FH. The
P(r) function gives an independent calculation of the
RG and I(0) values that is based on the full scattering
curve and gives the maximum length of FH, denoted
L. The RG and I(0)/c values from P(r) were in good
agreementwiththeGuinierRGvalues(Fig.1candd).
The eight P(r) curves show a concentration-indepen-
dent peak M1 at r=4.8±0.3 nm. A second peak M2
was observed at r=10.2±0.6 nm, and peak M2
increased in itsrelativeintensity asthe concentration
increased. L increased from 32 nm at 0.9 mg/ml to
38 nm at 8.7 mg/ml (Fig. 1f). These changes are
attributed to oligomer formation in FH. As before,
23
the value of L between 32 and 38 nm is about half the
length of 73 nm expected if the 20 SCR domains in
FH are in a fully extended arrangement. When com-
pared with the P(r) curve from 2001 at 3.6 mg/ml in
25 mM Tris–HCl, 140 mM NaCl and 0.5 mM EDTA
buffer,pH7.4,
23 peakM2isnowgreaterthanM1and
L is 40 nm (Fig. 1f). This difference is consistent with
the presence of minor aggregation in FH from 2001.
The superimposition of the I(Q) curves from 1991
and 2001 upon the current ones shows increased
intensities at low Q that are consistent with
aggregation (not shown). Figure 1f shows that the
SCR domains in FH are bent or folded back upon
themselves in solution, both for the monomer and its
oligomeric and aggregated forms.
Sedimentation equilibrium of FH oligomers
Sedimentation equilibrium experiments on an FH
sample in Hepes buffer prepared 16 days before-
hand were monitored using both absorbance and
interference optics. Data were acquired at 4, 20 and
37 °C at 20 concentrations between 0.07 and
7.11 mg/ml and four rotor speeds between 8000
and 20,000 rpm. Absorbance data at 280 nm above
0.7 mg/ml were not fitted because of the saturation
of the optics; thus, interference data were fitted.
Data at 20 °C were fitted using SEDPHAT v4.10b
software,
40 initially using individual fits of 80 equi-
librium curves and subsequently using global fits of
between 9 and 20 curves. Similar fit outcomes were
obtained with the data at 4 and 37 °C. In the indi-
vidual fits, the fitting of a monomer–dimer model to
the 11,000 rpm data at 1.32 mg/ml gave a reduced
χ
2 value of 3.7 compared with that of 34.8 from a
monomer model using the same data. In global fits
up to 1.32 mg/ml and based on a fixed molecular
mass of 145 kDa, the monomer–dimer model
(reduced χ
2 of 11) gave significantly improved fits
compared with a monomer model that gave a high
molecular mass of 187 kDa and an increased
reduced χ
2 of 22. Low random residuals were ob-
tained (upper nine fits in Fig. 2). This showed that a
monomer–dimer equilibrium existed in a physiolo-
gical concentration range.
At higher FH concentrations, the formation of
higher oligomers was detected. Between 2.86 and
7.11 mg/ml, the monomer–dimer model did not
result in good fits. Large deviations in the residuals
were consistent with aggregate formation (lowest
three fits in Fig. 2).
41 Tests with other fit models
based on the inclusion of trimers or tetramers gave
no improvement in the residuals or reduced χ
2
values. The reduced χ
2 values of between 269 and
980 for these fits at higher concentrations showed
that none of the monomer–dimer, monomer–dimer–
trimer and monomer–dimer–tetramer self-associa-
tion models would fit. Hence, these data do not
correspond to an equilibrium between monomers
and higher oligomers.
Non-reducing SDS-PAGE of the samples at three
concentrations after ultracentrifugation showed that
a dimer band was observed at the higher concen-
trations used, and fainter bands corresponding
approximately to trimers and tetramers could be
observed (Fig. 3b). There is no unpaired Cys residue
in FH that would explain this. Size-exclusion gel
filtration of the equilibrium samples 78 days after
their original purification showed that the single
homogenous peak originally obtained between 65
and 75 ml was supplemented by additional peaks
that eluted between 50 and 65 ml (Fig. 2a). This
showed that oligomers had formed during the ultra-
centrifugation experiment and the subsequent sam-
ple storage at 4 °C.
Sedimentation velocity of higher FH oligomers
The sedimentation coefficient s
0
20,w monitors
macromolecular elongation and provides an inde-
pendent monitor of the scattering data through its
ability to detect sample polydispersity. Sedimen-
tation velocity experiments were performed at six
894 Self-association of Factor Hrotor speeds between 25,000 and 60,000 rpm
using three FH preparations at nine concentrations
between 0.07 and 5.9 mg/ml in Hepes buffer and
between 0.05 and 0.35 mg/ml in PBS. Data analyses
utilised size-distribution c(s) analyses in SEDFIT
v9.3b in order to identify species other than
Fig. 2. Sedimentation equilibrium of wild-type FH. Fits for FH in Hepes buffer at 20 °C are shown in a concentration
series from 0.07 to 7.1 mg/ml using rotor speeds of 8000, 11,000, 15,000 and 20,000 rpm with two Beckman XL-I analytical
ultracentrifuges equipped with AnTi50 and AnTi60 rotors. The upper nine panels show the outcome of a global fit using
SEDPHAT when five concentrations between 0.07 and 1.32 mg/ml were fitted to the “monomer–dimer self-association”
model using the “M and s” fitting routine. The monomer molecular mass was fixed at 145 kDa, while the baseline and the
dissociation constant KD were floated. The fit residuals are shown above each panel. The lower three panels show the poor
fits to the monomer–dimer self-association model when higher concentrations of FH (2.86 and 7.11 mg/ml) were fitted.
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42,43 T h ef i t sw e r eb a s e do na
resolution of 200 and a fixed frictional coefficient
ratio f/fo of 1.78, while allowing both the meniscus
and the cell bottom to float within a narrow range of
0.01 cm. At all concentrations, monomeric FH was
observed to sediment at s
0
20,w=5.65±0.05 S. This is
in good agreement with previous determinations of
the s
0
20,w value of 5.5 to 5.6 S and 5.3±0.1 S.
2,23,36
A concentration dependence of the c(s) distribu-
tions was observed. At 0.17 mg/ml, the shape of the
boundaries in Fig. 4b indicated a predominantly
single sedimentation species. Between 0.05 and
0.63 mg/ml in either Hepes buffer or PBS, a second
peak was observed in the c(s) analyses at 9.2±0.5 S
and its relative intensity increased with concen-
tration (Fig. 4c). The c(M) size-distribution plots
showed that the major peak at 5.65 S corresponds to
a molecular mass of 142±2 kDa. This is consistent
with the global fit of the sedimentation equilibrium
data (Fig. 2). At higher FH concentrations between
1.53 and 5.92 mg/ml and with the use of a 1-day-old
FH preparation, the boundary fit of Fig. 4a indicated
a more complex sedimentation profile. As the con-
centration increased, six smaller sedimentation
species were consistently observed at s
0
20,w values
of 7.3±0.2, 9.2±0.2, 11.3±0.4, 13.4±0.06, 15.4±0.2
and 17.2±0.4 S at 50,000 rpm. This suggested that
FH formed not only dimers but also trimeric to hep-
tameric oligomers in small but significant amounts
of about 15% in total.
This interpretation was verified starting from the
four best-fit glycosylated FH models previously
generated by constrained scattering modelling.23
The present RG value of 8.9 nm for monomeric FH
(Fig.1c)meantthatthesepreviousmodelswhichhad
anRGvalue of9.9nmwerenowtooelongated.Thus,
linkers in one of the previous four best-fit FH models
were adjusted in order to generate a more compact
SCRarrangement.Insatisfactoryagreementwiththe
experimental s
0
20,w value of 5.65 S, an s
0
20,w value of
5.2 S was obtained from this glycosylated model
using HYDROPRO v7c,
44 with the default value of
0.31nmfortheatomicelementradiusforallatomsin
order to represent the hydration shell. The s
0
20,w
calculations were insensitive to the presence or
absence of six biantennary oligosaccharide chains
at Asn511, Asn784, Asn804, Asn864, Asn893 and
Asn1011 (mature protein numbering).
23 If an FH
monomer became spherical in its shape, the maxi-
mum possible s
0
20,w value would be 9.4 S. Hence,
postulatingtheoccurrenceofconformationalchanges
in monomeric FH is unable to explain the discrete
peaks seen at the larger s
0
20,w values in Fig. 4c.
Models to account for oligomer formation were
arbitrarily created from dimerisation sites at oppo-
site ends of the FH monomer model. Oligomers
Fig. 3. Size-exclusion gel filtra-
tion and non-reducing SDS-PAGE
analyses of wild-type FH. (a) FH
samples at 3 mg/ml were loaded
onto a Superose™ 6 prep grade XK
16/60 column following purifica-
tion (black) and 78 days after pur-
ification (red). The small peak at
80 ml (black) corresponds to resi-
dual human serum albumin from
the purification. The elution posi-
tions of three molecular mass stan-
dards are shown. (b) Non-reducing
SDS-PAGE analyses of FH after ultra-
centrifugation. Lane A, Himark™
Prestained High Molecular Weight
Standard, labelled to the left; lane
B, 0.16 mg/ml of FH; lane C,
1.42 mg/ml of FH; lane D,
2.74 mg/ml of FH. The higher
molecular-weight bands seen in FH are labelled on the right by 1, 2, 3 and 4 to denote monomer, dimer, trimer and
tetramer, respectively.
Fig. 4. Sedimentation velocity of wild-type FH. Experiments at 20 °C were performed with FH in Hepes buffer in a
concentration series from 0.07 to 5.92 mg/ml at speeds of 25,000, 40,000, 50,000 and 60,000 rpm to confirm reproducibility
on two Beckman XL-I analytical ultracentrifuges equipped with AnTi60 rotors. (a) The 200 scan boundaries for FH at
5.92 mg/ml at 50,000 rpm were fitted using Lamm equation fits with SEDFIT. Only every 10th scan is shown for reason of
clarity. (b) The corresponding boundary fits are shown for FH at 0.17 mg/ml at 40,000 rpm. Other details follow (a). (c) In
the five c(s) size-distribution analyses, the major sedimentation species at 5.65 S is labelled as 1. Its intensity was
normalised in all five analyses for clarity. From bottom to top, the FH concentrations were 0.17, 0.63, 1.53, 2.99 and
5.92 mg/ml. The oligomeric FH peaks in increasing order of S values are labelled from 2 to 7. The five analyses are
displaced by 10% of the intensity of peak 1, and in the top c(s) analysis, peak 2 is 7% of the intensity of peak 1. Underneath,
six schematic models for oligomers of FH that yield the predicted s
0
20,w values given in brackets are shown. The
monomers are denoted by different colours and numbered. Monomers 2 and 3 are viewed in the same orientation in all
the models except for the dimer.
896 Self-association of Factor Hwere created using INSIGHT II 98.0 molecular
graphics software (Accelrys, San Diego, CA) on
Silicon Graphics OCTANE workstations (Fig. 4). The
predicted s
0
20,w value for a dimer model in an
extended conformation was 7.5 S, in good agree-
ment with the observed peak at 7.3 S. The addition
of a third monomer to this dimer model resulted in
a predicted s
0
20,w value of 9.2 S, in good agreement
with the observed peak at 9.2 S. Starting with the
tetramer, it was found necessary to add further
monomers in a more compact arrangement to give
models with predicted s0
20,w values that agreed
within error of the experimental values. The move-
ment of monomer 1 in the tetrameric model towards
the centre of the model gave a predicted value of
11.3 S, in good agreement with the observed peak at
Fig. 4 (legend on previous page)
897 Self-association of Factor H11.3S.Thepentamer,hexamerandheptamermodels
gave predicted values of 13.5, 15.2 and 16.9 S,
respectively, which agreed well with the experi-
mental values of 13.4, 15.4 and 17.2 S, respectively.
These agreements support the assignment of the six
additional peaks at high S values in the c(s) plots to a
series of FH oligomers.
Conclusions
Knowledge of the oligomeric state of FH is crucial
for understanding its immunological function in
complement regulation and its likely roles in AMD
and aHUS. The new data collection in this study
clarified that wild-type FH exhibits oligomeric
forms after all, as originally proposed.
21 A mono-
mer–dimer equilibrium was identified at the lowest
concentrations. Partial FH dimerisation has been
reported by two other laboratories.
8,13,32 As the
concentration increases, higher oligomeric struc-
tures that can be as large as heptamers and are not
in equilibrium with each other were identified. Our
2001 and 1991 studies on wild-type FH had reported
RG values that were stated to be approximate for
reason of the need to access the lowest Q values,
which are difficult to measure with highly elongated
proteins. Under these conditions, the aggregation of
a highly elongated protein can be difficult to iden-
tify. Here, the use of freshly purified FH resulted in
a lower RG value of 8.90 nm, in place of the apparent
RG values of 11.4 and 12.4 nm from before. The
sequence-calculated molecular mass of FH is
150,000 Da, assuming six N-linked oligosaccharides.
In 2001, the molecular mass of FH was determined
as 148,000–182,000 Da, as the result of which FH was
deduced to be monomeric.
23 In 1991, its molecular
mass was determined to be 250,000–320,000 Da,
leading to the deduction that FH was dimeric.
21
The new data suggest that the 1991 result is best
explained in terms of the presence of monomeric FH
together with sufficient FH oligomers to double its
averaged observed molecular mass. Oligomerisa-
tion in the 1991 study was favoured by the higher
FH concentrations that were necessary for the X-ray
data collection at that time.
This study on FH oligomerisation resulted from
the unexpected observation of weak monomer–
dimer equilibria for two fragments of FH. One
equilibrium for the SCR-6/8 fragment of FH has a
KD of about 40 μM. Detailed ultracentrifugation
equilibrium and velocity measurements were
required to establish this as the compact structure
of this SCR-6/8 dimer meant that dimerisation was
not readily detected by X-ray scattering.
26 However,
the presence of the SCR-6/8 dimer was requisite for
good X-ray modelling fits to its structure. The
second weak monomer–dimer equilibrium with a
KD of 16 μM for the SCR-16/20 fragment was readily
detected by both X-ray scattering and ultracentrifu-
gation because this dimer has an extended struc-
ture.
27 Both these KD values are comparable with the
value of 28 μM for wild-type FH from the SEDPHAT
global fits below 1.36 mg/ml (Fig. 2). This suggests
that the dimerisation of both SCR-6/8 and SCR-16/
20 is physiologically relevant, although both were
recombinant proteins. As FH concentrations range
between 0.235 and 0.810 mg/ml in blood,
19 so long
as no other factor requires consideration, this KD
value of 28 μM indicates that about 5–15% of FH in
blood will be dimeric. The complement regulatory
function of FH will be affected by dimer formation
in serum. Thus, ligands may be sterically blocked
from approaching their binding sites if they are
proximate to either of the two presumed FH dimer
sites or may not bind because of aggregate forma-
tion. Alternatively, ligand binding may be enhanced
if binding sites are distant from the FH dimer sites,
because FH would become multivalent in that case.
Future studies on FH-ligand binding will be com-
plicated by the observation of dimerisation. Thus,
FH-ligand binding studies that disregard dimerisa-
tion are open to misinterpretation, as exemplified by
a recent SEDPHATsedimentation equilibrium study
on SCR-6/8.
12 Alternative approaches are required
to establish 1:1 complex formation with ligands in
the presence of dimers, such as that described in
Fig. 3 of the original ultracentrifugation study on
the SCR-6/8 complex with heparin, where titrations
witharangeofheparin–proteinratioswereanalysed
using SEDFITc(s) size-distribution plots.
26
A mechanistic pathway for oligomer formation is
suggested from this work. At higher concentrations,
the existence of two weak self-association sites in FH
suggests that FH can self-associate continuously by
intermolecular contacts that occur alternately
through both these sites to form large oligomers.
These higher oligomers were indeed directly ob-
served above 2 mg/ml in fresh FH samples by
velocity experiments (Fig. 4). At low FH concentra-
tions, the model in Fig. 4 suggests that extended
dimer structures were formed, which would explain
its reversibility. At higher concentrations, the for-
mation of higher oligomers is predicted to involve
more compact associations of the monomer (Fig. 4),
and this would explain its lack of reversibility (Fig.
2). The storage of FH samples may facilitate the
formation of more stable higher oligomers. Further
studies on this are in progress. These results suggest
that the use of freshly gel-filtrated FH samples
stored below 1-mg/ml concentrations may be
required for complement regulatory functional
studies. The aggregation of FH is relevant for
AMD, for which a risk factor is the observation of
drusen deposits at the retinal surface. Currently,
there is no detailed knowledge of the mechanism of
drusen formation in AMD. It is possible that the
localised accumulation of higher FH concentrations
within the eye may facilitate the slow formation of
protein precipitates within drusen during the course
of a lifetime. For such a mechanism to operate, any
FH precipitation in drusen would appear to neces-
sitate concentrations of FH much higher than those
seen physiologically in serum, and this would occur
in the presence of a number of other components
that are present. The latter would alter the kinetics
and thermodynamics of deposit formation when
898 Self-association of Factor Hcompared with a mechanism based only on FH self-
association. In this context, it is intriguing that the
His402 genetic polymorphism that is a risk factor for
AMD showed a slightly higher propensity to self-
associate than the lower-risk Tyr402 form when the
SCR-6/8 fragment was studied by X-ray scattering
and ultracentrifugation.
26
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Polymorphisms in factor H (FH), a major regulator of complement
activation, and the accumulation of high zinc concentrations in the outer
retina are both associated with age-related macular degeneration. FH is
inhibited by zinc, which causes FH to aggregate. To investigate this, we
quantitatively studied zinc-induced FH self-association by X-ray scattering
and analytical ultracentrifugation to demonstrate uncontrolled FH oligo-
merisation in conditions corresponding to physiological levels of FH and
pathological levels of zinc in the outer retina. By scattering, FH at 2.8–7.0 μM
was unaffected until [Zn] increased to 20 μM, whereupon the radius of
gyration, RG, values increased from 9 to 15 nm at [Zn]=200 μM. The
maximum dimension of FH increased from 32 to 50 nm, indicating that
compact oligomers had formed. By ultracentrifugation, size-distribution
analyses showed that monomeric FH at 5.57 S was the major species at [Zn]
up to 60 μM. At [Zn] above 60 μM, a series of large oligomers were formed,
ranging up to 100 S in size. Oligomerisation was reversed by ethylenedia-
minetetraacetic acid. Structurally distinct large oligomers were observed for
Cu, while Ni, Cd and Fe showed low amounts of oligomers and Mg and Ca
showed no change. Fluid-phase assays showed reduced FH activities that
correlated with increased oligomer formation. The results were attributed to
different degrees of stabilisation of weak self-dimerisation sites in FH by
transition metals. The relevance of metal-induced FH oligomer formation to
complement regulation and age-related macular degeneration is discussed.
© 2008 Elsevier Ltd. All rights reserved.
Edited by R. Huber
Keywords: complement factor H; X-ray scattering; analytical ultracentrifu-
gation; age-related macular degeneration; inflammation
Introduction
In the innate immune response, C3 is activated to
C3b by the cleavage of the small anaphylatoxin C3a,
thereby initiating the alternative complement path-
way. C3b is regulated by factor H (FH) among other
proteins to prevent complement-mediated host cell
damage: FH acts as a cofactor for the factor I-
mediated cleavage of C3b to form iC3b, C3c and
C3dg.
1–3 FH also accelerates the decay of the C3
convertase C3bBb
2,4 and competes with factor B for
binding to C3b.
5 FH is composed of a linear
arrangement of 20 short complement regulator
(SCR) domains, each of about 61 residues in length.
6
FH possesses multiple binding sites for C3b and
heparin, the latter being an analogue of heparan
sulfatethatisfoundonhostcellsurfaces,andFHalso
binds to such other proteins as C-reactive protein.
7–9
FH protects host cells by binding to heparin-like
negativelychargedclustersontheirsurfacesthrough
its C-terminal end, which is then followed by N-
terminal regulatory activity against C3b.10,11 FH
involvement in uncontrolled inflammation is asso-
ciated with disease, namely, atypical haemolytic
uraemic syndrome and membranoproliferative glo-
merulonephritis type II
12 and age-related macular
degeneration(AMD).
13–16 AMDisthemostcommon
cause of blindness in the elderly in the Western
world.In2005,severalgroupsidentifiedaTyr402His
FH polymorphism that increased the risk of
*Corresponding author. E-mail address:
s.perkins@medsch.ucl.ac.uk.
Abbreviations used: AMD, age-related macular
degeneration; FH, factor H; RPE, retinal pigment
epithelium; SCR, short complement regulator; sRPEd,
subretinal pigment epithelial deposit.
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13–16 Since then,
other FH variants have been shown to modify the
riskforAMD.
17–19 Even withtheanalysisof over 100
genetic alterations in FH,
12 no clear molecular
mechanism for diseases based on the involvement
of defective forms of FH has been proposed so far.
An early hallmark of AMD is the appearance of
subretinal pigment epithelial deposits (sRPEds) that
can be focal (drusen) or diffuse (basal linear and
laminar). These deposits contain oxidised lipids and
over 120 aggregated proteins, including FH and
other complement components that are secreted by
retinal pigment epithelium (RPE) cells or delivered
by choroidal blood circulation.20,21 These deposits
develop within Bruch's membrane, an extracellular
matrix layer interposed between the RPE and the
choroidal vasculature.
22,23 Recently, millimolar con-
centrations of zinc have been found in sRPEds and
Bruch's membrane, suggesting that the pathological
release of zinc from surrounding tissues such as the
zinc-rich RPE choroid complex might be involved in
sRPEd formation.
24,25 In the context of AMD, the
presence of FH and zinc in sRPEd is of interest,
because, first, zinc inhibits the factor I-mediated
cleavage of C3b leading to uncontrolled inflamma-
tion
26 and, second, an initial X-ray scattering study
showed that FH aggregates in the presence of high
zinc concentrations.27
The molecular basis of the self-associative inter-
action between FH and zinc is unknown. The overall
structure of native FH is not straightforward to
characterise by methods such as crystallisation and
NMR for reason of its large size, glycosylation and
inter-SCR flexibility between its 20 domains,
although several crystal and NMR structures have
been published for small domain fragments of FH.
Solution structural methods such as X-ray and
neutron scattering and analytical ultracentrifugation
have been applied to demonstrate that native FH
possesses a partially folded-back SCR structure in
solution.28,29 Recently, we showed that native FH is
predominantly monomeric and partly dimeric at
physiological concentrations in serum and forms
higher oligomers as its concentration increases if no
other factor requires consideration.
30 The original
X-ray scattering study on FH–zinc complexes was
limited by a requirement for relatively high FH
concentrations at that time, that only Guinier
analyses at low scattering angles were consequently
measured and that the resulting averaged FH
structure was mostly dimeric.
27 Since that time, the
availability of monomeric FH at low concentra-
tions
30 and improvements in X-ray scattering instru-
mentation at the European Synchrotron Radiation
Facility
30 have permitted a more detailed investiga-
tion of the role of zinc and FH in a physiological
concentration range. By performing quantitative
titration studies on FH with a range of different
metals by X-ray scattering, supplemented by analy-
tical ultracentrifugation, we show here that mono-
meric FH aggregates in the presence of zinc.
Unexpectedly, not only zinc but also other transition
metals such as copper induce different degrees of
uncontrolled FH oligomer formation. We correlate
these results with FH activity assays in the presence
of zinc and copper. We discuss whether the high zinc
concentrations associated with Bruch's membrane
may drive the aggregation of FH in the environment
of the retina; we also discuss the molecular implica-
tions of our results for complement regulation and
sRPEd formation.
Results and Discussion
Guinier X-ray scattering analyses of FH–metal
complexes
Freshly purified FH for scattering and ultracen-
trifugation studies resulted in a homogeneous peak
by gel filtration, which was verified by SDS-
PAGE.
30 FH concentrations were generally main-
tained at 1 mg/ml or lower with storage at 4 °C to
avoid irreversible oligomer formation30 and studied
at this or a lower concentration to be comparable
with physiological FH concentrations between 0.235
and 0.810 mg/ml in serum.
12 The effect of metals on
FH was studied by synchrotron X-ray scattering
and analytical ultracentrifugation in Hepes buffer
(Materials and Methods). Phosphate buffer was not
used in order to avoid precipitation issues.
Solution scattering enabled the overall structure
and size of FH to be studied.
28 FH at 0.42 mg/ml
(2.8 μM) and that at 1.05 mg/ml (7.0 μM) were
titrated with 0–200 μM ZnSO4. Excellent signal–
noise ratios were obtained with no detectable effect
from radiation damage. Linear Guinier analyses at
low Q values (where Q=4π sin θ/λ;2 θ=scattering
angle; λ=wavelength) gave the radius of gyration,
RG, in satisfactory Q·RG ranges below 1.1 (Fig. 1).
For native FH without zinc, the mean RG value was
8.45±0.14 nm at 1.05 mg/ml and 8.28±1.18 nm at
0.42 mg/ml (Fig. 2a). Both values were consistent
with the recently reported RG value of 8.90±0.19 nm
for monomeric FH.30 The present RG values starting
from a monodisperse preparation of FH were con-
sistently lower than the old RG values for FH that
had partially self-aggregated.27 Here, the RG values
increased significantly when [Zn]≥20 μM( Figs. 1a
and 2a). The Guinier I(0)/c value that is proportional
to molecular weight also showed a large increase at
[Zn]≥20 μM( Fig. 2b). Hence, these changes are
attributable to the strong FH oligomer formation
previously seen for dimeric FH.27 Comparison of
200 μM ZnSO4 and 200 μM ZnCl2 with 0.93 mg/ml
of FH showed no difference in the Guinier para-
meters of Fig. 2, hence ruling out any anion effect.
The present experiments extend our previous X-ray
work by demonstrating that zinc causes monomeric
FH to aggregate.
The cross-sectional Guinier analyses monitor the
structural proximity relationships between non-
neighbouring SCR domains (RXS-1) and neighbour-
ing SCR domains (RXS-2).
31 Linear fits for both
parameters were obtained within satisfactory Q·RXS
1342 Metal-Induced Self-Association of Factor Hranges (Fig. 1b and c). Without zinc, the RXS-1 value
was determined to be 2.68±0.08 nm at 1.04 mg/ml
and 2.40±0.16 nm at 0.42 mg/ml, in good agree-
ment with the previously determined RXS-1 value of
2.51±0.06 nm for the FH monomer.
30 The RXS-1
values significantly increased when [Zn]≥20 μM
(Fig. 2c). This change showed that the FH oligomers
associated in a side-by-side, not end-to-end, manner.
Without zinc, the RXS-2 value was determined to be
1.78±0.03 nm, in good agreement with the pre-
viously reported value of 1.79±0.01 nm.27,30,31 When
zincwasadded,theRXS-2valuedidnotalter(Fig.2d),
Fig. 2. Dependence of the Guinier parameters on the zinc or copper concentration. Each value was measured in
quadruplicate and averaged. The three titrations correspond to 1.05 mg/ml of FH titrated with zinc (○, continuous line),
0.42 mg/ml of FH titrated with zinc (●, dashed line) and 0.93 mg/ml of FH titrated with copper (▵, red continuous line).
(a and c) The data were fitted to a three-parameter function y=y0+aln(x−x0). (b) The lines correspond to a two-parameter
function y=ln(a+bx). (d) The straight line indicates the averaged RXS-2 values for FH at 0.42 mg/ml, with statistical error
bars shown where visible.
Fig. 1. Guinier analyses for native FH titrated with zinc. The filled symbols correspond to the Q range used to
determine the RG and RXS values. The symbols ○, ▵, □, ▿, and ◊ represent [Zn]=2, 6, 20, 60 and 200 μM, respectively. The
Q·RG and Q·RXS fit ranges are arrowed. (a) RG plots of ln I(Q) versus Q
2 for 1.05 mg/ml of FH using a Q range of 0.06–
0.13 nm
−1. (b and c) The corresponding cross-sectional RXS-1 and RXS-2 plots of ln I(Q).Q versus Q
2 for the same five
scattering curves in Q ranges of 0.16–0.26 and 0.4–0.8 nm
−1 are shown. In (c), the five curves are successively displaced in
steps of 0.5 ln units for clarity.
1343 Metal-Induced Self-Association of Factor Hindicating that the linear arrangement of neighbour-
ing SCR domains was unchanged.
Control experiments with other metals were per-
formed with 200 μM CaCl2, MgCl2, NiCl2, CdCl2
and FeSO4 with FH at 0.93 mg/ml. No change was
detected for CaCl2 and MgCl2. Small increases in the
RG, RXS-1 and I(0)/c values compared with zinc were
observed for NiCl2, CdCl2 and FeSO4. The result for
nickel was unexpected, as 100 μMN i
2+ had pre-
viously shown no effect,
27 and the difference is
attributed to the improved signal–noise ratio avail-
able at the European Synchrotron Radiation Facility.
Even more unexpected was the large effect caused
by CuSO4, which revealed strong FH oligomerisa-
tion similar in magnitude to that for ZnSO4 (Fig. 2).
Copper had not been tested previously.26,27 The
reversibility of oligomer formation with zinc and
copper was demonstrated by the addition of 1.5 mM
ethylenediaminetetraacetic acid (EDTA) (final con-
centration) to FH at 0.93 mg/ml with 200 μMZ n S O 4
or CuSO4, Their RG, RXS-1 and I(0)/c values dec-
reased to their metal-free values.
X-ray distance distribution function of FH–metal
complexes
The distance distribution function P(r) is calcu-
lated from the full scattering curve and reports the
distances between all pairs of atoms within FH. The
calculation of the RG and I(0) values from the P(r)
curve agreed well with the Guinier RG and I(0)
values above, showing that the scattering curve is
self-consistent across the observed Q range. The
intensity of the P(r) curve increased significantly
with an increase in [Zn] (Fig. 3a). The maximum
dimension L is determined when P(r)=0 at a large r.
When [Zn] was between 0 and 2 μM, the L value of
FH was 32 nm, in good agreement with previous
data for metal-free FH.
30 When [Zn] increased from
2 to 200 μM, L increased to 50 nm (Fig. 3a and b). The
r value of the maximum M in the P(r) curve gives the
most commonly occurring distance within the
macromolecule. Peak M1a tr=5.2±0.6 nm was
observed for [Zn] up to 6 μM, which agrees with the
previous M1 determination of 4.8±0.3 nm for metal-
free FH.
27 Peak M2 was previously observed for
metal-free FH at 10.2±0.6 nm, but here its position
shifted from a starting value of 10.8 nm at [Zn]=
6 μM up to 17.0 nm at [Zn]=200 μM( Fig. 3b). The
changes in the P(r) curves with an increase in [Zn]
showed that zinc formed relatively compact FH
oligomers with maximum dimensions not much
larger than those for monomeric metal-free FH.
Similar P(r) changes were seen for 200 μM ZnCl2and
in the CuSO4 titration, although the change seen
with 200 μM copper differed from that seen with
zinc when M2 and L both increased by about 10 nm
(Fig. 3c). The P(r) curves reverted to the metal-free
P(r) curve when EDTA was added (not shown).
Other metals showed divergent effects. The addi-
tion of CaCl2 and MgCl2 had no effect (Fig. 3c). The
P(r) intensities increased in the presence of 200 μM
NiCl2, CdCl2, FeSO4, CuSO4 and ZnSO4, in that
order. The L values, however, increased in the
presence of 200 μM FeSO4, CdCl2, NiCl2, ZnSO4
and CuSO4, in that order, which is different and
Fig. 3. Dependence of the distance distribution function P(r) on metal. (a) The unnormalised P(r) curves were
calculated from the five scattering curves in Fig. 1. From bottom to top, the [Zn] values are 2, 6, 20, 60 and 200 μM,
represented by alternate continuous and dashed lines in gray and black. The two maxima occur at M1 and M2. The
maximum length L values were determined to be 32, 35, 38, 42 and 50 nm (numbered 1, 2, 3, 4 and 5, respectively) with an
increase in [Zn]. (b) The five P(r) curves in (a) are normalised to 100 to show that M1 is unchanged at 5.2±0.6 nm while M2
increases from 10.8 to 17.0 nm with an increase in [Zn]. The alternate continuous and dashed lines correspond to those in
(a). (c) The eight P(r) curves for 0.93 mg/ml of FH in the presence of seven metals at 200 μM are shown. The M2 and L
values are arrowed for each curve. The L values were 32 nm (no metal, Mg, Ca), 37 nm (Fe, blue), 39 nm (Cd, green), 47 nm
(Ni, cyan), 50 nm (Zn, black) and 62 nm (Cu, red).
1344 Metal-Induced Self-Association of Factor Hshows that different metals caused different struc-
tural effects on FH.
Sedimentation velocity analyses of FH–metal
complexes
Analytical ultracentrifugation follows the sedi-
mentation behaviour of FH on subjecting this to a
high centrifugal force.
29 The sedimentation coeffi-
cient s
o
20,w monitors macromolecular elongation
and is analogous to the RG value. Velocity experi-
ments were performed at four rotor speeds up to
60,000 rpm for FH at 0.35 and 0.87 mg/ml, each
titrated with zinc at eight concentrations between 0
and 200 μM. In comparison with the run at 6 μM
zinc, rapidly sedimenting species were observed at
60 μM zinc, and even more so at 200 μM zinc (Fig.
4a–c). The observed sedimentation boundaries were
fitted using size-distribution analyses c(s) in which
the frictional ratio f/fo was held fixed (Materials and
Methods), and good fits were obtained in all cases
(Fig. 4a–c). These revealed the presence of distinct
FH oligomers through the appearance of resolved,
stable multiple peaks (Fig. 4d and e). At all zinc
concentrations, an FH monomer peak was observed
at s
o
20,w=5.57±0.12 S (Fig. 4e). A c(M) mass dis-
tribution plot showed that this corresponded to a
molecular mass of 138±7 kDa. This value agreed
well with the sequence-determined molecular mass
of 155 kDa, previous s
o
20,w determinations of 5.65±
0.12 S and 5.3±0.1 S and mass determinations of
142±2 and 145 kDa for FH monomers.
30,31 At all
zinc concentrations, the c(s) distributions showed
additional peaks that correspond to larger FH
oligomers as [Zn] increased. For [Zn] between 0
and 20 μM, dimers were visible at an s
o
20,w value of
7.7±0.3 S. In addition, smaller amounts of trimers to
nonamers of FH were consistently observed at s
o
20,w
values of 10.0±0.6, 11.8±0.7, 14.2±0.7, 16.1±0.8,
18.5±0.9, 22.6±1.5 and 27.0±0.5 S (Fig. 4e).
27 At
0 μM zinc, 12% oligomers were seen in agreement
with previous data.
30 At [Zn]=60 μM, sizeable
amounts of larger FH oligomers with s
o
20,w values
up to 50 S were observed in the c(s) distribution (Fig.
4d and e). At [Zn]=200 μM, the size of the FH
oligomers reached 100 S, together with an increase
in their intensities (Fig. 4d). Integration of the c(s)
size-distribution analyses showed that, at 0.35
and 0.87 mg/ml of FH, 50% oligomer formation
occurred at approximately 35 and 50 μM [Zn],
respectively (Fig. 5). The slight difference is attrib-
uted to the larger zinc/FH ratio at the lower FH
concentration, meaning that more FH oligomers
were formed at 0.35 mg/ml of FH for a given zinc
concentration.
Control experiments were performed. The rever-
sibility of the zinc-induced FH oligomers was tested
by sedimentation velocity on 0.87 mg/ml of FH with
120 μM zinc, to which a final concentration of
1.5 mM EDTA was added. The large zinc-induced
FH oligomers in the c(s) plot reverted back to the
level of oligomers seen for 0.87 mg/ml of native FH
(Fig. 6). The percentage of FH oligomers decreased
from 62% to 16%. The comparison of 200 μM ZnSO4
and ZnCl2 on 0.93 mg/ml of FH showed no diffe-
renceinthec(s)distributions;hence,oligomerforma-
tion is not dependent on the anion. As for X-rays,
the effect of 2 to 200 μM CuSO4 on 0.81 mg/ml of
FH caused significant oligomer formation to take
place, for which 50% oligomer formation occurred
Fig. 4. Size-distribution c(s) ana-
lyses of native FH titrated with zinc.
The [Zn] values in micromolar are
denoted by red numbers. The
experimental runs were performed
at 50,000 rpm with 0.87 mg/ml of
FH (black), and the boundary fits
are shown in red. (a) Every 6th scan
boundary for 200 μMz i n cw a s
fitted. (b) Every 15th scan boundary
for 60 μM zinc was fitted. (c) Every
6th scan boundary for 6 μM zinc
was fitted. (d) The c(s) size-distribu-
tion analyses for 20, 60 and 200 μM
zinc are shown. Here and in (e), the
intensity of the monomer peak at
5.57 S was set to 100 for clarity. (e)
The c(s) size-distribution analyses
for 0, 0.2, 2, 6, 20 and 60 μM zinc are
shown. The FH oligomers are num-
bered from 2 to 9 in increasing
order of S values.
27 The six analyses
are displaced vertically in steps of
0.7 U for clarity.
1345 Metal-Induced Self-Association of Factor Hat approximately 150 μM [Cu] (Fig. 5). FH at
0.93 mg/ml was also studied with 200 μM CaCl2,
MgCl2, NiCl2, CdCl2, FeSO4,C u S O 4 and ZnSO4.
The c(s) plots for NiCl2, CdCl2 and FeSO4 showed
an increase in oligomer formation from 12% to 20%
when compared with those of FH alone and with
CaCl2 or MgCl2 (Fig. 6b and c). Oligomer formation
increased further with CuSO4 and ZnSO4 (Fig. 6c).
Fluid-phase activity assays of FH–metal
complexes
Assays of fluid-phase ammonium-inactivated C3
cleavage by factor I were performed in the presence
and in the absence of metals in order to test whether
the formation of FH oligomers is correlated with the
regulatory cofactor role of FH.
26 Previous comple-
ment functional assays routinely employed FH con-
centrations that were significantly lower than the
0.235–0.81 mg/ml (1.6–5.4 μM) observed in vivo (e.g.,
45 μg/ml,
26 3 μg/ml, 32 30 μg/ml
33 and 75 μg/ml34).
Accordingly,ourassayswereperformedat0.3mg/ml
of FH (2 μM )f o rd i r e c tc o m p a r i s o nw i t ht h e
analytical ultracentrifugation data and to be more
comparable with serum levels. Figure 7a showed
that the α-chain of haemolytically inactive C3 was
cleaved by factor I in the presence of FH to produce
two major degradation fragments at apparent sizes
of 45 and 75 kDa. The influence of zinc or copper on
this reaction was investigated at the concentrations
of 0, 2, 20, 60, 120 and 200 μM. The cleavage rate was
decreased by both metals, and this became notice-
able with zinc at 120 and 200 μM( Fig. 7b) and to a
lesser extent with copper at 200 μM( Fig. 7c). This
matched the growth of oligomers illustrated in Fig.
5, indicating that the oligomerisation of FH is able to
a c c o u n tf o rt h ed e c r e a s eo fa c t i v i t yo fF Hb y
blocking FH access to C3u and/or factor I. Factor I
Fig. 6. The comparative effects of different metals on
FH oligomerisation. The sedimentation velocity data were
obtained at 50,000 rpm. The intensity of the monomer
peak at 5.57 S was set to 100 for clarity. The oligomer peaks
are labelled from 2 to 9 to follow Fig. 4. (a) The c(s)
distribution analyses for 0.87 mg/ml of FH with 120 μM
zinc and after the addition of EDTA to a final concentra-
tion of 0.22 mg/ml of FH, 30 μM zinc and 1.5 mM EDTA.
(b) The c(s) distribution analyses for 0.93 mg/ml of FH for
five metals at 200 μM (labelled). (c) Proportions of FH
monomer and oligomers in the presence of different
metals at a concentration of 200 μM. The hatched columns
correspond to FH monomer, and the solid columns
correspond to FH oligomers.
Fig. 5. Comparison of the proportions of FH monomer
and oligomers in titrations with zinc and copper. The
percentages were derived by integration of the c(s)
analyses and correspond to the mean value obtained at
50,000 and 60,000 rpm. Monomers are denoted by filled
symbols; oligomers, by open symbols (0.87 mg/ml of FH
with zinc: black ●, ○; 0.35 mg/ml of FH with zinc: black ▪
, □; 0.81 mg/ml of FH with copper: red ▴, ▵).
1346 Metal-Induced Self-Association of Factor Hactivity is unaffected by zinc,
34 while C3b binds to
zinc with little change in activity.
32,33
Conclusions
Metals have not been generally considered as FH
ligands. In distinction to our original study,
27 we
have shown here that five transition metals cause
monomeric FH to form large oligomers at the FH
concentration seen in serum. Zinc and copper have
the most significant effects, followed by other
transition metals, while calcium and magnesium
have no effect. We also show that zinc- and copper-
induced FH oligomerisation is matched by loss of
activity. Therefore, zinc and copper should be con-
sidered as newly identified inhibitory FH ligands at
pathological metal concentrations above 60 μM.
Zinc and copper promote uncontrolled FH oligomer
formation; in addition, the preformed oligomers can
be disassembled by chelation using EDTA.
FH is a major complement regulator in blood and
is expressed and secreted by many cell types,
including the RPE.
35 Many functional studies on
FH binding to its major ligand C3b, and to others
such as heparin and C-reactive protein, have been
performed. In distinction, surprisingly little atten-
tion has been given to FH self-association and its
effect on its regulatory function. The originally re-
ported inhibition of C3b cleavage in 1000 μM zinc
26
could be explained in terms of the non-specific
aggregation of FH first reported by X-ray scattering,
because the protein aggregates would block acces-
sibility to the functionally active regions in FH.
27
While FH is often considered to be monomeric,
several groups have reported its ability to dime-
rise.9,10,36 To date, two dimerisation sites have been
located within the FH SCR-6/8 and SCR-16/20
fragments, with Kd values of about 40 and 16 μM,
respectively.
37,38 Ultracentrifugation showed that
native FH exists in a reversible monomer–dimer
equilibrium with a dissociation constant Kd of 28 μM
up to 1.36 mg/ml, indicating that about 5%–15% of
FH in serum is reversibly dimeric and that non-
reversible higher oligomers form at higher concen-
trations, presumably through an alternating chain of
dimerisation events at the two dimer sites.
30 The
effect of dimerisation on regulatory function is not
known. Here, with the use of physiological concen-
trations of native FH from pooled serum, our
scattering data showed the formation of large but
compact oligomers of FH in the presence of zinc and
copper, while our ultracentrifugation data showed
that FH is 85% oligomeric in 200 μM zinc and 50%
oligomeric in 200 μM copper. FH activity was pro-
portionately reduced by oligomer formation (Fig. 7).
In a physiological scenario, because this metal
binding is weak, the zinc- or copper-induced uncon-
trolled oligomerisation of FH can only occur in
tissues where a sufficient amount of zinc or copper is
Fig. 7. Cleavage of fluid-phase
inactive C3 (C3u) in the presence of
zinc or copper. (a) Reducing SDS-
PAGE analysis of C3u cleavage in
20 μM zinc (lanes 4–15 correspond
to the reaction times in minutes as
labelled). Lane 1, 0.3 mg/ml of C3u;
lane 2, 0.3 mg/ml of C3u and
0.3 mg/ml of FH; lane 3, 0.3 mg/
ml of C3u, 0.3 mg/ml of FH and
zinc. FH, C3 α-chain and C3 β-
chain are arrowed on the left, and
the C3 α-chain cleavage products
are arrowed on the right. (b) The
percentage cleavage of C3 α-chain
is shown as a function of [Zn], with
their values shown as labels (0 μM,
●;2μM, ○;2 0μM, ▴;6 0μM, ▵;
120 μM,▪
; 200 μM, □). (c) As with
(b) except that copper was used
instead of zinc.
1347 Metal-Induced Self-Association of Factor Hpresent. For example, the total zinc concentration of
12.5 μM in serum is clearly too low to induce FH
oligomerisation according to our data (Figs. 2and 5).
This level remains low at 14.7 μM even after a daily
diet supplement with 80 mg of zinc in the AREDS
trials.39,40 Few tissues have total zinc concentrations
high enough to release biologically reactive zinc in
therangeof20–200μM.
41 Theretinaappearstobean
exception, as this has the highest concentration of
zincpergramoftissue.
42 Retinal zincisconcentrated
mostly in the RPE–choroidal complex, where
sRPEds are formed, bound to melanin, metallo-
thionein and other zinc binding proteins.
24,43 Cell-
ular damage to the RPE, which may occur through
stress factors such as excessive light, smoking or
oxidative processes during ageing, is one of the first
pathologicaleventsleadingtoAMD.DamagetoRPE
cells may trigger the release of pathological levels of
zinc from protein complexes into extracellular
regions, and the local bioavailable zinc level may
reach N60 μM, which will be sufficient to initiate FH
oligomerisation (Fig. 2) and its precipitation into
sRPEds.
41 Theconceptthatzincmightbeinvolvedin
the initiation of AMD appears to contradict the
clinicalobservation that zincsupplementsareableto
slow the development of blindness in patients.
39,40
However, AMD is a progressive disease, and de-
cades elapse between the appearance of sRPEds and
the degeneration that eventually leads to blindness.
Therefore, it is possible that too much bioavailable
zinc in the early stages of the disease can trigger the
problem by facilitating the formation of sRPEds,
while decades later zinc supplementation can be
beneficial if much of the zinc in the tissues is trapped
in sRPEds and the surrounding tissues are relatively
depleted.
44
At present, there is no simple mechanistic under-
standing of the formation of sRPEds and the slow
progression to AMD over several decades of a life
span. In the absence of metal, FH self-association
involving probably SCR-7 and SCR-20 may lead to
the formation of higher oligomers of FH through a
set of alternating dimeric interactions between FH
molecules.30,37,38 It is intriguing that the SCR-6/8
fragment with the His402 allotype that is a risk
factor for AMD shows a slightly higher propensity
to self-associate than the wild-type Tyr402 allo-
type,
37 and this by itself could enhance the deposi-
tion of FH into sRPEds over several decades. How-
ever, if the alternative pathway is involved in AMD,
as suggested from the involvement of FH polymor-
phisms13–16 (and not the classic pathway that is
regulated by membrane-bound regulators, including
membrane cofactor protein and decay-acceleration
factor), and if FH–metal complexes contribute to the
onset of AMD, a pathway for zinc-induced oligomer
formation is suggested by our results. Zinc is tetra-
hedrally coordinated in proteins.
45 Given that zinc
ligands at protein interfaces often include pairs of
surface Asp and His residues and that Tyr402 is
exposed at the surface of SCR-7,
37 it is also
intriguing that the AMD-risk Tyr402His poly-
morphism involves the introduction of a His resi-
due.13–16 This raises the possibility that an Asp–His
pair on the surface of an SCR domain forms half a
zinc binding site, and zinc may pair these two SCR
domains together in a symmetric arrangement.
Other scenarios based on other metal coordinations
are possible. Possible zinc binding sites in FH are
currently being investigated to clarify this. Irrespec-
tive of whether zinc interacts with specific residues
on the surface of SCR domains or promotes the
previously observed self-association dimer sites in
SCR-6/8 and SCR-16/20, it is clear that, in the
presence of zinc, FH will form indefinite oligomers
more readily than in its absence. Different metals
will cause different oligomerisation properties
depending on their relative affinity for different
self-association sites. For example, the more com-
pact zinc-promoted oligomers seen in Fig. 3c may be
formed through a stronger pairing of two central
SCR domains of FH, while the more extended
copper-induced oligomers may result from a stron-
ger pairing of SCR domains at one end of FH (Fig. 8).
As zinc is more abundant in sRPEds than any other
metal,
46 a compact association mechanism might be
more relevant. While such an aggregation me-
chanism may be directly relevant to AMD, it is not
known whether this proposed aggregation mechan-
ism may act as a trigger for sRPEd formation or
facilitates the growth of sRPEd into larger and
clinically relevant sizes over several decades of a life
span. An aggregation mechanism will be distinct
from that in which excessive complement activation
and uncontrolled inflammation caused by reduced
FH regulation will generate the slow buildup of
protein and lipids after complement attack of host
cells.
13–16,47
The molecular effect of dimerisation on FH func-
tion is not known presently, but Fig. 7 indicates that
complement regulation by FH will be diminished by
oligomer formation. The C3b or factor I ligands may
be sterically blocked from interaction with FH
aggregates by zinc. Alternatively, or simultaneously,
zinc may enhance the deposition of FH binding
proteins, together with FH, into sRPEds contribut-
ing to the accelerated protein built up in Bruch's
membrane. This process might be slow, given that it
couldbetriggeredbythegradualdeclineofRPEcells
that may happen without relevant visual impair-
mentoftheperipheralretina.
48 However,theprocess
might be accelerated by the several environmental,
cellular and genetic factors associated with AMD,
especially when the damage affects the macula.
49 If
FH–metal complexes contribute to the onset of
AMD, a pathway for zinc-induced oligomer forma-
tion is suggested by analogy with our recent
work.
37,38 By this, two weak dimer sites will initiate
FHdimerformationateithersite.As shown inFig.8,
these are arbitrarilypostulated tobe inthe vicinity of
SCR-7 and SCR-20. In the absence of metal, these
sites will lead to higher oligomers of FH at a high
concentration through a set of alternating dimeric
interactions between FH molecules.
30 If the process
of self-association at two dimer sites is enhanced by
the presence of zinc (not necessarily at SCR-7 and
1348 Metal-Induced Self-Association of Factor HSCR-20), FH will form indefinite oligomers more
readily (Fig. 8). The varied effect of different tran-
sition metals on the FH oligomer structure is ex-
plained schematically in Fig. 8, depending on which
of the two dimer sites is more strongly promoted
by metal. For example, the more compact zinc-
promoted oligomers of Fig. 3c may be formed
through a stronger dimerisation effect at a central
SCR domain of FH (Fig. 8b), while the more
extended copper-induced oligomers may result
from a stronger effect at a C-terminal region of FH
(Fig. 8c). Note that zinc is more abundant in the
retina than copper.
50 While such an aggregation
mechanism for FH may be directly relevant to AMD,
it is possible that the high bioavailability of zinc in
the retina may exert apathogenic effect bythis route.
Given that zinc ligands at protein interfaces often
include surface Asp and His residues and that
Tyr402 is exposed at the surface of SCR-7,
37 it is
also intriguing that the AMD-risk polymorphism in
FH replaces Tyr402 with His402.13–16
Given the unambiguous association between
complement activation and AMD, the presence of
FH and other complement-related proteins in
sRPEds
21 and the indication that FH plays a role in
the age-related thickening of Bruch's membrane,
51
an improved understanding of the role of FH may
lead to novel therapies for AMD. For example, if a
metal-induced aggregation mechanism or metal-
induced complement dysregulation proves to be
significant, then the reversibility of FH oligomerisa-
tion with EDTA offers the possibility of capturing
this oligomerisation before the irreversible cross-
linking of proteins with photo-oxidised lipids takes
place.20 Similar arguments may be relevant to other
deposit-forming diseases in which trace metals are
involved, such as Alzheimer's disease, for which a
zinc buffering compound is already in clinical
trials.
52
Materials and Methods
Protein purification
Native FH and factor I were purified from a pool of
just-outdated anonymised human plasma using mono-
clonal affinity chromatography with MRC-OX23 and
MRC-OX21 Sepharose columns.
53 Bound FH and factor
I were each eluted from the column using 3 M MgCl2,
pH 6.9, and then each was dialysed into Hepes buffer
(10 mM Hepes and 137 mM NaCl, pH 7.4) in the presence
of 0.5 mM EDTA to remove Mg2+, and then each was
passed through a HiTrap Protein G HP column to remove
the contaminant immunoglobulin G. Non-specific aggre-
gates and human serum albumin were removed using
Superose 6 gel filtration. Native C3 was purified from the
eluate after the MRC-OX23 column stage by ion-exchange
chromatography. Haemolytically inactive C3 (C3u) was
prepared by incubating native C3 in 200 mM hydrazine at
37 °C for 1 h.
54 Protein concentrations were determined
from absorption coefficients of 16.7 for FH, 12 for factor I
and 9.4 for C3u (1%; 280 nm; 1 cm path length).31,55,56
Proteins were dialysed into Hepes buffer for experi-
ments, and their integrity was routinely checked by SDS-
PAGE before and after scattering, ultracentrifugation and
assays.
Fig. 8. Hypothetical cartoon of the differential effects of metals on FH oligomerisation. (a) A partially folded-back FH
monomer structure is depicted, with SCR-7 and SCR-20 highlighted in black as possible dimerisation sites in native FH. It
is stressed that the FH monomer is more compact in its folded-back structure than that shown, which is drawn for clarity.
(b) A putative compact oligomer is formed, initially as a dimer, through contacts in the region near SCR-20. The presence
of zinc promotes further dimerisation in a central region of FH near but not necessarily at SCR-7, and this leads to a set of
compact oligomers (Fig.3c).(c) More extended oligomerscan be formed if a different metal promotes a different pattern of
oligomer formation. In the schematic view shown, dimers are initially formed near SCR-7, and the presence of copper
leads to further dimerisation near one end of FH, not necessarily at SCR-20. More extended oligomers are formed in the
presence of copper (Fig. 3c).
1349 Metal-Induced Self-Association of Factor HX-ray scattering data collection and analysis
X-ray scattering is a diffraction method used to study
solution structures of macromolecules in random orienta-
tions.
28 The X-ray data I(Q) as a function of the scattering
vector Q were acquired in two beam sessions on beamline
ID02 at the European Synchrotron Radiation Facility
(Grenoble, France) with a ring energy of 6.0 GeV and
operating in 4- and 16-bunch modes to reduce the incident
flux. Storage ring currents ranged from 22 to 41 mA for the
4-bunch mode and from 67 to 92 mA for the 16-bunch
mode. Potential radiation damage was eliminated by
continuous movement of the sample in a flow cell during
beam exposure, use of 10 time frames of 0.2- or 0.5-s
duration each during each acquisition and online checks
for the absence of radiation damage at low Q. FH was
studied at concentrations of 1.05 mg/ml (7.0 μM) and
0.42 mg/ml (2.8 μM), with ZnSO4 concentrations between
0 and 200 μM and 0.93 mg/ml (6.2 μM) with CuSO4 in the
same concentration range as well as 200 μM ZnCl2, CaCl2,
MgCl2, NiCl2, CdCl2 and FeSO4. Other details, including
data reduction, are described elsewhere.
37,38
In a given solute–solvent contrast, Guinier analyses of ln
I(Q) versus Q
2 at low Q give the RG and the forward
scattering at zero angle I(0). The RG is a measure of overall
FH structural elongation, and I(0)/c (c=concentration) is a
measure of its molecular weight. For elongated structures,
the cross-sectional radius of gyration RXS and cross-
sectional intensity at zero angle [I(Q)·Q]Q→0 are obtained
from analyses at larger Q ranges. These provide informa-
tion on the structural relationship between adjacent SCR
domains. Indirect transformation of the scattering data
I(Q) in reciprocal space to give the distance distribution
function P(r) in real space was carried out using GNOM.
The P(r) curve reports the distribution of distances r
between all volume elements within the protein. This
offers an alternative calculation of the RG and I(0) values
that is based on the full scattering curve I(Q), and not that
at low Q. It also gives the maximum dimension of the
macromolecule L. The X-ray curve utilised up to 211 data
points for Q between 0.06 and 1.50 nm
−1 for0.42 mg/ml of
FH, up to 309 data points for Q between 0.06 and
2.10 nm
−1 for 1.05 mg/ml of FH and up to 599 data points
for Q between 0.09 and 2.10 nm
−1 for 0.93 mg/ml of FH.
Other details are described elsewhere.30,31,37,38
Sedimentation velocity data collection and analyses
Analytical ultracentrifugation studies the sedimentation
behaviour of macromolecules on subjecting these to a high
centrifugal force in order to determine their sizes and
shapes.29 Data were obtained on a Beckman XL-I ins-
trument using AnTi50 or AnTi60 rotors at 20 °C. Sedi-
mentation velocity experiments were performed at rotor
speeds up to 60,000 rpm in two-sector cells with a column
height of 12 mm for 0.87 and 0.35 mg/ml of FH titrated
with ZnSO4 at eight concentrations between 0 and 200 μM,
0.81 mg/ml of FH titrated with CuSO4 at eight concen-
trations from 0 to 200 μM and 0.93 mg/ml of FH with
200 μM ZnCl2, CaCl2, MgCl2, NiCl2, CdCl2 and FeSO4.
Data analyses were performed using SEDFIT (version 9.4).
The size-distribution analyses c(s) that provided size and
shape data were based on a fixed resolution of 200 and a
frictional ratio f/fo of 1.78 and floated on the meniscus, the
bottom of the cell and the baseline until the overall rmsd
and fits between the observed and calculated sedimenta-
tion boundaries were satisfactory. The percentage fraction
of oligomers in the total loading concentration was de-
rived using the c(s) integration function. Other details are
described elsewhere.30,38
Fluid-phase activity assays
The reaction mixtures contained 0.3 mg/ml of FH,
0.3 mg/ml of C3u and 0.003 mg/ml of factor I in six
concentrations of ZnSO4 or CuSO4 (0, 2, 20, 60, 120 and
200 μM) and were incubated in a water bath at 37 °C. At
timed intervals, 5-μl aliquots were removed for reducing
SDS-PAGE analyses. Three controls were used: 0.3 mg/ml
of C3u, 0.3 mg/ml of C3u and 0.3 mg/ml of FH; and
0.3 mg/ml of C3u, 0.3 mg/ml of FH and zinc or copper.
The C3 α-chain band densities from SDS-PAGE were
measured using the gel analysis system SYNGENE
(Synoptics, Ltd., Cambridge, UK). The C3 α-chain cleav-
age was referenced to the averaged density of the
uncleaved bands in the controls.
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